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Abstract 
PART I: Benzylisoquinoline alkaloids derived from either enantiomer of reticuline represent 
a large class of secondary metabolites that occur across many families of herbaceous plants. Oxidative 
enzymatic transformations give rise to a variety of skeletal subtypes and complex polycyclic 
frameworks that have been used as therapeutic agents for centuries, often serving as lead compounds 
for the development of new drugs. While different enantiomers of the same molecule are known to be 
produced across plants of different species, the occurrence of the same compound in scalemic fashion 
in the same host is highly unusual, given that the enzymes involved in their biosynthesis normally 
operate with very high enantioselectivity. Sinoracutine however (I, Scheme A), which was isolated 
from Stephania cepharantha and Sinomenium acutum, was found to occur in different optical purities 
across the different source plants. With the ultimate goal to determine the origin of discrepancy, we 
devised an enantioselective approach to sinoracutine, in which the stereochemistry could be controlled 
by a benzylic alcohol introduced early in the synthesis. Starting from inexpensive isovanillin, an 
enantioselective reduction delivered enantiopure II which was transformed into tricycle III by 
Pauson–Khand reaction. Stereoselective reduction and Claisen rearrangement gave aldehyde IV. After 
reductive amination, a iodoamination-Kornblum oxidation sequence delivered tetracycle V, which 
could provide sinoracutine in excellent optical purity. We determined that upon mild heating in protic 
solvent, this material underwent complete racemization within five days. Our results suggest that the 
pyrrolidine ring of sinoracutine could undergo ring-opening and closure to factually destroy the 
stereochemical configuration of the all-carbon quaternary stereocenter and allow for the formation of 
(+)-sinoracutine, explaining the optical variability observed in plant-derived samples of sinoracutine.  
 
Scheme A. Enantioselective synthesis of (–)-sinoracutine using a series of  
diastereoselective synthetic transformation and its facile racemization  
 
Abstract 
VIII 
PART II: The second part of this thesis describes investigations towards the strained 
piperazine alkaloids herquline A (VI) and B (VII, Scheme B). Isolated from the fungus Penicillium 
herquei, they have shown interesting blood-platelet aggregation activity, as well as anti-influenza 
proprieties. In our synthetic approaches, we wanted to take advantage of the pseudosymmetrical nature 
of herquline B and devise a two-directional strategy aimed at the first total syntheses of these unique 
natural products. 
An oxidative enolate coupling strategy was pursued for the formation of the 12-membered 
ring. The required precursor (VIII) could be prepared from two L-tyrosine units by a short reaction 
sequence. Several conditions for the formation of IX were investigated, either from VIII itself, its 
derived bis-enolate, or the bis-silyl enol ether. Unfortunately, IX was not formed, and studies on 
different model systems suggest that β,γ-unsaturated ketones are not able to undergo radical 
dimerization at the α-position under the conditions examined.  
A second approach based on the early introduction of the 1,4-dicarbonyl moiety was next 
investigated. For the synthesis of the bis-cyclohexenone rings of herquline B, a twofold allylation 
strategy was investigated. After extensive optimization, we determined that bifunctional allylboron 
reagent X was uniquely suited for the formation of the required products. The reactivity of X is 
explored, and its use in the double allylation / double ring-closing metathesis sequence has been 
demonstrated on model substrates (e.g. giving XI) to successfully form the northern bis-cyclohexene 
segment featured in herquline B (VI). 
 
Scheme B. Synthetic approaches towards herquline B outlined in this thesis:  
oxidative coupling strategy (top) and two-fold allylation – metathesis sequence (bottom) 
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 General introduction – Alkaloids 1.
1.1. The Beginning of Alkaloid Chemistry 
Although only defined and classified for the first time at the beginning of the 19
th
 century, for 
thousands of years the naturally occurring small molecules known today as “alkaloids” have played a 
central role in the evolution of human society. The causality link that was recognized between the 
ingestion of a certain alkaloid-containing plants and the resulting effect on the body was documented 
as early as 5000 years ago in the form of a Sumerian clay slab from Nagpur (India), which comprised 
twelve recipes for drug preparation containing over 250 various plants.
[1]
 Independently, similar 
knowledge developed in China, with the drafting of the botanical treaty “Pen T’Sao” (2500 BC), 
describing the proprieties of 365 medicinal herbs.
[2]
 Over the centuries, based on empirical 
observations, virtually every literate society developed their own compendium of bioactive plants and 
described their therapeutic (and sometimes toxic) proprieties: from the Ebers papyrus (1550 BC) in 
Ancient Egypt to the Historia Plantarum of Theophrastus of Eresos (372–287 BC), as well as the 
works of Pliny the Elder (23–79) and Galen  (129–199).[3] 
With the advent of the moveable type printing press in the 15
th
 century, several so-called 
“herbals” based on the abovementioned compendia became widely distributed to inform scholars 
about the identity and proprieties of hundreds of plants.
[4]
 As we know today, many of them owe their 
bioactivity to the alkaloids they contain. However, the idea that a single molecule can produce a 
determined effect on the body with perfect cause-effect relationship, the very mechanism on which 
modern medicine is based, was recognized only in the 17
th
 century. 
Interestingly, many researchers attribute the paradigm shift to Paracelsus (1493–1541), whose 
iconoclast ideas revolutionized the medieval conceptions of anatomy and physiology passed down by 
Avicenna and Galen.
[5]
 Paracelsus’ teachings entailed that within every object there was a “spirit”, the 
so-called quintessence, which was ultimately responsible for the experienced effect. This substance 
was “contained in the mystery of nature, which is termed “purity”, while the remainder of the body, in 
which the quintessence was trapped, was termed “impurity”.[6,7] For example, searching for the spirit 
of wine, he was able to isolate its “essence”, ethanol, by distillation.[8] Although Paracelsus’ alchemy 
was guided by astrological and mystical theories, with the ultimate goal of freeing substances from 
their earthly qualities and to elevate them to a spiritual level, his chemical approach to medicine lived 
on through the centuries. In the late 18
th
 century, the concept of “purity” and of “pure substance”, now 
more aligned with contemporary meaning, together with the advances in analytical chemistry 
(specifically the concepts of solubility solvent extraction methods), stimulated pharmacists to analyze 
vegetable drugs in common use at the time.
[9]
 
The most popular among them was opium, the dried latex originating from the seed pods of 
Papaver somniferum, which had a reputation as a panacea (Figure 1). It was used against diarrhea for 
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its constipating effect, was prescribed as a cough suppressant in cases of bronchitis and tuberculosis, 
and its sedative proprieties were recognized in the treatment of insomnia and mental illness. It had an 
exquisite capability to relieve pain and also to induce euphoria, relaxation and dream-like states, which 
propagated its recreational use.
[10]
 However, it was also known that its consumption was accompanied 
with severe addiction and withdrawal symptoms, while higher doses could lead to unconsciousness 
and death. Nevertheless, the opium trade became a worldwide operation by the end of  18
th
 century, 
and prompted several investigations into its composition with the aim of finding a way to precisely 
dose the drug to avoid health risks, as well as discover adulterated batches with inferior quality and 
potency.
[11]
 
   
Figure 1. F. W. A. Sertürner (left), who isolated morphine, the active ingredient from raw opium 
(middle), the dried latex from the seed pods of Papaver somniferum (right).
[12–14]
 
First reports on the successful extraction and purification of opium were carried out between 
1803 and 1806 by the pharmacists Friedrich Wilhelm Adam Sertürner (1783–1841), Charles Derosne 
(1780–1846), Armand Seguin (1767–1835) and Bernard Courtois (1777–1838).[15] Although their 
preparations had similar effect to opium, they did not pose significant advantages and were likely 
mixtures of compounds. Sertürner continuously experimented with new procedures, and in 1817 he 
described the successful isolation of a pure compound from raw opium after extraction with hot water 
and precipitation using ammonia.
[16]
 The obtained white crystals were poorly soluble in water, but 
soluble in alcohol. Most importantly, they reacted with acids to neutralize them and to form fully 
water-soluble salts. Hence, he had demonstrated the isolation of a compound with “basic” proprieties. 
Sertürner stated that it was similar to ammonia “in the order of salifiable bases”.[17] 
This finding was groundbreaking: at the time, only acidic compounds were thought to exist in 
plants (Sertürner himself isolated meconic acid from Papaver somniferum 1805).
[18]
 Furthermore, 
“because experiments on animals do not give exact results”, he also described dosing himself and 
three young men with the compound.
[19]
 The experiment caused confusion and fatigue in the test 
subjects, one of his friends suffered severe nausea and headaches after being rendered unconscious by 
the drug for several hours. However, at lower doses Sertürner experienced relief for his toothache, and 
drowsiness if he doubled the amount of compound.
[20]
 He named the compound morphium, in honor of 
the Greek god of dreams Morpheus, and anticipated that other alkalis were to be found in other plants. 
In the following years, compounds such as the highly toxic strychnine (2), the cycloplegic atropine (3), 
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the antimalarial quinine (4), and the stimulant caffeine (5), were isolated in pure form, giving birth to 
the modern era of alkaloid chemistry, pharmacy, and medicine (Figure 2).
[21]
 
 
Figure 2. Prominent alkaloids isolated at the beginning of the 19
th
 century. 
1.2. Definition of Alkaloid 
The word “alkaloid” was coined in 1818 by the German pharmacist Carl Friedrich 
Wilhelm Meißner (1792–1853) by merging the Arabic word alkali “al-quali”, referring to the 
calcinated ashes of plants, and the Greek suffix “-oid” meaning “alike”. This name reflects the basic 
nature of these compounds, but stresses their different chemical composition compared to the known 
alkalis of the time (essentially potash, soda, and ammonia).
[17]
 Anecdotal evidence resulting from the 
discoveries since 1815 led to the belief that they would only occur in higher plants (see above). 
Therefore, a first definition of alkaloid was: “the plant component which shows basic properties and a 
strong biological effect”.[22] Over the past decades, as the chemistry of natural products progressed and 
broadened its hunting ground, it allowed the isolation of compounds with similar proprieties, but from 
sources other than plants (Figure 3). For example, the highly toxic batrachotoxin (6) was isolated from 
the skin of Dendrobates “poison dart” frogs, and polycyclic alkaloids such as precoccinelline (7) were 
found to occur in the ladybug beetle. The cytotoxic dragmacidin A (8) was isolated from a deep sea 
sponge, and the macrocyclic pheromone muscopyridine (9) is found in the ventral glands of the musk 
deer.
[23–26]
 
 
Figure 3. Structurally diverse alkaloids from sources other than plants.
[27–30]
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Although all the above mentioned molecules react as bases due to the presence of a non-
bonding electron pair on the nitrogen atom, other compounds that do not possess such functionality are 
still classified as alkaloids (Figure 4). Colchicine (10) is commonly used for the treatment of gout, and 
capsaicin (13) is responsible for the hot sensation of chili peppers.
[31,32]
 Furthermore, biosynthetic 
processing targeting the nitrogen atom can give rise to oxidized compounds such as the aristolochic 
acid (11), which contains a nitro group, and lycopsamine N-oxide (12).
[33,34]
 However, not all nitrogen-
containing metabolites are classified as alkaloids. Early biosynthetic intermediates and primary 
metabolites indispensable for the organism’s survival such as simple amino acids, purines and 
pyrimidines, as well as complex polypeptides and proteins, do not fall into this category. Nevertheless, 
amino acids can, through enzymatic processing and the merger of different biosynthetic pathways, 
give rise to alkaloidal metabolites such as cytochalasin A (14), which incorporates phenylalanine into 
a polyketide-derived alkyl chain. Glutamic acid and a monoterpene unit are the bioprecursors for 
kainic acid (16), while nominine (15) contains a C20-diterpene scaffold in which a nitrogen atom is 
introduced. 
[29–31]
 Furthermore, the notorious pufferfish poison tetrodotoxin (17) is likely derived from 
arginine, although its origin is still under debate despite extensive studies since its isolation in 1909.
[35]
 
 
Figure 4. Examples of non-basic plant alkaloids (top);  
Alkaloids derived from mixed polyketide or terpenoid biosynthetic pathways (bottom). 
Based on the above examples, structurally diverse compounds originating from all living 
domains can be classified as alkaloids as long as they contain a nitrogen atom. Despite the fact that 
this principle might seem vague, if contextualized within the experience accumulated in the past 200 
years, a sensible classification of alkaloids is possible. As famously put by natural product isolation 
chemist Geoffrey Cordell: “You know one when you see one”.[36] 
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1.3. Significance and Opportunities 
In a series of reviews, Newman
 
and Cragg estimated that about 64% of the all marketed drugs 
between 1981 and 2014 were either directly or indirectly derived from natural products.
[37]
 Although 
only 6% of these were unmodified natural products, the remaining 58% is made up by: a) 
semisynthetic modifications of natural products, b) entirely synthetic molecules whose pharmacophore 
was originally discovered owing to a natural product, or c) synthetic natural product mimics and 
analogues with the same mode of action as the natural product itself. 
The century-long tradition in their use as medicines has been the main source of inspiration for 
these developments. The advances initiated by the discovery of morphine are a glaring example of 
this. Not only did it mark the dawn of alkaloid chemistry and their use in therapy, it also sparked 
several forays into the investigation of its biosynthesis and its structure-activity relationships. It led to 
the discovery of the complex physiological mechanisms of endogenous opioid regulation and, along 
with advances in analytical instrumentation and synthetic chemistry, several new drugs. Figure 5 
shows how structural modifications (both semi-synthetic and totally synthetic) of morphine (1) did 
lead to several essential therapeutic agents: oxycodone (18) is an excellent analgesic that has been 
widely prescribed in the past 20 years. It also exhibits high addiction potential and often initiates illicit 
drug abuse.
[38]
 The O-demethylated and N-allylated analogue naloxone (19) can counteract its effect, 
and is a ubiquitous emergency medication in response to an opioid overdose. Removal of functional 
groups in the optical antipode of morphine leads to the phenantrenoid skeleton of dextromethorphan 
(20), which is used as a cough suppressant and has highly diminished analgesic and anesthetic 
proprieties relative to the (S)-configured series. Although their structure suggest otherwise, the fully 
synthetic analogues fentanyl (21) and sufentanyl (22) are respectively 100 and 500 times more potent 
than morphine. The former is used for the control of severe pain, and the latter is used as a sedative 
during general surgical anesthesia.
[39]
 The structurally closely related loperamide (23) on the other 
hand, has been used for the past 50 years as an antidiarroic.
[40]
 If taken orally, it has very low central 
nervous system penetration, thereby selectively manifesting only the constipating proprieties (i.e. 
promotes intestinal water absorption) of morphine without sedative and euphorizing effects. Most 
importantly, many other alkaloids have served as inspiration for the development of drugs, either as 
structural templates or as physiochemical probes. Among them are tubocurarine, atropine, 
camptothecin, staurosporine, and vinblastine.
[41,42]
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Figure 5. Morphine and six derivatives with improved therapeutic profiles. 
Although alkaloids comprise only about 15% of all the known natural products, they account 
for 46% of all plant-derived pharmaceuticals.
[43]
 While it may be argued that their centennial history 
and availability have led plants to be investigated in much more detail compared to other sources of 
natural products (e.g. marine organisms or fungi), this percentage is still remarkably high. 
Furthermore, a study among the 21.120 known plant-derived alkaloids described in the “Natural 
Products Alert” database  (out of approximately 27000 in total) has shown that only 24% have been 
evaluated for bioactivity at all.
[44]
 Considering these numbers in relation to the historical success of 
alkaloids in therapy and the nearly limitless possibilities of synthetic chemistry, many more interesting 
discoveries lie ahead of us. 
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1. Introduction 
1.1.  Structural Variety of Benzylisoquinoline Alkaloids 
Benzylisoquinoline alkaloids (BIAs) are a structurally diverse group of plant metabolites that 
include more than 2500 structures and share a common benzylisoquinoline skeleton (24, Figure 6) in 
different oxidation and substitution patterns.
[45]
 Their topological complexity is increased by 
intramolecular cyclization and ring-opening reactions resulting in diverse structures and biological 
activity (Figure 6). For example, they include the narcotic analgesic morphine (1), the antibiotic 
berberine (25), the muscle relaxants tubocurarine (26) and papaverine (27), the cough suppressant 
noscapine (28), the antiparkinsonian apomorphine (29), and the anticancer drug dauricine (30). All 
these alkaloids stem from the same fundamental biosynthetic pathway using metabolites derived from 
shikimic acid, and exhibit plant-specific diversity as a result of the enzymatic array present in the 
producing organism.   
 
Figure 6. Structural variety of plant-derived alkaloids with benzylisoquinoline core structure. 
In contrast to wooden phenotypes, where the shikimate pathway primarily serves to form 
cinnamic acids and alcohols necessary for the formation of lignin and condensed tannins, BIAs can be 
found in herbaceous plant families (Papaveraceae, Ranunculaceae, Berberidaceae and 
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Menispermaceae). Here, the products of the shikimate pathway are heavily diverted towards 
phenylalanine, the primary substrate for the biosynthesis of BIAs (Scheme 1). Oxidation of 
phenylalanine to L-tyrosine followed by oxidative deamination and decarboxylation leads to the 
formation of 4-hydroxyphenylacetaldehyde. Alternatively, aromatic oxidation of L-tyrosine followed 
by decarboxylation leads to the synthesis of dopamine.
[46]
 Condensation of these two intermediates and 
Pictet–Spengler reaction forms norcoclaurine (31), the first benzylisoquinoline alkaloid encountered in 
the biosynthetic pathway. Four additional enzymatic steps result in the formation of reticuline (32), the 
most important branching point in the formation of several benzylisoquinoline alkaloids.  
 
Scheme 1. Biosynthesis of (S)-reticuline from (S)-phenylalanine. 
(S)-Reticuline (32) features an (S)-configured benzylic stereocenter at C9. This stereochemical 
information is retained in further downstream transformations except in cases where aromatization to a 
benzylisoquinoline occurs (e.g. papaverine 27, Figure 6). In certain plants however, (S)-reticuline can 
be isomerized via oxidation and enzymatic reduction to its antipode (R)-reticuline (33, Scheme 2).
[47,48]
 
The dextrorotatory reticuline can also undergo similar downstream transformations with conservation 
of the benzylic stereocenter (now in (R)-configuration). Among the most important enzymatic 
conversions of reticuline (in either enantiomeric form) is the phenolic o,o-coupling between positions 
12 and 13 (Scheme 2) that leads to a phenantrenoid ring system. So, starting from (R)-reticuline this 
oxidative coupling forms (+)-salutaridine (35), which serves as the gateway to the morphine alkaloids. 
This pathway is operative in several species of the Papaveraceae family such as Papaver Somniferum, 
which delivers morphine (1). Conversely, (S)-reticuline can undergo the oxidative coupling to form    
(–)-salutaridine (34), widely referred to as sinoacutine, which is the entry point into the hasubanan 
alkaloids. This transformation is predominant in the Menispermaceae family, prominently represented 
by species such as Sinomenium acutum. Further plant-specific downstream transformations in either 
enantiomeric series greatly increase the structural variety of these tetracyclic alkaloids. However, a 
common denominator is an all-carbon quaternary stereocenter in the benzylic position, from which a 
two-carbon chain terminating in a nitrogen atom projects. This nitrogen can be connected to the 
remainder of the skeleton at different positions to provide structures that contain various five- or six-
membered heterocycles (Scheme 2).  
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Scheme 2. Tetracyclic alkaloids derived from (S)- and (R)-reticuline. 
In the morphinan series, exemplified by morphine, the original C–N connection at C9 is 
preserved to form a piperidine ring. In the hasubanan series, exemplified by hasubanonine (36), the 
nitrogen substituent is moved from the C9 to the C14 position, forming a 5-membered ring and a 
[4.4.3]aza-propellane.
[49]
 Oxidative transformations can lead to hydroxylation at C10 as seen in 
metaphanine (37).
[50]
 C–N bond fission can also occur with concomitant ring closure at C6, giving rise 
to cepharatine-type alkaloids such as cepharatine A (38).
[51–53]
 Further enzymatic processing of 
hasubanan-type alkaloids can also lead to skeletal rearrangements and loss of carbon atoms, for 
example in the acutumine alkaloid series, where the northern aromatic ring is cleaved and rearranged 
to a cyclopentenone through a Favorskii rearrangement followed by decarboxylation.
[54–56]
 
Although most of the skeletal subtypes mentioned above have been known for decades, many of 
them have succumbed to total synthesis only recently (e.g. acutumine (39) was isolated in 1929 and 
first synthesized in 2009). New compounds belonging to these structural classes are being discovered 
in present times and continue to capture the attention of organic chemists.
[56,57]
 Occasionally, new 
alkaloids containing unprecedented skeletal subtypes are also discovered. One such alkaloid is 
sinoracutine, which is the present object of study.  
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1.2. Sinoracutine 
1.1.1. Isolation, Structure and Absolute Stereochemistry. 
In 2009, a structurally unusual alkaloid was isolated from the dried stems of Sinomenium 
acutum. It was termed sinoracutine and was fully characterized by NMR, IR, and mass spectroscopic 
methods (40, Figure 7).
[58]
 Additional structural proof was obtained by X-ray crystallographic analysis. 
Sinoracutine features an unprecedented 6/6/5/5 tetracyclic skeleton with an aromatic ring bearing a 
methoxy and a hydroxyl group. A benzylic quaternary carbon connects an N-methyl pyrrolidine ring 
to a cyclopentenone moiety which is, in turn, connected to the aromatic ring through a cyclohexene 
ring. As a result, a highly conjugated -system (n–* = 393 nm) is formed.  
 
 
 
 
Figure 7. Leaves of Sinomenium acutum (left); structure and ORTEP plot of sinoracutine (right). 
 
The X-ray structure shows that the phenolic hydroxy group engages in an intramolecular 
hydrogen bond with the tertiary amine in the pyrrolidine ring. The pyrrolidine ring stands 
perpendicular to the carbocyclic 6/6/5 system, which assumes a slightly helical conformation. 
Moreover, the isolated sample exhibited a levorotatory optical power of –7.4 (c = 0.35, CHCl3). 
In 2010, (–)-sinoracutine was also found to occur in Stephania cepharantha, another member of the 
Menispermaceae family. In this case, the optical rotation was reported to be considerably higher: 
–754.5 (c = 1.14, CHCl3).
[59]
 Interestingly, in 2014, the “optical isomer” of (–)-sinoracutine, namely 
(+)-sinoracutine, was reportedly isolated from Sinomenium acutum.
[60]
 The structural assignment was 
carried out exclusively using X-ray crystallography, and no optical rotation was reported to 
substantiate this unusual finding. 
Interestingly, a closer look at the two available X-ray structures reveals that they depict the 
same enantiomer, namely the molecule bearing (R)-configuration at C13, which was assigned as (–)-
sinoracutine by Bao. However, this could be the result of a production error during manuscript 
preparation. Nevertheless, inspection of the crystallographic data of purported (+)-sinoracutine 
revealed the centrosymmetric space group Pbca, whose unit cell contains both enantiomers. 
Furthermore, examination of the crystallographic data file for the X-ray structure of purported (–)-
sinoracutine also exhibited a centrosymmetric unit cell with both enantiomers present, namely P21/n. It 
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was erroneously reported in the publication as the chiral space group P21. Taken together, these data 
suggest that in Sinomenium acutum sinoracutine occurs in scalemic form, but that the racemate 
crystallizes preferentially. Furthermore, the large differences in the absolute values of the optical 
rotations indicate that (–)-sinoracutine isolated from Stephania cepharanta is also scalemic, albeit of 
higher optical purity than the material derived from Sinomenium acutum. This is a very interesting 
circumstance and hints either to a biosynthetic pathway that operates with imperfect enantioselectivity, 
which has never been observed in reticuline-derived alkaloids, or to a partial racemization of the 
natural product either upon storage or isolation. However, no studies to assess the veracity of these 
hypotheses have been carried out by the isolation teams. 
 
 
 
Figure 8: ORTEP rendering of the crystal structure of sinoracutine reported by Bao, in which 
the unit cell contains both (R)- and (S)-sinoracutine (H-atoms omitted for clarity). 
1.1.2. Biosynthesis 
Several alkaloids that are believed to be biosynthetically related to sinoracutine have been 
isolated from Sinomenium acutum and Stephania cepharanta. Although the reported X-ray structures 
of sinoracutine represent racemic material, the published CD spectrum obtained from a sample 
originating from Sinomenium acutum suggests the configuration at the benzylic quaternary carbon to 
be (R). Thereby in the biosynthesis of sinoracutine, the morphinan-type alkaloid sinoacutine (34, 
Scheme 2) could be enlisted as the first committed biosynthetic intermediate after the phenolic o,o-
coupling of (S)-reticuline. This intermediate has been isolated from both Sinomenium acutum and 
Stephania cepharanta.
[59]
 A biosynthetic proposal, shown in Scheme 3, was put forth by the isolation 
team led by Bao. It involves an oxidative deamination of sinoacutine to cleave the piperidine bridge to 
give ketone 42.
[58]
 Reduction and elimination of the resulting alcohol would give 43 featuring the fully 
conjugated eastern backbone of sinoracutine.  Conjugate addition of the secondary amine to the α-
methoxy enone gives pyrrolidine 44. Then, Baeyer–Villiger oxidation would furnish 7-membered 
lactone 45 which upon hydrolysis undergoes a Dieckmann-type condensation to form sinoraculine 
(46), the carboxylated congener of sinoracutine (40). This compound was isolated in 2012 from 
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Stephania cepharanta as well and is very likely to occur in Sinomenium acutum as well.
[61]
 With the 
6/6/5/5 system in place, ester hydrolysis to 47 and decarboxylation of the exocyclic carboxylic acid 
finally results in sinoracutine (40).  
 
Scheme 3. Proposed biosynthesis of sinoracutine (40) from sinoacutine (34). 
1.1.3. Bioactivity 
Sinomenium acutum and Stephania cepharanta, from which sinoracutine has been isolated, are 
commonly used in traditional Chinese medicine for the treatment of inflammatory diseases such as 
rheumatoid arthritis, neuralgia, and edema.
[62]
 A root cause for these diseases is prominently linked to 
oxidative stress resulting from the surplus of reactive oxygen species (
•
O
−
2 ,
•
OH, H2O2) that are either 
byproducts of cell metabolism or generated by external stimuli (e.g. radiation, metabolism of 
xenobiotics).
[63]
 Increased levels of ROS lead to chronic inflammation that is manifested by the 
abovementioned pathologies and plays a major role in a variety of other degenerative illnesses 
including cancer, diabetes, pulmonary hypertension, coronopathy, as well as Alzheimer’s or 
Parkinson’s diseases.[64] 
In this context, sinoracutine has been investigated by Bao and co-workers for its antioxidant and 
cell-protective effects.
[58]
 As a neuronal replacement model, the rat pheochromocytoma derived PC12 
cells were treated with hydrogen peroxide to simulate endogenously produced ROS and induce 
oxidative stress. When PC12 cells were incubated with (–)-sinoracutine prior to exposure to hydrogen 
peroxide cell viability was increased and the survival rate rose from 59.4% in the control sample to 
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62.5% in the cultures treated with sinoracutine (1 µM). These values show the same trend as those 
obtained for the positive control huperzine A (64.3%, 10 µM), a lycopodium-type alkaloid first 
isolated from Huperzia serrata which is marketed as a dietary supplement for memory improvement. 
It has also been demonstrated that it can improve cognitive function and daily living activity in 
subjects with Alzheimer’s disease.[65,66] 
1.3. Project Aims 
The unique structure of sinoracutine and the open questions concerning its optical purity, together 
with the probable biosynthetic and pharmacological implications, prompted us to devise a synthetic 
route that could access the natural product both in a racemic as well as in enantiopure form. Given its 
high lipophilicity by virtue of an intramolecular hydrogen bond, that effectively mitigates the polarity 
of a basic tertiary amine and free phenolic OH, sinoracutine could serve as a template for the synthesis 
of new neuroprotective agents with central nervous system penetration ability. 
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 Results and Discussion 2.
2.1. Retrosynthesis 
The projected key transformation for the synthesis of sinoracutine was envisaged to be a 
Pauson–Khand reaction of 3-aryldihydropyrroline 48 bearing a pendant alkyne (Scheme 4). This 
retrosynthetic disconnection would allow the synthesis of two of the four rings of the natural product 
in a single step. Completion of the synthesis would then require elimination of the benzylic alcohol.   
 
Scheme 4. Proposed key disconnection via Pauson–Khand reaction. 
Enamines are known to engage in Pauson–Khand reactions, although the literature precedent 
is thin (Scheme 5). Interestingly, every example reported employs an N-carbamoyl-pyrrolidine and 
forms a quaternary carbon at the cyclopentenone junction, the same arrangement required for this 
synthetic plan. 
[67–70]
 
 
Scheme 5. Representative Pauson–Khand reaction employing an enamine. 
Additionally, this Pauson–Khand disconnection could enable a stereoselective synthesis of 
sinoracutine by exploiting the steric bulk of an appropriately protected enantiomerically pure alcohol 
48 (Scheme 6). The configuration of the secondary alcohol and its protecting group could conceivably 
promote the formation of a single diastereoisomer during the Pauson–Khand reaction by imparting a 
decisive conformational preorganization of the starting enyne. This intermediate could be prepared in 
enantioenriched form from aldehyde 49. Several methods for the synthesis of enantiopure 48 could be 
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employed, such as an asymmetric propargylation of aldehyde 49 or an asymmetric reduction of the 
ketone derived from racemic secondary alcohol 48 itself.
[71–76]
 
The required aldehyde 49 is the product resulting from a cross-coupling of literature-known 
iodoenamine 50 with boronate 51, which is easily derived from inexpensive isovanillin (Scheme 6).  
Although the steric hindrance of 49 is worthy of note, the coupling of o,o-disubstituted arenes has 
been reported several times in literature, establishing isovanillin as a convenient entry to the aromatic 
portion of many natural products.
[77–79]
 The second building block (50) is derived from pyrrolidinone 
52 (Scheme 6).
[80]
.  
 
Scheme 6. Retrosynthetic analysis of 1,7-enyne 48. 
2.1.1. Synthesis of the Pyrrolidine Coupling Partner 
The synthesis of halogenated enamine 50 commenced from commercially available Boc-
protected pyrrolidinone 53 (Scheme 7).
[80]
 Reduction of the carbonyl to give a hemiaminal, followed 
by in situ elimination furnished 2-pyrroline 54, which was subjected to halogenation conditions. 
 
Scheme 7. Reduction and elimination of lactam 53. 
As summarized in Table 1, bromination using NBS in the presence of base gave no reaction, 
while the use of molecular bromine resulted only in low product yield and partial decomposition of the 
starting material even at –78 °C (Entries 1 to 3).[81–83] The reaction was more successful after the 
addition of 4 Å MS and bromide 55 could be isolated in moderate yield, provided the reaction was 
stopped as soon as the disappearance of 54 was observed by TLC (Entry 4). 
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Table 1. Bromination of Boc-protected pyrroline 54. 
 
Entry Reagent Base Solvent Additive Temp. (°C) Time (h) Yielda (%) 
1 NBS Et3N CH2Cl2 - rt 16 - 
2 Br2 Et3N CH2Cl2 - 0 2 32 
3 Br2 DIPEA toluene/CH2Cl2 - –78 2 38 
4 Br2 Et3N CH2Cl2 4 Å MS rt 2 47 
a) decomposition of 55 was observed; 
 
Iodide 50 was synthesized next. Analogous to the synthesis of bromide 55, a one-step 
preparation was attempted by direct iodination of 54 (Table 2). Although the reaction is known to 
proceed on the corresponding Boc-dehydropiperidine, either no conversion at room temperature 
(Entries 1 to 3) or slow decomposition of the starting material at higher temperatures was observed 
under the examined conditions (Entries 4 and 5). 
[84–86]
 
Table 2. Iodination of Boc-protected pyrroline 54. 
 
Entry Reagent Base Solvent Temp. (°C) Time (h) Yielda 
1 NIS Et3N CH2Cl2 rt 17 - 
2 I2 Cs2CO3 1,4-Dioxane rt 10 - 
3 I2 K2CO3 THF rt 10 - 
4 I2 Cs2CO3 1,4-Dioxane 65 6 - 
5 I2 K2CO3 THF 80 6 - 
a) decomposition of 54 was observed; 
 
Consequently, we turned to a previously reported two-step preparation of 50 (Scheme 8).
[87]
 
Pyrroline 54 was treated with ICl in methanol to give addition product 56. Subsequent acid-mediated 
elimination of MeOH with citric acid led to decomposition of the starting material. Changing the acid 
to TFA and reducing its stoichiometry to 0.1 eq provided moderate yields of  50.
[88]
  
 
Scheme 8. Synthesis of iodinated pyrroline 50.  
Unfortunately, the TFA-mediated elimination reaction did not prove amendable to scale-up 
beyond 1.5 mmol. The reaction time increased with scale, which invariably led to lower yields due to 
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the concomitant decomposition of the product under the reaction conditions. Therefore, the route to 
iodinated pyrroline was modified (Scheme 9).
[89]
 After Boc-protection of p-tosyl amine (57) and 
subsequent Mitsunobu reaction of 58 with but-3-yn-1-ol to give 59, detosylation furnished alkyne 60. 
Diiodination and intramolecular Ullman-type reaction afforded vinyl iodide 50.
[90–93]
 With gram-
quantities of 50 in hand, we focused on the preparation of different isovanillin type building blocks. 
 
Scheme 9. Alternative route to iodinated pyrroline 50. 
2.1.2. Synthesis of the Aromatic Coupling Partner 
As previously shown by Curran and co-workers, iodide 50 can be successfully coupled to 
arylboronic esters using the Suzuki reaction.
[87]
 Fortunately, the functional group compatibility of this 
method is excellent and can be carried out in the presence of aldehydes.
[94]
 As shown in Scheme 10, 
iodination of isovanillin followed by benzylation furnished 63. Borylation using 
bis(pinacolato)diboron proceeded well, whereas the use of less expensive pinacolborane was found to 
be slightly inferior.
[78,95,96]
 
 
Scheme 10. Synthesis of the borylated isovanillin 64. 
A second substrate, in which the hydroxy group of 2-iodoisovanillin (62) was protected as the 
corresponding isopropoxy ether, was prepared next (65, Scheme 11). The isopropoxy group was 
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chosen because cross-coupling reactions of this building block are known and a selective deprotection 
of the isopropyl ether in presence of the methyl ether is possible using Lewis acids.
[97]
 Using a 
Miyaura borylation, the corresponding pinacol ester 66 was obtained in good yield (Scheme 11).
.[95]
  
 
Scheme 11. Synthetic route to access different isovanillin type building blocks.  
Other borylated building blocks were obtained from 2-bromoisovanillin 67 (Scheme 12): 
Williamson ether synthesis and olefination delivered styrene 69 which was treated with n-BuLi at low 
temperature followed by addition of isopropoxyboronic acid pinacol ester to give boronic ester 70 in 
excellent yield. To further increase the options for the cross-coupling reaction, the potassium 
trifluoroborate analog of 70 was prepared.
[98,99] 
 
 
Scheme 12. Synthetic route to access borylated aromatic building blocks. 
The use of styrene 70 in the cross-coupling could give an alternative precursor for the Pauson–
Khand reaction after oxidation to aldehyde 73 and acetylide addition (Scheme 13).
[100–102]
 As 74 
contains a propargylic alcohol instead of a homopropargylic alcohol (48), the effect on 
diastereoselectivity in the cyclization reaction could be probed.  
 
Scheme 13. Proposed conversion of styrene 72 into sinoracutine. 
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2.1.3. Cross-Coupling Attempts 
With building blocks 50 and 64 in hand, several cross-coupling conditions used successfully 
for sterically hindered aryl coupling partners as well as for electron-rich heteroatom-bearing vinyl 
halides were screened.
[87,103–105]
 The formation of 76 could not be observed, and protodeborylated 64 
was the major byproduct (Table 3). Iodide 50 was completely consumed in every instance, indicating 
that oxidative addition proceeded well, but the subsequent transmetallation step, even in the presence 
of alcoholic solvents and water that activate the boron center through formation of a boronate 
complex, did not proceed at all.
[106]
 
Table 3. Suzuki cross-coupling of iodoenamine 50 with aldehyde 64. 
 
Entry Pd Sourcea Ligandb Base Solvent System Temp. (°C) Time (h) Yieldc 
1 Pd(PPh3)4 - K2CO3 Benzene/MeOH/H2O 70 14 - 
2 Pd(PPh3)4 - Na2CO3 Toluene/EtOH 105 16 - 
3 Pd(PPh3)4 - KOH Toluene/H2O 105 16 - 
4 Pd(dppf)Cl2 - K2CO3 DMSO 80 16 - 
5 Pd(OAc)2 CyJohnPhos Ba(OH)2 1,4-Dioxane 80 2 - 
6 Pd(OAc)2 CyJohnPhos K3PO4 1,4-Dioxane 80 2 - 
7 Pd(OAc)2 SPhos K3PO4 Toluene/H2O 80 5 - 
a) 10 mol%;    b) 20 mol%;    c) decomposition of 50 observed, protodeboronation of 64 as determined by LCMS. 
 
Similar results were observed in the attempted coupling of iodoenamine 50 with isopropoxy-
protected aldehyde 66 (Table 4) as well as styrene 70 (Table 5). Using potassium tetrafluoroborate 71 
in conjunction with iodide 50 was not successful either (Table 6).
[107–110]
 These results suggest that 
steric hindrance, and not electronic bias, might be the culprit for the failure of this cross-coupling. 
Additionally, since 66 had been reported to undergo cross-coupling with aryl bromides, the 
halogenated enamine seems to be the main problem for the unsuccessful reaction outcomes. In fact, 
using this building block, only one example of cross-coupling can be found in literature.
[87]
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Table 4. Suzuki cross-coupling of iodoenamine 50 with isopropoxy-protected aldehyde 66. 
 
Entry Pd Sourcea Ligandb Base Solvent System Temp (°C) Time (h) Yieldc 
1 Pd(PPh3)4 - K2CO3 benzene/MeOH/H2O 70 14 - 
2 Pd(PPh3)4 - Na2CO3 toluene/EtOH 105 16 - 
3 Pd(PPh3)4 - K3PO4 1,4-dioxane 80 7 - 
4 Pd(OAc)2 CyJohnPhos Ba(OH)2 1,4-dioxane 60 48 - 
5 Pd(OAc)2 SPhos K3PO4 toluene/H2O 100 5 - 
a) 10 mol%;    b) 20 mol%;    c) decomposition of 50 observed, protodeboronation of 66 as determined by LCMS. 
 
Table 5. Suzuki cross-coupling of iodoenamine 50 with isopropoxy-protected styrene 70. 
 
Entry Pd Sourcea Ligandb Base Solvent System Temp (°C) Time (h) Yieldc 
1 Pd(PPh3)4 none K2CO3 benzene/MeOH/H2O 70 14 - 
2 Pd(PPh3)4 none Na2CO3 toluene/EtOH 105 16 - 
3 Pd(PPh3)4 none K3PO4 1,4-dioxane 80 16 - 
4 Pd(OAc)2 CyJohnPhos Ba(OH)2 1,4-dioxane 80 16 - 
5 Pd(OAc)2 SPhos K3PO4 toluene/H2O 100 5 - 
a) 10 mol%;   b) 20 mol%;    c) decomposition of 50 observed, protodeboronation of 70 as determined by LCMS. 
 
Table 6. Suzuki cross-coupling of iodoenamine 50 with potassium tetrafluoroborate 71. 
 
Entry Pd Sourcea Ligandb Base Solvent System Temp (°C) Time (h) Yieldc 
1 Pd(dppf)Cl2 none Ag2O toluene 100 18 - 
2 PdCl2(PhCN)2 none K2CO3 1,4-dioxane/H2O 80 16 - 
3 PdCl2 none K2CO3 1,4-dioxane/H2O 80 16 - 
4 Pd(PPh3)4 none K2CO3 DMF/H2O 100 12 - 
5 Pd(dppf)Cl2 none CsCO3 toluene 100 18 - 
6 Pd(OAc)2 PPh3 K3PO4 THF/H2O 60 24 - 
a) 10 mol%;   b) 20 mol%;    c) decomposition of 50 observed, protodeboronation of 71 as determined by LCMS. 
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We attempted to overcome the lack of reactivity in the cross-coupling by substituting the 
boronic ester-based Suzuki reaction with a Negishi reaction of organozinc reagents, which have been 
shown to participate in cross-coupling reactions even at ambient temperature.
[111]
 Styrene 69 was 
chosen as the substrate this study. After Br/Li exchange with t-BuLi, lithiated 69 was treated with 
ZnCl2 and subjected to various Pd-mediated cross-coupling protocols (Table 7).
[112]
 Although 50 was 
completely consumed in the reaction, no desired product was formed, and the main side-product was 
dehalogenated 69 resulting from protolysis of the intermediate organozinc species.  
Table 7. Negishi cross-coupling of 50 and 69 to form enamine 79. 
 
Entry Pd Sourcea Ligandb Solvent  Temp (°C) Time (h) Yieldc 
1 Pd2dba3 SPhos THF 60 16 - 
2 Pd2dba3 RuPhos THF 60 16 - 
3 Pd2dba3 XPhos THF 60 16 - 
a) 5 mol%;    b) 20 mol%;    c) decomposition of 50, protodemetalation of 69 observed. 
 
Next, the brominated enamine was examined as cross-coupling partner, as it was believed to 
be less reactive than the iodide which was evidently too unstable under the reaction conditions (see 
Table 8, next page). Despite using the very general systems reported by Buchwald and co-workers, the 
Negishi cross-coupling reaction of 55 and 69 did not lead to product formation.
[113,114]
 Examination of 
H2O-quenched reaction aliquots after 2 h indicated only the Br/H exchange of 69 and traces of 55. 
After 16 h, 55 was completely consumed and only the Br/H exchange product could be identified in 
the crude reaction mixture. These disappointing results on the cross-coupling of halogenated enamines 
50 and 55 led us to reverse the polarity of the coupling partners. 
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Table 8. Negishi cross-coupling reaction of bromoenamine 55 and styrene 69. 
 
 Entry Pd Sourcea Ligandb Solvent  Temp. (°C) Time (h) Yieldc  
 1 SPhos G2 SPhos THF 60 16 -  
 2 XPhos G3 XPhos THF 60 16 -  
 3 RuPhos G2 RuPhos THF 60 16 -  
 4 PEPPSI-IPr none THF 60 16 -  
 5 Pd(P(o-tolyl)3)2Cl2 none THF 60 16 -  
 6 Pd(dppf)Cl2 none THF 60 16 -  
 a) 10 mol%;    b) 10 mol%;    c) decomposition of 55, protodemetalation of 69 observed.  
2.1.4. Alternative Fragment Union 
Placement of the halogen on the isovanillin building block, rendered electron-poor by the 
presence of the aldehyde moiety, should favor oxidative addition during the Pd-catalyzed cross-
coupling process (Scheme 14). In fact, similar compounds have shown to engage in cross-coupling 
reactions.
[115–117]
 The electron-rich nature of the enamine should facilitate the introduction of a boron 
atom and the subsequent Suzuki cross-coupling. Furthermore, we decided to employ unprotected 2-
bromo isovanillin 67 in the cross-coupling. The benzyl group was left out to remove any possible 
steric hindrance during oxidative addition.  
 
Scheme 14. Envisioned building blocks for the formation of aldehyde 80. 
For the synthesis of borylated enamine 81 conditions similar to the Pd-catalyzed borylation of 
isovanillin were investigated.
[118–121]
 As shown in Table 9, all the conditions tested resulted in 
degradation of vinyl iodide 50  
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Table 9. Formation of borylated enamine 81 using palladium catalysis. 
 
Entry Pd Sourcea Ligandb Base Solvent Temp. (°C) Time (h) Yieldd 
1c Pd(OAc)2 CyJohnPhos Et3N 1,4-dioxane 80 1 -
 
2d Pd(dppf)Cl2 none K2CO3 1,4-dioxane 80 16 - 
3d Pd(dppf)Cl2 none KOAc DMSO 80 3 - 
4d Pd(OAc)2 none KOAc DMF 80 5 - 
a) 10 mol%;    b) 20 mol%;    c) HBPin was used as the boron source;    d) B2pin2 was used as the boron source;    
d) decomposition of 50 was observed. 
 
Therefore, a microwave accelerated C–H borylation of enamine 54 was investigated using the 
conditions reported by Steel and co-workers for the borylation of pyrrole (Scheme 15).
[122]
 This 
reaction formed the desired borylated enamine in moderate yield and gram-quantities of 81 could be 
synthesized using sequential reactions on 1 mmol scale. Brominated isovanillin 67 was prepared 
following a literature procedure (Scheme 15).
[123]
 
 
Scheme 15. Synthesis coupling partners with reversed polarity. 
With borylated enamine 81 and bromoisovanillin 67 in hand, another screening of conditions 
for the Suzuki cross-coupling was performed using catalytic systems known to engage boronic esters 
containing free phenols (Table 10).
[52,82,124]
 While reactions carried out at 100 °C resulted in complex 
mixtures (Entries 1 and 2), a reaction carried out at room temperature did not show appreciable 
conversion (Entry 3). The use of microwave irradiation, which is routinely used to accelerate 
challenging Suzuki coupling, also resulted in a complex mixture of products despite the moderate 
temperature and short reaction time (Entries 5 and 6).
[125,126]
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Table 10. Suzuki cross-coupling of boronate 81 and bromoisovanillin 67. 
 
Entry Pd Sourcea Ligandb Base Solvent System Temp. (°C) Time(h) Yieldd 
1 Pd(PPh3)4 none K2CO3 1,4-dioxane/H2O 100   2 - 
2 Pd(PPh3)4 none K3PO4 DMF 100 18 -  
3 Pd(OAc)2 SPhos K3PO4 DMC r.t. 48 -
 
4 Pd(OAc)2 SPhos K3PO4 n-BuOH/H2O 100 1 -
 
5c Pd(OAc)2 SPhos K3PO4 MTBE/H2O 100 0.15 -
 
6c Pd(dppf)Cl2 none KOH MTBE/H2O 80 0.15 -
 
a) 10 mol%;    b) 20 mol%;    c) reaction performed in the microwave;    d) decomposition of 81 was observed. 
2.1.5. Stepwise Construction of the Pyrroline Ring 
Our unsuccessful attempts at a convergent cross-coupling of an aromatic building block with a 
pyrroline unit prompted us to devise a stepwise construction of the pyrroline ring from a substrate that 
already incorporates the o,o-disubstituted aromatic ring. Previous work conducted by Andreas Bellan 
showed that that a high-yielding Negishi coupling of acetal 82 with bromoacrylate 83 could afford 
α,β-unsaturated ester 84 (Scheme 16).[127] Subsequent 1,4-addition of nitromethane followed by 
reduction and cyclization gave lactam 85 after N-methylation. Efforts to reduce this compound to the 
desired enamine 86, or effect enolization to form a vinyl triflate or vinyl phosphonate, remained 
unsuccessful. Steric hindrance due to the flanking ortho-substituents on the aromatic ring severely 
obstructs productive reactivity of the five-membered ring and forced us to revise our synthetic 
approach. 
 
Scheme 16. Stepwise construction of 3-aryl substituted lactam 85. 
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2.2.  Revised Retrosynthesis 
Failure to synthesize a pyrrolidine ring in the sterically hindered position of an o,o-disubstituted 
arene led us to modify our synthetic approach and focus on the introduction of a less bulky substituent, 
thereby postponing the formation of the pyrrolidine ring at a later stage in the synthesis. As shown in 
Scheme 17, the ring closure was planned to be performed on ketone 86 bearing a pendant amine 
following treatment with an amination agent. Pertinent examples for this reaction, that constitutes a 
formal umpolung of the -position of a ketone, have been employed in total synthesis (Scheme 
17).
[128–134]
  
 
Scheme 17. Proposed α-amination of 86 and relevant literature precedents. 
Formation of the crucial benzylic quaternary stereocenter could be achieved by a [3,3]-
sigmatropic rearrangement, i.e. the oxy-Cope rearrangement, in which alkene 87 could be formed in 
high stereoselectivity after the addition of allylmagnesium bromide to ketone 88 (Scheme 18).
[56]
 
Alternatively, a 1,4-addition of an allyl or vinyl nucleophile could allow the introduction of the C2-
unit after appropriate functional group manipulations. In any case, the required tricycle bearing 
α,β-unsaturated ketone (88) would result from a Pauson–Khand reaction of enyne 89 that could be 
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accessed from isovanillin following Sonogashira coupling and allylation. As put forth in Section 2.1, 
the allylic alcohol may serve as a stereocontrolling element to enable a diastereoselective Pauson–
Khand reaction and therefore an enantioselective synthesis of sinoracutine. The rigidity of the formed 
tricycle should allow for the stereoselective introduction of the allyl group required for the projected 
oxy-Cope rearrangement and stereochemical relay from 88 to the final product.
[135]
 
 
Scheme 18. Full retrosynthetic plan for sinoracutine starting from isovanillin. 
2.2.1. Synthesis of the Isovanillin Portion 
Isovanillin was regioselectively iodinated to give 62, whose free hydroxyl group was 
benzylated to afford 63 (shown in Scheme 10).
[136]
 Sonogashira cross-coupling of 63 with 
trimethylsilyl-acetylene and subsequent allylation with allylmagnesium bromide afforded enyne 91 
(Scheme 19).
[137]
 Cleavage of the terminal TMS group with K2CO3 in MeOH proceeded smoothly on 
small scale, but side products and lower yields were observed during scale-up. Instead, deprotection of 
91 using TBAF proceeded in excellent yield and Pauson–Khand precursor 93 was obtained after 
treatment with TBSCl and imidazole. 
 
Scheme 19. Synthesis of TBS-protected enyne 93 from protected iodoisovanillin 63. 
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2.2.2. Pauson–Khand Reaction 
Addition of solid Co2(CO)8 to 93 in CH2Cl2 led to the formation of an alkyne cobalt complex 
within 4 hours as determined by TLC analysis. Then, slow addition of NMO delivered the desired 
tricycle 94 in moderate yield and as a single diastereoisomer (Scheme 20). The relative configuration 
could be assigned on the basis of NOE data.  
 
Scheme 20. Pauson–Khand reaction to form the 6,6,5-carbocycle (94) of sinoracutine. 
Assuming that the steric demand of the TBS group might be responsible for the moderate 
yields, the reaction was performed with free benzylic alcohol 92.  As seen in Table 11, application of 
the same reaction conditions resulted in only 24% yield (Entry 1). By modification of the reaction 
parameters, we determined that oxidatively promoted reactions at ambient temperature performed 
better than thermally promoted cyclizations. Between the oxidative protocols, TMANO consistently 
showed better results than NMO (Entry 3). Among the thermal protocols, the reaction with Co2(CO)8 
in substochiometric amounts (0.5 eq.) using TMTU as an additive under CO atmosphere (balloon) 
gave the best result (Entry 9).
[138]
 
Table 11. Conditions for the Pauson–Khand reaction with free benzylic OH-group. 
 
Entry Solvent Co2(CO)8 (eq.) Oxidant/Additive Temp. (°C) Time (h) Yield (%) 
1 benzene 1.2 NMO (3 eq.) 0 to r.t. 16 24 
2 THF 1.2 NMO (3 eq.) 0 to r.t. 16 40 
3 benzene 1.2 TMANO (3 eq.) 0 to r.t. 16 52 
5 THF 1.2 TMANO (3 eq.) 0 to r.t. 16 53 
4 benzene 1.2 TMANO (3 eq.) 70 16 31 
6 benzene 1.2 none 70 24 35 
7 benzene 1.2 TMTU (3 eq.) 70 24 37 
8 benzene 1.2 TMTU (6 eq.) 70 24 24 
9a benzene 0.5 TMTU (3 eq.)
 70 24 46 
a) under CO pressure (balloon). 
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Next, reaction conditions for the TBS protected enyne 93 were examined (Table 12). In 
accordance with the previous results, TMANO proved to be more efficient than NMO, and the 
reaction showed solvent-specific variability, with DCE being the solvent of choice (Entry 9). Thermal 
promotion also afforded the desired product in good yields (Entry 12), and commonly employed 
additives such as n-BuSMe, celite or 4 Å molecular sieves did not provide benefit (Entry 13 to 
15).
[70,139] Consistently higher yields were achieved compared to precursor 92 bearing a free benzylic 
OH group. Upon scale-up, we observed decreased yields (cf. Entries 9 and 10), presumably due to the 
insolubility of TMANO in DCE and inefficient mixing of the reaction partners. Therefore, continuous 
and vigorous stirring had to be ensured, and was best realized using round bottom flasks no larger than 
250 mL equipped with appropriately sized stirring bars (3 cm length). Scale-up reactions were 
performed in parallel batches and could be combined for work-up and purification to allow reliable 
material throughput. Also, the use of a freshly opened bottle of Co2(CO)8 was crucial to achieve 
reproducibly high yields, whereas bottles that had been opened for longer than 1 week resulted in yield 
drops in the range of 20 to 25%, despite using every precaution to prologue its shelf-life (storage under 
a blanket of argon in a –25 °C freezer). 
Table 12. Conditions for the Pauson–Khand reaction with benzylic TBS ether 93. 
 
Entrya Solvent Co2(CO)8 (eq.) Oxidant/Additive Temp. (°C) time (h) Yield (%) 
1 benzene 1.2 TMANO (3 eq.) 0 to rt 16 41 
2 benzene 1.2 NMO (3 eq.) 0 to rt 16 31 
3 THF 1.2 TMANO (3 eq.) 0 to rt 16 58 
4 THF 1.2 NMO (3 eq.) 0 to rt 16 16 
5 THF 1.2 TMANO (6 eq.) 0 to rt 16 50 
6 CH2Cl2 1.2 TMANO (3 eq.) 0 to rt 16 50 
7 CH2Cl2 1.2 TMANO (6 eq.) 0 to rt 16 66 
8 CH2Cl2 1.2 NMO (6 eq.) 0 to rt 16 50 
9 DCE 1.2 TMANO (6 eq.) 0 to rt 16 75 
10b DCE 1.2 TMANO (6 eq.) 0 to rt 16 56 
11 toluene 1.2 TMANO (6 eq.) 0 to rt 16 68 
12 toluene 1.2 - rt to 70 24 61 
13 toluene 1.2 BuSMe (3.5 eq.) rt to 70 24 60 
14 toluene 1.2 Celite (10x w/w) rt to 70 24 64 
15 toluene 1.2 4 Å MS (10x w/w) rt to 70 24 27 
a) all reactions performed on 0.2 mmol scale except Entry 10;  b) carried out on 1 mmol scale. 
 
To probe if the presence of coordinating or bulky functionalities had detrimental effect on the 
yield of the reaction, the TBS ether was removed via ionic reduction and the resulting product 97 was 
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submitted to Pauson–Khand reaction conditions (Scheme 21). A low yield of cyclization product 98 
was obtained, even lower that the reaction of 92 bearing the free benzylic hydroxyl group. This 
suggests that while a possible coordination site is advantageous to the reaction, a high steric demand 
of the benzylic position in proximity of the alkene is crucial for optimal reactivity by enforcing a 
favorable conformation between the alkyne-Cobalt complex and the approaching alkene.
[140]
 
 
Scheme 21. Removal of benzylic alcohol followed by Pauson–Khand reaction. 
2.2.3. Introduction of the Quaternary Stereocenter 
2.2.3.1. 1,4-Addition  
Having constructed the tricyclic framework of sinoracutine, we proceeded with the 
introduction of the last ring. The first strategy pursued was analogous to the Mulzer–Trauner morphine 
synthesis, i.e. vinylcuprate addition to an enone.
[141]
 Andreas Bellan showed that Pauson-Khand 
product 99 could undergo 1,4-addition with vinylmagnesium bromide, but despite several optimization 
attempts, the reaction was low-yielding and irreproducible, and plagued by the concomitant formation 
of 1,2-addition product (Scheme 22).
[127]
 Therefore, the addition of ionic vinyl- or allylmetal species 
was not further investigated. 
 
Scheme 22: Previously investigated 1,4-addition with vinylcopper reagent. 
Next, the conjugate addition of allyltributylstannane to enone 94 was investigated in 
collaboration with Till Reinhardt according to the procedure developed by Trauner and coco-
workersworkers.
[142]
 They reported the successful 1,4-addition to cyclic enones upon prior 
electrophilic activation of the carbonyl with trifluoroacetic anhydride (TFAA) or 
trifluoromethanesulfonic anhydride (Tf2O).
[143]
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Table 13. Conditions examined for the 1,4-allylation and enolate trapping. 
 
Entry Activating agent  Allyltributyltin Additives Solvent Yield (101 or 102)a 
1 TFAA (1.2 eq.) 1.2 eq. DTBP, 4 Å MS CH2Cl2/MeCN = 1/1 no reaction 
2 TFAA (1.2 eq.) 1.2 eq. DTBP, 4 Å MS CH2Cl2 no reaction 
3 Tf2O (1.2 eq.) 1.4 eq. DTBP, 4 Å MS CH2Cl2/MeCN = 1/1 101, 47% 
4 Tf2O (1.2 eq.) 1.4 eq. DTBP, 4 Å MS CH2Cl2 101, 26% 
DTBP = 2,6-di-tert-butylpyridine;    a) stereochemsitry of the addition not determined. 
 
As shown in Table 13, TFAA was not successful in activating enone 94, and neither the enol 
trifluoroacetate 102 nor its desired hydrolysis product 103 could be observed. On the other hand, the 
reaction with Tf2O furnished a single intermediate, tentatively assigned as vinyl triflate 101. 
Attempted hydrolysis of this compound to the desired ketone 103 could  not be effected under several 
base-mediated conditions (Scheme 23).
[144,145]
 Therefore, we explored an alternative strategy that 
would yield intermediate 103 by intramolecular allyl transfer – namely the anionic oxy-Cope reaction. 
 
Scheme 23. Attempted hydrolysis of presumed enol triflate to ketone 103. 
2.2.3.2. Oxy-Cope Rearrangement 
The oxy-Cope reaction has been successfully employed in various alkaloid syntheses that bear 
a benzylic quaternary stereocenter.
[55,56,105]
 In contrast to the neutral variant of the reaction that requires 
prolonged times at elevated temperature (> 200 °C), the  [3,3]-sigmatropic rearrangement of 1,5-diene 
alkoxides proceeds at very high rates due to the weakening effect by the alkoxide anion on the 
adjacent carbon-carbon bond.
[146]
 This allows the reaction to be performed at cryogenic temperatures 
within a few hours. A literature review reveals a strong counterion dependence (order of reactivity: 
K>Na>Li), and that further acceleration can be achieved by addition of appropriate ionophores to 
generate a more reactive “naked” anion. Additionally, a model study by Evans and co-workers 
illustrated that maximum yield and rate improvements were achieved using no more than 3.0 eq. of 
18-crown-6.
[147]
 With these considerations in mind, treatment of 94 with allylmagnesium bromide 
afforded allylic alcohol 104, the precursor for the rearrangement, as a single diastereomer (Scheme 
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24). It proved unstable to silica gel chromatography and was subjected to anionic oxy-Cope reaction 
conditions immediately after aqueous workup.  
 
Scheme 24. Preparation of tertiary allylic alcohol 104. 
 
Table 14. Conditions applied for the anionic oxy-Cope rearrangement of 104. 
 
 Entrya Base Additive Temp. (°C) Time (h) Yield (%)  
 1b KOt-Bu (2.0 eq.) 18-crown-6 (2.0 eq.) 0 to rt 3 10  
 2 KHMDS (3.0 eq.) 18-crown-6 (3.0 eq.) 0 to rt 3 41  
 3 KHMDS (3.0 eq.) 18-crown-6
 (3.0 eq.) –5 to rt 3 48  
 4 KHMDS
 (1.5 eq.) 18-crown-6 (1.5 eq.) –5 to rt 3 43  
 5 LiHMDS (1.5 eq.) 12-crown-4 (1.5 eq.) 0 to rt to 60 48 -  
 6 NaHMDS (1.5 eq.) 18-crown-5 (1.5 eq.) 0 to rt to 60 48 -  
 a) all reactions conducted in THF    b) TBS-cleavage product 105 was isolated in 46% yield.  
   
As seen in Table 14, employing KOt-Bu as base afforded the desired product 103 only in poor 
yield. Additionally, cleavage of the TBS group was observed. Under the reaction conditions and in the 
presence of the crown ether, the naked t-butoxy anion was able to attack and cleave the silyl ether. 
Hence, we decided to employ the non-nucleophilic base KHMDS and were able to improve the yield 
to 48% (Entry 3).  While no TBS-cleavage product was observed in this case, the starting material was 
completely consumed and gave rise to non-specific decomposition products as evidenced by darkening 
of the reaction mixture. By comparison, the corresponding lithium and sodium HMDS-bases with the 
appropriately sized crown ether ionophores were investigated (Entries 5 and 6). Even after prolonged 
reaction times, no rearrangement product was observed, and the starting allylic alcohol slowly 
decomposed. Due to these problems and the limited options for improvement, primarily due to the 
instability of alcohol 103, we decided to investigate an alternative approach. 
2.2.3.3. Claisen Rearrangement 
The required allylic alcohol for the introduction of the quaternary carbon at C13 by Claisen 
rearrangement was envisaged to be accessed diastereoselectively by reduction of 94 (Scheme 25). The 
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reaction was expected to be highly diastereoselective, as the addition of allylMgBr had proceeded in a 
completely diastereoselective manner (Scheme 24). After successful rearrangement, the last ring could 
be formed by cyclization of the pendant amine onto cyclopentene 108 (Scheme 25). 
 
Scheme 25. Envisaged synthesis of sinoracutine via Claisen rearrangement of allyl alcohol 106. 
Reduction of 94 was successful using different reducing agents (NaBH4/CeCl3, DIBALH), but 
LiAlH4 provided the cleanest reaction profile and most convenient workup, merely necessitating a 
filtration of the reaction mixture over a pad of silica after quenching with H2O and NaOH (Scheme 
26). As anticipated, 106 was formed as a single diastereomer and its relative stereochemistry could be 
established through X-ray crystallographic analysis by Nynke Vepřek.  
 
Scheme 26. Diastereoselective reduction of enone 94 and X-ray structure of allylic alcohol 106. 
With gram-quantities of alcohol 106 in hand, we turned our attention to the Claisen 
rearrangement. First, an Eschenmoser–Claisen reaction was attempted (Scheme 27).[148] Unfortunately, 
the starting material decomposed within 5 minutes upon heating to 100 °C and the reaction mixture 
turned bright red, suggesting that a major decomposition pathway might include quinoidal 
intermediates likely to be formed after solvolytic removal of the benzylic silyl ether by liberated 
methanol (112) or by ionization of the conjugated allylic alcohol (113). The same red color was 
observed under Johnson–Claisen conditions employing triethyl orthoacetate in the presence of either 
propionic acid or 2-nitrophenol.
[149]
 Control experiments carried out by heating the reaction mixture in 
the presence of triethyl orthoacetate without acid additive also resulted in decomposition. Another 
experiment carried out using boiling ethanol, which is liberated by triethyl orthoacetate during the 
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rearrangement reaction, resulted in the same red color, confirming the instability of intermediate 106 
to protic solvent at high temperatures.  
 
Scheme 27. Attempted Claisen-type rearrangements and possible decomposition intermediates. 
 
Next, protocols that involve the formation and rearrangement of vinyl ether 114 were 
examined. As shown in Table 15, palladium-mediated vinyl ether formation was attempted.
[150,151]
 
Unfortunately, the desired product was not formed (Entries 1 to 4). Therefore, we turned to the well-
precedented formation of vinyl ethers assisted by mercury salts.
[152]
  As previously shown by Nynke 
Vepřek, reacting 106 with mercury acetate in the presence of either ethyl vinyl ether or the higher-
boiling butyl vinyl ether afforded 114, which was used after filtration over alumina to remove Hg-salts 
(Entries 5 and 6). Unfortunately, heating of 114 in either xylene or benzonitrile did not form any 
aldehyde product and resulted in decomposition (Table 16). We also tested the rearrangement in wet 
dioxane, which was reported by Grieco to occur at lower temperatures, but this resulted in no product 
formation and hydrolysis of the labile vinyl ether (Entry 3).
[153]
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Table 15. Conditions examined for the formation of vinyl ether 114 from alcohol 106. 
 
Entry Catalysta Vinyl Ether Donor Temp. (°C) Yield (%) 
1 116 tris(diethyleneglycol) divinyl ether 130 complex mixture 
2 116 butyl vinyl ether 75 no reaction 
3 115 butyl vinyl ether 75 no reaction 
4 115 ethyl vinyl ether 35 no reaction 
5 Hg(OAc)2 ethyl vinyl ether 35 83
b 
6 Hg(OAc)2 butyl vinyl ether 75 61
b 
a) 10 mol%     b) crude yield reported; product contaminated with unidentified impurities. 
 
Table 16. Conditions examined for the thermal rearrangement of vinyl ether 114. 
Entry Solvent Temp. (°C) Time (h) Yield Comment 
1 benzonitrile 160   5  n.d. decomposition 
2 xylene 140   5 n.d. decomposition 
3 dioxane/H2O 110 48 n.d. no rearrangement, hydrolysis to 106 
      
 
The results involving the synthesis and isolation of vinyl ether 114 led us to consider a Claisen 
strategy originally reported by Mandai in which the isolation of hemistable vinyl ether 114 is not 
necessary.
[154]
 Instead, the required intermediate is formed in situ starting from sulfoxide 117 which 
undergoes Grieco-type elimination with expulsion of a sulfenic acid at elevated temperature (>150 
°C), where the subsequent sigmatropic rearrangement occurs readily (Scheme 28). Therefore, we 
prepared sulfoxide 117 through conjugate addition of 106 to phenyl vinyl sulfoxide using NaH and 
catalytic KH. The adduct was isolated in very good yield as an inseparable mixture with excess vinyl 
sulfoxide. Thankfully, subjection of the crude reaction mixture to methylamine in isopropanol 
scavenged unreacted vinyl sulfoxide and rendered the isolation of pure 117 possible.  
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Scheme 28. Synthesis of sulfoxide 117 and proposed conversion into aldehyde 107. 
Heating of 117 in o-dichlorobenzene showed that the desired product was formed, but yields 
were variable and longer reaction times were necessary on larger scales, which resulted in side product 
formation and lower overall yield.
[155]
 Attempts to shorten the reaction time by the use of microwave 
irradiation were also unsuccessful.
[156]
 Therefore, we investigated the reaction variables in more detail. 
As can be seen in Table 17 the reaction provides variable yields, even if set up in parallel on 
the same scale (Entries 2 to 5). In line with the original report, NaHCO3 was the base of choice but we 
observed higher yields when a large excess of base was used (>50 eq.), as opposed to 30 eq. in the 
original publication. Furthermore, NaHCO3 outperformed other bases such as NaOAc and KOAc 
(Entries 20 and 21). The absence of base resulted in no product formation, whereas the use of a 
thiophilic scavenger (PPh3) to trap liberated sulfenic acid was possible, but not advantageous (Entries 
22 and 23).
[157]
 For reactions conducted in screw-cap vials using a heated metal block, a temperature of 
165 °C was optimal (Entries 24 - 26), while lower temperatures resulted in prolonged reaction times 
and a slight decrease in yield (entries 6 to 11). Reactions above 200 mg of substrate, exemplified by 
entry 27, were conducted in a round bottom flask and heated in an oil bath set at a temperature of 
10 °C higher than desired to compensate for heat dissipation. The reaction was monitored by 
1
H NMR 
of reaction aliquots withdrawn every hour.  
Figure 9 shows that the starting material is consumed at a higher rate compared to the rate of 
product formation. Additionally, the product aldehyde 107 is not stable under the reaction conditions, 
resulting in low isolated yields if the reaction is not monitored frequently and stopped after the 
disappearance of 117. Taking these findings into account, the reaction reproducibly afforded aldehyde 
107 in 60 to 65% isolated yield on scales up to 3 mmol.  
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Table 17. Conditions examined for the thermolysis and Claisen rearrangement of sulfoxide 117. 
 
Entrya Scale (mg) Base Eq. Solvent Conc. (mM) Temp. (°C) Time (h)b Yield (%)c 
1 8 NaHCO3 30 Mesitylene 4 150 8 31 
2 10 NaHCO3 30 1,2-DCB 4 150 6 42 
3 10 NaHCO3 30 1,2-DCB 4 150 6 41 
4 10 NaHCO3 30 1,2-DCB 4 150 6 27 
5 10 NaHCO3 30 1,2-DCB 4 150 6 28 
6 66 NaHCO3 30 1,2-DCB 4 150 11 40 
7 9 NaHCO3 5 1,2-DCB 5 150 8 51 
8 9 NaHCO3 10 1,2-DCB 5 150 8 55 
9 9 NaHCO3 25 1,2-DCB 5 150 8 56 
10 9 NaHCO3 50 1,2-DCB 5 150 8 58 
11 9 NaHCO3 100 1,2-DCB 5 150 8 49 
12 10 NaHCO3 50 1,2-DCB 5 170 5 29 
13 53 NaHCO3 50 1,2-DCB 5 170 2 38 
14 48 NaHCO3 50 1,2-DCB 5 170 2 37 
15 48 NaHCO3 50 1,2-DCB 2.5 170 2 29 
16 50 NaHCO3 83 1,2-DCB 5 170 2 38 
17 40 NaHCO3 100 1,2-DCB 5 170 2 35 
18 40 NaHCO3 100 1,2-DCB 5 160 4 35 
19 40 NaHCO3 100 1,2-DCB 5 160 5 40 
20 36 NaOAc 35 1,2-DCB 5 170 2 27 
21 36 KOAc 35 1,2-DCB 5 170 2 29 
22 36 PPh3 3 1,2-DCB 5 170 2 25 
23 36 PPh3 10 1,2-DCB 5 170 2 36 
24 90 NaHCO3 80 1,2-DCB 5 165 6 85 
25 90 NaHCO3 80 1,2-DCB 5 165 4 72 
26 90 NaHCO3 80 1,2-DCB 5 165 4 81 
27d 1818 NaHCO3 90 1,2-DCB 5 175 6 73 
a) all reactions carried out with catalytic amounts of BHT as additive;    b) time until disappearance of starting material as 
monitored by 1H NMR every hour;   c) NMR yield using phenanthrene as internal standard;   d) isolated yield: 61%. 
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a) Product distribution calculated by 1H NMR against phenanthrene as internal standard; 
Figure 9. Time-dependent formation and decomposition of aldehyde 107. 
Hoping to improve the yield further, we turned to the reaction of p-chloro phenyl sulfone 118, 
reported to give higher yields than the parent phenyl sulfone 117.
[154]
 Table 18 shows that, for chloro-
substituted arene 118, KOAc was the best base for the transformation. Although 140 °C was sufficient 
to effect the rearrangement (Entry 7), shorter reaction times were achieved at 160 °C (Entry 6). 
Interestingly, NaHCO3 was ineffective for this substrate (Entries 2 and 14). Nevertheless, yields were 
lower compared to the parent system using 117. Given that p-chloro phenyl vinyl sulfoxide is not 
commercially available and requires multistep synthesis, the use of 118 was not implemented.
[158]
 
Table 18. Conditions examined for the thermolysis and Claisen rearrangement of sulfoxide 118. 
 
Entrya Base Eq. Temp. (°C) Timeb (h) Yield (%)c 
1 no base 10 175 3 0 
2 NaHCO3 10 175 3 0 
3 NaOAc 10 175 3 33 
4 KHCO3 10 175 3 16 
5 KOAc 10 175 3 59 
6 KOAc 10 160 2 71 
7 KOAc 10 140 16 68 
8 KOAc 10 150 18 60 
9 BaCO3 10 150 3 0 
10 no base 10 150 18 35 
11 KHCO3 10 150 18 73 
12 KH2PO3 10 150 18 0 
13 K2HPO3 10 150 18 0 
14 NaHCO3 10 150 18 0 
15 NaH2PO3 10 150 18 0 
16 Na2HPO3 10 150 18 0 
a) all reactions carried out using 10 mg of 118 in 1,2-DCB (4 mM) and catalytic 
amounts of BHT;    b) time until disappearance of starting material as monitored by 
1H NMR every hour;    c) NMR yield using phenanthrene as internal standard. 
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2.2.4. Formation of the Pyrrolidine Ring 
Reductive amination of aldehyde 107 using an ethanolic solution of methylamine proceeded 
smoothly to deliver secondary amine 108 (Scheme 29). Since direct oxidative cyclization to 120 was 
not viable, we decided to activate the alkene electrophilically to effect the attack of the pendant 
nitrogen and form the pyrrolidine ring. The ketone could then be introduced at a later stage.
[156]
 
 
Scheme 29. Reductive amination and projected ring closure to ketone 120. 
Nynke Vepřek demonstrated that treatment of 108 with NIS resulted in rapid conversion of the 
starting material to a single intermediate (119, Scheme 30). This compound proved to be unstable to 
aqueous workup, but structural assignment was possible by NMR analysis and mass spectrometry. 
When crude 119 was treated with 1 M aqueous LiOH solution in DME, introduction of a hydroxyl 
group was effected to give secondary alcohol 121.
[159]
 Unfortunately, the yield for the transformation 
was low and not reproducible. In addition, secondary alcohol 121 did not deliver ketone 120 under 
standard alcohol oxidation conditions.  
 
Scheme 30. Formation of the pyrrolidine ring and introduction of oxygen functionality. 
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Although the product derived from the reaction using NIS defied our isolation attempts, we 
decided to carry on with the formed intermediate and optimize its formation. From a screening of 
several electrophilic iodination reagents and their stoichiometry, NIS (2 eq.) emerged as the optimal 
reagent (Table 19).
[160–162]
  
Table 19. Conditions for the iodocyclization of 108. 
 
 Entrya Reagent Eq. Solvent Yieldb (%)  
1 NIS 2 CH2Cl2 64 
2 122 2 CH2Cl2 58 
3 123 2 CH2Cl2 43 
4 124 2 CH2Cl2 12 
5 125 1 CH2Cl2 49 
6 126 2 CH2Cl2 12 
7 NIS 0.5 CD2Cl2 7 
8 NIS 1 CD2Cl2 33 
9 NIS 1.5 CD2Cl2 42 
11 NIS 2.5 CD2Cl2 38 
12 NIS 2 MeCN 45 
13c NIS 2 MeCN 52 
 a) Reactions performed at room temperature except entries 12 
and 13 (–20 °C)    b) determined by 1H NMR using diphenyl-
methane as internal standard    c) solution of NIS added slowly 
via syringe pump. 
 
   
As can be seen in Table 20, treatment of 108 with NIS in different aprotic solvents led to the formation 
of the product in low to moderate yields. The reaction occurred in all the solvents examined, but 
CH2Cl2 and MeCN provided the cleanest reaction profile and were selected for further optimization 
(Entries 1 and 5).  
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Table 20. Solvents examined for the iodocyclization of 108 using NIS. 
 
Entry Solvent Yielda (%) Comment 
1 CH2Cl2 47 clean conversion 
2 CHCl3 56 several side products 
3 DCE 42 - 
4 DME 40 - 
5 MeCN 53 clean conversion 
6 THF 42 - 
7 DMF 44 several side products 
8 benzene 42 - 
9 DMSO 27 several side products 
10 toluene 42 - 
a) determined by 1H NMR using diphenylmethane as internal standard. 
 
We observed that in all cases the consumption of starting material was very fast (< 10 
minutes), but the product yield was moderate. Therefore, we attempted to lower the reaction 
temperature and decrease the concentration to slow down the reaction, diminish side product 
formation, and improve the yield of the major product (Table 21).  
Table 21. Variation of reaction conditions for iodocyclization reaction of alkene 108. 
 
 
 
 Entrya Solvent Conc. (mM) Temp. (°C) Yieldb (%)  
1 CH2Cl2 12 –20 55 
2 CH2Cl2 20 –20 49 
3 CH2Cl2 40 –20 56
c 
4 CH2Cl2 12 rt 53 
5 CH2Cl2 25 rt 53 
6 CH2Cl2 50 rt 53 
7 CH2Cl2 62 rt 38 
8 MeCN 10 –20 54 
9 MeCN 20 –20 59 
10 MeCN 40 –20 51 
11 MeCN 75 –20 48 
12 MeCN 150 –20 46 
a) reaction time 30 min;    b) determined by 1H NMR of the crude 
mixture using diphenylmethane as internal standard; c) incomplete 
consumption of starting material observed. 
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Although the reaction was complete within 30 minutes even at –20 °C, lowering the 
temperature only gave minimal improvements in yield. For example, a reaction in CH2Cl2 at 12 mM 
carried out at –20 °C gave the product in 55% yield, while the reaction at room temperature gave the 
product in 53% yield (cf. Entries 1 and 4). Furthermore, NMR analysis showed that increasing 
concentration led to several unidentified side products and lower overall yields. Optimum 
concentrations for the CH2Cl2 reaction was found to be 12 mM, while in MeCN the best yield was 
achieved at 20 mM and at ambient temperature. 
To displace the iodine atom with an oxygen nucleophile, the reaction mixture containing 119 
was diluted with DMSO in the presence of halophilic silver tetrafluoroborate.
[163]
 Addition of an amine 
base (i.e. triethylamine) would then effect deprotonation of the sulfonium ion resulting from 
substitution of the secondary iodide, lead to the loss of dimethyl sulfide, and give ketone 120 (see 
Scheme in Table 22). Indeed, the desired ketone could be synthesized in moderate yield. Whereas in 
typical Kornblum conditions the base is added after several hours in order to complete the substitution 
reaction of DMSO with the halide, we found that the Et3N could be added to the reaction from the 
beginning to achieve the same result. Furthermore, these substitutions in Kornblum oxidations 
generally require elevated temperatures and are only successful for activated alkyl halides (i.e. 
primary, or benzylic, allylic).
[164]
 In our case, the reaction proceeds readily at room temperature, and is 
similarly efficient if carried out without silver salts (cf. Entries 1 and 2 or Entries 3 and 4). These 
results suggest the neighboring group participation of the adjacent amine to form aziridinium 127 that 
obviates the use of silver salts by internal displacement of the iodide and conformationally locks 
intermediate 127 to favor the attack by DMSO.  
Table 22. Proposed neighboring-group participation Kornblum reaction of iodide 119. 
 
 
 
 Entrya Solvent Base Additive Yieldb  
1 50% DMSO in CH2Cl2 Et3N AgBF4 54%
 
2 50% DMSO in CH2Cl2 Et3N none 53%
 
3 50% DMSO in CH2Cl2 Et3N AgBF4 53%
 
4 50% DMSO in MeCN Et3N none 50%
 
a) substitution reaction carried out at –15 °C to room temperature for 16 hours; 
b) determined by 1H NMR using diphenylmethane as internal standard. 
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As can be seen in Table 23, the requirement for low concentrations during the oxidation is 
instrumental for high yield of ketone 120 in both CH2Cl2 and MeCN. Decreasing the temperature for 
the addition of Et3N from room temperature to –20 °C gave similar yields for both solvent mixtures 
when the reaction was performed in comparable concentrations (Entries 2 and 10). 
Table 23. Reaction conditions for the synthesis of ketone 120 via Kornblum oxidation. 
Entry 
Cyclizationa  Oxidationb 
Yieldc 
solvent Temp. (°C) Conc. (mM)  solvent Temp. (°C) Conc. (mM) 
1 MeCN –20 °C 20  50% MeCN in DMSO –15 10 63% 
2 MeCN –20 °C 40  50% MeCN in DMSO –15 20 52% 
3 MeCN –20 °C 72  50% MeCN in DMSO –15 38 53% 
4 MeCN –20 °C 150  50% MeCN in DMSO –15 75 38% 
5 MeCN 0 °C 20  50% MeCN in DMSO rt 10 65% 
6 MeCN –20 °C 40  50% MeCN in DMSO rt 20 56% 
7 MeCN –20 °C 75  50% MeCN in DMSO rt 38 48% 
8 MeCN –20 °C 150  50% MeCN in DMSO rt 75 42% 
9 MeCN –20 °C 20  50% MeCN in DMSO rt 10 62% 
10 CH2Cl2 –20 °C 40  50% CH2Cl2 in DMSO –15 20 54% 
11 CH2Cl2 –20 °C 20  50% CH2Cl2 in DMSO rt 10 58% 
12 CH2Cl2 0 °C 20  50% CH2Cl2 in DMSO rt 10 61% 
a) performed using 2 eq. of NIS; time: 15 min;    b) performed using 3 eq. of Et3N, time: 24 h;    c) isolated yield. 
 
In a last series of experiments we examined the possibility of performing a solvent switch to 
DMSO after the iodocyclization reaction. As 119 was not stable towards aqueous workup and silica 
gel chromatography, we feared it would also be unstable during the required manipulations. In fact, we 
determined that solvent removal had to be performed in the dark while setting the water bath 
temperature below 25 °C (at 35 °C, 50% of the product decomposed upon redissolution). In doing so, 
solvent-free 119 could be handled in air for short time and used for the substitution reactions.  
As can be seen by the comparison of Table 23 with Table 24, DMSO alone was slightly superior for 
the Kornblum oxidation to mixtures containing either MeCN of CH2Cl2. For example, oxidation in 
DMSO at room temperature in 5 mM solution yielded in 73% (Table 24, Entry 3), whereas the highest 
yields achieved with 1/1 mixtures of MeCN/DMSO or CH2Cl2/DMSO were 65% and 61% 
respectively (Table 23, Entries 5 and 12).  
Table 24 Variation of reaction conditions for the synthesis of ketone 120 in pure DMSO. 
Entry 
Cyclizationa  Oxidationb 
Yieldc 
solvent Temp. (°C) Conc. (mM)  solvent Temp. (°C) Conc. (mM) 
1 CH2Cl2 –20 °C 12.5  DMSO rt 5 64 
2 CH2Cl2 rt 12.5  DMSO rt 5 73 
3 CH2Cl2 –20 °C 12.5  DMSO rt 10 67 
4 CH2Cl2 rt 25  DMSO rt 10 65 
5 CH2Cl2 rt 12.5  DMSO rt 20 45 
6 CH2Cl2 rt 50  DMSO rt 20 58 
a) performed using 2 eq. of NIS; time: 15 min;    b) performed using 3 eq. of Et3N, time: 24 h;   c) isolated yield. 
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Additionally, we determined that ketone 120 was heavily retained on regular silica gel, which 
led to a yield loss of 20%. This issue could be resolved by pretreatment of silica gel with the eluent 
mixture containing 1% Et3N followed by loading and elution with amine-free eluent. Interestingly, 
purification using Et3N in the eluent mixture resulted in lower yields (10%). Using the optimized 
conditions described above, 120 could reliably be accessed on scales up to 1 mmol in 60 to 70% 
isolated yield. 
2.2.5. Completion of the Synthesis 
The one-pot iodoamination–Kornblum oxidation sequence successfully installed the 
tetracyclic ring system of sinoracutine. The fully conjugated eastern backbone required elimination of 
the benzylic TBS ether and oxidation of the ketone to the α,β-unsaturated ketone. 
Styrene 128 could be best accessed by treatment of silyl ether 120 with CSA (Scheme 31). Its structure 
was established by X-ray crystallographic analysis and confirmed the diastereoselective installation of 
the quaternary stereocenter and the anti-orientation of the pyrrolidine ring with respect to the angular 
proton of the cyclopentene moiety. For the introduction of unsaturation, we decided to apply the 
method of Mukaiyama using LDA followed by sulfimidoyl chloride (130).
[165–167]
 Gratifyingly, this 
oxidation protocol cleanly afforded benzylsinoracutine 129 in good yield as an intensely yellow oil.  
 
Scheme 31. Elimination of benzylic alcohol to tetracycle 128 and its Mukaiyama oxidation. 
Final debenzylation was attempted using BCl3 in the presence of pentamethylbenzene, a 
reagent combination that has shown to selectively remove benzyl groups in presence of methoxy 
groups and other Lewis basic sites.
[168,169]
 As shown in Table 25, BCl3 did not react with starting 
material at –40 °C but cleavage of the benzyl ether could be observed at –20 °C. However, significant 
amounts of demethylated product were observed by LCMS, reflecting the electron-deficient nature of 
the methoxy group that is in direct conjugation with the carbonyl (Entry 4). When the stronger Lewis 
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acid BBr3 was used, both benzyl- and methyl ethers were cleaved at competing rates even at –78 °C 
(Entry 5).  Trifluoroacetic acid was examined next, as it had been reported to cleave phenolic benzyl 
groups in complex peptides.
[170]
 When used in conjunction with electron-rich aromatic compounds 
such as trimethoxybenzene or pentamethylbenzene, dramatic rate acceleration and higher yields were 
observed, likely a result of efficient scavenging of the generated benzylic cation.
[171]
 Upon treatment of 
129 in neat TFA with pentamethylbenzene for 48 h, selective removal of the benzyl group was 
effected to afford sinoracutine. The reaction could be carried out at 40 °C with comparable efficiency 
(Entry 7).  
Table 25. Conditions examined for the debenzylation of 129 to give sinoracutine. 
 
Entry Reagenta Temp. (°C) Time (h) 
Product distribution (%, HPLC relative peak area) 
Starting material (129) Sinoracutine (40) 131 (undesired) 
1 BCl3 –40 24 - no reaction - 
2 BCl3 –20 12 10 80 10 
3 BCl3 –15 6 10 85 15 
4 BCl3 0 6 5 50 50 
5 BBr3 –78 2 3 0 97 
6 TFA rt 48 15 85 0 
7 TFA 40 24 11 89 0 
a) All reactions carried out in the presence of pentamethylbenzene (10.0 eq.). 
 
In an effort to shorten the overall reaction sequence, silyl ether 120 was oxidized under 
Mukaiyama conditions to afford enone 132, which was subjected to trifluoroacetic acid at 40 °C 
(Scheme 32). The elimination of the benzylic alcohol to 129 could be observed by LCMS within 10 
minutes and subsequent debenzylation progressed over the course of 16 hours. Sinoracutine could be 
isolated after extractive workup and chromatography on silica gel to remove excess 
pentamethylbenzene. We experienced difficulties in obtaining an analytically pure sample of 40, 
which is not stable to silica gel as evidenced by two-dimensional TLC analysis and could not be 
purified on aluminum oxide. Gratifyingly, purification by semipreparative HPLC (reverse phase, 
H2O/MeCN + 1% FA) followed by direct lyophilization of the product-containing fractions was 
successful. This material could also be recrystallized from slow diffusion of hexane into a solution of 
40 in CH2Cl2. 
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Scheme 32. Oxidation of silyl ether 120 followed by sequential elimination/debenzylation. 
2.2.6. Asymmetric Synthesis of Sinoracutine 
With a reliable route to racemic sinoracutine in hand, we moved on to render our synthesis 
asymmetric. As stated in Chapter 2.2, preparation of Pauson–Khand precursor 94 in enantiopure form 
should allow the enantioselective synthesis of sinoracutine by virtue of the stereoselectivity exhibited 
by Pauson–Khand reaction, the 1,2-reduction, and by the ensuing Claisen rearrangement.  
2.2.6.1. Enantioselective Allylation 
A literature review showed that catalytic enantioselective methods for the allylation of o-
substituted benzaldehydes tend to give low enantioselectivities and are highly substrate dependent.
[172]
 
Among the methods investigated (chiral N-oxide catalysts in conjunction with allyltrichlorosilane, 
titanium-BINOL complexes with allyltributyltin, chiral phosphoric acids with allylpinacolborane) all 
exhibited moderate enantioselectivities, especially with o-alkynyl-substituted substrates relevant for 
this project.  
Therefore, we started our investigations using stoichiometric chiral allylation reagents. Among 
the methods at our disposal, the allylsilane developed by Leighton was tested first.
[173]
 The reaction 
was performed using TMS-protected 90 under standard conditions (Table 26). At room temperature, 
no reaction took place. Heating did not improve conversion and led to decomposition of the starting 
material. Also the addition of Sc(OTf)3, reported to improve reactivity in reluctant substrates, was not 
successful in our hands.
[174]
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Table 26. Asymmetric allylation of TMS-alkyne 90 with Leighton’s chiral allylsilane 133. 
 
Entry Solvent Additive Temp. (°C) Time (h) Yielda (%) ee (%) 
1 CH2Cl2 none 4 012 - n.d. 
2 CH2Cl2 none rt 012 - n.d. 
3 CH2Cl2 none rt to 40 036 - n.d. 
4 CH2Cl2 Sc(OTf)3 (8 mol%) rt to 40 100 - n.d. 
a) decomposition of 90 was observed; n.d. =  not determined. 
 
A recent protocol using a cinchona-alkaloid based catalyst in conjunction with 
allyltrichlorosilane and DIPEA as Lewis-basic activator was examined next.
[175]
 To determine the 
influence of the protecting group on the allylation, in addition to the TMS-protected Sonogashira 
product (90), we also used the free alkyne (134), which could easily be accessed by TBAF-promoted 
desilylation. Unfortunately, both aldehydes did not give the allylated product and decomposed under 
the reaction conditions (Table 27). 
Table 27. Asymmetric allylation mediated by chiral organocatalyst 135. 
 
Entry Substrate Solvent Temp. (°C) Time (h) Yielda (%) ee (%) 
1 90 (R = TMS) toluene rt 12 - n.d. 
2 134 (R = H) toluene rt 12 - n.d. 
a) decomposition of 90 or 134 was observed;     n.d. =  not determined. 
 
Due to these unsatisfactory results using silicon-based reagents, we turned our attention to the 
highly powerful and well-established allylboranes derived from terpene-based chiral auxiliaries 
introduced by Brown and co-workers (138, Scheme 33).
[176,177]
 They can be prepared in situ from 
pinene-derived B-diisopinocampheylmethoxyborane (136) or B-chlorodiisopinocampheylborane (137) 
by treatment with allylmagnesium bromide.  
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Scheme 33. Synthesis of B-allyldiisopinocampheylborane from α-pinene. 
Furthermore, treatment of the so-formed reagent with pentane effects complete precipitation of 
the formed inorganic salts (MgCl2 or Mg(OMe)2) that slow down the reaction by complexation with 
the allylborane. Filtration through a pre-dried glassfiber filter can increase the reaction rate 
markedly.
[178]
 This is especially important as the reaction is usually performed at –100 °C for several 
hours resulting in a complicated experimental setup requiring constant monitoring and refrigerant 
addition.  
Table 28. Brown allylation of 90 by in situ-generated B-allyldiisopinocampheylborane. 
 
Entry Filtration solvent Temp. (°C) Time (h) Yield
a (%) eeb (%) 
1 yes Et2O –100 to rt 3.5 76 58.4 
2 yes Et2O 0–78 to rt 3.5 70 19.7 
3 no Et2O 0–78 to rt 3.5 90 89.7 
4 no THF 0–78 to rt 3.5 91 90.2 
a) contaminated with isopinocampheol, component ratio calculated by 1H NMR;  
b) determined by HPLC analysis on chiral stationary phase. 
 
The reactions performed after filtration of the precipitated magnesium salts exhibited lower 
enantioinduction than the unfiltered experiments (Table 28, Entries 1 and 2). This is probably due to 
the presence of unreacted allylmagnesium bromide that was preferentially transferred to the reaction 
flask. Also, Brown’s allylation reagent partially decomposed during filtration, thereby increasing the 
relative ratio of achiral reagent. Although we achieved good yields and enantiomeric excess without 
filtering the in situ formed allylborane (Entry 4), it was impossible to separate 91 from 
isopinocampheol, which was formed after the oxidative scission of the pinene-derived chiral auxiliary.  
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To examine the effect of alternative chiral auxiliaries on optical purity and ease of purification, 
we decided to substitute the pinene-derived allyldiisopinocamphenylborane (138, Scheme 33) by 
allylbis(4-isocaranyl)borane  (140, Scheme 34), which is reported to achieve higher 
enantioselectivies.
[179] 
Its precursor (139) was prepared by hydroboration of (+)-3-carene with 
BH3∙SMe2 and subsequent methanolysis (Scheme 34). 
 
Scheme 34. Preparation of B-allyldi-4-isocaranylborane from (+)-3-carene. 
As can be seen in Table 29, decreasing the temperature from –78 °C to –100 °C revealed no 
improvement but slight deterioration of the enantioselectivity (Entries 1 and 2). The reaction carried 
out without filtration gave the product with very high enantiomeric excess, albeit with moderate yield 
(Entry 3). For the unprotected substrate, we determined that THF was inferior to diethyl ether (cf. 
Entries 4 and 5), likely due to its coordinating ability. Again, the low temperature did not improve the 
enantioinduction and resulted only in lower yields and a slower reaction. Increasing the stoichiometry 
of the reagent to 2.2 equivalents was beneficial (entries 8 and 10), but also resulted in a very 
challenging purification due to the presence of caranyl alcohol. At this point, although we were able to 
access the desired alcohols in enantioenriched form in moderate yields, we decided to investigate 
asymmetric reduction methods before implementing the Brown allylation in our synthesis. The better 
result obtained for the TMS-protected substrate also place the labor- and mass-intensive allylation 
reaction one step earlier in the synthesis. 
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Table 29. Allylation of aldehyde 90 or 134 with in situ-generated B-allyldi-4-isocaranylborane. 
 
Entry Filtration Solvent Allylborane 140 generation Temp. (°C) Time (h) Yielda (%) eeb (%) 
For R = TMS (90) 
1 yes Et2O 
2 eq. 139 
1.5 eq. AllylMgBr 
–100 to rt 7 72 84.9 
2 yes Et2O 
2 eq. 139, 
1.5 eq. AllylMgBr 
–78 to rt 7 67 82.3 
3 no Et2O 
2 eq. 139, 
1.5 eq. AllylMgBr 
–78 to rt 7 58 95.6 
For R= H (134) 
4 no Et2O 
1.5 eq. 139, 
1.5 eq. AllylMgBr 
–78 to rt 8 38 93.9 
5 no THF 
1.5 eq. 139, 
1.5 eq. AllylMgBr 
–78 to rt 8 61 34.8 
6 no Et2O 
1.5 eq. 139, 
1.5 eq. AllylMgBr 
–100 to rt 8 22 85.3 
7 no THF 
1.5 eq. 139, 
1.5 eq. AllylMgBr 
–100 to rt 8 32 37.8 
8 yes Et2O 
2.9 eq. 139, 
2.2 eq. AllylMgBr 
–100 to rt 7 67 86.2 
9 yes Et2O 
2.9 eq. 139, 
2.2 eq. AllylMgBr 
–78 to rt 7 20 89.4 
10 no Et2O 
2.9 eq. 139, 
2.2 eq. AllylMgBr 
–78 to rt 7 59 93.4 
a) contaminated with 4-caranol, ratio calculated by 1H-NMR;     b) determined by HPLC analysis on chiral stationary phase. 
2.2.6.2. Asymmetric Reduction of Prochiral Ketones. 
Oxidation of racemic allylation product 91 using Dess–Martin periodinane gave prochiral 
ketone 141 (Scheme 35). Similarly, ketone 142 bearing a free alkyne group was prepared by DMP-
oxidation of deprotected allylation product 92. 
 
Scheme 35. Oxidation of allylic alcohol using Dess-Martin periodinane. 
First, asymmetric reduction employing the Corey–Bakshi–Shibata protocol was investigated 
on both the protected and the free alkyne substrates (Table 30). To determine the maximum achievable 
enantioselectivity, the reactions were carried out using a stoichiometric amount of chiral borane 
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(formed by treating oxazabrolidine 143 with a borane source).
[180]
 An initial experiment conducted 
according to a general procedure determined that the TMS-protected substrate 141 produced the 
corresponding alcohol in lower yield and enantiomeric excess (Table 30, entries 1 and 2).
[181]
 Further 
experiments carried out on free alkyne 142 were not promising: lowering the reaction temperature was 
detrimental to the yield (Entry 4), while a reaction at ambient temperature resulted in complete 
decomposition of the starting material (Entry 3). The use of the sterically more hindered and less 
reactive catecholborane as hydride source was unsatisfactory with respect to yield and 
enantioinduction both at room temperature and at low temperature (Entries 5 and 6).  
Table 30. Enantioselective reduction of ketones 141 or 142 with CBS-reagent. 
 
Entry Substrate Conditions Temp (°C) Time (h) Yield (%) eeb (%) 
1 141 (R = TMS) 1 eq. 143, 1.5 eq. BH3·SMe2 –20 5 54 73.0 
2 140 (R = H) 1 eq. 143, 1.5 eq. BH3·SMe2 –20 5 65 84.6 
3 140 (R = H) 1 eq. 143, 1.5 eq. BH3·SMe2 rt 21 -
a n.d. 
4 140 (R = H) 1 eq. 143, 1.5 eq. BH3·SMe2 –78 21 4 87.0 
5 140 (R = H) 1 eq. 143, 2.3 eq. HBcat rt 21 38 60.8 
6 140 (R = H) 1 eq. 143, 2.3 eq. HBcat –78 21 17 73.7 
a) decomposition of 140 was observed;    n.d. =  not determined;    HBcat = catecholborane;    b) determined by 
HPLC analysis on chiral stationary phase. 
 
Parallel to our efforts in using the CBS-reagent 143, we investigated the reduction mediated by 
DIP-Cl.
[182–184]
 Exposure of the protected ketone 141 to DIP-Cl (137) in THF at –40 °C furnished 
homoallylic alcohol in 70% yield with an excellent enantiomeric excess of 93% (Table 31). Even 
better results were achieved by reduction of the free alkyne (cf. Entries 2 and 3). Reduction of 142 
delivered multigram quantities of corresponding alcohol 92 in 72% yield and an excellent optical 
purity approaching 99% ee (Entry 5).  
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Table 31. Enantioselective ketone reduction mediated by DIP-Cl. 
 
 Entry Substrate Scale (mg) Yield (%) eea (%)  
 1 141 (R = TMS) 64 80% 87.7  
 2 141 (R = TMS) 64 70% 93.2  
 3 142 (R = H) 79 76% 97.1  
 4 142 (R = H) 79 73% 96.4  
 5 142 (R = H) 4200 72% 98.7  
 a) determined by HPLC analysis on chiral stationary phase.  
2.2.6.3. Completion of the Enantioselective Synthesis  
Silylation of enantioenriched alcohol 92 delivered enyne 93, which was subjected to 
previously optimized conditions for the Pauson–Khand reaction. Tricycle 94 was obtained in good 
yield and excellent enantiomeric excess. It could be recrystallized to afford crystals suitable for X-ray 
analysis, allowing us to assign the absolute configuration (Scheme 36).  
 
Scheme 36. Pauson-Khand reaction and absolute configuration of enone 94. 
Reduction of 94 followed by Mandai–Claisen rearrangement delivered aldehyde 107 which 
was treated with methylamine and NaBH4 to give 108. Tandem Iodocyclization-Kornblum oxidation 
delivered Ketone 120 which, under Mukaiyama conditions, was transformed into enone 132. 
Elimination and debenzylation with TFA in the presence of pentamethylbenzene finally afforded 
(–)-sinoracutine (40) in excellent enantiopurity (see Section 2.2.7). 
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Scheme 37. Completion of the enantioselective synthesis of (–)-sinoracutine. 
2.2.7. Stereochemical Identity and Racemization of Sinoracutine 
Using a racemic sample of sinoracutine, we developed a method to separate its enantiomers 
using HPLC on chiral stationary phase. (see Experimental Part for further details). Pleasingly, the 
material resulting from our asymmetric synthesis showed an enantiomeric excess of 98.9%. This 
material also exhibited the same levorotatory optical power as the natural isolate from Sinomenium 
acutum. With an optical rotation of     
  = –1067.3 (c = 0.35, CHCl3), the magnitude of the synthetic 
sample was considerably higher than the value of the original isolation report by Bao:     
  = –7.4 (c = 
0.35, CHCl3). Furthermore, the sample of sinoracutine from Stephania cepharantha also exhibited a 
lower optical power:     
  = –754.5 (c = 1.14, CHCl3). Although different factors can influence the 
value of optical rotation (water content in solvent, pH, presence of nonchiral impurities that interact 
with the compound of interest), this supports the observation that the enantiopurity of sinoracutine 
varies in nature. In particular, the X-ray of purported (+)-sinoracutine, where no value for optical 
rotation was reported, stands in contrast to the original isolation report of (–)-sinoracutine, which also 
features crystallographic structural proof. Since we had the crystallographic data for racemic 
sinoracutine available, the three datasets were compared. 
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Table 32. Selected crystallographic parameters for available X-ray structures of sinoracutine. 
 This work (2016) Wang et al. (2014)
[60]  Bao et al. (2009)
[58] 
net formula C17H17NO3 C17H17NO3  C17H17NO3 
Mr (g/mol) 283.31 283.31  283.31 
crystal size (mm) 0.10 × 0.07 × 0.01 0.20 × 0.43 × 0.50  0.56 x 0.48 x 0.06 
T (K) 100.(2) 93  293 
crystal system orthorhombic orthorhombic  monoclinic 
space group Pbca Pbca  P21/n 
a (Å) 14.8795(5) 14.888(3)  8.6507 (14) 
b (Å) 10.3203(3) 10.331(2)  10.4644(16) 
c (Å) 17.7065(6) 17.724(4)  16.078(3) 
α (°) 90 90  90 
β (°) 90 90  104.9 
γ (°) 90 90  90 
V (Å3) 2719.03 2726.3  1406.5 
Z 8 8  4 
 
As can be seen in Table 32, the crystal structure of our racemic compound is identical to the 
structure reported by Wang and co-workers in 2014. Both crystals have identical cell parameters and 
belong to the centrosymmetric space group Pbca whose unit cell contains both enantiomers. The same 
goes for the purported structure of (–)-sinoracutine, which belongs to the centrosymmetric P21/n. So 
far, all crystallographic data in the literature and available to us describe racemic samples of 
sinoracutine, which might explain the high variability in optical rotation in the different reports.  
The existence of racemic sinoracutine in nature and the variable optical rotations raise the 
question on the origin of these stereochemical differences. It seems very unlikely that the enzymes 
involved in the biosynthesis of sinoracutine are able to process both enantiomers of every intermediate 
in the biosynthetic pathway and funnel them towards the final product, which would then appear as a 
scalemic mixture. Another possibility is that sinoracutine is subject to racemization once formed. 
Reasonable mechanisms, which could occur without enzymatic assistance, are shown in Scheme 38. 
They both rely on the planarization of the benzylic all-carbon quaternary stereocenter. Thereby, a 
retro-Mannich reaction would lead to ring-opening of the pyrrolidine ring to an intermediate eight-
membered azocane 145, in which the benzylic quaternary carbon is destroyed and becomes sp
2
-
hybridized. The resulting vinylogous enolate intermediate can undergo a Mannich-type ring-closure to 
reform the pyrrolidine ring and give sinoracutine, now in racemic form. Alternatively, after proton 
transfer from the phenolic oxygen to the carbonyl oxygen, a retro-Michael reaction through the 
intermediacy of o-quinone methide 146 occurs to give a ring opened intermediate – again with loss of 
stereochemical information.  Ring closure of the resulting enol to the newly formed, highly 
electrophilic o-quinone methide affords racemic sinoracutine after proton transfer. 
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Scheme 38. Racemization mechanisms of sinoracutine via ring-opening and -closure. 
Interestingly, the final reaction in the synthesis uses forcing conditions to achieve 
debenzylation of 132 (neat TFA, 40 °C, 14 hours), but delivered an enantiopure sample of 
sinoracutine. Under these conditions it can be assumed that the nitrogen is fully protonated. This 
indicates that protonation of the tertiary amine might inhibit a racemization through the indicated 
mechanisms above either by discouraging the imminium ion formation of 145, or by preventing proton 
transfer and ketone enolization to give 146. Under neutral conditions on the other hand, racemization 
occurs. 
Therefore, we set out to examine the racemization of sinoracutine experimentally under 
neutral conditions. A protic solvent was added to a sample of enantiopure sinoracutine to encourage 
proton transfer, as it is a requirement for the proposed mechanisms shown above to be operative. 
Fascinatingly, when a sample of sinoracutine exhibiting 98.9% ee that had been stored in a solution of 
heptane/iPrOH/MeOH = 6/2/2 was kept at room temperature for 67 days, we noticed a very small but 
measurable erosion of enantiopurity to 95.7% ee. Heating the same sample to 60 °C for 5 days 
delivered a nearly racemic product (3.2% ee). A control experiment with a sample that was kept neat 
at –25 °C for the same time, still showed an enantiomeric excess of 98.7%. Indeed, racemization of 
sinoracutine does occur slowly at ambient temperature and can be accelerated thermally.  
It is likely that during the isolation process (e.g. during solvent evaporation or recrystallization) 
racemization of sinoracutine might have occurred. Alternatively, during the natural life cycle of the 
plant, which lasts several years, accumulated sinoracutine might have undergone gradual racemization. 
Although further studies are necessary to determine the culprit of this erosion of stereochemistry in 
nature, theoretical calculations are being performed to assess the legitimacy of the mechanisms 
proposed in Scheme 38. These results represent a highly unusual, and to the best of our knowledge, 
unique racemization of an all-carbon substituted quaternary stereogenic center. 
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 Summary 3.
Part I of this thesis described the total synthesis of the tetracyclic alkaloid sinoracutine, which 
was isolated from Sinomenium Acutum and Stephania cepharanta. It occurs as scalemic mixture in 
contrast to the vast majority of reticuline-derived alkaloids, which occur as single enantiomers. Two 
strategies were pursued to synthesize an appropriately protected 2-arylpyrrolidine bearing a pendant 
alkyne as substrate for an enamine Pauson–Khand reaction (Scheme 39). A cross-coupling strategy 
using halogenated dihydropyrroles of type 147 in conjunction with o,o-disubstituted aromatic partners 
(148) was not successful. Several possible coupling partners were investigated without success, and 
the polarity reversal of the partners was also unfruitful. Failure of the approach lies in the steric 
hindrance of the aromatic substrate and the instability of the pyrroline coupling partner under the 
reaction conditions examined. A stepwise construction of the pyrrolidine ring was successful and gave 
rise to N-methylated lactam 85. However, attempted reduction or enolization of the pyrrolidinone in 
order to introduce the required enamine functionality (86), was not possible.  
 
Scheme 39. Failed approaches for the synthesis of sinoracutine. 
Therefore, the synthetic plan was modified to employ a 1,7-enyne bearing a benzylic silyl 
ether as a stereocontrolling element and to introduce the pyrrolidine ring at a later stage in the 
synthesis (Scheme 40). The construction of a 6,6,5-tricycle was achieved by Pauson–Khand reaction. 
Installation of the quaternary benzylic stereocenter was best accomplished by the Mandai–Claisen 
protocol after diastereoselective reduction of the allylic alcohol derived from Pauson–Khand product 
94. From this intermediate, reductive amination followed by a tandem iodocyclization–Kornblum 
oxidation delivered tetracyclic intermediate 120. Oxidation, elimination and debenzylation afforded 
racemic sinoracutine. The route could be rendered asymmetric by using enantiopure enyne 92, 
synthesized by an enantioselective reduction of the corresponding ketone mediated by DIP-Cl. To 
explain the scalemic occurrence of sinoracutine in variable optical purity across different natural 
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isolates, we set out to determine whether enantiopure (–)-sinoracutine could undergo racemization. 
While in acidic medium the enantiomeric purity of the natural product remains constant, we were able 
to demonstrate the exceptionally facile racemization of (–)-sinoracutine in protic solvent. Presumably, 
the mechanism of racemization involves ring-opening of the cyclopentenone ring followed by ring-
closure. Most notably, this results in the loss of stereochemical information of an all-carbon 
substituted quaternary stereocenter, and represents a highly unusual result that had never been 
observed in the series of reticuline-derived alkaloids, as well as other natural product classes.  
 
Scheme 40. Synthesis of (–)-sinoracutine and its racemization. 
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 Experimental Part 4.
4.1. General Experimental Details 
4.1.1. Materials and Methods 
Unless noted otherwise, all reactions were performed in flame-dried glassware fitted with rubber septa 
under a positive pressure of nitrogen. Air- and moisture-sensitive liquids were transferred via syringe 
or stainless steel cannula through rubber septa. Solids were added under inert gas or were dissolved in 
appropriate solvents. The reactions were magnetically stirred and monitored by NMR spectroscopy 
where noted or analytical thin-layer chromatography (TLC) using glass plates precoated with silica gel 
(0.25 mm, 60-Å pore size, Merck) impregnated with a fluorescent indicator (254 nm). TLC plates 
were visualized by exposure to ultraviolet light (UV, 254 or 366 nm), were stained by submersion in 
either aqueous potassium permanganate solution (KMnO4), ceric ammonium molybdate solution 
(CAM) or acidic p-anisaldehyde solution (PAA) and were developed by heating with a heat gun. 
Flash-column chromatography on silica gel (60 Å pore size, 40–63 µm, Merck KGaA) was performed 
as described by Still
[185]
 or using a Biotage Isolera™ Prime Automated Flash Purification system. 
Triethylamine-deactivated silica was obtained by preparing a slurry of silica gel (20% v/v in the initial 
eluent mixture + 5% v/v Et3N) followed by magnetic stirring for 1 h. The slurry was poured into a 
chromatography column and flushed with 5 column volumes of amine-free eluent prior to sample 
loading and elution.  
Tetrahydrofuran (THF) and diethyl ether (Et2O) were distilled from Na/benzophenone prior to use. 
Dichloromethane (CH2Cl2), triethylamine (Et3N), N,N-diisopropylamine (DIPA) were distilled under 
nitrogen atmosphere from CaH2 prior to use. Benzene, 1,2-dichloroethane (DCE), dimethyl sulfoxide 
(DMSO), 1,2-dichlorobenzene (DCB) were purchased from Acros Organics as 'extra dry' and used as 
received. All other reagents and solvents were purchased from chemical suppliers (Sigma-Aldrich, 
Acros Organics, Alfa Aesar, Strem Chemicals, ABCR) and were used as received. Solvents for 
extraction, crystallization and flash-column chromatography on silica gel were purchased as technical 
grade and distilled under reduced pressure prior to use. The molarity of n-butyllithium solutions was 
determined by titration to a blue endpoint against N-benzylbenzamide
[186]
  at −40 °C (average of three 
determinations).  
Unless noted otherwise, yields refer to chromatographically and spectroscopically (
1
H and 
13
C NMR) 
pure material. 
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4.1.2. Melting Point  
Melting points were measured on a Stanford Research Systems MPA120 EZ-Melt apparatus in open 
glass capillaries. 
4.1.3. NMR Spectroscopy  
NMR spectra were measured at room temperature (22 °C) on a Bruker Avance III HD 800 MHz 
spectrometer equipped with a CryoProbe
TM
 operating at 800 MHz for proton nuclei and 200 MHz for 
carbon nuclei or a Bruker Avance III HD 400 MHz spectrometer equipped with a CryoProbe
TM
 
operating at 400 MHz for proton nuclei and 100 MHz for carbon nuclei. Proton chemical shifts are 
expressed in parts per million (ppm, δ scale) and are referenced to residual protium in the NMR 
solvent (CHCl3: δ 7.26, C6HD5: 7.16). Carbon chemical shifts are expressed in parts per million (ppm, 
δ scale) and are referenced to the carbon resonance of the NMR solvent (CDCl3: δ 77.16, 
C6D6: 128.06). 
1
H NMR spectroscopic data are reported as follows: Chemical shift in ppm 
(multiplicity, coupling constants J (Hz), integration intensity). The multiplicities are abbreviated with 
s (singlet), d (doublet), t (triplet), q (quartet), app (apparent), broad (br), combinations thereof, and m 
(multiplet). In case of combined multiplicities, the multiplicity with the larger coupling constant is 
stated first. Except for complex and overlapping multiplets, where a resonance range is given, the 
chemical shift of all other symmetric signals is reported as the center of the resonance range. 
13
C NMR 
spectroscopic data are reported as follows: Chemical shift in ppm. Additionally to 
1
H and 
13
C NMR 
measurements, 2D NMR techniques such as homonuclear correlation spectroscopy (COSY), 
heteronuclear single quantum coherence (HSQC) and heteronuclear multiple bond coherence (HMBC) 
were used to assist signal assignment. For further elucidation of 3D structures of the products, nuclear 
Overhauser enhancement spectroscopy (NOESY) was conducted. All raw FID files were processed 
and the spectra analyzed using the program Mnova 10.0.2 from Mestrelab Research S. L.  
4.1.4. Mass Spectrometry  
All mass spectra were measured by the Analytical division of the Department of Chemistry, Ludwig-
Maximilians-Universität München. Mass spectra were recorded on the following spectrometers 
(ionisation mode in brackets): MAT 95 (EI) and MAT 90 (ESI) from Thermo Finnigan GmbH and 
were recorded in high-resolution. The method used is reported in the relevant section of the 
experimental part.  
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4.1.5. IR Spectroscopy  
IR spectra were recorded on a Perkin Elmer Spectrum BX II FT-IR system and the compound was 
applied as thin film directly on the ATR unit (either as neat substance or as solution in CH2Cl2). Data 
are represented as follows: absorption frequency (expressed in cm
−1
) and intensity of absorption: s 
(strong), m (medium), w (weak), br (broad).  
4.1.6. Optical Rotation  
Optical rotation values were recorded on an Anton Paar MCP 200 polarimeter. The specific rotation is 
calculated as follows:  
    
 
 
       
   
 
Thereby, the wavelength λ is reported in nm and the measuring temperature in °C. α represents the 
recorded optical rotation, c the concentration of the analyte in 10 mg/mL and d the length of the 
cuvette in dm. Thus, the specific rotation is given in 10
−1
·deg·cm
2
 ·g
−1
 . Use of the sodium D line 
(λ = 589 nm) is indicated by D instead of the wavelength in nm. The sample concentration as well as 
the solvent is reported in the relevant section of the experimental part 
4.1.7. HPLC Analyses 
Analytical HPLC on Chiral Stationary Phase was performed on a computer-operated Shimadzu system 
(Windows 10, LabSolutions Software, two LC-20AP pumps, manual injection (2 mL sample loop), 
CTO-20A column oven, SPD-M20A Diode Array detector). Column, oven temperature, solvent 
system, flow rate, detection mode and retention times are given in the relevant section of the 
experimental part.  
Preparative HPLC was performed on a computer-operated Varian instrument (Windows XP, Galaxie 
Chromatography Software, two PrepStar SD-1 pumps, manual injection with 2 mL sample loop, 
ProStar 335 Photo Diode Array Detector, Agilent 440-LC Fraction Collector). Column, solvent 
system, flow rate, detection mode and retention times are given in the relevant section of the 
experimental part. 
4.1.8. X-ray Diffraction Analysis 
Experiments were carried out by Dr. Peter Mayer (Ludwig-Maximilians-Universität München). The 
data collections were performed an a Bruker D8Venture using MoKα-radiation (λ = 0.71073 Å, 
graphite monochromator). The CrysAlisPro software (version 1.171.33.41) was applied for the 
integration, scaling and multi-scan absorption correction of the data. The structures were solved by 
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direct methods with SIR9713 and refined by least-squares methods against F2 with SHELXL-97.14. 
All nonhydrogen atoms were refined anisotropically. The hydrogen atoms were placed in ideal 
geometry riding on their parent atoms. Further details are summarized in the tables at the different 
sections. Plotting of thermal ellipsoids in this document and in the main text was carried out using 
Ortep-3 for Windows.
[187]
 
 
4.2. Experimental Procedures  
tert-Butyl 2,3-dihydro-1H-pyrrole-1-carboxylate (54) 
 
To a solution of N-Boc-pyrrolidin-2-one (10.0 g, 54.0 mmol, 1.00 eq.) in toluene (74 mL) at –78 °C 
was added lithium triethylborohydride (1 M in THF, 59.0 mmol, 1.10 eq.) over 40 min using a syringe 
pump. After stirring for 1 h at –70 °C (internal temperature), DMAP (66.0 mg, 0.54 mmol, 0.01 eq.) 
was added. DIPEA (54.0 mL, 318 mmol, 5.40 eq.) was added dropwise over 10 min. Then TFAA 
(9.1 mL, 65.0 mmol, 1.20 eq.) was added dropwise over 20 min in order to keep the internal 
temperature below –70 °C. After complete addition the cooling bath was removed and the mixture was 
stirred for further 2 h at room temperature. The solution was quenched by dropwise addition of water 
(80 mL). The phases were separated and the organic layer was washed with water (3 x 30 mL) and 
brine (3 x 30 mL). The mixture was dried over MgSO4, filtered and the solvent was removed in vacuo. 
The crude product was submitted to flash column chromatography (SiO2, hexanes/EtOAc = 19/1) to 
afford 54 as a colorless liquid (6.20 g, 36.7 mmol, 68 %). Spectral data match the previously reported 
values.
[188]
 
Rf = 0.26 (hexanes/EtOAc = 19/1). 
Note: NMR spectra are complex due to the presence of rotamers. 
1
H NMR (400 MHz, CDCl3): δ = 6.52 – 6.38 (m, 1H), 4.94 – 4.90 (m, 1H), 3.68 – 3.61 (m, 2H), 
2.60 – 2.51 (m, 2H), 1.41 (s, 9H). 
13
C NMR (100 MHz, CDCl3): δ = 130.0, 107.6, 80.1, 45.4, 44.9, 29.9, 28.6. 
Note: The carbonyl carbon was not visible in the 
13
C spectrum. 
HRMS (EI) for C9H15NO2 [M]
∙+
: calcd.: 169.1103, found: 169.1106. 
IR (ATR):  ̃ = 2976 (w), 1697 (s), 1618 (w), 1478 (w), 1405 (s), 1378 (s), 1258 (m), 1174 (m), 1132 
(s), 1092 (m). 
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tert-Butyl 4-bromo-2,3-dihydro-1H-pyrrole-1-carboxylate (55) 
 
A solution of bromine (30.0 μL, 0.59 mmol, 1.00 eq.) in CH2Cl2 (1.20 mL) was added over 1 h to a 
suspension of enamine 54 (0.50 g, 2.95 mmol, 1.00 eq.), Et3N (1.44 mL, 10.3 mmol, 3.50 eq.) and 
activated 4 Å molecular sieves (114 mg) in CH2Cl2 (10.0 mL) at 0 °C. After addition was completed 
the ice bath was removed and the mixture was stirred for another hour at room temperature. 
Afterwards the mixture was filtered through a Celite pad, the solvent was removed under reduced 
pressure and the crude product was purified by flash column chromatography (SiO2, hexane/EtOAc = 
19/1) to afford 55 as yellow oil (346 mg, 37.0 mmol, 47 %). 
Note: The product was unstable upon storage at room temperature and therefore stored in a benzene 
matrix at −25 °C (100 mg/10 mL). 
Rf = 0.46 (hexanes/EtOAc = 19/1). 
Note: NMR spectra are complex due to the presence of rotamers. 
1
H NMR (400 MHz, CDCl3) δ = 6.62 (s, 1H), 3.89 − 3.67 (m, 2H), 2.84 (t, J = 9.1 Hz, 2), 1.45, 
(s, 9H). 
13
C NMR (100 MHz, CDCl3) δ = 151.5, 151.0, 129.9, 100.2, 100.0, 80.9, 80.7, 46.2, 45.6, 36.6, 35.6, 
29.8, 28.4. 
HRMS (EI) for C9H14BrNO2
∙+
 [M]
∙+
: calcd.: 247.0208, found: 247.0207. 
IR (ATR):  ̃ = 2975 (w), 1694 (s), 1628 (w), 1478 (w), 1381 (s), 1366 (s), 1324 (m), 1255 (m), 1007 
(s), 962 (m), 918 (m), 876 (s), 844 (m), 772 (m). 
Rac-tert-butyl (2S,3R)-3-iodo-2-methoxypyrrolidine-1-carboxylate (56)  
 
ICl (1 M in CH2Cl2, 29.25 mmol, 1.1 eq.) was added dropwise to a solution of sodium methoxide 
(2.87 g, 53.2 mmol, 2.00 eq.) and N-Boc-2,3-dihydro-1H-pyrrole 54 (4.5 g, 26.6 mmol, 1.00 eq.) in 
MeOH (95 mL) at room temperature. After stirring for 30 min, a saturated solution of Na2S2O3 
(20 mL) was added and the mixture was stirred for further 30 min. The phases were separated and the 
aqueous phase was extracted three times with Et2O (40 mL). The combined organic layers were 
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washed with water (3 x 30 mL) and brine (3 x 30 mL), dried over MgSO4, filtered and the solvent was 
removed in vacuo. The crude product was purified by flash column chromatography (SiO2, 
hexane/EtOAc = 5/1) to afford 56 as beige oil (5.91 g, 18.08 mmol, 68 %). Spectral data match the 
previously reported values.
[87]
 
Rf = 0.31 (hexanes/EtOAc = 5/1) 
Note: NMR spectra are complex due to the presence of rotamers. 
1
H NMR (400 MHz, CDCl3) δ = 5.37 and 5.24 (s, 1H), 4.21 (d, J = 5 Hz, 1H), 3.69 – 3.55 (m, 1H), 
3.48 – 3.42 (m, 1H), 3.40 and 3.35 (s, 3H), 2.54 – 2.43 (m, 1H), 2.15 – 2.07 (m, 1H), 1.49 (s, 9H). 
13
C NMR (100 MHz, CDCl3) δ = 155.2, 154.6, 96.6, 96.4, 80.7, 80.5, 56.4, 56.1, 45.1, 44.5, 33.9, 
33.1, 28.5, 27.2, 26.3. 
HRMS (EI) for C10H18INO3
∙+
 [M]
∙+
: calcd.: 327.0331, found: 327.0343. 
IR (ATR):  ̃ = 2976 (w), 1702 (s), 1478 (w), 1378 (s), 1258 (w), 1162 (s), 1115 (m), 1076 (s), 
1030 (w). 
tert-butyl 4-iodo-2,3-dihydro-1H-pyrrole-1-carboxylate (50)  
 
A solution of trans-tert-butyl 3-iodo-2-methoxypyrrolidine-1-carboxylate 56 (700 mg, 2.14 mmol, 
1.00 eq.) and TFA (15 µL, 0.2 mmol, 0.10 eq.) in toluene (46 mL) was submerged in an oil bath 
preheated to 130 °C for 90 min. After cooling to room temperature with the aid of an ice bath, Et3N 
(90 µL, 0.6 mmol, 0.30 eq.) was added, the solvent was removed in vacuo and the residue was 
submitted to flash column chromatography (SiO2, hexane/EtOAc = 19/1) to afford 50 as colorless oil 
(450 mg, 1.51 mmol, 71%). Spectral data match the previously reported values.
[87]
 
Note: The product is sensitive towards light and temperature. It can be stored in a benzene matrix at –
25 °C in dilute solution (0.1 M). A 0.5 M solution was found to decompose within 14 days even if 
stored at –25°C. 
Rf = 0.29 (hexanes/EtOAc = 19/1) 
Note: NMR spectra are complex due to the presence of rotamers. 
1
H NMR (400 MHz, CDCl3) δ = 6.76 and 6.62 (s, 1H), 3.76 – 3.71 (m, 2H), 2.86 – 2.79 (m, 2H), 
1.45 (s, 9H). 
13
C NMR (100 MHz, CDCl3) δ = 151.1, 150.5, 136.0, 81.0, 80.7, 66.3, 46.7, 46.1, 39.9, 38.9, 28.5. 
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HRMS (EI) for C9H15O2NI
∙+
 [M]
∙+
: calcd.: 296.0142, found: 296.0134. 
IR (ATR):  ̃ = 2976 (w), 2931 (w), 1702 (s), 1478 (w), 1455 (w), 1391 (s), 1284 (w), 1243 (m), 1173 
(m), 1127 (m). 
tert-butyl tosylcarbamate (58)  
 
To a solution of 4-methylbenzenesulfonamide 57 (20.03 g, 117.0 mmol, 1.00 eq.), Et3N (16.8 mL, 
120.5 mmol, 1.03 eq.) and DMAP (1.43 g, 11.70 mmol, 0.10 eq.) in CH2Cl2 (190 mL) at 0 °C was 
added a solution of Boc2O (29.11 g, 133.4 mmol, 1.14 eq.) in CH2Cl2 (100 mL). The reaction mixture 
was stirred for 14 h. Then, the solvent was removed under reduced pressure and the residue was taken 
up in EtOAc (200 mL), washed with aqueous HCl (1 M, 100 mL), water (100 mL), brine (100 mL), 
dried over MgSO4 and filtered. The solvent was removed in vacuo and the crude product was 
recrystallized from EtOAc/hexanes (280/100 mL) to afford, after filtration, 58 as white crystalline 
solid (21.0 g, 77.2 mmol, 66 %). Spectral data match the previously reported values.
[189]
  
Rf = 0.19 (hexanes/EtOAc = 7/3). 
Melting point = 97.0 – 99.2 °C. 
1
H NMR (400 MHz, CDCl3) δ = 7.90 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), 7.08 (br s, 1H), 
2.45 (s, 3H), 1.39 (s, 9H). 
13
C NMR (100 MHz, CDCl3) δ = 149.0, 144.9, 136.0, 129.7, 128.4, 84.2, 28.0, 21.8. 
HRMS (EI) for C12H17NO4S
∙+
 [M]
∙+
: calcd.: 271.0837, found: 271.0878. 
IR (ATR):  ̃ = 3246 (w), 2982 (w), 1746 (m), 1598 (w), 1435 (w), 1347 (m), 1238 (w), 1147 (s), 1090 
(m), 912 (w), 830 (w).  
tert-butyl but-3-yn-1-yl(tosyl)carbamate (59)  
 
To a solution of tert-butyl tosylcarbamate 58 (8.28 g, 30.5 mmol, 1.00 eq.), 3-butyn-1-ol (2.77 mL, 
36.6 mmol, 1.20 eq.) and triphenylphosphine (16.0 g, 61.0 mmol, 2.00 eq.) in THF (165 mL) at 0 °C 
was slowly added diethyl azodicarboxylate (40% in toluene, 9.56 g, 54.9 mmol, 1.80 eq.,) was added 
dropwise via syringe pump. The solution was stirred at 0 °C while slowly warming to room 
Part I: Experimental Procedures 
65 
temperature over 4 h. The solvent was removed in vacuo and the resulting solid was submitted to flash 
column chromatography (SiO2, hexane/EtOAc = 8/2 to 1/1) to afford 59 as a white solid 
(6.88 g, 21.3 mmol, 70%). Spectral data match the previously reported values.
[190]
 
Rf = 0.50 (hexanes/EtOAc = 7/3). 
Melting point = 77.0 – 79.0 °C 
1
H NMR (400 MHz, CDCl3) δ = 7.80 (d, J = 8.3 Hz, 2H), 7.31 (d, J = 8.3 Hz, 2H), 4.00 (t, J = 7.4 Hz, 
2H), 2.66 (td, J = 7.4 Hz, 2.7 Hz, 2H), 2.44 (s, 3H), 2.02 (t, J = 2.7 Hz, 1H), 1.35 (s, 6H). 
13
C NMR (100 MHz, CDCl3) δ = 150.9, 144.4, 137.3, 129.4, 128.1, 84.7, 80.6, 70.6, 45.4, 28.0, 21.8, 
20.1. 
HRMS (EI) for C16H21NO4S
∙+ 
[M]
∙+
: calcd.: 323.1191, found: 323.1301. 
IR (ATR):  ̃ = 3295 (m), 2982 (w), 1722 (s), 1597 (m), 1494 (w), 1448 (w), 1372 (m), 1355 (s), 1327 
(m), 1287 (m), 1167 (s), 1135 (s), 1093 (s), 1077 (m), 970 (w). 
tert-butyl but-3-yn-1-ylcarbamate (60) 
 
To a solution of tert-butyl but-3-yn-1-yl(tosyl)carbamate 59 (5.87 g, 18.2 mmol, 1.00 eq.) in MeOH 
(180 mL) were added magnesium turnings (4.42 g, 182 mmol, 10.00 eq.). The reaction mixture was 
sonicated for 2 h after which all magnesium has been dissolved. The solvent was removed in vacuo, 
diluted with CH2Cl2 (100 mL), poured onto aqueous HCl (0.5 M, 100 mL) and the resulting white 
precipitate was filtered off. The organic phase was separated, washed with saturated aqueous NaHCO3 
(100 mL), brine (100 mL), dried over MgSO4 and filtered. The solvent was removed in vacuo and the 
crude product purified by flash column chromatography (SiO2, hexanes/Et2O = 8/2, to 7/3) to afford 
60 as colorless oil (1.93 g, 11.4 mmol, 63 %). Spectral data match the previously reported values.
[191]
 
Rf = 0.39 (hexanes/EtOAc = 7/3). 
Melting point = 77.0 – 79.0 °C 
1
H NMR (400 MHz, CDCl3) δ = 4.84 (br s, 1H), 3.28 (d, J = 6.4 Hz, 2H), 2.38 (td, J = 6.4, 2.7 Hz, 
2H), 2.00 (t, J = 2.7 Hz, 1H), 1.45 (s, 9H) 
13
C NMR (100 MHz, CDCl3) δ = 155.8, 81.8, 79.6, 70.0, 39.4, 28.5, 20.1. 
HRMS (EI) for C9H16NO2
∙+ 
[M]
∙+
: calcd.: 170.1181, found: 170.1181. 
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IR (ATR):  ̃ = 3306 (w), 2979 (w), 2935 (w), 1692 (s), 1513 (m), 1456 (w), 1392 (w), 1366 (m), 1251 
(m), 1169 (s), 1074 (w). 
tert-butyl 4-iodo-2,3-dihydro-1H-pyrrole-1-carboxylate (50) 
 
Note: The following reaction was performed under the exclusion of light: laboratory and fume hood 
lights were turned off, the reaction flask wrapped in aluminum foil and flasks connected to a rotary 
evaporator were covered with aluminum foil. 
To a solution of tert-butyl but-3-yn-1-ylcarbamate 60 (1.86 g, 11.0 mmol, 1.00 eq.) in anhydrous 
CH2Cl2 (76 mL), were added sodium iodide (8.81 g, 58.7 mmol, 5.30 eq.) and iodine (6.00 g, 
23.7 mmol, 2.15 eq.). The reaction mixture was stirred for 15 h in and quenched with a saturated 
aqueous Na2S2O3 (120 mL). The phases were separated and the aqueous phase was extracted with 
CH2Cl2 (3 × 50 mL). The combined organic layers were washed with brine (100 mL), dried over 
MgSO4, filtered and concentrated in vacuo. The resulting crude tert-butyl (E)-(3,4-diiodobut-3-en-1-
yl)carbamate 61 appeared as yellow oil and was immediately used for the next step without further 
purification. 
To a solution of crude (E)-(3,4-diiodobut-3-en-1-yl)carbamate (4.65 g, 11.0 mmol, 1.00 eq., based on 
a hypothetical 100 % yield of the diiodination reaction) toluene (170 mL) was added CuI (1.05 g, 
5.50 mmol, 0.50 eq.), K3PO4 (7.01 g, 33.0 mmol, 3.00 eq.), 2,2'-bipyridine (1.72 g, 11.0 mmol, 
1.00 eq.) and water (0.178 mL, 9.90 mmol, 0.90 eq.) and the resulting red mixture was heated to reflux 
for 72 h. The solution was allowed to cool to room temperature, filtered through a pad of celite and 
concentrated in vacuo. The residue was directly submitted to flash column chromatography (SiO2, 
hexane/EtOAc = 10/1) and afforded 50 as colorless oil (1.04 g, 3.41 mmol, 32%). 
Spectral data matched the values reported on page 63. 
Note: The product is sensitive towards light and temperature. It can be stored in a benzene matrix at –
25 °C in dilute solution (0.1 M). A 0.5 M solution was found to decompose within 14 days even if 
stored at –25°C. 
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tert-butyl-4-boropinacolato-2,3-dihydro-1H-pyrrole-1-carboxylate (81)  
 
A solution of bis(pinacolato)diboron (254 mg, 1.0 mmol, 1.00 eq.), 4,4'-di-tert-butyl-2,2'-dipyridyl 
(8 mg, 30.0 µmol, 0.03 eq.) and (cycloocta-1,5-diene)(methoxy)iridium(I) dimer (9.9 mg, 15.0 µmol, 
0.015 eq.) in methyl tert-butyl ether (2.4 mL) was degassed (freeze-pump-thaw, three cycles). The 
resulting solution was added to 54 (169 mg, 1.0 mmol, 1.00 eq.) in a 10 mL glass microwave tube. 
The vessel was sealed and irradiated in a CEM Discover microwave apparatus (200 Watt, 80 °C) for 
13 min. The resulting mixture was directly applied onto a chromatography column. After 
chromatography (SiO2, hexanes/EtOAc = 19/1) 81 was obtained as colorless liquid (142 mg, 480 
µmol, 48 %). 
Note: The solution of bis(pinacolato)diboron, 4,4'-di-tert-butyl-2,2'-dipyridyl and (cycloocta-1,5-
diene)(methoxy)iridium(I) dimer in methyl tert-butyl ether can be prepared and stored in a Schlenk 
tube under Argon and used for subsequent experiments. This solution was found to be functional after 
14 days if stored under the exclusion of light. 
Rf = 0.29 (hexanes/EtOAc = 19/1, UV 254 nm, CAM) 
Note: NMR spectra are complex due to the presence of rotamers. 
1
H NMR (400 MHz, CDCl3) δ = 7.18, 7.03 (s, 1H), 3.77-3.72 (m, 2H), 2.70-2.66 (m, 2H), 1.47 (s, 
9H), 1.27 (s, 12H). 
13
C NMR (100 MHz, CDCl3) δ = 151.2, 141.9, 83.5, 83.1, 80.8, 46.2, 29.8, 28.6, 28.4, 25.1, 24.8. 
HRMS (EI) for C15H26BNO4 [M]
∙+
: calcd.: 295.1955, found: 295.1959. 
IR (ATR):  ̃ = 2976 (w), 1742 (w), 1695 (m), 1610 (w), 1474 (m), 1380 (m), 1368 (s), 1328 (s), 1269 
(m), 1140 (s), 983 (m), 851 (s), 774 (m), 676 (s). 
3-hydroxy-2-iodo-4-methoxybenzaldehyde (62) 
 
An aluminum-foil wrapped dropping funnel was charged with 1,4-dioxane (611 mL) and ICl (100 g, 
616 mmol, 1.03 eq.) in 1,4-dioxane (611 mL). This solution was added dropwise to a solution of 
isovanillin (91.0 g, 598 mmol, 1.00 eq.) in pyridine (340 mL, 4.19 mol, 7.00 eq.) in a 2 L round-
bottom flask. The reaction mixture was stirred for 8 d under the exclusion of light. After the solvents 
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were removed in vacuo, water (500 mL) was added and the aqueous layer was acidified with aqueous 
HCl (1 M, 800 mL). The aqueous layer was extracted with EtOAc (3 x 1.2 L). The combined organic 
layers were washed with NaHSO3 (2 x 600 mL) and brine (600 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure. 
The solid residue was filtered over a Büchner funnel and washed with cold EtOAc (3 x 100 mL). 
Arene 62 was obtained as a light-yellow solid (127 g, 457 mmol, 76%) and as a 9/1 ratio of product 
and starting material (determined by 
1
H NMR) that was used for the next step without further 
purification. An analytically pure sample was obtained by flash column chromatography (SiO2, 
hexanes/EtOAc = 7/3). Spectral data match the previously reported values.
[137]
 
Rf = 0.29 (hexanes/EtOAc = 7/3, UV 254 nm, CAM). 
Melting point = 171.1 – 173.5 °C. 
1
H NMR (400 MHz, CDCl3) δ = 10.03 (s, 1H), 7.55 (d, J = 8.5 Hz, 1H), 6.92 (d, J = 8.5 Hz, 1H), 6.32 
(s, 1H), 4.00 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ = 195.0, 150.8, 145.8, 128.8, 124.0, 111.1, 88.2, 56.7. 
HRMS (ESI) for C8H6IO3
–
 [M–H]–: calcd.: 276.9367, found: 276.9370. 
IR (ATR):  ̃ = 4241 (w), 1558 (s), 1584 (m), 1558 (m), 1488 (m), 1460 (m) 1436 (m), 1386 (w), 1330 
(w), 1281 (s), 1201 (s), 1166 (m), 1126 (m), 1011 (s), 982 (m), 822 (m), 808 (s), 781 (m), 654 (m). 
3-(benzyloxy)-2-iodo-4-methoxybenzaldehyde (63)  
 
To a solution of iodoisovanillin (62) (45.1 g, 162 mmol, 1.00 eq.) in acetonitrile (550 mL) were added 
potassium carbonate (67.3 g, 487 mmol, 3.00 eq.)  and benzyl bromide (21.3 mL, 178 mmol, 1.10 eq.). 
The resulting yellow suspension was heated to 60 °C and stirred for 2.5 h. The dark orange precipitate 
was filtered over celite, rinsed with EtOAc (3 x 200 mL) and the filtrate was concentrated under 
reduced pressure. Upon addition of Et2O, the product 63 precipitated as light-yellow solid (47.5 g, 
129 mmol, 83%).  Spectral data match the previously reported values.
[136]
 
Rf  = 0.29 (hexanes/EtOAc = 7/3, UV 254 nm, CAM). 
Melting point = 89.3 – 90.5 °C. 
1
H NMR (400 MHz, CDCl3) δ = 10.03 (s, 1H), 7.74 (d, J = 8.6 Hz, 1H), 7.62 – 7.57 (m, 2H), 7.45 –
 7.32 (m, 3H), 7.00 (d, J = 8.6 Hz, 1H), 5.04 (s, 2H), 3.97 (s, 3H). 
Part I: Experimental Procedures 
69 
13
C NMR (100 MHz, CDCl3) δ = 195.3, 158.0, 147.6, 136.7, 129.2, 128.7, 128.6, 128. 4, 127.7, 112.0, 
101.1, 74.6, 56.4. 
HRMS (ESI) for C15H14IO3
+
 [M+H]
+
: calcd. 368.9982, found: 368.9985. 
IR (ATR):  ̃ = 2944 (w), 2850 (w), 1675 (s), 1574 (m), 1555 (w), 1495 (w), 1479 (m), 1453 (w), 1437 
(w), 1382 (w), 1360 (w), 1302 (w), 1278 (s), 1252 (s), 1221 (m), 1177 (w), 1134 (w), 1080 (w), 1021 
(s), 1000 (m), 940 (w), 911 (m), 845 (w), 821 (m), 779 (w), 750 (w), 739 (w), 696 (m). 
3-Benzyloxy-2-boropinacolato-4-methoxybenzaldehyde (64) 
 
A solution of aldehyde 63 (200 mg, 0.54 mmol, 1.00 eq.), bis(pinacolato)diboron 
(152 mg, 0.60 mmol, 1.10 eq.) and KOAc (160 mg, 1.63 mmol, 3.00 eq.) in DMF (2.1 mL) was 
degassed by subsurface sparging with Ar for 15 min. Then, Pd(OAc)2 (3.7 mg, 16 µmol, 0.03 eq.) was 
added. The mixture was stirred for 5 h at 85 °C. After cooling to room temperature, water (10 mL) was 
added and the mixture was extracted using EtOAc. The organic phase was washed with LiCl 
(10% w/w, 3 x 10 mL), water (3 x 20 mL), brine (20 mL), dried over MgSO4 and filtered. The solvent 
was removed in vacuo and the crude product was purified by flash column chromatography (SiO2, 
pentane/EtOAc = 9/1) to afford 64 as a colorless solid (103 mg, 0.33 mmol, 61%). 
Rf = 0.24 (pentane/EtOAc = 9/1, UV 254 nm, KMnO4) 
Melting point = 85.6 – 93.1 °C 
1
H NMR (200 MHz, CDCl3) δ = 9.82 (s, 1H), 7.56 (d, J = 8.3 Hz, 1H), 7.53-7.48 (m, 2H), 7.39-7.34 
(m, 2H), 7.33- 7.28 (m, 1H), 7.02 (d, J = 8.3 Hz, 1H), 5.04 (s, 2H), 3.92 (s, 3H), 1.34 (s, 12H). 
13
C NMR (75 MHz, CDCl3) δ = 191.6, 157.5, 151.7, 137.9, 133.7, 130.6, 128.4, 128.2, 127.9, 112.4, 
84.4, 75.7, 56.0, 25.1. 
Note: The peak belonging to the boron-bound carbon was not observed due to quadrupolar 
relaxation. 
HRMS (FAB) for C21H26O5B
∙+ 
[M+H]
 ∙+
: calcd.369.1868, found: 369.1860. 
IR (ATR):  ̃ = 2976 (w), 1683 (m), 1561 (m), 1455 (m), 1435 (m), 1372 (m), 1336 (s), 1312 (s), 1267 
(s), 1232 (m), 1169 (w), 1138 (m), 1050 (m). 
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2-Iodo-3-isopropoxy-4-methoxybenzaldehyde (65)  
 
To a solution of 3-hydroxy-2-iodo-4-methoxybenzaldehyde 62 (11.5 g, 41.3 mmol, 1.00 eq.) in DMF 
(75 mL) were added K2CO3 (8.56 g, 62.0 mmol, 1.50 eq.), tetrabutylammonium iodide (3.81 g, 
10.3 mmol, 0.25 eq.) and isopropyl bromide (5.66 mL, 60.3 mmol, 1.46 eq.). The reaction mixture was 
stirred for 5 h at 60 °C. The mixture was cooled to room temperature, diluted with water (20 mL) and 
extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with aqueous HCl (1 
M, 50 ml) and brine (50 mL), dried over MgSO4 and filtered. The solvent was removed in vacuo and 
the crude product was purified by flash column chromatography (SiO2, hexanes/EtOAc = 9/1) to 
afford 65 as light yellow solid (8.37 g, 26.0 mmol, 63%). 
Rf = 0.40 (hexanes/EtOAc = 9/1, UV 254 nm, CAM). 
Melting point = 34.1 – 35.5 °C. 
1
H NMR (400 MHz, CDCl3) δ = 10.04 (s, 1H), 7.68 (d, J = 8.6 Hz), 6.95 (d, J = 8.6 Hz, 1H), 4.71 
(sep, J = 6.2 Hz, 1H), 3.92 (s, 3H), 1.37 (d, J = 6.2 Hz, 6H). 
13
C NMR (100 MHz, CDCl3) δ = 195.7, 158.0, 147.0, 129.3, 126.7, 111.7, 102.3, 76.3, 56.3, 22.8. 
HRMS (ESI) for C11H13IO3
∙+ 
[M]
∙+
: calcd.: 319.9909, found: 319.9906. 
IR (ATR):  ̃ = 2973 (w), 2933 (w), 2841 (w), 1675 (s), 1569 (s), 1473 (m), 1369 (m), 1296 (m), 1269 
(s), 1203 (m), 1098 (s), 1017 (s).  
3-Isopropoxy-4-methoxy-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzaldehyde (66) 
 
To a mixture of 2-iodo-3-isopropoxy-4-methoxybenzaldehyde 65 (1.00 g, 3.13 mmol, 1.00 eq.), 
KOAc (2.78 g, 9.38 mmol, 3.00 eq.) and bis(pinacolato)diboron (952 mg, 3.75 mmol, 1.20 eq.) in 
DMF (11.6 mL) was added a solution of Pd(OAc)2 (42.1 mg, 0.19 mmol, 0.06 eq.) in DMF (11.6 mL). 
The black suspension was stirred for 48 h at 80 °C. The reaction was diluted with water (20 mL) and 
EtOAc (20 mL). The layers were separated and the aqueous layer was extracted with EtOAc 
(5 × 10 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over 
MgSO4 and filtered. The solvent was removed under reduced pressure and the crude product was 
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purified by flash column chromatography (SiO2, hexanes/EtOAc = 7/3) to afford 66 as light yellow 
solid (731.8 mg, 2.28 mmol, 73%). 
Rf = 0.39 (hexanes/EtOAc = 7/3). 
Melting point = 80 – 83 °C. 
1
H-NMR (400 MHz, CDCl3): δ = 9.79 (s, 1H), 7.50 (d, J = 8.3 Hz), 6.97 (d, J = 8.3 Hz, 1H), 4.72 
(sept, J = 6.2 Hz, 1H), 3.90 (s, 3H), 1.46 (s, 12H), 1.27 (d, J = 6.2 Hz, 6H). 
13
C-NMR (100 MHz, CDCl3): δ = 191.8, 157.7, 150.2, 133.7, 130.1, 112.1, 84.3, 74.4, 55.9, 25.3, 
22.6. 
Note: The peak belonging to the boron-bound carbon was not observed due to quadrupolar 
relaxation. 
HRMS (EI) for C17H25BO5
∙+ 
[M]
∙+
: calcd.: 320.1795, found: 320.1798. 
IR (ATR):  ̃ = 2973 (w), 1675 (s), 1564 (m), 1438 (m), 1370 (m), 1334 (m), 1302 (s), 1269 (s), 1235 
(m), 1108 (m), 1031 (s), 917 (m). 
2-Bromo-3-hydroxy-4-methoxybenzaldehyde (67)  
 
To a suspension of isovanillin (20.0 g, 131.0 mmol, 1.00 eq.), NaOAc (21.6 g, 263 mmol, 2.00 eq.) 
and iron powder (734 mg, 13 mmol, 0.10 eq.) in acetic acid (131.5 mL), a solution of bromine (7.4 
mL, 145 mmol, 1.10 eq.) in acetic acid (20 mL) was added dropwise over 20 min using a syringe 
pump. After 2 h, the mixture was poured into an ice bath. The resulting precipitate was filtered, 
washed with cold water (100 mL) and recrystallized from hot ethanol (1 L) to afford, after filtration, 
67 as light brown solid (25.1 g, 108.7 mmol, 83%). Spectral data match the previously reported 
values.
[123]
  
Rf = 0.29 (hexanes/EtOAc = 2/1). 
Melting point = 195.0 – 199.2 °C. 
1
H NMR (400 MHz, CDCl3): δ = 10.26 (s, 1H), 7.58 (d, J = 8.5 Hz, 1H), 6.93 (d, J = 8.6 Hz, 1H), 
6.06 (s, 1H), 4.01 (s, 3H). 
13
C NMR (101 MHz, CDCl3): δ = 191.0, 151.8, 143.3, 127.4, 122.9, 113.0, 109.4, 56.7. 
HRMS (ESI) for C8H8BrO3
+
 [M+H]
+
: calcd.: 230.9651, found: 230.9652. 
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IR (ATR):  ̃ = 3221 (br, m), 1667 (s), 1592 (m), 1563 (s), 1461 (m), 1385 (w), 1334 (w), 1277 (s), 
1233 (m), 1204 (s), 1168 (m), 1131 (m), 1015 (s). 
2-Bromo-3-isopropoxy-4-methoxybenzaldehyde (68)  
 
To a solution of 2-bromo-3-hydroxy-4-methoxybenzaldehyde 67 (7.94 g, 34.3 mmol, 1.0 eq.) in DMF 
(62 mL) were added K2CO3 (7.12 g, 51.5 mmol, 1.5 eq.), isopropyl bromide (4.71 mL, 50.2 mmol, 
1.46 eq.), and tetrabutylammonium iodide (3.17 g, 8.59 mmol, 0.25 eq.). The reaction mixture was 
stirred for 2.5 h at 60 °C. The mixture was cooled to room temperature, diluted with water (60 mL) 
and extracted with EtOAc (4 × 50 mL). The combined organic layers were washed with 1 M HCl (50 
mL) and brine (50 mL), dried over MgSO4 and filtered. The solvent was removed in vacuo and the 
residue was purified by flash column chromatography (SiO2, hexanes/EtOAc = 9/1 to 7/3) to afford 68 
as slightly yellow solid (9.17 g, 33.6 mmol, 98%). Spectral data match the previously reported 
values.
[193]
 
Rf = 0.41 (hexanes/EtOAc = 7/1). 
Melting point = 33.0 – 34.0 °C. 
1
H NMR (400 MHz, CDCl3): δ = 10.26 (s, 1H), 7.70 (d, J = 8.7 Hz, 1H), 6.93 (d, J = 8.7 Hz, 1H), 
4.59 (sep, J = 6.2 Hz, 1H), 3.92 (s, 3H), 1.34 (d, J = 6.2 Hz). 
13
C NMR (101 MHz, CDCl3): δ = 191.5, 158.9, 144.6, 127.6, 126.0, 124.1, 110.8, 76.4, 56.3, 22.6. 
HRMS (EI) for C11H13BrO3
∙+ 
[M]
∙+
: calcd.: 272.0048, found: 272.0037. 
IR (ATR):  ̃ = 2973 (w), 2929 (w), 2863 (w), 1675 (s), 1576 (s), 1482 (m), 1376 (m), 1303 (m), 1275 
(s), 1211 (m), 1097 (s), 906 (s). 
2-Bromo-3-isopropoxy-4-methoxy-1-vinylbenzene (69)  
 
To a suspension of NaH (60% w/w in mineral oil, 432 mg, 18.0 mmol, 1.50 eq.) in THF (72 mL) at 
0 °C was portionwise added methyltriphenylphosphonium iodide (5.82 g, 14.4 mmol, 1.20 eq.). The 
mixture was stirred for 5 min at 0 °C and for 25 min at room temperature. 2-Bromo-3-isopropoxy-4-
methoxybenzaldehyde 68 (3.28 g, 12.0 mmol, 1.00 eq.) was added portionwise slowly and the 
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resulting white suspension was stirred for 16 h, quenched by slow addition of water (60 mL) and 
extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with water (50 mL) and 
brine (50 mL), dried over MgSO4 and filtered. The solvent was removed in vacuo and the residue was 
purified by flash column chromatography (SiO2, hexanes/EtOAc = 9/1 to 7/3) to afford 69 as a 
colorless oil (2.83 g, 10.4 mmol, 87%). Spectral data match the previously reported values.
[193]
 
Rf = 0.41 (hexanes/EtOAc = 7/1). 
1
H NMR (400 MHz, CDCl3): δ = 7.27-7.24 (m, 1H), 7.03 (dd, J = 17.4, 10.9 Hz, 1H), 6.84 (d, J = 8.6 
Hz, 1H), 5.56 (dd, J = 17.4, 1.2 Hz, 1H), 5.24 (dd, J = 10.9, 1.2 Hz, 1H), 4.56 (sept, J = 6.2 Hz, 1H), 
3.84 (s, 3H), 1.33 (d, J = 6.2 Hz, 6H). 
13
C NMR (101 MHz, CDCl3): δ = 153.4, 144.6, 136.1, 131.5, 121.3, 120.7, 114.9, 111.4, 76.0, 56.2, 
22.7. 
HRMS (EI) for C12H15O2Br
∙+
[M]
∙+
: calcd.: 270.0255, found: 270.0246. 
IR (ATR):  ̃ = 2973 (w), 2929 (w), 2863 (w), 1675 (s), 1576 (s), 1482 (m), 1376 (m), 1303 (m), 1275 
(s), 1211 (m), 1097 (s), 906 (s). 
2-(2-Isopropoxy-3-methoxy-6-vinylphenyl)-4,4,5,5-tetramethyl-1,3,2-
dioxaborolane (70) 
 
A solution of 69 (1.00 g, 3.70 mmol, 1.00 eq.) in THF (18.6 mL) was cooled to –78 °C and a solution 
of t-BuLi (2.1 M in heptane, 1.93 mL, 4.07 mmol, 1.10 eq.) was added. The resulting mixture was 
stirred for 30 min at –78 °C and 1-Isopropoxy-3,3,4,4-tetramethylborolane (1.12 mL, 5.51 mmol, 
1.49 eq.) was added dropwise. After stirring for 2 hat −78 °C, the cooling bath was removed and the 
mixture stirred for additional 90 min. The reaction was quenched with water (20 mL) and extracted 
with Et2O (3 × 30 mL). The combined organic layers were washed with water (50 mL) and brine (50 
mL), dried over MgSO4 and filtered. The solvent was removed under reduced pressure and the crude 
product was purified by flash column chromatography (SiO2, hexanes/Et2O = 9/1 to 7/3) to afford 70 
as a white solid (1.12 g, 3.51 mmol, 95%). Spectral data match the previously reported values.
[193]
 
Rf = 0.16 (hexanes/Et2O = 9/1). 
Melting point = 73.0 – 75.0 °C. 
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1
H NMR (400 MHz, CDCl3): δ = 7.21 (d, J = 8.4, 1H), 6.85 (d, J = 8.4 Hz, 1H), 6.75 (dd, J = 17.4, 
10.8 Hz, 1H), 5.56 (dd, J = 17.4, 1.2 Hz, 1H), 5.12 (dd, J = 10.8, 1.2 Hz, 1H), 4.68 (sept, J = 6.2 Hz, 
1H), 3.80 (s, 3H), 1.39 (s, 12H), 1.25 (d, J = 6.2 Hz, 6H). 
13
C NMR (101 MHz, CDCl3): δ = 151.6, 149.2, 136.7, 134.7, 120.5, 114.0, 113.4, 84.0, 73.9, 55.9, 
25.2, 22.6. 
HRMS (EI) for C18H27O4B
∙+ 
[M]
∙+
: calcd.: 318.2003, found: 318.1997. 
IR (ATR):  ̃ = 2975 (w), 2933 (w), 1562 (w), 1472 (m), 1430 (m), 1328 (s), 1303 (s), 1261 (s), 
1140 (m), 1106 (m), 1045 (s) 991 (m). 
Trifluoro(2-isopropoxy-3-methoxy-6-vinylphenyl)-l4-borane, potassium salt (71) 
 
To a solution of 70 (101.8 mg, 0.32 mmol, 1.00 eq) in MeOH (1.0 mL) was added aqueous KHF2 
(4.5 M, 2 mL). The reaction mixture was stirred at room temperature for 40 min and the solvent was 
removed under reduced pressure. The residue was redissolved in methanol/water (3 mL, 50% v/v) and 
the solvent was removed under reduced pressure. This procedure was repeated three times. The 
resulting white residue was suspended in hot acetone (2 mL), the supernatant was filtered through a 
syringe filter (glassfiber, 45 μm) and the solvent was removed in vacuo to afford 71 as white solid 
(77.3 mg, 0.26 mmol, 81%). 
Rf = 0.16 (hexanes/Et2O = 9/1). 
Melting point = > 200 °C (decomposition). 
1
H NMR (400 MHz, CDCl3): δ = 7.33 (dd, J = 17.8, 10.8 Hz, 1H), 7.09 (d, J = 8.3 Hz, 1H), 6.66 (d, 
J = 8.3 Hz, 1H), 5.24 (d, J = 17.8 Hz, 1H), 4.78 (d, J = 10.8 Hz, 1H), 4.18 (sept, J = 6.1 Hz, 1H), 3.65 
(s, 3H), 1.06 (d, J = 6.1 Hz, 6H). 
13
C NMR (101 MHz, CDCl3): δ = 152.3, 149.6, 141.3, 135.5, 119.2, 109.7, 108.0, 73.8, 55.3, 22.3. 
HRMS (ESI) for C12H15BF3O2
- [M−K]-: calcd.: 259.1117, found: 259.1120. 
IR (ATR):  ̃ = 2973 (w), 2936 (w), 1563 (w), 1458 (m), 1417 (w), 1285 (m), 1207 (m), 1117 (m), 
966 (s). 
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3-(benzyloy)-4-methoxy-2-((trimethylsilyl)ethynyl)benzaldehyde (90)  
 
To a solution of benzyl iodoisovanillin (63) in THF (130 mL) was added triethylamine (26.3 mL, 
189 mmol, 6.00 eq.), giving a dark-brown solution. CuI (0.30 g, 1.58 mmol, 0.05 eq.), Pd(PPh3)2Cl2 
(0.55 g, 0.79 mmol, 0.025 eq.) and TMS-acetylene (11.2 mL, 78.8 mmol, 2.50 eq.) were added. The 
reaction was stirred at 60 °C for 12 h under air. The reaction was cooled to room temperature, filtered 
over celite and the filter cake rinsed with EtOAc (3 x 50 mL). The solvent was removed under reduced 
pressure and the crude product was purified by flash column chromatography (SiO2, Hex/EtOAc = 9/1 
to 8/2), giving 90 as orange crystalline solid (10.6 g, 31.3 mmol, 99%). 
Crystals suitable for X-ray analysis were grown from EtOAc. 
Rf = 0.61 (hexanes/EtOAc = 9/1, UV 254 nm, PAA). 
1
H NMR (CDCl3, 400 MHz) δ = 10.40 (s, 1H), 7.72 (d, J = 8.7 Hz, 1H), 7.61 – 7.53 (m, 2H), 7.45 –
 7.28 (m, 3H), 6.98 (d, J = 8.7 Hz), 5.13 (s, 2H), 3.92 (s, 3H), 0.26 (s, 9H). 
13
C NMR (CDCl3, 100 MHz) δ = 190.9, 158.0, 137.2, 130.0, 128.4, 128.4, 128.2, 124.4, 122.2, 112.3, 
107.1, 96.2, 75.3, 56.3, 56.3, –0.12. 
HRMS (ESI) for C20H23O3Si
+ 
[M+H]
+
: calcd.: 339.1411, found: 339.1412. 
IR (ATR):  ̃ = 3032 (w), 2959 (w), 2899 (w), 2841 (w), 2744 (w), 2151 (w), 1687 (s), 1580 (s), 1497 
(w), 1482 (m), 1455 (w), 1438 (m), 1386 (w), 1373 (w), 1307 (m), 1280 (s), 1251 (s), 1194 (w), 1167 
(w), 1080 (s), 1016 (w), 962 (w), 904 (w), 840 (s), 786 (m), 760 (m), 731 (m), 697 (m).  
1-(3-(benzyloxy)-4-methoxy-2-((trimethylsilyl)ethynyl)phenyl)but-3-en-1-ol (91) 
 
Sonogashira product 90 (9.97 g, 29.5 mmol, 1.00 eq.) was dissolved in benzene and concentrated in 
vacuo. The residue was dissolved in THF (120 mL) and cooled to 0 °C. A solution of allylmagnesium 
bromide (1 M in diethyl ether, 35.3 mL, 35.3 mmol, 1.20 eq.) was added dropwise to the reaction. 
After 1 h, the reaction was quenched with saturated aqueous NH4Cl (100 mL). After the addition of 
EtOAc (50 mL) the layers were separated and the aqueous phase was extracted with EtOAc 
Part I: Experimental Procedures 
76 
(2 x 100 mL). The combined organic layers were dried over MgSO4, filtered and concentrated under 
reduced pressure. Purification of the crude product by flash column chromatography 
(SiO2, hexanes/EtOAc = 9/1) gave 91 as a yellow oil (10.6 g, 27.9 mmol, 89%).  
Rf = 0.5 (hexanes/EtOAc = 9/1, UV 254 nm, PAA). 
1
H NMR (CDCl3, 400 MHz) δ = 7.58 – 7.56 (m, 2H), 7.39 – 7.29 (m, 3H), 7.18 (d, J = 8.56 Hz, 1H), 
6.92 (d, J = 8.56 Hz), 5.86 (dddd, J = 16.9 Hz, 10.1 Hz, 7.6 Hz, 6.5 Hz, 1H), 5.21 – 5.06 (m, 3H, H-
10), 5.11 (s, 2H), 3.85 (s, 3H), 2.71 – 2.58 (m, 1H), 2.47 – 2.36 (m, 1H), 2.30 (d, J = 4.2 Hz, 1H), 0.25 
(s, 9H). 
13
C NMR (CDCl3, 100 MHz) δ = 151.9, 149.5, 139.5, 137.7, 135.1, 128.4, 128.3, 128.0, 121.0, 118.1, 
116.0, 113.2, 104.7, 98.9, 75.1, 71.3, 56.2, 42.8, 0.0. 
HRMS (ESI) for C23H27O2Si
+
 [M–OH–]+: calcd.: 363.1775, found: 363.1779. 
IR (ATR):  ̃ = 3404 (w), 2957 (m), 2150 (w), 1598 (w), 1482 (m), 1433 (m), 1372 (w), 1272 (m), 
1249 (s), 1085 (s), 1025 (w), 914 (w), 843 (s), 759 (w), 696 (w). 
Enantiomeric excess of 91 was determined by HPLC analysis on chiral stationary phase (DAICEL 
CHIALPAK IC, 4.6 x 250 mm, 25 °C, 1 mL/min, 3% i-PrOH in heptane, detection at 254 nm); tR first 
enantiomer = 11.390 min, tR second enantiomer = 14.840 min. 
Rac-1-(3-(benzyloxy)-2-ethynyl-4-methoxyphenyl)but-3-en-1-ol (92) 
 
A solution of alcohol 91 (10.6 g, 27.9 mmol, 1.00 eq.) in THF (220 mL) was cooled to 0 °C and a 
solution of TBAF (1 M in THF, 33.4 mL, 33.4 mmol, 1.20 eq.) was added dropwise over 15 minutes. 
The brown reaction was stirred for 45 min at 0 °C, quenched with saturated aqueous NH4Cl (70 mL) 
and diluted with EtOAc (70 mL). The two layers were separated and the aqueous phase was extracted 
with EtOAc (3 x 70 mL). The combined organic layers were washed with brine, dried over MgSO4 
and concentrated under reduced pressure. Purification by flash column chromatography (SiO2, 
hexanes/EtOAc = 8/2 to 6/4) gave 92 as a yellow oil (5.50 g, 17.8 mmol, 98%).  
Rf = 0.35 (hexanes/EtOAc = 7/3, UV 254 nm, PAA). 
1
H NMR (100 MHz, CDCl3) δ = 7.57 – 7.51 (m, 1H), 7.40 – 7.28 (m, 3H), 7.21 (d, J = 8.6 Hz, 1H), 
6.95 (d, J = 8.6 Hz, 1H), 5.85 (dddd, J = 16.9, 10.2, 7.7, 6.5, 1H), 5.19 – 5.09 (m, 3H), 5.10 (s, 
2H), 3.85 (s, 3H), 3.51 (s, 1H), 2.69 – 2.56 (m, 1H), 2.49 – 2.39 (m, 1H), 2.21 (d, J = 3.4 Hz, 1H). 
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13
C NMR (100 MHz, CDCl3) δ = 151.8, 149.7, 139.2, 137.4, 134.8, 128.4, 128.2, 128.0, 121.1, 118.2, 
115.2, 113.3, 86.6, 77.6, 75.1, 70.8, 56.0, 42.7. 
HRMS (ESI) for C20H19O2
+ 
[M–OH–]+: calcd.: 291.1380, found: 291.1381. 
IR (ATR):  ̃ = 3280 (m), 3065 (w), 3031 (w), 2939 (w), 2837 (w), 1740 (w), 1642 (w), 1601 (w), 
1570 (w), 1480 (s), 1454 (m), 1374 (m), 1321 (w), 1293 (m), 1267 (s), 1249 (s), 1218 (s), 1193 (m), 
1169 (w), 1117 (w), 1066 (s), 1021 (m), 994 (m), 981 (s), 930 (w), 913 (s), 891 (m), 871 (s), 842 (m), 
809 (s), 791 (w), 747 (s), 700 (s). 
Enantiomeric excess of 92 was determined by HPLC analysis on chiral stationary phase. Conditions 
for the separation of the enantiomers are reported on page 80. 
Telescoped Procedure for the synthesis of Rac-92. 
 
To a solution of benzyl iodoisovanillin (63) (10.5 g, 28.5 mmol, 1.00 eq.) in THF (120 mL) were 
added triethylamine (23.8 mL, 171 mmol, 6.00 eq.), CuI (0.27 g, 1.42 mmol, 0.05 eq.), Pd(PPh3)2Cl2 
(0.5 g, 0.71 mmol, 0.025 eq.) and TMS-acetylene (10.1 mL, 71.2 mmol, 2.50 eq.) in sequence. The 
reaction flask was sealed with a plastic cap and heated to 60 °C for 12 h.  
After full conversion of the starting material 63 (Rf = 0.53 in hexanes/EtOAc = 7/3) to the 
intermediate Sonogashira product 90 (Rf = 0.61 in hexanes/EtOAc = 9/1), the solution was cooled to 0 
°C (ice-acetone bath) and allylmagnesium bromide (1 M in diethyl ether, 71.2 mL, 71.2 mmol, 
2.50 eq.) was added dropwise to the reaction via cannula.  
After stirring for 2 h, the dark grey reaction mixture was cooled to 0 °C (ice-acetone bath) and MeOH 
(117 mL, 2.88 mol, 100 eq.) was added dropwise. Then, KOH pellets (7.99 g, 142 mmol, 9.29 eq.) 
were added. After 7 h, TLC showed incomplete consumption of the starting material S4 (Rf = 0.5 in 
hexanes/EtOAc = 9/1), and a second charge of KOH pellets (7.99 g, 142 mmol, 9.29 eq.) was added. 
After further 3 h the reaction was complete, and the mixture was filtered over a pad of celite and 
washed with MeOH (300 mL). The solvent was evaporated under reduced pressure, and the black 
residue was taken up in water (100 mL), saturated aqueous NH4Cl (100 mL) and EtOAc (100 mL). 
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The layers were separated and the aqueous phase was extracted with EtOAc (2 x 100 mL). The 
combined organic layers were dried over MgSO4, filtered and concentrated under reduced pressure. 
Purification of the crude product by flash column chromatography (SiO2, hexanes/EtOAc = 8/2) gave 
92 as a clear yellow oil (6.47 g, 21.0 mmol, 74%).  
Spectral data matched the ones reported on page 76. 
1-(3-(benzyloxy)-2-ethynyl-4-methoxyphenyl)but-3-en-1-one (142) 
 
A solution of allylic alcohol 92 (6.47 g, 21.0 mmol, 1.00 eq.) in CH2Cl2 (213 mL) was cooled to 0 °C 
and powdered NaHCO3 (7.93 g, 94.5 mol, 4.50 eq.) was added, followed by Dess-Martin periodinane 
(10.1 g, 23.7 mmol, 1.13 eq.). After 1 h, a half-saturated solution of Na2SO3 (100 mL) was added and 
the reaction mixture was vigorously stirred for 30 minutes. The reaction was diluted with water (100 
mL) and CH2Cl2 (100 mL). The layers were separated and the aqueous layer was extracted with 
CH2Cl2 (2 x 100 mL). The combined organic layers were washed with aqueous NaOH (1 M, 150 mL), 
brine (150 mL), dried over MgSO4, filtered and concentrated under reduced pressure. Purification of 
the crude product by flash column chromatography (SiO2, hexanes/EtOAc = 20/1 to 6/4) gave 142 as a 
white solid (4.20 g, 13.7 mmol, 66%).  
Rf = 0.57 (hexanes/EtOAc = 7/3, UV 254 nm, CAM). 
Melting point = 61.0 – 62.3 °C. 
1
H NMR (400 MHz, CDCl3) δ = 7.57 – 7.48 (m, 3H), 7.41 – 7.29 (m, 3H), 6.94 (d, J = 8.7 Hz, 1H), 
6.05 (ddt, J = 17.1, 10.4, 6.8 Hz, 1H), 5.25 – 5.14 (m, 2H), 5.10 (s, 2H), 3.89 (s, 3H), 
3.85 (dt, J = 6.7, 1.5 Hz, 2H), 3.59 (s, 1H). 
13
C NMR (CDCl3, 100 MHz) δ = 198.9, 155.9, 150.8, 137.2, 134.3, 131.4, 128.5, 128.5, 128.4, 128.4, 
128.3, 128.2, 125.9, 118.6, 116.5, 112.0, 87.7, 78.3, 77.4, 75.2, 56.1, 46.3. 
HRMS (EI): for C20H18O3
∙+
 [M
∙+
]: calcd.: 306.1256, found: 306.1250. 
IR (ATR):  ̃ = 3273 (w), 3030 (w), 2841 (w), 2357 (w), 1650 (m), 1582 (m), 1562 (m), 1453 (m), 
1269 (s), 1246 (s), 1171 (m), 1096 (m), 1072 (s), 991 (m), 809 (m), 697 (s). 
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(S)-1-(3-(benzyloxy)-2-ethynyl-4-methoxyphenyl)but-3-en-1-ol (92) 
 
Ketone 4 (4.20 g, 13.7 mmol, 1.00 eq.) was dissolved in THF (14.6 mL) and cooled to −60 °C.  A 
solution of (−)-B-Chlorodiisopinocampheylborane (60% in heptane, 12.4 mL, 20.6 mmol, 1.50 eq.) 
was added at −60 °C. The mixture solidified and was placed in a −40 °C cooling bath (dry 
ice/isopropanol) connected to a cryostat and was stirred at this temperature for 3 days.  After complete 
consumption of the starting material (TLC taken directly from the reaction mixture), acetaldehyde 
(3.46 mL, 61.7 mmol, 4.50 eq.) was added dropwise and the solution was warmed to room 
temperature over the course of 1 h. The solvent was removed under reduced pressure and the residue 
was dissolved in Et2O (47 mL) and diethanolamine (2.89 mL, 30.2 mmol, 2.20 eq.) was added at room 
temperature. The formation of a white precipitate was observed. The suspension was stirred for 2 h 
before it was filtered over a silica plug (d = 5 cm, h = 2 cm) and the filter cake was rinsed with EtOAc 
(4 x 50 mL). Removal of the volatiles in vacuo and purification by flash column chromatography 
(SiO2, hexanes/EtOAc = 8/2) afforded alcohol 92 as a yellow oil (3.05 g, 9.88 mmol, 72%). 
Rf = 0.35 (hexanes/EtOAc = 7/3, UV 254 nm, PAA). 
Melting point = 79.4 − 81.7 °C. 
    
   = –58.2° (c = 2.60, CH2Cl2). 
Spectral data matched the racemic sample prepared according to the procedure reported on page 76. 
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Enantiomeric excess of 92 was determined by HPLC analysis on chiral stationary phase 
(DAICEL CHIALPAK IC, 4.6 x 250 mm), 25 °C, 1 mL/min, 15% i-PrOH in heptane, detection at 269 
nm) to be 95.5% by comparison with a racemic sample and coinjection; tR major enantiomer = 14.221 
min, tR minor enantiomer = 35.710 min. 
d 
- Racemic sample of 92: 
 
- Enantioenriched sample of 92: 
  
- Coinjection: 
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(S)-((1-(3-(benzyloxy)-2-ethynyl-4-methoxyphenyl)but-3-en-1-yl)oxy)(tert-
butyl)dimethylsilane (93) 
 
To a stirred solution of 92 (5.74 g, 18.6 mmol, 1.00 eq.) in DMF (87 mL) imidazole (3.17 g, 
46.5 mmol, 2.50 eq.) and TBSCl (3.37 g, 22.3 mmol, 1.20 eq.) were added. Stirring was continued for 
4 h at room temperature before the reaction was quenched with saturated aqueous NH4Cl. The layers 
were separated and the aqueous layer was extracted with EtOAc (3 x 80 mL). The combined organic 
layers were washed with aqueous LiCl (10% w/w, 4 x 50 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure. Purification of the crude product was performed by flash column 
chromatography (SiO2, hexanes/EtOAc = 9/1) to afford 93 as a yellow oil (7.02 g, 16.6 mmol, 89%).  
Rf = 0.54 (hexanes/EtOAc = 9/1, UV 254 nm, CAM). 
1
H NMR (400 MHz, CDCl3) δ = 7.56 – 7.51 (m, 2H), 7.40 – 7.27 (m, 3H), 7.22 (d, J = 8.6 Hz, 1H), 
6.93 (d, J = 8.6 Hz, 1H), 5.84 (ddt, J = 19.1, 9.3, 7.1, 1H), 5.16 – 5.09 (m, 2H), 5.11 (s, 2H), 5.05 –
 5.01 (m, 1H), 5.00 – 4.97 (m, 1H), 3.84 (s, 3H), 3.48 (s, 1H), 2.48 – 2.28 (m, 2H), 0.88 (s, 9H), 0.03 
(s, 2H), –0.13 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ = 151.4, 149.1, 140.9, 137.6, 135.6, 128.6, 128.3, 128.1, 121.9, 116.9, 
114.8, 113.3, 86.2, 77.8, 75.1, 72.0, 56.1, 44.4, 26.0, 18.4, –4.6, –4.8. 
HRMS (ESI) for C26H38O3NSi
+
 [M+NH4]
+
: calcd.: 440.2615, found: 440.2623. 
IR (ATR):  ̃ = 3287 (w), 2929 (m), 2856 (m), 1598 (w), 1483 (s), 1432 (m), 1372 (w), 1294 (m), 
1256 (s), 1077 (s), 1002 (m), 912 (m), 835 (s), 811 (m), 776 (m), 740 (w), 698 (w). 
    
   = –40.0 (c = 1.35, CH2Cl2). 
(3aR,5S)-9-(benzyloxy)-5-((tert-butyldimethylsilyl)oxy)-8-methoxy-3,3a,4,5-
tetrahydro-2H-cyclopenta[a]naphthalen-2-one (94) 
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Note: Due to a 15% yield drop upon further scale-up, the following procedure was performed in two 
separate flasks with identical amounts of substrate, which were combined for purification. The use of 
a new bottle of Co2(CO)8 provided better and more reproducible results.  
In a 250 mL round-bottom flask, enyne  93 (1.64 g, 3.88 mmol, 1.00 eq.) was dissolved in DCE 
(78 mL) and stirred at room temperature. Under exclusion of light, Co2(CO)8 (1.59 g, 4.66 mmol, 1.20 
eq.) was added in one portion and the reaction was stirred in the dark. After successful complexation 
(monitored by TLC in hexanes/Et2O = 9/1; Rf of 93 = 0.32; Rf of Co-complex = 0.9; approx. 4 h) the 
reaction was cooled to 0 °C and trimethylamine N-oxide dihydrate (2.59 g, 23.3 mmol, 6.00 eq.) was 
added portionwise to the light-protected brown reaction mixture. Stirring was continued for 12 h and 
the reaction was allowed to warm to room temperature while a color change to dark violet was 
observed. The reactions were filtered over silica (ø = 6 cm, h = 4 cm) and the filter pad was rinsed 
with EtOAc until only colorless filtrate was obtained. Concentration of the filtrate under reduced 
pressure and purification by flash column chromatography (SiO2, dry loading by adsorption on SiO2, 
hexanes/EtOAc = 98/2 to 5/5) afforded tricycle 94 as an off-white solid (2.46 g, 5.46 mmol, 70%).  
Crystals suitable for X-ray analysis were grown from EtOAc by slow evaporation. 
Rf = 0.11 (hexanes/EtOAc = 95/5, UV 366 nm, CAM). 
Melting point = 128.3 – 132.7 °C. 
1
H NMR (400 MHz, CDCl3) δ = 7.42 – 7.37 (m, 2H), 7.37 – 7.27 (m, 3H), 7.04 (d, J = 5.5 Hz, 1H), 
7.01 (d, J = 4.5 Hz, 1H), 6.90 (d,  J = 1.9 Hz, 1H), 5.06 (d, J = 10.7 Hz, 1H), 4.97 (d, J = 10.7 Hz, 
1H), 4.86 (t, J = 2.8 Hz, 1H), 3.90 (s, 3H), 3.55 – 3.44 (m, 1H), 2.67 (dd, J = 18.5, 6.7 Hz, 1H), 2.24 –
 2.18 (m, 1H), 2.07 (dd, J = 18.5, 3.3, 1H), 1.73 (td, J = 13.1, 3.0 Hz, 1H), 0.88 (s, 9H), 0.17 (s, 3H),  
0.10 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ = 209.9, 171.0, 152.6, 147.0, 136.8, 133.2, 129.7, 128.7, 128.5, 128.3, 
126.3, 124.8, 115.0, 74.6, 68.4, 56.1, 41.0, 39.0, 34.9, 25.9, 18.2, –4.1, –4.2. 
HRMS (ESI) for C20H24O2N
+
 [M+NH4]
+
: calcd.: 310.1802, found: 310.1806. 
IR (ATR):  ̃ = 2953 (m), 2927 (m), 2875 (w), 2855 (m), 1699 (m), 1676 (s), 1592 (m), 1480 (m), 
1470 (m), 1454 (m), 1442 (m), 1404 (w), 1358 (w), 1346 (w), 1333 (w), 1315 (w), 1302 (m), 1261 (s), 
1246 (s), 1232 (m), 1215 (w), 1206 (w), 1178 (m), 1112 (m), 1060 (s), 1041 (s), 1006 (m), 968 (s), 
944 (m), 911 (w), 898 (m), 874 (w), 831 (s), 811 (m), 795 (s), 771 (s), 762 (s), 725 (m), 700 (s). 
     
   = –29.9 (c = 1.5, CH2Cl2). 
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Enantiomeric excess of 94 was determined by HPLC analysis on chiral stationary phase (DAICEL 
CHIALPAK IC, 4.6 x 250 mm, 25 °C, 1mL/min, 30% i-PrOH in heptane, detection at 254 nm) to be 
97.7% by comparison with a racemic sample and coinjection; tR major enantiomer = 12.780 min, tR 
minor enantiomer = 19.122 min. 
 
- Racemic sample of 94: 
 
- Enantioenriched sample of 94: 
  
- Coinjection: 
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Rac-9-(benzyloxy)-5-hydroxy-8-methoxy-3,3a,4,5-tetrahydro-2H-
cyclopenta[a]naphthalen-2-one (95) 
 
To a solution of enyne 92 (60.0 mg, 195 µmol, 1.00 eq.) in THF (3.2 mL) was added Co2(CO)8 
(79.8 mg, 223 µmol, 1.20 eq.) in one portion and the reaction was stirred in the dark. After successful 
complexation (monitored by TLC, 6h) the reaction was cooled to 0 °C and N-methylmorpholine N-
oxide (68.4 mg, 584 µmol, 3.00 eq.) was added portionwise to the light-protected brown reaction 
mixture. After 16 h, the reaction mixture was filtered over silica (ø = 2 cm, h = 2 cm) and the filter pad 
was rinsed with EtOAc until only colorless filtrate was obtained. Concentration of the filtrate under 
reduced pressure and purification by flash column chromatography (SiO2, dry loading by adsorption 
on SiO2, hexanes/EtOAc = 1/1 to 3/7) afforded tricycle 95 as a colorless oil (26.0 mg, 
77.3 µmol, 40%).  
Rf = 0.10 (hexanes/EtOAc = 1/1, UV 254 nm, KMnO4) 
1
H NMR (400 MHz, CDCl3) δ = 7.40 (d, J = 6.8 Hz, 2H), 7.37 – 7.29 (m, 3H), 7.16 (d, J = 8.4 Hz, 
1H), 7.04 (d, J = 8.4 Hz, 1H), 6.88 (s, 1H), 5.04 (d, J = 10.6 Hz, 1H), 4.94 (d, J = 10.6 Hz, 1H), 4.89 
(t, J = 2.5 Hz, 1H), 3.89 (s, 3H), 3.50 – 3.40 (m, 1H), 2.68 (dd, J = 18.6 Hz, 6.6 Hz, 1H), 2.35 (d, J = 
13.1 Hz, 1H), 2.28 (br s, 1H), 2.07 (dd, J = 18.6, 3.2 Hz, 1H), 1.75 (td, J = 13.1 Hz, 3.2 Hz, 1H). 
13
C NMR (100 MHz, CDCl3) δ = 209.8, 170.3, 153.0, 147.1, 136.7, 132.4, 129.9, 128.6, 128.5, 128.4, 
126.3, 124.7, 115.3, 74.7, 67.7, 56.1, 40.9, 37.8, 34.8. 
HRMS (ESI) for C21H21O4
+
 [M+H]
+
: calcd.: 337.1434, found: 337.1436. 
IR (ATR):  ̃ = 3386 (br, m), 3031 (w), 2938 (w), 2839 (w), 2361 (s), 1699 (m), 1665 (s), 1583 (s), 
1479 (s), 1454 (m), 1439 (m), 1406 (w), 1374 (w), 1340 (s), 1304 (m), 1263 (s), 1196 (m), 1178 (m), 
1112 (s), 1056 (m), 1035 (s), 1002 (m), 964 (w), 921 (w), 876 (m), 846 (w), 820 (m), 752 (w), 733 
(w), 697 (m), 682 (w). 
2-(benzyloxy)-4-(but-3-en-1-yl)-3-ethynyl-1-methoxybenzene (97) 
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Allylic alcohol 92 (100 mg, 324 µmol, 1.00 eq.) was dissolved in CH2Cl2 (1.70 mL) and the solution 
cooled to –5 °C. Triethylsilane (210 µL, 1.30 mmol, 4.00 eq.) was added, followed by the dropwise 
addition of boron trifluoride etherate (80.0 µL, 649 µmol, 2.00 eq.). After 30 minutes, the reaction was 
quenched with sat. NaHCO3 (5 mL) and the layers were separated and the aqueous phase was 
extracted with CH2Cl2 (3 x 10 mL). The combined organic phases washed with brine (20 mL) and 
dried over MgSO4. The crude product was purified by flash column chromatography 
(SiO2, hexanes/Et2O = 20/1) to afford 97 as a pale yellow oil (66.0 mg, 226 µmol, 70%). 
Rf  = 0.50 (hexanes/Et2O = 9/1, UV 254 nm, CAM). 
Melting point = 171.1 – 173.5 °C. 
1
H NMR (400 MHz, CDCl3) δ = 7.57 (d, J = 7.0 Hz, 2H), 7.42 – 7.29 (m, 3H), 6.91 (d, J = 8.4 Hz, 
1H), 6.86 (d, J = 8.4 Hz, 1H), 5.88 (ddt, J = 17.0, 10.2, 6.6 Hz, 1H), 5.12 (s, 2H), 5.05 (dd, J = 17.0, 
1.7 Hz, 1H), 4.99 (dd, J = 10.2 ,1.7 Hz, 1H), 3.83 (s, 3H), 3.46 (s, 1H), 2.83 (t, J = 8.0, 6.6 Hz, 2H), 
2.39 (q, J = 8.0, 6.6 Hz, 2H). 
13
C NMR (100 MHz, CDCl3) δ = 151.0, 150.1, 138.3, 137.7, 128.5, 128.3, 128.0, 124.3, 117.3, 114.9, 
113.2, 85.2, 78.6, 75.2, 56.2, 34.7, 33.5. 
HRMS (ESI) for C20H24O2N
+
 [M+NH4]
+
: calcd.: 310.1802, found: 310.1806. 
IR (ATR):  ̃ = 3286 (w), 3065 (w), 3031 (w), 3001 (w), 2935 (w), 2837 (w), 2361 (w), 2101 (w), 
1639 (w), 1598 (w), 1570 (w), 1482 (s), 1463 (m), 1453 (m), 1433 (m), 1372 (m), 1335 (w), 1265 (s), 
1221 (m), 1162 (w), 1105 (w), 1074 (s), 1026 (s), 996 (m), 909 (s), 806 (m), 735 (s), 697 (s). 
Rac-9-(benzyloxy)-8-methoxy-3,3a,4,5-tetrahydro-2H-cyclopenta[a]naphthalen-2-
one (98)  
 
To a solution of enyne 97 (180 mg, 615 µmol, 1.00 eq.) in CH2Cl2 (24 mL) was added Co2(CO)8 (252 
mg, 738 µmol, 1.20 eq.) in one portion and the reaction was stirred in the dark. After successful 
complexation (monitored by TLC, 2 h) the reaction was cooled to 0 °C and trimethylamine N-oxide 
dihydrate (410 mg, 3.69 mmol, 6.00 eq.) was added portionwise to the light-protected brown reaction 
mixture. After 16 h, the reaction mixture was filtered over silica (ø = 3 cm, h = 4 cm) and the filter pad 
was rinsed with EtOAc until only colorless filtrate was obtained. Concentration of the filtrate under 
reduced pressure and purification by flash column chromatography (SiO2, dry loading by adsorption 
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on SiO2, hexanes/EtOAc = 9/1 to 1/1) afforded tricycle 98 as a colorless oil (52.0 mg, 162 µmol, 
26%).  
Rf  = 0.30 (hexanes/EtOAc = 8/2). 
1
H NMR (CDCl3, 400 MHz): δ = 7.42 (d, J = 6.6 Hz, 2H), 7.37 – 7.28 (m, 3H), 6.98 (d,
 
J = 8.4 Hz, 
1H), 6.93 (d, J = 8.4 Hz, 1H), 6.88 (d, J = 1.7 Hz, 1H), 5.04 (d, J = 10.7 Hz, 1H), 4.96 (d, J = 10.7 Hz, 
1H), 3.88 (s, 3H), 2.99 – 2.88 (m, 3H), 2.67 (dd, J = 18.5, 6.6 Hz, 1H), 2.25 – 2.18 (m, 1H), 2.07 
(dd, J = 18.5, 3.2 Hz, 1H), 1.63 – 1.53 (m, 1H). 
13
C NMR (CDCl3, 100 MHz): δ = 209.8, 171.2, 151.2, 147.5, 136.9, 132.4, 129.2, 128.6, 128.5, 128.2, 
125.1, 124.9, 115.4, 74.5, 56.3, 41.4, 41.0, 30.2, 29.8. 
HRMS (ESI) for C21H21O3
+
 [M+H]
+
: calcd.: 321.1485, found: 321.1487. 
IR (ATR):  ̃ = 2938 (w), 2906 (s), 2836 (s), 2361 (w), 2340 (w), 1701 (s), 1678 (s), 1584 (s), 1479 
(s), 1455 (m), 1439 (m), 1375 (s), 1298 (m), 1275 (s), 1263 (s), 1171 (m), 1111 (s), 1053 (m), 1022 
(m), 997 (m), 963 (s), 911 (w), 845 (s), 804 (w), 747 (w), 698 (w). 
9b-allyl-9-(benzyloxy)-5-((tert-butyldimethylsilyl)oxy)-8-methoxy-1,3,3a,4,5,9b-
hexahydro-2H-cyclopenta[a]naphthalen-2-one (103) 
 
The Pauson–Khand product 94 (200 mg, 444 µmol, 1.00 eq.) was dissolved in benzene (10 mL) and 
the solvent was removed under reduced pressure. The residue was dissolved in THF (16 mL) and the 
solution was cooled to –78 °C. Allylmagnesium bromide (1.06 M in Et2O, 460 µL, 488 µmol, 1.1 eq.) 
was added dropwise, the yellow solution was stirred for 2 h. Subsequently, the reaction was quenched 
with saturated aqueous NH4Cl (10 mL). The aqueous layer was extracted with EtOAc (3 x 20 mL) and 
the combined organic phases were washed with saturated aqueous NaHCO3 (30 mL), brine (30 mL), 
dried over MgSO4 and filtered. The solvent was removed in vacuo to afford 104 (143.8 mg, 292 µmol, 
66%) that was directly subjected to the next step without further purification.  
Note:  104 could be stored for several weeks in a benzene matrix at –25 °C (100 mg/5 mL). Attempts 
to purify it by silica gel chromatography resulted in decomposition. 
To a solution of tertiary alcohol 104 (100 mg, 203 µmol, 1.0 eq.) in THF (4 mL) at –5 °C was added 
18-crown-6 (161 mg, 609 µmol, 3.00 eq.) followed by KHMDS (1M in THF, 609 µL, 609 µmol, 
3.00 eq.). The orange solution was stirred for 3 h and was slowly allowed to warm to room 
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temperature in the cooling bath. The reaction mixture was cooled to 0 °C and quenched with 
pH 7 buffer. The solution was extracted with EtOAc (3 x 20 mL), successively washed with saturated 
aqueous KCl (2 x 20 mL), brine (20 mL) and dried over MgSO4. After filtration the crude product was 
purified by purified by flash column chromatography (SiO2, hexanes/EtOAc = 9/1) to yield the 
rearrangement product 103 as a yellow oil (40.8 mg, 82.8 µmol, 48%).  
Rf  = 0.42 (hexanes/Et2O = 8/2) 
1
H NMR (CDCl3, 400 MHz): δ = 7.48 (d, J = 7.3 Hz, 2H), 7.40 (t, J = 7.3 Hz, 2H), 7.33 (t, J = 7.3 Hz, 
1H), 6.97 – 6.90 (m, 1H), 6.89 – 6.83 (m, 1H), 5.60 – 5.47 (m, 1H), 5.16 (d, J = 11.3 Hz, 1H), 5.04 (d, 
J = 11.3 Hz, 1H), 4.97 (d, J = 17.1 Hz, 1H), 4.91 (d, J = 10.5 Hz, 1H), 4.79 – 4.72 (m, 1H), 3.87 (s, 
3H), 3.18 – 3.02 (m, 2H), 2.82 (d, J = 19.2 Hz, 1H), 2.78 – 2.66 (m, 1H), 2.53 – 2.42 (m, 1H), 2.41 – 
2.28 (m, 1H), 2.04 (d, J = 19.2 Hz, 1H), 1.92 – 1.80 (m, 1H), 1.70 – 1.56 (m, 1H), 0.89 (s, 9H), 0.17 
(s, 3H), 0.15 (s, 3H). 
13
C NMR (CDCl3, 100 MHz): δ = 220.2, 152.6, 146.7, 138.0, 136.0, 135.2, 132.3, 128.6, 127.8, 127.4, 
124.9, 117.0, 111.0, 73.6, 68.6, 55.8, 50.5, 44.6, 43.3, 43.0, 36.6, 32.6, 25.9, 18.1, -4.1, -4.4. 
HRMS (ESI) for C30H44O4NSi
+
 [M+NH4]
+
: calcd.: 510.3034, found: 510.3043. 
IR (ATR):  ̃ = 3069 (w), 3032 (w), 2953 (m), 2928 (m), 2855 (w), 2361 (w), 2252 (w), 1737 (s), 1638 
(w), 1598 (w), 1577 (w), 1483 (m), 1463 (m), 1434 (m), 1403 (w), 1353 (m), 1324 (w), 1297 (m), 
1270 (s), 1251 (s), 1201 (w), 1172 (m), 1136 (w), 1079 (s), 1055 (s), 1025 (m), 1002 (s), 974 (s), 947 
(m), 910 (m), 878 (w), 833 (s), 815 (m), 795 (m), 773 (s), 732 (s), 696 (s).  
Rac-(3aR,5S,9bR)-9b-allyl-9-(benzyloxy)-5-hydroxy-8-methoxy-1,3,3a,4,5,9b-
hexahydro-2H-cyclopenta[a]naphthalen-2-one (105) 
 
To a solution of the rearrangement product 103 (23.0 mg, 46.7 µmol, 1.00 eq.) in THF (1.70 mL) was 
added tetrabutylammonium fluoride hydrate (1 M in THF, 100 µL, 0.10 mmol, 2.14 eq.) at 0 °C. The 
reaction mixture was stirred at room temperature for 12 h and subsequently quenched with saturated 
aqueous NH4Cl (5 mL). The aqueous layer was extracted with EtOAc (3 x 10 mL) and combined 
organic phases were washed with brine (20 mL) and dried over MgSO4. The crude product was 
purified by purified by flash column chromatography (SiO2, hexanes/EtOAc = 1/1) to yield the 
rearrangement product 105 as a pale yellow oil (12.0 mg, 31.7 µmol, 68 %). 
Rf  = 0.26 (hexanes/EtOAc = 1/1). 
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1
H NMR (CDCl3, 400 MHz): δ (ppm) = 7.43 (d, J = 7.5 Hz, 2H), 7.20 (t, J = 7.5 Hz), 7.11 (t, J = 7.4 
Hz, 1H), 6.88 – 6.77 (m, 1H), 6.50 (d, J = 8.3 Hz, 1H), 5.52 – 5.35 (m, 1H), 5.19 (d, J = 11.2 Hz, 1H), 
4.89 – 4.74 (m, 3H), 4.50 (s, 1H), 3.26 (s, 3H), 3.14 (dd, J = 13.0, 5.6 Hz), 2.85 – 2.75 (m, 2H), 2.42 – 
2.29 (m, 2H), 2.07 – 1.97 (m, 1H), 1.76 (d, J = 19.0 Hz, 1H), 1.70 – 1.60 (m, 1H), 1.24 (t, J = 13.6 Hz, 
1H). 
13
C NMR (C6D6, 100 MHz): δ (ppm) = 216.5, 153.1, 147.3, 138.5, 136.2, 135.5, 132.6, 128.8, 128.1, 
125.3, 117.5, 111.6, 74.0, 68.2, 55.4, 50.6, 44.7, 43.0, 35.3, 32.6. 
(2S,3aS,5S)-9-(benzyloxy)-5-((tert-butyldimethylsilyl) oxy)-8-methoxy-3,3a,4,5-
tetrahydro-2H-cyclopenta[a]naphthalen-2-ol (106) 
 
Enone 94 (1.56 g, 3.47 mmol, 1.00 eq.) was added portionwise to a stirred suspension of LiAlH4 
(92.3 mg, 2.43 mmol, 0.70 eq.) in Et2O (30 mL) placed in an ice-acetone bath (0 °C). The reaction was 
stirred for 45 minutes and quenched by sequential slow addition of water (125 µL), 
aqueous NaOH (2.5 M, 125 µL) and water (375 µL). The yellow suspension was filtered over a pad of 
silica (d = 5 cm, h = 3 cm) and the filter cake rinsed with EtOAc (200 mL). Evaporation of the filtrate 
gave a white foam, which was triturated with EtOAc and hexanes under sonication to afford 7 as white 
solid (1.55 g, 3.44 mmol, 98%).  
In the racemic series, crystals suitable for X-ray analysis were grown from EtOAc by slow 
evaporation.  
Rf = 0.23 (hexanes/EtOAc = 8/2, UV 254 nm, CAM). 
Melting point = 111.8 – 113.5 °C. 
1
H NMR (400 MHz, CDCl3) δ = 7.51 – 7.45 (m, 2H), 7.41 – 7.29 (m, 3H), 6.98 (d, J = 8.4 Hz, 1H), 
6.86 (d, J = 8.4 Hz, 1H), 6.64 (t, J = 2.1 Hz, 1H), 5.01 (d, J = 10.6 Hz, 1H), 4.97 (d, J = 10.8 Hz, 1H), 
4.76 (t, J = 3.0 Hz, 1H), 3.86 (s, 3H), 3.21 – 3.08 (m, 1H), 2.62 (dt, J = 12.5, 7.2 Hz, 1H), 2.07 (dt, J = 
13.0, 3.7 Hz, 1H), 1.64 (s, 1H), 1.59 (dt, J = 13.2, 3.4 Hz, 1H), 1.31 – 1.18 (m, 1H), 0.88 (s, 9H), 0.15 
(s, 3H), 0.06 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ = 152.5, 146.2, 140.2, 137.8, 132.7, 131.9, 128.4, 128.4, 128.0, 125.9, 
125.6, 112.0, 78.0, 73.6, 69.3, 56.1, 41.2, 39.3, 37.7, 26.0, 18.2, –4.1, –4.2. 
HRMS (ESI) for C27H33O3Si
– 
[M–H3O
+
]: calcd.: 433.2215, found: 433.2209. 
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IR (ATR):  ̃ = 3343 (br, w), 2952 (m), 2928 (m), 2883 (m), 2866 (m), 2361 (w), 1597 (w), 1571 (w), 
1479 (s), 1440 (m), 1408 (w), 1377 (m), 1350 (m), 1327 (m), 1303 (m), 1267 (s), 1255 (s), 1220 (m), 
1164 (w), 1124 (m), 1109 (m), 1052 (s), 977 (s), 920 (m), 832 (s), 808 (m), 795 (m), 773 (s), 752 (m), 
731 (m), 696 (m), 677 (m). 
    
   = −17.2 (c = 2.95, CH2Cl2). 
(((2S,3aS,5S)-9-(benzyloxy)-8-methoxy-2-(2-(phenylsulfinyl)ethoxy)-3,3a,4,5-
tetrahydro-2H-cyclopenta[a]naphthalen-5-yl)oxy)(tert-butyl)dimethylsilane 
(117) 
 
To a suspension of NaH (60% w/w in mineral oil, 103 mg, 2.58 mmol, 1.00 eq.) in THF (30 mL) was 
added dropwise a solution of alcohol 106 (1.13 g, 2.58 mmol, 1.00 eq.) in THF (8 mL). The reaction 
was stirred for 30 minutes and phenyl vinyl sulfoxide (1.09 mL, 7.73 mmol, 3.00 eq.) was added, 
followed by catalytic amount of washed KH (oil free, stored under argon, tip of a Pasteur pipette). The 
reaction was stirred at room temperature for 21 h and then quenched at 0 °C with saturated aqueous 
NH4Cl (50 mL). After separation of the layers, the aqueous layer was extracted with EtOAc 
(3 x 50 mL) and the combined organic layers were washed with brine, dried over MgSO4, filtered and 
concentrated in vacuo to afford a mixture of 117 and unreacted phenyl vinyl sulfoxide. Although 
remaining phenyl vinyl sulfoxide does not interfere with the subsequent reaction, spectral analysis, 
was facilitated if it was removed. To this end, the crude reaction mixture was dissolved in i-PrOH, and 
a solution of methylamine was added (33% in EtOH, 33.2 mmol, 3.63 mL, 10.00 eq.). The light 
orange solution was stirred for 3 h at room temperature, upon which time TLC analysis indicated 
complete disappearance of phenylvinlyl sulfoxide (Rf = 0.48 in hexanes/EtOAc = 6/4, stains very 
strongly with KMnO4). The solvent was removed in vacuo and the crude reaction mixture was purified 
by flash column chromatography (SiO2, hexanes/EtOAc = 9/1 to 2/8) to give 117 as a colorless oil 
(1.74 g, 2.95 mmol, 89%). 
Rf = 0.52 (hexanes/EtOAc = 6/4, UV 254 nm, CAM). 
Note: NMR spectra are complex due to the presence of diastereoisomers resulting from the sulfoxide 
moiety. 
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1
H NMR (400 MHz, CDCl3) δ = 7.74 – 7.58 (m, 2H), 7.48 (ddt, J = 7.6, 5.8, 1.6 Hz, 5H), 7.42 – 7.28 
(m, 3H), 6.97 (dd, J = 8.4, 3.0 Hz, 1H), 6.85 (dd, J = 8.4, 1.7 Hz, 1H), 6.71 – 6.59 (m, 1H), 5.30 (s, 
1H), 4.99 (d, J = 1.9 Hz, 2H), 4.84 – 4.59 (m, 2H), 4.02 – 3.79 (m, 4H), 3.62 (ddt, J = 18.0, 10.2, 5.1 
Hz, 1H), 3.13 (d, J = 9.8 Hz, 1H), 3.07 – 2.85 (m, 2H), 2.52 (ddt, J = 26.8, 12.3, 7.2 Hz, 1H), 2.24 – 
1.97 (m, 1H), 1.63 (ddd, J = 12.7, 7.2, 3.1 Hz, 2H), 1.47 – 1.19 (m, 2H), 0.87 (s, 9H), 0.14 (d, J = 1.7 
Hz, 3H), 0.05 (d, J = 2.3 Hz, 3H). 
13
C NMR (100 MHz, CDCl3) δ = 152.5, 152.4, 146.3, 146.2, 144.2, 144.2, 140.7, 140.7, 138.0, 137.8, 
132.7, 132.6, 131.1, 129.3, 128.6, 128.5, 128.5, 128.4, 128.3, 128.0, 127.9, 125.9, 125.8, 125.5, 124.1, 
124.1, 112.1, 112.1, 85.8, 85.7, 73.7, 73.6, 69.3, 61.6, 61.2, 60.5, 58.8, 58.7, 56.1, 39.2, 39.1, 37.5, 
37.3, 37.3, 26.0, 21.2, 18.2, 14.3, -4.1, -4.2. 
HRMS (ESI) for C35H44NaO5SSi
+
 [M+H]
+
: calcd.: 627.2576, found: 627.258. 
IR (ATR):  ̃ =  3403 (br, w), 2953 (m), 2928 (m), 2855 (m), 1596 (w), 1570 (w), 1479 (m), 1442 (m), 
1339 (m), 1305 (m), 1269 (s), 1221 (w), 1164 (w), 1129 (m), 1085 (s), 1049 (s), 980 (m), 932 (m), 834 
(s), 809 (m), 796 (m), 775 (m), 747 (m), 695 (m). 
    
   = +18.0° (c = 0.66, CH2Cl2). 
2-((3aS,5S,9bS)-9-(benzyloxy)-5-((tert-butyldimethylsilyl)oxy)-8-methoxy-
3,3a,4,5-tetrahydro-9bH-cyclopenta[a]naphthalen-9b-yl)acetaldehyde (107) 
 
A 500 mL three-neck round-bottom flask fitted with a water-cooled Liebig-type reflux condenser, an 
internal thermometer and a rubber septum was charged with 117 (1.67 g, 2.83 mmol, 1.00 eq.), DCB 
(115 mL), NaHCO3 (21.34 g, 254 mmol, 90.0 eq.), and 3,5-di-tert-4-butylhydroxytoluene (31.1 mg, 
141 µmol, 0.05 eq.). Phenanthrene (262 mg, 1.47 mmol, 0.52 eq.) was added as internal standard and 
nitrogen was bubbled through the reaction mixture for 20 minutes via a 22-gauge steel needle under 
vigorous stirring (800 rpm). The needle was retracted from below the solvent surface and the setup 
was lowered in a preheated oil bath (197 °C). In the next hour, the clear reaction mixture foams and 
vapor accumulates in the head of the reflux condenser. After 2 h, the internal temperature reaches and 
stabilizes at 176 °C under moderate refluxing and occasional fizzing. 
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Every hour, a 0.1 mL aliquot is withdrawn with a syringe from the hot reaction mixture, diluted with 
CDCl3 and analyzed by 
1
H NMR (integration of signals against phenanthrene). After disappearance of 
the starting material 117 (6 h), the reaction is lifted from the oil bath, left to cool for one hour while 
stirring and filtered (porosity 3 glass frit covered with a thin layer of sand). The filter cake is washed 
with CHCl3 (2 x 100 mL) and the resulting orange solution is concentrated on a rotary evaporator (40 
°C water bath, 10 mbar) followed by distillation in a short-path apparatus (50 °C water bath, 3 mbar) 
to remove residual DCB. The brown residue was purified via flash column chromatography (SiO2, 
hexanes/Et2O = 100/1 to 85/15) to afford aldehyde 107 as light brown oil (838 mg, 1.80 mmol, 64%).  
Note: The reaction must be stopped as soon as the starting material is fully converted as judged by 
NMR analysis. Longer reaction times invariably lead to lower isolated yields. 
Rf = 0.52 (hexanes/EtOAc = 9/1, CAM). 
1
H NMR (400 MHz, CDCl3) δ = 9.63 (t, J = 3.3 Hz, 1H), 7.53 – 7.47 (m, 2H), 7.44 – 7.37 (m, 2H), 
7.36 – 7.31 (m, 1H), 7.22 (dd, J = 8.5, 0.9 Hz, 1H), 6.89 (d, J = 8.6 Hz, 1H), 6.87 – 6.82 (m, 1H), 
5.93 (ddd, J = 5.9, 3.0, 1.6 Hz, 1H), 5.26 (d, J = 11.2 Hz, 1H), 4.94 (ddd, J = 7.2, 2.0, 0.9 Hz, 1H), 
4.84 (d, J = 11.2 Hz, 1H), 3.86 (s, 3H), 2.58 – 2.47 (m, 1H), 2.36 – 2.18 (m, 4H), 2.03 – 1.92 (m, 2H), 
0.95 (s, 9H), 0.19 (s, 3H), 0.18 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ = 204.1 , 151.7 , 143.8, 138.0, 137.9, 136.5, 132.9, 132.4, 128.9, 
127.8, 127.6, 125.7, 111.0, 74.5, 68.1, 55.9, 51.4, 50.2, 45.1, 33.6, 32.9, 26.1, 18.3, –4.0, –4.4. 
HRMS (ESI) for C29H42O4NSi
+
 [M+NH4]
+
: calcd.: 496.2878, found: 496.2886. 
IR (ATR):  ̃ = 2929 (s), 2855 (s), 2740 (w), 2359 (w), 1718 (s), 1601 (w), 1573 (w), 1497 (w), 1474 
(s), 1439 (m), 1374 (m), 1345 (w), 1301 (m), 1256 (s), 1219 (m), 1165 (w), 1145 (m), 1130 (m), 1100 
(m), 1076 (m), 1049 (s), 987 (m), 938 (m), 910 (m), 832 (s), 812 (m), 775 (s), 732 (m), 697 (m).  
    
   = –18.2 (c = 0.66, CH2Cl2). 
2-((3aS,5S,9bS)-9-(benzyloxy)-5-((tert-butyldimethylsilyl)oxy)-8-methoxy-
3,3a,4,5-tetrahydro-9bH-cyclopenta[a]naphthalen-9b-yl)-N-methylethan-1-amine 
(108) 
 
Claisen rearrangement product 107 (836 mg, 1.80 mmol, 1.00 eq.) was dissolved in methanol (45 mL) 
and MgSO4 (867 mg, 7.20 mmol, 4.00 eq.) was added in one portion. Then a solution of methylamine 
(33% in EtOH, 1.97 mL, 18.00 mmol, 10.0 eq.) was added dropwise to the reaction. Upon 
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disappearance of the starting material (monitored by 1H NMR following withdrawal of a 0.1 mL 
aliquot of the reaction mixture, evaporation, and dissolution in CDCl3), the reaction was cooled to 
0 °C and NaBH4 (204.0 mg, 5.40 mmol, 3.00 eq.) was added in one portion. After stirring at room 
temperature for 3 h the reaction was quenched by the addition of water (20 mL) and diluted with brine 
(50 mL) and CHCl3 (50 mL). The layers were separated and the aqueous phase was extracted with 
CHCl3 (4 x 50 mL). The combined organic layers were washed with brine, dried over MgSO4, filtered 
and concentrated under reduced pressure to afford a brown oil. Purification was performed by flash 
column chromatography (SiO2, CHCl3/MeOH = 95/5 + 1% Et3N to 9/1 + 1% Et3N) and the reductive 
amination product 108 was obtained as a brown foam (865 mg, 1.75 mmol, 97%).  
Rf = 0.47 (CHCl3/MeOH = 9/1 + 1% Et3N, UV 254 nm, CAM). 
1
H NMR (400 MHz, CDCl3) δ = 7.43 – 7.39 (m, 2H), 7.34 – 7.28 (m, 2H), 7.26 – 7.21 (m, 1H), 7.16 
(dd, J = 8.6, 0.9 Hz, 1H), 6.74 (d, J = 8.6 Hz, 1H), 6.68 (d, J = 6.0 Hz, 1H), 5.75 (ddd, J = 6.0, 2.9, 
1.5 Hz, 1H), 5.07 (d, J = 11.0 Hz, 1H), 4.9 (td, J = 5.5, 1.0 Hz, 1H), 4.59 (d, J = 11.0 Hz, 1H), 3.76 (s, 
3H), 2.57 (td, J = 11.4, 5.2 Hz, 1H), 2.45 (td, J = 11.5,
 
5.1 Hz, 1H), 2.31 – 2.25 (m, 2H), 2.20 (s, 3H), 
2.18 –2.10 (m, 1H), 1.99 – 1.88 (m, 1H), 1.85  – 1.77 (m, 1H), 1.50 (td, J = 11.8, 5.2 Hz, 1H), 1.36 (td, 
J = 11.7, 5.0 Hz, 1H), 0.86 (s, 9H), 0.08 (s, 3H), 0.06 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ = 151.3, 143.9, 138.8, 138.2, 138.0, 132.9, 131.8, 128.5, 127.8, 127.7, 
124.6, 74.5, 67.6, 55.8, 52.0, 48.4, 46.0, 35.9, 35.6, 33.7, 33.6, 26.1, 18.3, –4.00, –4.5. 
HRMS (ESI) for C30H44O3NSi
+
 [M+H]
+
: calcd.: 494.3085, found: 494.3091. 
IR (ATR):  ̃ = 2929 (m), 2884 (w), 2855 (m), 1600 (w), 1573 (w), 1472 (m), 1439 (m), 1374 (m), 
1300 (m), 1253 (s), 1167 (w), 1144 (w), 1116 (m), 1076 (m), 1048 (s), 990 (m), 937 (m), 909 (m), 
813 (s), 773 (s), 729 (s), 697 (m). 
    
   = +22.6 (c = 0.21, CH2Cl2). 
(3aR,5aR,7S,11bS)-11-(benzyloxy)-7-((tert-butyldimethylsilyl)oxy)-10-methoxy-
3-methyl-1,2,3,3a,5,5a,6,7-octahydro-4H-benzo[6,7]indeno[1,7a-b]pyrrol-4-one 
(120) 
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Note: The following reaction was performed under the exclusion of light: laboratory and fume hood 
lights were turned off, the reaction flask wrapped in aluminum foil and flasks connected to a rotary 
evaporator were covered with aluminum foil. 
Reductive amination product 108 (350 mg, 0.709 μmol, 1.00 eq.) was dissolved in CH2Cl2 (64 mL). 
NIS (319 mg, 1.42 mmol, 2.00 eq.) was added in one portion at room temperature and the mixture was 
stirred for 10 min. The flask was moved to a rotary evaporator and the solvent was removed in vacuo 
(25 °C water bath, 5 mbar) followed by drying on high vacuum for 5 min (0.5 mbar). The resulting 
rusty brown foam (119) was dissolved in DMSO (143 mL) and stirred for 5 min at room temperature 
before Et3N (296 μL, 2.13 mmol, 3.00 eq.) was added. The reaction was sealed with a polyethylene 
cap and stirred for 22 h at room temperature. The solution was cooled to 0 °C and water (100 mL) was 
added. After the mixture was stirred for 5 min, it was diluted with EtOAc (100 mL) and 10% LiCl 
(200 mL). The aqueous layer was extracted with EtOAc (3 x 100 mL) and the combined organic layers 
were washed with 10% LiCl (3 x 100 mL), brine, dried over MgSO4 and filtered. The solvent was 
removed in vacuo and the resulting brown oil was purified by flash column chromatography (Et3N-
deactivated SiO2, hexanes/EtOAc = 9/1 to 8/2) to afford 120 as light yellow oil (231 mg, 455 μmol, 
64%).  
Rf = 0.39 (hexanes/EtOAc = 8/2, UV 254 nm, CAM). 
1
H NMR (400 MHz, C6D6) δ = 7.61–7.53 (m, 2H), 7.42 (dd, J = 8.5, 1.0 Hz, 1H), 7.25 (dd, 
J = 8.3, 6.9 Hz, 3H), 6.60 (d, J = 8.5 Hz, 1H), 5.14 (d, J = 11.1 Hz, 1H), 4.91 (d, J = 11.1 Hz, 1H), 
4.80 (ddd, J = 7.7, 4.6, 1.1 Hz, 1H), 3.98 (s, 1H), 3.29 (s, 3H), 2.90 (dt, J = 8.4, 6.8 Hz, 1H), 2.48 (s, 
3H), 2.42 (td, J = 7.6, 5.1 Hz, 1H), 2.17 – 2.04 (m, 1H), 2.03 – 1.79 (m, 5H), 1.44 (ddd, J = 12.2, 6.7, 
5.2 Hz, 1H), 1.07 (s, 9H), 0.20 (s, 3H), 0.15 (s, 3H). 
13
C NMR (100 MHz, C6D6) δ = 213.4, 152.4, 144.3, 139.1, 138.8, 132.7, 128.6, 128.5, 123.5, 110.5, 
75.1, 73.9, 67.8, 55.4, 55.2, 53.7, 39.2, 37.0, 35.4, 35.0, 26.2, 18.4, –4.1, –4.6. 
HRMS (ESI) for C30H42O4NSi [M+H]
+
: calcd.: 508.2878, found: 508.2874. 
IR (ATR):  ̃ = 2929 (w), 2886 (m), 2856 (w), 2794 (w), 1736 (m), 1600 (w), 1576 (w), 1472 (m), 
1375 (w), 1304 (m), 1253 (s), 1156 (w), 1125 (m), 1077 (m), 1052 (m), 986 (m), 929 (m), 833 (s), 774 
(s), 733 (m), 697 (m), 678 (w). 
    
   = –99.3 (c = 0.22, CH2Cl2). 
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Rac-(3aR,5aS,11bS)-11-(benzyloxy)-10-methoxy-3-methyl-1,2,3,3a,5,5a-
hexahydro-4H-benzo[6,7]indeno[1,7a-b]pyrrol-4-one (128) 
 
Kornblum oxidation product 120 (120 mg, 237 μmol, 1.00 eq.) was dried on high vacuum for 5 min 
before it was dissolved in benzene (25 mL). Camphor-10-sulfonic acid (165 mg, 71.0 μmol, 3.00 eq.) 
was added at room temperature and the flask was sealed with a polypropylene cap. After stirring for 
1 h, saturated aqueous NaHCO3 (50 mL) was added and the mixture was diluted with EtOAc (50 mL). 
The aqueous layer was extracted with EtOAc (3 x 30 mL) and the combined organic layers were 
washed with brine, dried over MgSO4 and concentrated under reduced pressure. Purification by flash 
column chromatography (Et3N-deactivated SiO2, hexanes/EtOAc = 8/2) gave the elimination product 
128 as a colorless oil that solidified upon standing (61.2 mg, 163 μmol, 69%) 
Crystals suitable for X-ray analysis were grown from benzene by slow evaporation.  
Rf = 0.8 (hexanes/EtOAc = 8/2, UV 254 nm, CAM). 
Melting point = 111.8 – 113.5 °C. 
1
H NMR (400 MHz, CDCl3) δ = 7.61 – 7.45 (m, 2H), 7.43 – 7.28 (m, 3H), 6.92 (d, J = 8.2 Hz, 1H), 
6.78 (d, J = 8.3 Hz, 1H), 6.53 (dd, J = 9.3, 3.0 Hz, 1H), 6.02 (dd, J = 9.2, 2.5 Hz, 1H), 5.23 (d, J = 
10.7 Hz, 1H), 4.92 (d, J = 10.8 Hz, 1H), 3.88 (s, 3H), 3.77 (s, 1H), 2.93 (ddt, J = 14.7, 7.8, 2.8 Hz, 
1H), 2.74 (td, J = 8.5, 6.0 Hz, 1H), 2.55 (ddd, J = 8.6, 6.8, 4.2 Hz, 1H), 2.51 – 2.30 (m, 2H), 2.35 (s, 
3H), 1.65 (ddd, J = 13.0, 6.1, 4.3 Hz, 1H). 
13
C NMR (100 MHz, CDCl3) δ = 216.8, 152.8, 143.8, 137.8, 137.3, 130.2, 128.5, 128.4, 128.2, 128.0, 
127.1, 123.7, 109.7, 75.3, 72.3, 55.8, 54.7, 54.2, 39.9, 39.9, 39.1, 35.1. 
HRMS (ESI) for C24H26O3N
+
 [M+H]
+
: calcd.: 376.1907, found: 376.1911. 
IR (ATR):  ̃ = 3032 (w), 2933 (m), 2840 (w), 2793 (w), 1735 (s), 1596 (w), 1562 (w), 1471 (s), 1438 
(m), 1305 (m), 1292 (w), 1259 (s), 1188 (w), 1161 (w), 1136 (m), 1081 (m), 1061 (m), 1050 (m), 1029 
(m), 929 (w), 909 (w), 816 (m), 735 (m), 697 (m). 
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Rac-(3aR,11bS)-11-(benzyloxy)-10-methoxy-3-methyl-1,2,3,3a-tetrahydro-4H-
benzo[6,7]indeno[1,7a-b]pyrrol-4-one (129) 
 
A solution of ketone 128 (33.0 mg, 87.9 µmol, 1.00 eq., dried by 3 times by azeotropic removal of 
water with benzene) in THF (1.8 mL) was cooled to –78 °C. A solution of LDA (0.2 M in THF, 132 
µmol, 659 µL, 1.5 eq., prepared 30 minutes prior from DIPEA in THF and n-BuLi (2.3 M in hexane) 
at 0 °C) was added and the resulting yellow solution was stirred for 30 min at the same temperature. 
Then, a freshly prepared solution of N-tert-butylbenzenesulfinimidoyl chloride (130 handled and 
stored in a freezer inside an Ar-filled glovebox) in THF (0.25 M, 132 µmol, 529 µL, 1.50 eq.) was 
added dropwise and stirring was continued for 1 h at –78 °C. A solution of AcOH in THF (0.1 M, 879 
µmol, 879 µL, 10.00 eq.) was injected into the cold, bright yellow reaction mixture. After 10 minutes, 
the reaction was placed in an ice-water bath and saturated aqueous NaHCO3 (4 mL) was slowly added 
dropwise (bubbling). After 10 minutes, the reaction was diluted with EtOAc (20 mL) and the aqueous 
phase was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine 
(50 mL), dried over MgSO4, filtered and evaporated. The crude product was purified by flash column 
chromatography (SiO2, hexanes/EtOAc = 95/5 to 1/1) to deliver benzyl-sinoracutine 129 as an 
intensely yellow oil (22.0 mg, 58.9 µmol, 87%). 
Rf = 0.21 (hexanes/EtOAc = 7/3, UV 254 nm, UV 366 nm, CAM). 
1
H NMR (400 MHz, C6D6) δ = 7.73 – 7.50 (m, 2H), 7.33 – 7.23 (m, 2H), 6.63 (d, J = 8.3 Hz, 1H), 
6.35 (d, J = 8.3 Hz, 1H), 6.28 (d, J = 9.4 Hz, 1H), 6.10 – 5.98 (m, 1H), 5.80 – 5.70 (m, 1H), 5.18 (d, J 
= 10.4 Hz, 1H), 4.88 (d, J = 10.3 Hz, 1H), 4.36 (s, 1H), 3.22 (s, 3H), 2.63 (s, 3H), 2.52 (ddd, J = 10.3, 
9.1, 5.4 Hz, 1H), 2.17 (ddd, J = 12.2, 5.4, 2.0 Hz, 1H), 1.79 (ddd, J = 12.2, 10.3, 6.8 Hz, 1H). 
13
C NMR (100 MHz, C6D6) δ = 205.8, 173.3, 154.8, 146.0, 138.8, 137.5, 135.2, 130.4, 128.7, 126.6, 
126.3, 125.5, 119.8, 110.5, 74.7, 70.9, 56.6, 55.4, 50.8, 41.5, 38.0. 
HRMS (ESI) for C24H24NO3
+
 [M+H]
+
: calcd.: 374,1751, found: 374,1747. 
IR (ATR):  ̃ = 3790 (w), 3061 (w) 2934 (w), 2841 (w), 2360 (w), 1682 (s), 1610 (s), 1576 m, 1475 
(m), 1440 (m), 1375 (w), 1336 (w), 1264 (s) 1260 (w), 1176 (w), 1096 (w),  1061(w), 986 (w), 892 
(w), 858 (w) 764 (w) 741 (m). 
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(3aR,7S,11bS)-11-(benzyloxy)-7-((tert-butyldimethylsilyl)oxy)-10-methoxy-3-
methyl-1,2,3,3a,6,7-hexahydro-4H-benzo[6,7]indeno[1,7a-b]pyrrol-4-one (132) 
 
A solution of ketone 120 (213 mg, 420 µmol, 1.00 eq., dried 3 times by azeotropic removal of water 
with benzene) in THF (8.5 mL) was cooled to –78 °C. LDA (0.2 M in THF, 139 µmol, 694 µL, 1.5 
eq., prepared 30 minutes prior by addition of n-BuLi (2.3 M in hexanes) to DIPEA in THF at 0 °C) 
was added and the resulting yellow solution was stirred for 30 min at the same temperature. Then, a 
freshly prepared solution of N-tert-butylbenzenesulfinimidoyl chloride (stored in a freezer and handled 
inside an Ar-filled glovebox) in THF (0.25 M, 139 µmol, 557 µL, 1.50 eq.) was added dropwise and 
stirring was continued for 1 h at –78 °C. A solution of AcOH in THF (0.1 M, 926 µmol, 926 µL, 10.00 
eq.) was injected into the cold reaction mixture. After 10 minutes, the reaction was placed in an ice-
water bath and saturated aqueous NaHCO3 (4 mL) was slowly added dropwise (bubbling). After 10 
minutes, the reaction was diluted with EtOAc (20 mL) and the aqueous phase was extracted with 
EtOAc (3 x 20 mL). The combined organic layers were washed with brine (50 mL), dried over 
MgSO4, filtered and evaporated under reduced pressure. The crude product was purified by flash 
column chromatography (Et3N-deactivated SiO2, hexanes/EtOAc = 95/5 to 6/4) and furnished the title 
compound 132 as light yellow oil (38.0 mg, 75.1 µmol, 81%).  
Rf = 0.43 (hexanes/EtOAc = 7/3, UV 254 nm, CAM). 
1
H NMR (400 MHz, C6D6) δ = 7.61 – 7.50 (m, 2H), 7.25 (t, J = 7.5 Hz, 2H), 7.19 – 7.05 (m, 3H), 6.92 
(d, J = 8.4 Hz, 1H), 6.54 (d, J = 8.4 Hz, 1H), 6.25 – 5.94 (m, 1H), 5.10 (d, J = 11.0 Hz, 1H), 4.78 (t, J 
= 3.7 Hz, 1H), 4.72 (d, J = 11.0 Hz, 1H), 3.69 (s, 1H), 3.26 (s, 3H), 2.82 (ddd, J = 9.0, 7.0, 2.3 Hz, 
1H), 2.60 (s, 3H), 2.58 – 2.36 (m, 3H), 2.22 (ddd, J = 12.0, 9.8, 7.0 Hz, 1H), 1.66 (ddd, J = 12.0, 5.7, 
2.3 Hz, 1H), 0.90 (s, 9H), 0.08 (s, 3H), 0.02 (s, 3H). 
13
C NMR (100 MHz, C6D6) δ = 203.7, 175.7, 153.5, 146.8, 139.1, 136.1, 131.6, 131.1, 127.6, 124.8, 
111.7, 74.1, 73.9, 70.8, 57.1, 55.4, 53.6, 38.4, 37.8, 36.3, 26.0, 18.3, –4.1, –4.1. 
HRMS (ESI) for C30H40NO4Si
+
 [M+H]
+
: calcd.: 506.2721, found: 506.2719. 
IR (ATR):  ̃ = 3854 (w), 3746 (w), 3676 (w), 2955 (m), 2929 (m), 2856 (m), 2360 (w), 1734 (w), 
1695 (s), 1635 (m), 1599 (w), 1481 (m), 1300 (m), 1275 (m), 1154 (m), 1095 (m), 1047 (m), 834 (s). 
    
   = +23.0 (c = 0.17, CH2Cl2).  
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Sinoracutine - (3aR,11bS)-11-hydroxy-10-methoxy-3-methyl-1,2,3,3a-tetrahydro-
4H-benzo[6,7]indeno[1,7a-b]pyrrol-4-one (40) 
 
A 25 mL-round bottom flask was charged with 132 (122 mg, 241 µmol, 1.00 eq.), 
pentamethylbenzene (2.41 mmol, 358 mg, 10 eq.) and placed in an ice-water bath. Then, TFA 
(181 mmol, 13.4 mL, 750 eq.) was added dropwise under heavy stirring (800 rpm), resulting in a dark 
orange solution. The flask was sealed with a polypropylene cap, lifted from the ice bath, and placed in 
a 40 °C oil bath. After 14 h, excess TFA was removed by rotary evaporation (100 mbar, 40 °C). The 
dark brown residue was dissolved in DCM (50 mL) and water (25 mL) was added. Aqueous NH3 
(10 M, 5 mL) was added dropwise and the biphasic mixture was stirred for 5 minutes. The bright 
yellow organic layer was separated and the aqueous layer was extracted with CH2Cl2 (4 x 25 mL). The 
combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated in 
vacuo. Purification of the resulting orange oil by flash column chromatography (SiO2, hexanes/CH2Cl2 
= 1/1 to CH2Cl2 to CH2Cl2/MeOH = 95/5) afforded sinoracutine (40) as an orange solid that was 
contaminated with slight impurities. Based on NMR integration against tetrachloroethane as internal 
standard, the yield for this step amounts to 80% (0.196 µmol, 54 mg). 
Note: Sinoracutine is not stable to silica as evidenced by two-dimensional TLC analysis. Purification 
on Et3N–deactivated silica or Davisil (eluents used: hexanes/CHCl3, hexanes/acetone, hexanes/EtOAc, 
CH2Cl2/MeOH) did not improve the purity of the product, while chromatography on basic Alumina 
(Macherey Nagel, 50–200 μm, Brockmann I grade) resulted in complete degradation. 
Spectroscopically pure sinoracutine was isolated by purification of the abovementioned sample by 
semipreparative HPLC (Dynamax Microsorb 60-8 C18, 250 x 21.4 mm; H2O/Acetonitrile containing 
0.1% formic acid; gradient: 10% to 90% acetonitrile over 30 minutes; flow rate 20 mL/min; detection 
at 254 nm; tR = 12.2 min). The product-containing fractions were combined and freeze-dried on a 
Christ Alpha 2-4 LDplus lyophilizer to afford sinoracutine as a yellow powder (91% recovery) 
Note: Attempted extraction of the purified product (dissolved in H2O/MeCN + 0.1% FA) with 
aqueous NH3 and CH2Cl2 resulted in impure product. In another attempt, removal of the purified 
product dissolved in the HPLC solvent mixture on a rotary evaporator (10 mbar, 35 °C) resulted in 
partial decomposition. 
When this protocol was applied to 132 on a 59 µmol scale, racemic sinoracutine (40) could be 
obtained in 72% isolated yield after HPLC purification (42 µmol, 12 mg).  
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In the racemic series, orange crystals suitable for X-ray analysis were grown from a CH2Cl2 solution 
by slow vapor diffusion of pentane at room temperature. 
Rf = 0.28 (hexanes/EtOAc = 1/1, visibly yellow, UV 254 nm, UV 366 nm, CAM) 
1
H NMR (800 MHz, CDCl3) δ = 6.78 (d, J = 9.4 Hz, 1H), 6.75 (d, J = 8.2 Hz, 1H), 6.74 (d, J = 8.2 
Hz, 1H), 6.54 (d, J = 9.4 Hz, 1H), 5.84 (s, 1H), 3.91 (s, 3H), 3.77 (s, 1H), 3.17 (app tt, J = 9.7, 8.5, 1.0 
Hz), 2.92 (s, 3H), 2.86 – 2.78 (m, 1H), 2.37 (ddd, J = 13.6, 8.0, 1.3 Hz, 1H), 2.10 (ddd, J = 13.6, 10.8, 
8.5 Hz, 1H). 
13
C NMR (200 MHz, CDCl3) δ = 206.77, 175.06, 151.22, 145.74, 138.31, 127.75, 124.25, 123.40, 
121.36, 118.14, 109.54, 72.48, 56.01, 53.85, 51.60, 41.69, 36.49. 
HRMS (ESI) for C17H18NO3
+
 [M+H]
+
: calcd.: 284.1281, found: 284.1284. 
IR (ATR):  ̃ = 3554 (br, w), 3057 (w), 2944 (w), 2834 (w), 2582 (br, w) 1680 (s), 1600 (s), 1569 (s), 
1547 (s), 1503 (w), 1453 (s), 1437 (s), 1401 (s), 1339 (s), 1293 (w), 1254 (s), 1228 (m), 1202 (m), 
1158 (m), 1099 (m), 1086 (m), 1058 (m), 986 (w), 948 (w), 886 (w), 840 (m), 810 (w), 759 (w), 751 
(w), 675 (w). 
    
   = −1067.3 (c = 0.35, CHCl3). 
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Enantiomeric excess of sinoracutine was determined by HPLC analysis on chiral stationary phase 
(DAICEL CHIALPAK ID, 4.6 x 250 mm), 25 °C, 1 mL/min, 40% i-PrOH in heptane 
+ 0.1% diethylamine, detection at 269 nm) to be 98.9% by comparison with a racemic sample and 
coinjection; tR major enantiomer = 15.848 min, tR minor enantiomer = 24.214 min. 
- Racemic sample of sinoracutine: 
 
- Enantioenriched sample of sinoracutine: 
 
- Coinjection: 
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4.3. Experimental Study on the Racemization of (–)-Sinoracutine 
A sample of (–)-sinoracutine, synthesized and purified according to the procedure reported on page 97, 
was dissolved in 60% heptane, 20% i-PrOH  and 20% MeOH at a concentration of 1.2 mg/ml in a 
borosilicate glass vial. Aliquots were withdrawn and directly injected into the HPLC instrument. 
After three days of storage at room temperature without precautions to exclude air or ambient light, the 
enantiomeric excess was determined to be 98.9%. After 67 days of storage at room temperature, the 
same sample was found to have an enantiomeric excess of 95.7%.  
- After room temperature storage in solution for 67 days: 
 
To accelerate the racemization, the same sample was then placed in an aluminum heating block 
thermostated to 60 °C. After the stated timepoints (see table below), the vial was cooled to room 
temperature, an aliquot was injected into the HPLC instrument, and heating was continued until the 
next withdrawal.  
Time (h) ee (%) 
0 95.7 
16 91.2 
30 51.7 
46 35.7 
60 20.2 
84 11.2 
100 6.2 
124 3.2 
 
Note: Retention times vary slightly due to the high volatility of diethylamine (0.1%) used as additive in 
the mobile phase, which was manually added via microsyringe to the i-PrOH/heptane mixture (also 
prepared manually using graduated cylinders).  
  
Part I: Experimental Study on the Racemization of (–)-Sinoracutine 
101 
- After room temperature storage for 67 days, followed by heating to 60 °C for 16h: 
 
- After room temperature storage for 67 days, followed by heating to 60 °C for a total of 30h: 
 
- After room temperature storage for 67 days, followed by heating to 60 °C for a total of 46h: 
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After room temperature storage for 67 days, followed by heating to 60 °C for a total of 60h: 
 
- After room temperature storage for 67 days, followed by heating to 60 °C for a total of 84h: 
 
- After room temperature storage for 67 days, followed by heating to 60 °C for a total of 100h: 
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- After room temperature storage for 67 days, followed by heating to 60 °C for a total of 124h: 
 
By comparison, an aliquot of the sample that was withdrawn prior to heating at 60 °C and stored at 
room temperature while the bulk of the sample underwent thermal treatment, still showed an 
enantiomeric excess of 95.7%. 
- After room temperature storage for 73 days: 
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Meanwhile, a sample originating from the same batch of synthetic (–)-sinoracutine used for the 
experiments at ambient temperature and at 60°C was stored in a freezer (–25 °C) for 67 days as a 
solution in CH2Cl2. After evaporation of the solvent and dissolution in 60% heptane, 20% i-PrOH and 
20% MeOH at a concentration 1.9 mg/ml. The enantiomeric excess of this sample was determined to 
be 98.5%. 
- After storage in solution for 67 days at –25 °C 
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4.4. Comparison of Natural and Synthetic Sinoracutine 
 
 
 1H NMR (δ in ppm, multiplicity, J in Hz)  13C NMR (δ in ppm) 
pos. Natural[58] 
(500 MHz) 
Natural[59] 
(400 MHz) 
Synthetic 
(800 MHz) 
 Natural[58] 
(125 MHz) 
Natural[59] 
(100 MHz) 
Synthetic 
(200 MHz) 
1 6.75 (d, 8.2) 6.75 (d, 8.2) 6.75 (d, 8.2) 
 
121.24 121.2 121.36 
2 6.73 (d, 8.2) 6.73 (d. 8.2) 6.74 (d, 8.2) 
 
109.42 109.3 109.54 
3 - - - 
 
151.07 151.0 151.22 
4 - - - 
 
145.58 145.5 145.74 
5 3.77 (s) 3.77 (s) 3.77 (s) 
 
72.31 72.3 72.48 
7 - - - 
 
206.56 206.6 206.77 
8 5.84 (s) 5.84 (s) 5.84 (s) 
 
123.27 123.2 123.4 
9 6.54 (d, 9.4) 6.55 (d, 9.4) 6.54 (d, 9.4) 
 
118.00 117.9 118.14 
10 6.78 (d, 9.4) 6.78 (d, 9.4) 6.78 (d, 9.4) 
 
138.11 138.1 138.31 
11 - - - 
 
124.11 124.0 124.25 
12 - - - 
 
127.59 127.5 127.75 
13 - - - 
 
53.71 53.6 53.85 
14 - - - 
 
174.94 174.9 175.06 
15 
 
2.73 (m)  
2.10 (m) 
2.78 (m)  
2.14 (m) 
2.37 (ddd,  13.6, 8.0, 1.3)  
2.10 (ddd,  13.6, 10.8, 8.5)  
41.52 
 
41.5 
 
41.69 
 
16 
 
3.18 (dd, 9.7, 8.7)  
not tabulated 
3.18 (m)  
not tabulated 
3.17 (app tt, 9.7. 8.5. 1.0)  
2.86 – 2.78 (m)  
51.46 
 
51.4 
 
51.60 
 
OCH3 3.91 (s) 3.91 (s) 3.91 (s)  55.87 55.8 56.01 
NCH3 2.92 (s) 2.92 (s) 2.92 (s)  36.35 36.3 36.49 
 
Notes: NMR spectra were recorded in CDCl3.  
 
The slight downfield drift in the δ-values of the 13C spectrum is attributed to different standards in spectral referencing (SiMe4 
in the isolation papers and CHCl3 in this work). 
 
The atom numbering follows the isolation paper in which the canonical numbering for morphinan and hasubanan structures is 
used. Since C6 is believed to be lost during biosynthesis, this atom is not reported in the table. 
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4.5. X-Ray Crystallographic Data  
Data for Alkyne 90. 
 
Figure 10. ORTEP plot of the molecular structure of alkyne 90. 
CCDC 1499487 contains the supplementary crystallographic data for 90. These data can  be  obtained  
free  of  charge  from  The  Cambridge  Crystallographic  Data  Centre  via 
www.ccdc.cam.ac.uk/data_request/cif 
net formula C20H22O3Si 
Mr/g mol
−1 338.46 
crystal size/mm 0.100 × 0.070 × 0.020 
T/K 100.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system monoclinic 
space group 'P 1 21/c 1' 
a/Å 11.1809(4) 
b/Å 12.2862(5) 
c/Å 13.8451(6) 
α/° 90 
β/° 107.4580(10) 
γ/° 90 
V/Å3 1814.30(13) 
Z 4 
calc. density/g cm−3 1.239 
μ/mm−1 0.144 
absorption correction Multi-Scan 
transmission factor range 0.9414–0.9705 
refls. measured 34131 
Rint 0.0482 
mean σ(I)/I 0.0258 
θ range 3.085–26.414 
observed refls. 3252 
x. y (weighting scheme) 0.0320. 1.1010 
hydrogen refinement constr 
refls in refinement 3705 
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parameters 221 
restraints 0 
R(Fobs) 0.0328 
Rw(F
2) 0.0834 
S 1.052 
shift/errormax 0.001 
max electron density/e Å−3 0.279 
min electron density/e Å−3 −0.267 
 
Data for Ketone 94. 
 
Figure 11. ORTEP plot of the molecular structure of ketone 94. 
CCDC 1499488 contains the supplementary crystallographic data for 94. These data can  be  obtained  
free  of  charge  from  The  Cambridge  Crystallographic  Data  Centre  via 
www.ccdc.cam.ac.uk/data_request/cif 
net formula C27H34O4Si 
Mr/g mol
−1 450.63 
crystal size/mm 0.100 × 0.080 × 0.040 
T/K 153.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system orthorhombic 
space group 'P 21 21 21' 
a/Å 12.5438(4) 
b/Å 14.0646(4) 
c/Å 42.9806(11) 
α/° 90 
β/° 90 
γ/° 90 
V/Å3 7582.8(4) 
Z 12 
calc. density/g cm−3 1.184 
μ/mm−1 0.122 
absorption correction Multi-Scan 
transmission factor range 0.8767–0.9705 
refls. measured 55451 
Rint 0.0385 
mean σ(I)/I 0.0419 
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θ range 3.191–27.482 
observed refls. 14643 
x. y (weighting scheme) 0.0512. 2.6535 
hydrogen refinement constr 
Flack parameter 0.03(3) 
refls in refinement 17251 
parameters 913 
restraints 0 
R(Fobs) 0.0492 
Rw(F
2) 0.1196 
S 1.044 
shift/errormax 0.001 
max electron density/e Å−3 0.503 
min electron density/e Å−3 −0.335 
  
Partially disordered. Split models applied. Underoccupied regions refined isotropically. The 
asymmetric unit contains three formula units. The figure shows all formula units in their most 
probable orientation, as well as in a further figure the only non-disordered molecule. 
Data for Alcohol 106. 
 
Figure 12. ORTEP plot of the molecular structure of alcohol 106. 
CCDC 1499486 contains the supplementary crystallographic data for 106. These data can  be  
obtained  free  of  charge  from  The  Cambridge  Crystallographic  Data  Centre  via 
www.ccdc.cam.ac.uk/data_request/cif 
net formula C27H36O4Si 
Mr/g mol
−1 452.65 
crystal size/mm 0.100 × 0.080 × 0.060 
T/K 100(2) 
radiation MoKα 
diffractometer 'Bruker D8Venture' 
crystal system triclinic 
space group 'P -1' 
a/Å 6.3389(3) 
b/Å 8.0829(4) 
c/Å 26.1368(11) 
α/° 81.4534(12) 
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β/° 88.7849(12) 
γ/° 67.2793(11) 
V/Å3 1220.56(10) 
Z 2 
calc. density/g cm−3 1.232 
μ/mm−1 0.127 
absorption correction multi-scan 
transmission factor range 0.7996–0.9585 
refls. measured 11997 
Rint 0.0285 
mean σ(I)/I 0.0399 
θ range 2.366–26.44 
observed refls. 4111 
x. y (weighting scheme) 0.0314. 0.8752 
hydrogen refinement mixed 
refls in refinement 4865 
parameters 299 
restraints 0 
R(Fobs) 0.0456 
Rw(F
2) 0.1036 
S 1.096 
shift/errormax 0.001 
max electron density/e Å−3 0.342 
min electron density/e Å−3 −0.291 
  
C-H: constr. O-H: refall. 
Data for Tetracycle 128. 
 
Figure 13. ORTEP plot of the molecular structure of tetracycle 128. 
CCDC 1499484 contains the supplementary crystallographic data for 128. These data can  be  
obtained  free  of  charge  from  The  Cambridge  Crystallographic  Data  Centre  via 
www.ccdc.cam.ac.uk/data_request/cif 
net formula C24H25NO3 
Mr/g mol
−1 375.45 
crystal size/mm 0.060 × 0.050 × 0.040 
T/K 100.(2) 
radiation MoKα 
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diffractometer 'Bruker D8 Venture TXS' 
crystal system triclinic 
space group 'P -1' 
a/Å 9.7230(4) 
b/Å 9.8365(4) 
c/Å 10.4360(4) 
α/° 80.7375(14) 
β/° 79.5349(15) 
γ/° 74.6194(14) 
V/Å3 939.63(7) 
Z 2 
calc. density/g cm−3 1.327 
μ/mm−1 0.087 
absorption correction Multi-Scan 
transmission factor range 0.8879–0.9590 
refls. measured 10343 
Rint 0.0411 
mean σ(I)/I 0.0531 
θ range 3.179–27.482 
observed refls. 3318 
x. y (weighting scheme) 0.0482. 0.4974 
hydrogen refinement constr 
refls in refinement 4298 
parameters 255 
restraints 0 
R(Fobs) 0.0491 
Rw(F
2) 0.1275 
S 1.033 
shift/errormax 0.001 
max electron density/e Å−3 0.340 
min electron density/e Å−3 −0.255 
Data for Racemic Sinoracutine. 
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Figure 14. ORTEP plot of the molecular structure of racemic sinoracutine (40). 
CCDC 1499485 contains the supplementary crystallographic data for racemic sinoracutine (40). These 
data can  be  obtained  free  of  charge  from  The  Cambridge  Crystallographic  Data  Centre  via 
www.ccdc.cam.ac.uk/data_request/cif 
net formula C17H17NO3 
Mr/g mol
−1 283.31 
crystal size/mm 0.100 × 0.070 × 0.010 
T/K 100.(2) 
radiation MoKα 
diffractometer 'Bruker D8 Venture TXS' 
crystal system orthorhombic 
space group 'P b c a' 
a/Å 14.8795(5) 
b/Å 10.3203(3) 
c/Å 17.7065(6) 
α/° 90 
β/° 90 
γ/° 90 
V/Å3 2719.03(15) 
Z 8 
calc. density/g cm−3 1.384 
μ/mm−1 0.095 
absorption correction Multi-Scan 
transmission factor range 0.8819–0.9593 
refls. measured 29303 
Rint 0.0827 
mean σ(I)/I 0.0460 
θ range 3.327–28.280 
observed refls. 2556 
x. y (weighting scheme) 0.0364. 2.0197 
hydrogen refinement C-H constr. O-H refall 
refls in refinement 3364 
parameters 196 
restraints 0 
R(Fobs) 0.0537 
Rw(F
2) 0.1194 
S 1.080 
shift/errormax 0.001 
max electron density/e Å−3 0.255 
min electron density/e Å−3 −0.236 
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4.6. NMR Spectra 
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   Introduction 1.
1.1. Peptide-derived Natural Products of Nonribosomal Origin 
The serendipitous discovery of penicillin and its antibiotic activity in 1928 represented one of 
the greatest medical advances in human history.
[194]
 This small molecule, produced by the fungal strain 
Penicillium notatum, not only pioneered the widespread use of antibiotics to universally improve 
healthcare from surgical outcomes to epidemic control, but also fostered several technological 
advancements in microbiology, chemical engineering, and synthetic organic chemistry. It also 
promoted the exploration of metabolites originating from microorganisms as a new source of 
pharmaceutical agents, which led to the discovery of numerous compounds with antimicrobial, 
immunosuppressive, antiviral, and antitumor activities. Interestingly, a large fraction of their structures 
can be traced back to a simple peptidic chain.
[195]
  
Although these natural products are based on amino acids, from a structural standpoint their 
makeup goes far beyond the 20 standard amino acids that are genetically encoded in eukaryotic cells 
and used by the ribosome to synthesize proteins.
[196]
 Penicillin G, for example, stems from a tripeptide 
containing two proteinogenic amino acids, cysteine and valine. The third building block, however, is 
the nonproteinogenic L-α-aminoadipic acid. Additionally, valine is present in its unnatural 
D-configuration. Early on, the biosynthetic origin of penicillin was proposed to be completely 
independent from the ribosome. In fact, large enzyme complexes, referred to as nonribosomal peptide 
synthetases (NRPS), have been identified as the biosynthetic machinery of penicillin as well as the 
large portion of peptide-derived natural product of fungal origin.
[197]
 They rely on a thiotemplation 
mechanism to produce polypeptide chains from single α-amino acids in an assembly-line process, 
similar to polyketide synthetases. As seen in Scheme 41, such an enzyme generates the precursor for 
penicillin termed ACV-tripeptide.
[198]
 Other than effecting the union of the three amino acids, this 
enzyme also subjects the Val-residue to epimerization. After release of ACV (150) from the NPRS, 
so-called tailoring enzymes process the linear peptide: 150 undergoes oxidative cyclization to 
thiazolidine containing 151 mediated by isopenicillin N synthase, and an acyltransferase enzyme then 
exchanges the adipic acid side-chain with a phenacetyl moiety to generate penicillin G (152), the 
archetypical penicillin that was discovered first.  
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Scheme 41. Biosynthesis of penicillin G. 
In general, the incorporation of several non-natural amino acids in the NRPS assembly line is 
common. Cyclization, dehydration, racemization and epimerization are also frequently encountered. 
Moreover, the NPRS-derived products are often macrocyclic, because along with hydrolysis, 
intramolecular cyclization is a standard release mechanism for the peptide chain from the thiol anchor 
on the NRPS.
[196]
 Ulterior processing by a variety of enzymes (e.g. methyltransferases, oxidases, 
reductases, cyclases, dehydrogenases, halogenases, acyltransferases, sulfotransferases, 
glycosyltransferases) that are either embedded in the NPRS multidomain or stand alone as tailoring 
enzymes makes the possibilities of diversification virtually limitless.
[199]
  
Figure 15 shows a small selection of natural products that derive from nonribosomal peptide 
synthetases.
[200]
 Besides penicillin, the most notorious nonribosomal peptide is vancomycin (153, from 
the bacterium Amycolatopsis orientalis), which is used as a last resort to fight antibiotic-resistant 
bacterial strains. It features five non-natural amino acids produced either by halogenation or 
hydroxylation.
[201–203]
 Additionally, oxidatively generated C-C and C-O biaryl rings and glycosylation 
patterns heavily modify the structure of this heptapeptide. The potent antimitotic agent diazonamide A 
(154, from the ascidian Diazona chinensis) can originally be traced back to a TyrValTrpTrp 
tetrapeptide, but extensive oxidative crosslinking, halogenation, and oxidation/cyclodehydration 
reactions generate a highly complex structure which could be verified only by total synthesis.
[204–206]
 
Molecules incorporating both polyketide and peptide building blocks are also associated with NRPS 
enzymatic machineries, such as bleomycin (155, from the bacterium Streptomyces verticillus), which 
is used to treat testicular, ovarian, and cervical cancer.
[207,208]
 Additionally, structures consisting of as 
few as two amino acids are also encountered. Often, they are classified as alkaloids. As such, 
azonazine (156, from Aspergillus insulicola) features a highly strained 10-membered ring resembling 
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diazonamide A and is derived from tyrosine and tryptophan.
[209,210]
 Mycocyclosin (157, from 
Mycobacterium tubercolosis) is derived from two molecules of tyrosine, and features an o,o-phenolic 
linkage between the aromatic rings to assemble a cyclophane-like 12-membered ring.
[211]
 Apart from 
oxidative transformations, which are ubiquitous in NRPS-derived products, reductive transformations 
are also sometimes encountered. It is the case for the antibiotic piperazinomicin (158, from 
Streptoverticillium neoenacticusi), also derived from two molecules of tyrosine.
[212–215]
 It features an 
oxidative phenolic C–O linkage (similar to vancomycin), but displays a piperazine ring resulting from 
reduction of a diketopiperazine moiety. In the following sections, we present our studies towards the 
related alkaloids herquline A and B, which are also biosynthetically derived from two molecules of 
tyrosine but have undergone extensive reductive metabolic processing. 
 
Figure 15. Natural products derived from nonribosomal peptide synthetases. 
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Herqulines A & B 
1.1.1. Isolation, Structure and Biosynthesis 
Herquline A (160) was isolated in 1979 from the culture broth of Penicillium herquei (strain 
FG 372).
[216]
 The isolation team, led by Prof. Satoshi Omura at the Kitasato Institute of Tokyo, 
classified it as an alkaloid due to positive reaction to Draggendorff’s stain. Judging by its IR, UV-Vis 
and mass spectrum it was structurally not related to other known alkaloid classes known to be 
produced by penicillium strains. This hypothesis was confirmed one year later, when the X-ray 
structure of its hydrobromide derivative was obtained (Figure 16).
[217]
 Despite its low molecular 
weight of 314 g/mol, herquline A features five rings including a central and highly strained nine 
membered ring that is nestled between a southern dodecahydropyrazino[1,2-a]indole core and a 
northern cyclohex-2-ene ring. The six stereocenters, of which four are contiguous, are all tertiary, and 
contribute to the bowl-like shape of this unique natural product. 
Continuing their search for other alkaloids from Penicillium herquei, Omura and co-workers 
discovered a novel compound in the fermentation broth.
[218]
 This molecule, which was termed 
herquline B (161), was isolated as a minor component during the isolation process (5.2 mg in 
comparison to 110 mg of herquline A, which was reisolated in the same campaign). It was found to be 
a structural isomer of herquline A, differing in the cleavage of the pyrrolidine ring and the concomitant 
introduction of a second alkene group, resulting in a twelve-membered ring (Figure 16). 
    
Figure 16. Scanning electron micrograph of Penicillium herquei (left); molecular and X-ray 
structures of herquline A (middle, HBr salt), and molecular structure of herquline B (right). 
Early on, it was postulated that herquline B could serve as a biosynthetic precursor for 
herquline A.
[218]
 As shown in Scheme 42, enolization of the ketone and tautomerization via dienolate 
162 followed by protonation in γ-position could reveal transient α,β-unsaturated ketone 163. 
Intramolecular 5-exo-trig attack by the pendant secondary amine would then give 160. Feeding 
experiments also showed that herquline A is overproduced in tyrosine-enriched medium. A plausible 
biosynthesis would begin with the condensation of two molecules of L-tyrosine to cyclodityrosine 
(164), followed by an oxidative phenolic coupling to yield mycocyclosin (157, Scheme 42). N-
Methylation and two reductive events need to take place to convert mycocyclosin into herquline B. 
While the reduction of a diketopiperazine is possible as seen in piperazinomycin (also produced by a 
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fungus), the dearomatization of the phenolic moiety to yield a cyclohex-2-one by formal addition of an 
H2-equivalent is rare.
[219]
 This reductive dearomatization could be facilitated by the high strain of the 
12-membered macrocycle, which can be relieved by pyramidalization of the sp
2
-carbon atoms in the 
ring after dearomatization and isomerization.
[220]
 
 
Scheme 42. Formation of herquline A from herquline B and biosynthetic proposal. 
In October 2016, while this thesis was in preparation, Tang, Houk and co-workers were able to 
defuse any doubts surrounding the biosynthesis of these alkaloids by isolating the gene cluster 
responsible for the production of the herqulines from Penicillium herquei.
[221]
 As shown in Figure 17, 
this cluster contains six genes that encode one nonribosomal peptide synthetases (hqlA), one 
N-methyltransferase (hqlE), one CYP450-dependent oxidase (hqlC), and three short-chain NADP-
dependent dehydrogenases (hqlB, hqlD, hqlF).  
 
Figure 17. Gene cluster from Penicillium herquei involved in herquline biosynthesis. 
Through a series of heterologous expression experiments in Aspergillus nidulans, it was 
demonstrated that hqlA activates tyrosine as the thioester and mediates the reduction to aminoaldehyde 
165, which spontaneously condenses to 166 (Scheme 43). Then, hqlB reduces the diimine 166 to 
piperazine 167. Without this reductase, pyrazine 168 is formed by spontaneous air oxidation. Under 
the influence of the hqlC, oxidative radical coupling to 169 can be effected. This intermediate, which 
represents a doubly dearomatized phenol tautomer, has been proven to be highly unstable and to 
spontaneously convert to biaryl piperazine 170. However, in the presence of hqlF and NADH, twofold 
reduction of the cyclohexadienone to bis-β,γ-unsaturated ketone 171 is possible to give desmethyl-
herquline B (171). This twofold reduction is very remarkable, and most likely facilitated by the 
macrocyclic framework of 169, which considerably slows down rearomatization to 170. Nevertheless, 
minor quantities of monoreduced product 172, resulting from incomplete reduction of 169, are also 
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observed. Using purified hqlE from E.coli in the presence of SAM, 171 gave herquline B (161) within 
2 hours. The relative stereochemistry of 161 could be assigned on the basis of NOE data. Furthermore, 
in slightly basic (pH = 8) aqueous solution, 161 underwent stereoselective formation of herquline A 
(160). DFT calculations also showed that only if the N-methyl group is in place a conformational 
change occurs and intramolecular aza-Michael type reaction takes place at all (intermediate 173 is not 
observed starting from 171).  
 
Scheme 43. Biosynthesis of herquline B and spontaneous conversion into herquline A. 
1.1.2. Bioactivity 
Herqulines A and B were shown to inhibit blood platelet aggregation, the process by which 
thrombocytes adhere to each other at sites of vascular injury. While blood clot formation is a critical 
requirement for effective hemostasis, unwanted activation of the clotting mechanism can lead to 
arterial thrombosis, with potentially fatal consequences. In fact, atherothrombosis is the leading cause 
of mortality in the industrialized world.
[222]
 It is associated with widespread conditions such as obesity, 
diabetes, smoking, hypertension, and very often medication to manage acute thrombogenesis is 
necessary as a result of stroke, atrial fibrillation, heart attack, or vascular surgery. The physiological 
mechanisms of the formation and lysis of blood clots are complex, and a variety of agents to dissolve 
Part II: Introduction 
160 
already formed clots (thrombolytics) as well as to prevent blood coagulation are available, such as 
antithrombotics, anticoagulants, and antiplatelet drugs (for a small collection, see Scheme 44).
[223]
 The 
different therapeutic options, based on distinct mechanism of action, are often used in combination to 
effectively treat underlying conditions that could be exacerbated by a constitutionally upregulated 
clotting mechanism.
[224]
 For example, patients that have suffered ischemic events are treated with both 
acetylsalicylic acid to inhibit COX-mediated production of proinflammatory prostaglandins, as well as 
the selective compound clopidogrel, which blocks the so-called P2Y12 receptor (whose endogenous 
ligand is ADP) found on the cell membrane of thrombocytes that play a key role in activation of 
platelets.
[225]
 
 
Scheme 44. Drugs with anti-platelet aggregation activity having different mechanisms of action. 
In an essay conducted with rabbit blood, herqulines A and B showed promising activity 
against platelet aggregation induced by both PAF and ADP, which are released at sites of 
inflammation and vascular injury.
[218]
 In both cases, herquline B was demonstrated to be roughly 50 
times more active in the PAF-promoted, and 100 times more active in the ADP-promoted pathways. 
The molecular target and exact mechanism of action have yet to be elucidated, but the non-selective 
blocking of two major aggregation pathways implies that a downstream receptor might be the actual 
target of the herqulines, and might open new therapeutic avenues for thrombosis-related diseases. 
Table 33. Antiplatelet activity of herqulines A and B. 
compound 
 
IC50 (μM) 
PAF aggregation ADP aggregation 
herquline A 240.0 180.0 
herquline B 5.0 1.6 
   
In 2016, during the course of an activity-based screening campaign for new anti-influenza 
compounds derived from fungal cultures, herquline A was found to inhibit replication of the influenza 
A virus (H1N1 subtype, “swine flu”).[226] Between 1918 and 1920, this virus killed more than 
50.000.000 people (between three and five percent of the world population) during a worldwide 
pandemic and reemerged prominently in 2009, causing roughly 17,000 deaths by early 2010.
[227]
 
Although vaccines for common seasonal influenza infections are available, zoonotic variants of the 
virus have been shown to be particularly deadly. In these cases, vaccination cannot be implemented 
quickly enough to prevent a pandemic, and antiviral drugs are the only other treatment option.
[228]
 Due 
to the relatively simple viral architecture, only three mechanisms of action for antiviral drugs are 
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currently exploited in therapy - the inhibition of neuraminidase, the M2 proton channel, and viral 
replication.
[229]
 However, resistance to M2 channel inhibitors such as amantadine (174) and 
rimantidine (175) has widely been reported, limiting treatment options to very few candidates: the 
neuraminidase inhibitors zanamivir (176) and oseltamivir (177), and the replication inhibitor ribavirin 
(178, Table 34).
[230,231]
 In a plaque assay, herquline A was shown to inhibit viral replication of the 
A/PR/8/34 strain (responsible for the 2009 influenza pandemic) with comparable potency to ribavirin 
and amantadine. It exhibited very interesting subtype selectivity, as it tested inactive against several 
other influenza strains to which the drugs shown in Table 34 respond. This suggest that the molecular 
target of 160 might be different from that of the other influenza drugs, and holds promise for 
developing new lead compounds against influenza pandemics. 
Table 34. Known antiinfluenza drugs and selected activities against influenza subtypes. 
 
     
 
Strain Subtype 
IC50 (μM)  
 herquline A amantadine  zanamivir ribavirin  
 A/PR/8/34 H1N1 10 60 0.0002 13  
 A/WSN/33 H1N1 >300 18 0.0010 42  
 A/Guizhou/54/89 H3N2 >300 87 0.0010 60  
 A/Aichi/2/68 H3N2 >300 4 0.0100 38  
 B/Ibaraki/2/85 B >300 100 0.0020 69  
        
 
1.2. Previous Synthetic Efforts  
Several synthetic approaches towards the total synthesis of herqulines have been reported in the 
past 20 years, a testimony to the active pursuit of a target that has yet to surrender to total synthesis 37 
years after its original isolation.  
In 1997, Kim reported an approach towards herquline A relying on an epoxide opening reaction 
of intermediate 179 to form the 9-membered ring of herquline A, followed by elimination of the 
resulting secondary alcohol to introduce the β,γ-unsaturated ketone moiety (Scheme 45).[232] Epoxide 
179 could be accessed through coupling of an N-methyl tyrosine derivative with a protected version of 
octahydroindole 180, which is also derived from tyrosine. 
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Scheme 45. Retrosynthesis of herquline A by Kim and co-workers. 
Bicycle 182 was formed in low yield via oxidative dearomatization of tyrosine to 181 
followed by base-mediated transesterification and aza-Michael addition (Scheme 46).
[233]
 Reductive 
manipulations and alcohol protection furnished bicycle 183 which was submitted to peptide coupling 
with N- and O-methylated tyrosine derivative 184. Unfortunately, the desired product 185 was not 
observed and no further progress on this route was reported. 
 
Scheme 46. Synthesis of octahydroindole 183 by Kim and attempted peptide coupling. 
In 2003, a poster abstract from the “Conference of the Chemical Society of Japan” outlined a 
synthetic approach by Kawai and co-workers following the biosynthetic origin starting from two 
tyrosine molecules. It relied on an intramolecular Ni-catalyzed Ullman-type coupling to form the 
12-membered ring (Scheme 47).  
 
Scheme 47. Retrosyntehsis of herqulines A and B by Kawai and co-workers. 
Iodotyrosine 186 was chosen as the starting material and was converted to cyclic 
diketopiperazine dimer 187. Subsequent intramolecular aryl coupling of 187 using transition metals 
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did not proceed (Scheme 48). However, they converted 187 into imino ether 188. Reductive 
intramolecular homocoupling of the aromatic iodides gave the desired target compound 189 in good 
yield.
[234]
 Although this product features the required atom connectivity (with exception of an N-
methyl group) and is only two reductive manipulations away from herquline B, completion of the 
synthesis was not possible. 
 
Scheme 48. Synthesis and macrocyclization via bislactim ether 188. 
In 2004, Hart described several strategies towards the herqulines based on the reduction of 
macrocyclic diketopiperazine 157, identical to the structure of mycocyclosin (see Figure 15).
[235]
 This 
key intermediate was planned to be formed either by direct phenolic coupling of cyclic tyrosine dimer 
164 or linear tyrosine dimer 190 followed by formation of the six-membered ring (Scheme 49). 
 
Scheme 49. Retrosynthetic plan by Hart and Johnson. 
As shown in Scheme 50, several direct oxidative intramolecular phenolic coupling reactions of 
diketopiperazine 164 were not successful. Similarly, the cyclization of protected dityrosine 190 to give 
12-membered ring 191 was not possible under conditions reported by Evans and co-workers.
[236]
 A 
nickel-mediated intramolecular coupling of iodinated dityrosine 192 was also not feasible. 
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Interestingly, similar reaction conditions did furnish, albeit in low yield, biaryl-linked tyrosine dimer 
194 starting from protected iodotyrosine 195. Clearly, conformational bias prevented the cyclizations 
from proceeding.  Furthermore, several model studies on 4-alkyl substituted phenols were also 
undertaken, but none of the strategies and methods could successfully be rerouted towards the target 
molecules (not depicted). 
 
Scheme 50. Attempted direct oxidative phenolic coupling (top),  
and transition-metal catalyzed homocoupling of iodoarenes (bottom). 
In 2012, Philipp Stawski reported an approach towards the synthesis of herqulines A and B 
using a two-directional strategy starting from a low-oxidation state building block derived from 
glutamic acid (Scheme 51).
[237]
 Herquline B was the primary target, to be accessed via isomerization of 
the C2-symmetical enone 196. Macrocyclization was envisaged to be achieved by homocoupling of α-
iodo cyclohexenone 197.  
 
Scheme 51. Retrosynthetic analysis via α,β-unsaturated ketone by Stawski and Trauner. 
Dimerization of pyroglutamic acid to the 2,5-diketopiperazine followed by hydrolysis and 
esterification gave 200 (Scheme 52). Dialdehyde 203 was obtained after redox-adjustments and N-
protection. Twofold 1,4-addition of methyl vinyl ketone, intramolecular aldol condensation and 
iodination gave rise to macrocyclization precursor 197. Separation of the three possible isomers (197a 
to c) by preparative HPLC set the stage for the key metal-mediated homocoupling reactions. Although 
several conditions for the formation of the 12-membered ring were investigated, the desired product 
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196 could not be isolated, and only dimers such as 208 or 209 were formed as only identifiable 
products. 
 
Scheme 52. Intramolecular cross-coupling approach by Stawski and Trauner. 
Through a private communication with Prof. Nigel Simpkins, we were able to access a PhD 
thesis by his student He Yang, who completed his doctorate in 2015.
[238]
 The retrosynthetic plan relied 
on the conversion of herquline B into herquline A (Scheme 53). Herquline B would be accessed from 
reductive dearomatization of N-methylated biaryl 211. 
 
Scheme 53. Retrosynthesis by Yang and Simpkins. 
Several intermediates with different protecting group patterns were prepared and subjected to 
attempted ring closure under a variety of conditions (Scheme 54). First, the phenolic coupling of 
cyclodityrosine-derived piperazines was investigated without success. Then, an oxidative 
dearomatization strategy of the same intermediate (212) was pursued, which delivered the tricyclic 
6,5,6-motif (214) found in herquline A (160). Unfortunately, ring closure to form the nine-membered 
ring was not successful.  
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Scheme 54. Attempted oxidative transformation of tyrosine-derived piperazine. 
Additionally, metal-mediated cyclization reactions were attempted on functionalized 
congeners of 212 (see Scheme 55). While the desired ring was formed on several occasions, the 
prohibitively low yield (4 to 6%) of the cyclization products 217 and 218 prevented further progress. 
Interestingly, on the related diketopiperazine substrate 219, the cyclization proceeded in good yield 
(220). This clearly indicates that the sp
2
-hybridized atoms in the boat-shaped diketopiperazine favor 
the ring closure by enforcing close proximity between the aromatic rings. On piperazine substrates 215 
and 216, which reside in a chair conformation, the cyclization is highly disfavored and very low yields 
of 217 or 218 were obtained. Nevertheless, after preparation of an appropriately protected macrocycle 
220, both the reduction of the aromatic ring with Birch conditions, as well as the reduction of the 
diketopiperazine to the piperazine were not successful, thereby stopping the advancement of the 
synthesis a mere three steps before its completion.  
An additional strategy based on an oxidative enolate coupling is also featured. A very similar 
approach was investigated independently in our laboratories. The discussion of this last approach, 
together with our results, can be found in Chapters 2.1.2 and 2.1.3. 
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Scheme 55. Attempted intramolecular coupling of iodoarenes for 12-membered ring formation. 
1.3. Project Aims 
The polycyclic strained architectures of herqulines A and B are unique among natural products.  
Despite their low molecular weight, they have never been synthesized. Several synthetic approaches 
were unsuccessful due to the difficulties in accessing either the 9-membered macrocycle of herquline 
A, or the 12-membered ring of herquline B. Moreover, the nonconjugated cyclohexenone moiety 
represents a very rarely encountered motif in natural products. The idiosyncratic relationship between 
the highly reduced piperazine ring and the northern cyclohexenone rings add to the synthetic 
challenge. Together with an interesting, but largely unexplored bioactivity, they are worthy targets for 
total synthesis.  
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 Results and Discussion 2.
2.1. Retrosynthesis: Early Introduction of the Piperazine Ring 
Following the biosynthetic considerations outlined in Chapter 1.2.1, herquline A can be 
accessed from herquline B. Clearly, the β,γ-unsaturated ketone (featured in herquline B) and the 
corresponding α,β-unsaturated ketone (163, Scheme 43), the necessary intermediate in the 
biosynthesis of herquline A, are comparable from an energetic point of view, as isomerization occurs 
under mildly basic conditions at ambient temperature.
[221]
 Within the macrocyclic framework provided 
by the 12-membered ring, the stability gained through conjugation is similar to the presence of 
trisubstituted, albeit nonconjugated olefin.
[239]
 
Previous approaches by the Trauner group investigated the intramolecular homocoupling of 
α,β-unsaturated ketones (see Scheme 52), which would then be subjected to isomerization. This 
strategy was not successful, and instead we decided to directly target the β,γ-unsaturated ketone. To 
exploit the C2-symmetry of the product, a two-directional approach can be pursued, where the key 
disconnection is the central C–C bond between the 1,4-dicarbonyl moiety of the two cyclohexenones. 
This substitution pattern requires the application of an “umpolung” strategy such as an oxidative 
enolate coupling reaction, in which a ketone enolate is oxidized by one-electron oxidation and the 
resulting diradical (222, Scheme 56) undergoes dimerization.
[240]
 Regioselective enolate generation on 
the β,γ-unsaturated ketone 207 should be feasible by taking advantage of the higher stability of the 
resulting dienolate 223 through conjugation.
[241]
 
 
Scheme 56. Umpolung strategy for the synthesis of the herqulines via oxidative enolate coupling. 
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The one-electron oxidation and resulting “umpoled” reactivity of enolate anions has been used 
in synthetic chemistry since the 1970’s.[242] Deprotonated esters, amides, carboxylic acids, and 
malonates have been shown to undergo efficient radical coupling to assemble 1,4-dicarbonyl 
compounds in a convergent manner. Based on the same mechanistic fundament, several experimental 
protocols have been developed. For example, ketones, predominantly via their lithium enolates, 
undergo dimerization upon treatment with Fe or Cu salts (Scheme 57).
[243,244]
 Silyl enol ethers have 
also been shown to undergo coupling both in intermolecular fashion as well as intramolecular fashion, 
most notably starting from a silyl-tethered dienol ether.
[245,246]
  
Several applications of the reaction in complex molecule synthesis have been reported to date, 
and three are shown below (Scheme 58). In the first example, the homodimerization of the enolate 
derived from 224 gives symmetrical product 225.
[247]
 If non-symmetrical products need to be 
synthesized, the reaction can be modified by synthesizing silyl dienol ethers such as 226 from the 
corresponding ketones.
[248]
 Intramolecular oxidative coupling gives the desired 1,4-dicarbonyl 227. In 
a third example, the intramolecular coupling with formation of a 6-membered ring leading to bicycle 
229 was effected starting from a ketone and a malonate as reaction partners (228).
[249]
 This result 
especially demonstrates that oxidative coupling is, in principle, possible in intramolecular fashion as 
required for the realization of our synthetic design. 
 
Scheme 57. Representative methods for oxidative enolate coupling. 
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Scheme 58. Recent applications of oxidative ketone coupling in natural product synthesis. 
As shown in Scheme 59, the required nonconjugated ketone 207 could arise from 
isomerization of enone 205, traced back to inexpensive pyroglutamic acid and methyl vinyl ketone. 
This compound was previously synthesized in the group.
[237]
 Alternatively, 207 could be synthesized 
from a protected tyrosine dimer bearing a piperazine ring (230) following partial reduction of the aryl 
rings using a Birch reduction. 
 
Scheme 59. Strategies for the synthesis of β,γ-unsaturated ketone 207. 
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2.1.1. Synthesis of C2-symmetric β,γ-unsaturated Ketone 
2.1.1.1. From L-Pyroglutamic Acid 
L-Pyroglutamic acid was treated with acetic anhydride in pyridine to furnish diketopiperazine 
198, which was hydrolyzed in neat sulfuric acid to yield glutamic diketopiperazine 199.
[250]
 
Esterification under previously optimized conditions furnished the methyl ester 200 which was taken 
on towards reduction.
[251]
 After several attempts at complete reduction using LiAlH4, we were unable 
to isolate the intermediate piperazine-diol (201, Scheme 60).  
  
Scheme 60. Synthesis and attempted reduction of glutamic diketopiperazine 200. 
Quenching the reaction with a minimal amount of water followed by in situ protection was 
possible to afford 202, whose structure could be proven by X-ray crystallographic analysis. This 
procedure was found to be highly irreproducible on larger scale (> 10 mmol) and called for alternative 
reaction conditions (Table 35). In situ generated AlH3 was also ineffective (Entry 6), whereas LiBH4 
(Entry 5) afforded a mixture of products.
[252]
 The use of borane, previously reported by Jung as the 
reagent of choice for reduction of simple diketopiperazines, was investigated next.
[253]
 While the use of 
in situ generated BH3 and its commercially available dimethyl sulfide adduct was not effective 
(Entries 7 and 8), the use of borane-THF complex was instrumental to obtaining a high yield, although 
we observed batch-related variabilities. Excess borane could be quenched with methanolic HCl, which 
allowed for the isolation of piperazine-alcohol 201 as its HCl salt, whose structure could also be 
verified by X-ray crystallographic analysis (see Page 236). Subjection of this compound to Boc-
protection then gave 202 (see Page 237 for X-ray analysis). Swern oxidation delivered dialdehyde 203 
which was reacted with methyl vinyl ketone using aminocatalyst 204.
[254]
 Robinson annulation of the 
so-obtained ketoaldehyde 204 under phase-transfer conditions and high dilution afforded 205 on a 
multigram scale as a mixture of diastereoisomers.
[255,256]
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Table 35. Conditions for the reduction and N-Boc protection of diketopiperazine 200. 
 
Entry Reagent Solvent Temp. (°C) Time (h) Quenching method Yield of 202 (%)  
1 LiAlH4 (15.0 eq.) THF 0 to 60 30 Fieser Workup
a 37%b 
2 LiAlH4 (15.0 eq.) THF 0 to 60 30 Rochelle’s Salt - 
4 LiAlH4 (15.0 eq.) THF 0 to 60 24 Na2SO4·10H2O - 
5 LiBH4 (10.0 eq.) THF 0 to rt 24 aq. NH4Cl - 
6 AlH3 (20.0 eq.)
c THF 0 to 60 24 aq. NH4Cl - 
7 BH3 (16.0 eq.)
d THF 0 to 60 14 conc. HCl - 
8 BH3·SMe2 (16.0 eq.) THF 0 to 60 14 conc. HCl - 
9 BH3·THF (16.0 eq.) THF 0 to 60 13 conc. HCl 27%
e 
10 BH3·THF (16.0 eq.) THF 0 to 60 13 HCl in MeOH 49%
e 
11 BH3·THF (13.0 eq.) THF 0 to 60 17 HCl in MeOH 40%
e 
12 BH3·THF (10.0 eq.) THF 0 to 60 17 HCl in MeOH 67%
e 
13 BH3·THF (10.0 eq.) THF 0 to 60 11 HCl in MeOH 63%
f 
a) Fieser workup: for every 1 g LiAlH4, 1 g H2O, 1 g aq. NaOH (10%), and 3 g H2O were added in sequence;    b) after 
protection using Boc2O (2.2 eq), NaHCO3, H2O/THF, 24 h;    c) generated from LiAlH4 (15.0 eq) and AlCl3 (5.0 eq);               
d) generated from NaBH4 (16.0 eq.) and I2 (8.0 eq.)    e) after protection using Boc2O (2.2 eq), Et3N (4.5 eq), CH2Cl2, 16 h;      
f) after Boc-protection using Boc2O (2.2 eq), NaOH (4.5 eq), 1,4-dioxane, 18 h. 
 
 
Scheme 61. Synthesis of N-protected C2-symmetric α,β-unsaturated cyclohexenone. 
Several strategies to effect the direct alkene isomerization of 205 to the desired trisubstituted 
β,γ-position were investigated (Table 36). Unfortunately, the use of acid catalysts that had been 
successfully used in olefin isomerization did not deliver any product (Entries 1 to 5).
[257–259]
 Basic 
conditions resulted in the reisolation of starting material  when a weak base was used (Entries 6 or 7), 
whereas stronger bases (e.g. t-BuOK) resulted in rapid degradation of 205 (Entries 8 and 9). Formation 
of the dienolate using various bases followed by kinetic protonation in the α-position was also not 
possible (Entries 11 to 14).  
Part II: Results and Discussion 
173 
Table 36. Attempted direct isomerization reactions for ketone 205. 
 
Entry Reagent(s) Solvent Temp. (°C) Time (h) Outcome 
1 RhCl3 (0.1 eq.) EtOH rt 8 no reaction 
2 RhCl3 (0.1 eq.) EtOH 80 1 complex mixture 
3 HCl (0.1 eq.) Et2O rt  24 no reaction 
4 HCl (0.1 eq.) EtOH rt to 60 24 complex mixture 
5 p-TSA (0.2 eq.) toluene rt to 80 16 no reaction 
6 DBU (2 eq.) toluene  rt 24 no reaction 
7 DBU (2 eq.) toluene 80 24 no reaction 
8 t-BuOK (6 eq.) t-BuOH rt 1 complex mixture 
9 t-BuOK (1 eq.) DMSO rt 0.1 complex mixture 
10a LDA (2 eq.), then AcOH (4 eq.) THF –78 to rt 1 no reaction 
11a LiHMDS, (2 eq.), then AcOH (4 eq.) THF –78 to rt 1  no reaction 
12a LiHMDS, (2 eq.), then AcOH (4 eq.) THF/HMPA –78 to rt 1 complex mixture 
13a NaH (2 eq.), then AcOH (4 eq.) THF 0 to rt 1 no reaction 
14a NaH (2 eq.), then AcOH (4 eq.) THF rt to 60 1 complex mixture 
a) addition of AcOH was performed at –78 °C; 
 
We next investigated two-step protocols for olefin isomerization through intermediate silyl 
dienol ether 231, which could be unmasked to the β,γ-unsaturated ketone after desilylation.[260] As can 
be seen in Table 37, deprotonation using lithium amide bases (LDA or LiHMDS) followed by trapping 
with TMSCl or TBSOTf did not result in the desired product even after addition of HMPA (Entries 1 
to 3). Application of the Kharash–Grignard reagent was examined next, in which the addition of 
catalytic FeCl3 to MeMgBr allows for the generation of an iron “ate” complex that engages in 
γ-selective deprotonation of α,β-unsaturated ketones.[261,262] Unfortunately, the desired product was not 
observed. Similarly, the use an amidocuprate reagent generated in situ from LDA and CuCN was also 
not fruitful.
[263]
 Next, we employed thermodynamic conditions to enforce formation of the desired 
product with TMSI or TMSBr (generated in situ).
[264]
 The reactions gave a complex mixture of 
products and low overall mass balance (Entries 7 to 10).  
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Table 37. Attempted formation of silyl dienol ether 231. 
 
Entry Reagent(s) Solvent Temp. (°C) Time (h) Outcome 
1 LiHMDS (2 eq.), then TMSCl (2.2 eq.) THF –78 to rt 3 mainly 205 
2 LiHMDS (2 eq.), then TBSOTf (2.2 eq.) THF –78 to rt 3 complex mixture 
3 LDA (2 eq.), then TMSCl (2.2 eq.) THF/HMPA –78 to rt 3 complex mixture 
4 LDA (4 eq.), LiCl (2 eq.), CuCN (2 eq.),  
then TMSCl, (4 eq.) Et3N (4 eq.) 
THF –78  complex mixture 
5 FeCl3 (0.1 eq), MeMgBr (2.5 eq.),  
then TMSCl, Et3N (3 eq. each) 
Et2O –78 2 no reaction 
6 FeCl3 (0.1 eq), MeMgBr (2 eq.),  
then TMSCl, Et3N (3 eq. each) 
THF/DMPU 0 12 complex mixture 
7 TMSCl (2 eq.) NaI (2 eq.), Et3N (2.2 eq.) MeCN –78 to rt 12 complex mixture 
8 TMSCl (2 eq.) NaI (2 eq.), Et3N (2.2 eq.) THF –78 to rt 12 mainly 205 
9 TMSCl (2 eq.) LiBr (2 eq.), Et3N (2.2 eq.) MeCN 0 to 60 12 complex mixture 
10 TMSCl (2 eq.) LiBr (2 eq.), Et3N (2.2 eq.) THF 0 to 60 12 complex mixture 
 
Previous attempts at thermodynamic deprotonation only returned starting material, and none 
of the desired nonconjugated isomer. Evidently, there is no energetic advantage to the formation a 
trisubstituted, albeit nonconjugated olefin at the expense of a conjugated ketone, and the stability gain 
through conjugation is too high to allow isomerization to occur. However, by masking the ketone 
functionality and removing this possibility for mesomeric stabilization, the desired double bond 
isomerization should be more facile and lead to the thermodynamically more stable olefin with a 
higher degree of substitution (Table 38). Afterwards, mild acidic hydrolysis could unmask the desired 
deconjugated product 207. This method, in the form of acid-mediated ketal formation, has been 
applied on decalin systems and steroidal carbocycles to effect deconjugation of an α,β-unsaturated 
ketone.
[265–267]
 
When 205 was treated with ethylene glycol at elevated temperature, we could indeed observe 
formation of isomeric olefin products by NMR spectroscopy (Table 38, entry 3). However, we also 
observed the product of direct ketal formation without double bond isomerization. Concomitant 
decomposition of the substrate was evident by darkening of the reaction mixture and resulted in very 
low overall yield. Exploratory studies conducted on the isomeric mixture of 232 indicated that either 
oxalic acid or diluted HCl could liberate the ketone functionality.
[268,269]
 Unfortunately, the products 
207 and 205 were found to be chromatographically inseparable in a variety of solvent systems. Paired 
with the long reaction times and low overall yield for the two step sequence, we were forced to 
abandon the glutamate-based route to cyclohexanone 207 in favor of an alternative approach.   
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Table 38. Ketal formation and alkene isomerization. 
 
Entry Catalyst Solvent Additive Temp. (°C) Time (h) Outcome 
1 p-TSA (0.2 eq.) toluene none 40 16 no reaction 
2 p-TSA (0.2 eq.) toluene MgSO4 rt to 100 24 decomposition 
3 p-TSA (0.2 eq.) toluene trimethyl orthoformate rt to 100 24 mixture, 13% overall
a 
3 p-TSA (0.2 eq.) toluene trimethyl orthoformate rt to 100 72 decomposition 
4 (+)-CSA (0.2 eq.) toluene MgSO4 rt to 100 24 decomposition 
a) 205/207 = 1.5/1, inseparable by chromatography;  
2.1.1.2. From L-Tyrosine 
According to Scheme 59, an alternative route to β,γ-unsaturated ketone from L-tyrosine was 
investigated (Scheme 62). L-tyrosine methyl ester was coupled with Boc-protected tyrosine to yield 
the dipeptide 233.
[211]
 Removal of the Boc group followed by basification and heating in an 
s-butanol/toluene mixture led to cyclization and afforded the highly insoluble diketopiperazine 164, 
which could be isolated in good yield after centrifugation. The phenolic hydroxyl group was 
selectively methylated to yield 234.
[270]
 
 
Scheme 62. Synthesis of O-methylated diketopiperazine 234. 
Reduction of 234 was performed according Jung and co-workers to give, after quenching with 
HBr, piperazine 235 as the bishydrobromide salt.
[253]
 An X-ray structure was obtained, confirming the 
cis-stereochemistry and that no racemization had occurred during the previous synthetic manipulations 
(Scheme 63). To avoid the use of corrosive HBr, the reaction mixture following the borane reduction 
was quenched with MeOH, and the solvent could be evaporated to give the piperazine-monoborane 
complex as determined by LCMS. Pd/C was added to a methanolic solution of 235 to effect 
decomplexation. After filtration over celite, the solution containing the free secondary amine could be 
protected in situ and gave Boc-protected piperazine 230 in moderate yield.
[271]
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Scheme 63. Reduction and protection of O-methylated cyclo-TyrTyr (234). 
Piperazine 230 was subjected to Birch reduction using elemental lithium in liquid 
ammonia.
[272]
 Success of the reaction was confirmed by NMR, but isolation of the enol ether 236 was 
not possible and resulted in partial rearomatization during chromatography. Instead, treatment of the 
crude reaction mixture with diluted HCl afforded ketone 207, which could be purified by column 
chromatography and was found to be stable upon storage in a benzene matrix. With a reliable route to 
the β,γ-unsaturated ketone 207 in hand, the regioselectivity of deprotonation of β,γ-unsaturated ketone 
207 was assessed. Gratifyingly, treatment with LiHMDS at –78 °C followed by addition with TESCl 
delivered conjugated dienol ether 237 as the only observed product.  
 
Scheme 64. Synthesis and deprotonation of the oxidative enolate coupling precursor. 
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2.1.2. Oxidative Enolate Coupling Reaction 
A systematic investigation of reaction conditions for the oxidative enolate coupling of ketone 
207 was performed. As shown in Table 39, the use of lithium amide bases with several Fe
3+
 salts was 
examined, as well as the influence of solvent additives such as DMF and HMPA, which are shown to 
improve the solubility of the oxidant and allow for productive reaction (entries 1 to 9).
[273]
 In every 
case, the desired coupling product could not be isolated. Similarly, Cu
2+
 salts were also ineffective in 
the formation of 221.
[274]
 Direct coupling of 207 without formation of the enolate was attempted using 
Cu(OAc)2 but did not convert the starting material, whereas NiO2 at elevated temperatures led to rapid 
degradation (Entry 20).
[275,276]
 In the majority of cases, we could determine that a mixture of products 
were formed, judging by the multitude of olefinic and aromatic signals present in the 
1
H NMR spectra. 
The use of alternative oxidants which are used for the oxidative coupling of oxazolidinone enolates 
(TiCl4) or ketone-indole systems (I2) were also investigated without success (Entries 10 and 11).
[277]
 
Table 39. Conditions examined for the intramolecular oxidative coupling of ketone 207. 
 
Entry 
Deprotonationa Oxidative couplingb Outcome 
Baseb Solvent Temp. (°C) Oxidant Temp. (°C) Time (h)  
1c LDA THF –78 FeCl3 (2.2 eq.) –78 to rt 16 complex mixture 
2c LDA Et2O –78 FeCl3 (2.2 eq.) –78 to rt 16 complex mixture 
3d LiHMDS THF –78 FeCl3 (2.2 eq.) –78 to rt 16 complex mixture 
4 LDA THF –78 FeBr3 (2.2 eq.) –78 to rt 24 complex mixture 
5 LiHMDS THF –78 Fe(acac)3 (2.2 eq.) –78 to rt 16 complex mixture 
6 LiHMDS THF –78 FeCl3/DMF complex (2.2 eq.) –78 to rt 24 complex mixture 
7c LiHMDS THF –78 FeCp2PF6 (5.0 eq.) –78 to rt 16 complex mixture 
8 LiHMDS THF –78 FeCp2BF4 (5.0 eq.) –78 to rt 16 complex mixture 
9 LDA Et2O –78 FeCl3 (2.2 eq.) –78 to rt 24 complex mixture 
10 LDA THF –78 TiCl4 (2.2 eq.) –78 to rt 20 complex mixture 
11 LDA THF –78 I2 (2.2 eq.) –78 to rt 20 complex mixture 
12 none DMF rt Cu(OAc)2 (2.2 eq.) 0 to rt 16 no reaction 
13 LDA THF –78 CuCl2 (2.2 eq.) –78 to rt 24 complex mixture 
14 LDA THF –78 Cu(2-ethylhexanoate)2 (4.5 eq.) –78 to rt 20 complex mixture 
15 LDA THF –78 Cu(acac)2 (4.5 eq.) –78 to rt 20 complex mixture 
16e LDA THF –78 Cu(OTf)2 (2.2 eq.) –78 to rt 24 complex mixture 
17f LDA THF –78 Cu(OTf)2 (2.2 eq.) –78 to rt 1 complex mixture 
18c LDA THF –78 Cu(OTf)2 (2.2 eq.) –78 to rt 1 complex mixture 
19 LDA THF –78 CuCl2 (2.2 eq.) –78 to rt 24 complex mixture 
20 none MeCN rt NiO2 (5.0 eq.) rt to 60 3 complex mixture 
a) reaction time: 30 min;    b) 2.2 eq. of base were used;    c) oxidant added as solution in DMF;   d) oxidant added as 
solution in HMPA;    e) oxidant added as solution in i-PrCN;    f) oxidant added as solution in pyridine; 
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Additionally, the silyl enol ether 231 could be prepared by treatment with TBSOTf/Et3N 
(Table 40). It was immediately subjected to oxidative coupling conditions due to its instability upon 
storage. The addition of several oxidants known to promote the intermolecular coupling of silyl enol 
ethers was not successful and resulted in degradation of 231 or desiliylation to give ketone 207.
[278–281]
 
The conditions reported by Thompson or Wirth for the intermolecular reaction of tethered silyl bis-
enol ethers were also ineffective (Entries 6, 7 and 10, 11).
[245,282]
 
Table 40. Conditions examined for the intramolecular coupling of silyl dienol ether 231. 
 
Entry Reagent Solvent Temp. (°C) Time (h) Outcome 
1 Ag2O (2.2 eq.) DMSO 100 4 complex mixture 
2 Ag2O (2.2 eq.) MeCN 100 4 complex mixture 
3 VOCl3 (3.0 eq.) CH2Cl2 –78 to rt 1 complex mixture 
4a VOCl3 (3.0 eq.) CH2Cl2 –78 4 desilylation of 231 
5a PhI(OAc)2 (2.1 eq.) CH2Cl2 –10 1 desilylation of 231 
6 PhI(OAc)2 (2.1 eq), BF3·OEt2 (3.0 eq.) MeCN –10 2 complex mixture 
7 PhI(OAc)2 (2.1 eq), BF3·OEt2 (3.0 eq.) CH2Cl2 –10 2 complex mixture 
8a Cu(OTf)2 (2.2 eq.) CH2Cl2 rt 12 desilylation of 231 
9 Pb(OAc)4 (2.1 eq.) CH2Cl2/THF –78 to rt 1 complex mixture 
10 CAN (2.2 eq.), NaHCO3 (4.4 eq.) DMSO/MeCN –10 to rt 16 complex mixture 
11 CAN (2.2 eq.), NaHCO3 (4.4 eq.) MeCN –10 to rt 16 complex mixture 
a) desilylation of 231 resulted in mixtures of 205 and 207; 
 
Next, we planned to preorganize the two reactive sites for oxidative coupling by tethering 
them to give 238, and perform the coupling on this precursor (Scheme 65). Unfortunately, only 
starting material could be reisolated after deprotonation and addition of siliyl-biselectrophiles.
[245]
 As 
silyl tethered bis-enol ethers have been shown to be stable upon aqueous workup, we suspect that 
cyclization to 238/239 did not occur at all, and conformational constrains prevented substrate 207 
from adapting a conformation necessary to allow the formation of 17-membered dioxasilacycle 238. 
 
Scheme 65. Attempted formation of macrocyclic silyl dienol ether 238. 
Intermolecular coupling experiments on model substrates were carried out to investigate 
whether the β,y-unsaturated ketone 207 might be at fault for the failure of the reaction (Scheme 66). 
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Treatment of the literature-known cyclohexenone 240 under several conditions only resulted in 
decomposition of the starting material or isomerization to the α,β-unsaturated ketone. The use of the 
extended silyl enol ether 241, or its silicon-tethered congener 242 also did not afford any coupling 
product. Clearly, enolate-derived radicals that benefit from allylic stabilization such as 243 are not 
able to undergo productive formation of 244 and allow for the synthesis of herqulines A and B. 
 
Scheme 66. Attempted oxidative coupling of model β,γ-unsaturated ketone or silyl enol ether. 
2.1.3. Conclusion and Analysis 
Starting from inexpensive and readily available amino acids, we prepared the desired 
N-protected β,γ-unsaturated ketone 221 and subjected it to oxidative coupling conditions. The desired 
cyclization product could not be observed either by using its enolate, or 221 itself. Similarly, the 
preformed silyl dienol ether 231 could also not be converted into the desired 12-membered ring. 
Tethering the reactive sites by formation of cyclic bis-enol ethers 238 or 239 was also not possible. As 
previously mentioned in chapter 1.3, we became aware of the work by Yang and Simpkins, who also 
investigated an oxidative enolate coupling in one of their approaches towards herqulines A and B.
[238]
 
They prepared sulfonyl-protected dienone 245 (see Scheme 67) and attempted the oxidative coupling 
reaction using conditions similar to those reported in Table 39. Unfortunately, no cyclization product 
was formed. Both the direct enolate coupling as well as the coupling of preformed silyl enol ethers 
was not possible. The reaction was also investigated on related substrates, such as the monomethylated 
compound 246 and the Boc-protected piperazine 207 (Scheme 67). On the sulfonylated substrate 245 
however, a product bearing the required mass of cyclization product was found to be present in trace 
quantities, but no spectral data were reported to confirm its identity. 
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Scheme 67. Oxidative enolate coupling strategy pursued by Simpkins and Yang. 
Taken together, these independently obtained results reinforced our conviction that β,γ-
unsaturated ketones with an isolated double bond are not competent substrates in oxidative enolate 
coupling. Although the formation of an 12-membered ring via intramolecular dimerization of two 
radicals represents a considerable challenge, model studies showed that the inability of β,γ-unsaturated 
ketones to undergo radical coupling even in intermolecular fashion is at fault. 
A main reason for the failure of previously reported approaches based on 12-membered ring 
formation via the union of two cyclohexene rings through C–C bond formation (e.g. via transition-
metal catalyzed coupling) lies in the preference of piperazines to adapt a chair conformation and the 
difficulty in bringing about a ring-flip to a boat or twist-boat conformation required for the junction of 
the two cyclohexenone fragments. To solve this problem, the synthesis of a cyclization precursor in 
which the piperazine ring adopts a boat conformation was thought to solve this issue. Literature 
precedent showed that sp
2
-hybridization of the ring atoms (as seen in a 2,5-diketopiperazine or 
bislactim ether 188) can allow the formation of a 12-membered ring (see Section 1.2, Scheme 48).
[211]
 
However, after following this insight, the reduction of either the aryl ring or the diketopiperazine 
moiety has proven challenging (see Section 1.2, Scheme 48 and Scheme 55). Although masking 
strategies for the double bond could be imagined, we decided to redesign our approach to avoid the 
late-stage formation of the central C–C bond of the 1,4-dicarbonyl moiety. 
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2.2. Revised Retrosynthesis: late-stage Piperazine Formation 
Until now, efforts from our and other research groups have relied on the early introduction of the 
piperazine ring and the construction of the 1,4-diketone moiety – and the required macrocycle – by 
joining the α-position of two cyclohexene ring. In the following sections, a strategically opposite 
approach is discussed. The two cyclohexenone rings are put in place early on in the synthesis, the 12-
membered macrocycle is closed thereafter, and the piperazine ring is formed last. Epimerization of the 
stereogenic center α to the ketone moiety, as well as the possibility of enforcing a favorable 
conformation of the cyclohexenone rings by templation of the 1,4-diol, should allow ring closure to 
the 12-membered ring either via Mitsunobu reaction or peptide bond formation (Scheme 68). A 
twofold ring-closing metathesis disconnection could afford the bis-cylohexenone motif starting from 
251, which results from the twofold allylation of an aldehyde (252) with the synthetic equivalent of a 
hexadienyl anion that bears two adjacent nucleophilic sites (253). The aldehyde coupling partner could 
be prepared from readily available L-glutamic acid and allows the introduction of several different 
oxidation and protecting group patterns (highlighted in the grey box, Scheme 68). 
 
 
Scheme 68. Retrosynthesis of herquline B using a late-stage piperazine formation strategy. 
For the formation of the 12-membered ring (247), literature precedent suggests that an intramolecular 
Mitsunobu–Fukuyama type reaction of an aminoalcohol of type 248 using the highly nucleophilic 
nosyl amine could be employed (Scheme 68). Beside amide bond formation, an intramolecular aza-
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Wittig reaction using an electrophilic pentafluorophenyl ester derived from 250 could also be 
investigated.
[283,284]
 The combination of the two strategies has, for example, been demonstrated by 
Fukuyama and co-workers in the total synthesis of orantine (254, Scheme 69), while the 
intramolecular cyclization of a Ns-amide is featured in the synthesis of the northern fragment of 
vinblastine (255, 11-membered ring formation), and lipogrammistin A (256, 18-membered ring 
formation).
[285–287]
 
 
Scheme 69 Macrocyclization via Mitsunobu reaction or intramolecular aza-Wittig reaction 
(top), or via epoxide opening or nucleophilic substitution using Ns-protected amines (bottom). 
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2.2.1. Development of a Bifunctional Allylation Reagent 
The substitution pattern of 251 (Scheme 68) has rarely been accessed using a short and 
convergent reaction sequence.
[288]
 One pertinent example pertains to the in situ generation of 
allylindium compound 257 (Scheme 70) starting from 1,2-diol 258, which gives the desired bis-
homoallylic 1,4-diol (259) in low yield, and as a diastereoisomeric mixture due to prominent side-
reactions (protodemetalation and 1,6 diol formation).
[289]
 Using a covalent allylic metal species, such 
as bisallylic silane 260, the same type of reaction can be imagined. Reagent 260 is obtained as an 
isomeric mixture by reaction of hexadiene with n-BuLi/TMEDA and addition of 2 eq. of TMSCl to 
the previously formed dianion.
[290]
 It was shown to react with 2 eq. of aldehyde under activation by 
Lewis acids to form tetrahydrofuran 261.
[291]
 Evidently, the desired 1,4-diol of type 259 is formed 
during the reaction, but suffered intramolecular nucleophilic substitution induced by the added Lewis 
acid (BF3 or TiCl4). Circumventing the use of a Lewis acid would require an inherently more Lewis-
acidic reagent that would not ionize the just formed alcohol. Along these lines, Bubnov and co-
workers developed an allylboron analog to silane 260.
[292]
 It is also synthesized by deprotonation of 
hexadiene followed by quenching with an electrophilic boron source (Et2BCl). The pyrophoric reagent 
262, which is isolated as a mixture of olefin isomers, reacts readily with aldehydes without the 
necessity for external Lewis acid activation, and ionization of the allylic alcohol to tetrahydrofuran 
261 is not observed (Scheme 70).
[293]
 Although the product is obtained as a mixture of 
diastereoisomers, it represented a good starting point for our investigations, as the stereochemistry of 
the 1,4-diol could be corrected at a later stage in the synthesis. 
 
Scheme 70. Synthetic approaches to 1,4-divinyl alcohols. 
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2.2.2. Exploratory Studies 
The synthesis of diallylborane 262 was attempted from freshly prepared diethyl chloroborane 
according to Bubnov’s procedure (Scheme 71).[293,294] Although the desired product was observed after 
reaction of benzaldehyde, the reagent was found to be inactive two days later in our hands, despite 
being stored at –20 °C under inert atmosphere. In an attempt to increase the ease of synthesis, 
diethylchloroborane was substituted with dicyclohexylchloroborane, a non-pyrophoric reagent widely 
used in aldol reactions.
[295]
 Application of the same reaction conditions led to the isolation of a 
colorless oil (263) that also proved competent in the double allylation reaction, albeit in low yield (< 
20%). However, also in this case, the reagent lost its activity within two days, both when stored neat 
and as solution in hexane.  
 
Scheme 71. Preparation of dialkylchloroboranes and reaction with hexadienyl anion. 
Alternative approaches that involved the formation of highly reactive allylmetal reagents 
without the necessity for isolation of reactive intermediates were evaluated. First, Barbier-type 
reaction of dialkyl halides (264 or 265) with elemental In, Sn, and Mg followed by treatment with 
benzaldehyde did not furnish the desired product, and resulted in decomposition of the starting 
materials.
[296–299]
 Confirming the presence of allylmetal species 266 by treatment of the reaction 
mixture with an electrophilic boron source to generate 268 were not successful. Protocols for the in-
situ formation of allylboronic esters were also explored following literature precedent by Szabo and 
co-workers.
[300,301]
 Although two possible precursors, the isomeric diols 258 and 269 were evaluated, 
268 was not formed and the reaction delivered a mixture of products. 
 
Scheme 72. Alternative approaches to bifunctional allylation reagents 266 and 268. 
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So far, our experiments did not lead to a practical synthesis of the desired 1,4 diol motif. 
Further developments and optimization efforts were discouraged by the lack of isolable and 
characterizable reaction intermediates, as well as the absence of any distinct side-products resulting 
from unwanted reaction pathways. However, we were convinced that it should be possible to find a 
more stable analog to trialkylborane 262 that would still be able to react in the desired manner. Hoping 
that the structural variety of allylboron reagents, whose reactivity can be modulated by the substituents 
on the boron atom, might allow us to find a suitable candidate, we examined this possibility in more 
detail. 
2.2.3. Synthesis and Reactivity of Bifunctional Allylboration Reagent (268) 
Allylboron reagents are among the most popular organometallic compounds for the synthesis 
of homoallylic alcohols.
[302]
 Their most important feature is that, despite a great structural diversity 
conferred to them by different ligands on the boron atom (vide infra), the same well-established 
mechanistic rationale applies to explain their reactivity in carbonyl addition. In fact, the majority of 
allylboron reagents react via a chair-like, rigid transition state.
[301]
 As shown in Scheme 73, 
minimization of 1,3-diaxial interactions paired with the inherent Lewis acidity of the boron atom lead 
to a  Zimmerman–Traxler transition state (270) in which the  aldehyde residue is placed in the 
equatorial position. By virtue of this assembly, the reaction is highly stereospecific. So, (Z)-
allylboranes (271) provide the syn-product 272, and the (E)-allylborane generates the corresponding 
anti-homoallylic alcohol 273 (Scheme 73).
[303]
 
 
Scheme 73. Diastereospecific allylboration reaction via chair-like transition state 
Several structural classes of allylboron reagents, which differ in the nature of the ligands on 
the boron atom, are used in the addition to carbonyl compounds (Scheme 74). The substitution pattern 
modulates the Lewis acidity of the boron center, and therefore the reactivity towards aldehydes. For 
example, difluoroallylboranes and alkylboranes react with aldehydes at very low temperatures.
[176]
 Due 
to their high Lewis acidity, they also suffer from rapid 1,3-borotropic shift resulting from 
intramolecular attack of the pendant allyl group to the boron atom that leads to the loss of 
stereoisomeric purity. To avoid the necessity for careful monitoring of the reaction conditions, 
heteroatom-substituted allylboron reagents have been developed, in which the empty p orbital of the 
boron atom can be populated with electron density from adjacent alkoxy or amido substituents.
[302]
 So, 
if one alkoxy ligand is present, the resulting allylborinic ester (276, Scheme 74) reacts with aldehydes 
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at –78 °C, but undergoes undergo 1,3-borotropic shift only upon warming to ambient temperature.[304] 
Allylboronic esters of type 274 bearing two alkoxy ligands, however, do not undergo 1,3-shift even at 
elevated temperatures and are usually slower to react with aldehydes. Minimization of the steric 
environment on the boron atom can enhance their reactivity, as does the manipulation of electronic 
properties on the diol backbone. For example, electron-withdrawing groups (e.g. tartaric esters, 275) 
allow similar reactivity to trialkylboron compounds due to enhanced Lewis-acidity and enable 
enantioselective addition with formation of chiral homoallylic alcohols.
[305]
  
 
Scheme 74. Reactivity and stability of various hydroxyl-substituted allylboron reagents. 
In general, reactivity towards carbonyl compound is proportional to the instability of the 
reagent towards hydrolysis and oxidation. Trialkylboranes (277) for instance are usually prepared and 
reacted in situ, and purification can be carried out exclusively by distillation under inert atmosphere. 
Only boronate esters of bulky diols (pinacol, pinanediol, benzopinacol) are stable towards routine 
manipulations, and can even be purified by column chromatography.
[306]
 The higher stability makes 
their addition to aldehydes less facile, with reaction times of several days, sometimes requiring 
elevated temperatures and ultrahigh pressure. Recently, it has been demonstrated that Lewis or 
Brønsted acids enhance the rate of allylboration while maintaining high diastereoselectivities (e.g. 
pinacol allylboronates react under the influence of AlCl3 even at –78 °C).
[307,308]
 Moreover, the advent 
of BINOL-derived chiral Lewis and Brønsted acids can impart high enantioselectivity and avoid using 
reagents that incorporate chiral auxiliaries, further increasing the synthetic utility of reagents of type 
274.
[74,309–312]
  
We wanted to address the challenge of synthesizing 1,4-bishomoallylic diols with an 
isomerically pure and structurally well-defined bifunctional allylation reagent. It should be readily 
prepared, amendable to storage, and easy to handle at room temperature. As discussed above, 
allylboronic esters (i.e. pinacolboronates) should provide the necessary stability upon storage and 
allow for the synthesis of a stereoisomerically pure reagent not suffering from 1,3-borotropic shift, 
while still allowing productive reaction with aldehydes – if needed under activation by Brønsted or 
Lewis acid catalysts. The mechanistic rationale of allylboration presented in Scheme 73 led us to 
maintain the 1,6-diborylhexadiene structural motif employed by Bubnov and Miginiac.
[290,293]
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We started our investigations with the implementation of the conditions for hexadiene 
deprotonation using the mixed alkyllithium/potassium alkoxide system developed by Schlosser (Table 
41).
[313]
 As already observed in the reactions towards the synthesis of allylborane 262, upon addition of 
hexadiene to the base, the reaction turned to a rusty red, unstirrable slurry, indicating formation of a 
highly conjugated carbanion. Cooling of the reaction mixture and addition of i-PrOBpin  led to 
complete solidification of the mixture and partial discoloration. After standard aqueous extractive 
workup, we obtained a complex mixture of products. Clearly, the formation of the hexadienyl anion 
was successful, but the heterogeneous reaction conditions prohibited a selective incorporation of boron 
into the terminal position due to the formation of concentration gradients within the reaction flask. The 
deprotonation conditions using alkyllithiums in the presence of TMEDA were investigated next, with 
the hope that the resulting dianion would be better solvated by the diamine.
[290]
 The resulting rusty red 
mixture was then treated with different trialkoxyboron species as electrophiles. In the case of 
(i-PrO)3B, transesterification with pinacol was performed to facilitate comparison with the other 
reactions (Entries 5 and 6). Although all experiments yielded the desired product, the use of i-PrOBpin 
was preferred as it favored the formation of a single predominant product, while the other electrophiles 
gave unselective addition leading to product mixtures.  
Table 41. Conditions investigated for the synthesis of hexadienyl pinacolboronate 
 
Entry Base/Additivea Temp. (°C) Time (h) Electrophile addition Outcome/Yield 
1 
n-BuLi (2.1 eq.),  
KOt-Bu (2.1 eq.),  
0 to rt 6 
i-PrOBpin (2.5 eq.) in Et2O,  
–78 °C to rt, 18 h 
complex mixture 
2 
n-BuLi (2.1 eq.),  
TMEDA (2.1 eq.) 
–30 to rt 2 
MeOBpin (2.1 eq.) in Et2O,  
–78 °C to rt, 3 h 
mixture of isomers 
3 
n-BuLi (2.1 eq.),  
TMEDA (2.1 eq.) 
–30 to rt 6 
MeOBpin (2.5 eq.) in Et2O, 
 –78 °C to rt, 3 h 
mixture of isomers 
4 
n-BuLi (2.1 eq.),  
TMEDA (2.1 eq.) 
–30 to rt 6 
MeOBpin (2.5 eq.) in Et2O,  
–78 °C to rt, 10 h 
mixture of isomers 
5 
n-BuLi (2.1 eq.),  
TMEDA (2.1 eq.) 
–30 to rt 2 
B(i-PrO)3 (2.2 eq.) in Et2O, 
 –78 °C to rt, 8 h 
mixture of isomersb 
6 
n-BuLi (2.1 eq.),  
TMEDA (2.1 eq.) 
–30 to rt 2 
B(i-PrO)3 (2.2 eq.) in Et2O,  
–30 °C to rt, 8 h 
mixture of isomersb 
7 
s-BuLi (2.1 eq.),  
TMEDA (2.1 eq.) 
–30 to rt 12 
i-PrOBpin (2.5 eq.) in Et2O, 
 –78 °C to rt, 24 h 
one major isomer 
(>80% purity) 
8 
n-BuLi (2.1 eq.),  
TMEDA (2.1 eq.) 
–30 to rt 12 
i-PrOBpin (2.5 eq.) in Et2O, 
 –78 °C to rt, 24 h 
one major isomer 
(>80% purity) 
9 
n-BuLi (2.1 eq.),  
TMEDA (2.1 eq.) 
–30 to rt 24 
i-PrOBpin (2.5 eq.) in Et2O, 
 –78 °C to rt, 24 h 
one major isomer  
(85% purity) / 42%c 
10 
n-BuLi (2.1 eq.),  
TMEDA (2.1 eq.) 
–30 to rt 24 
i-PrOBpin (2.5 eq.) in Et2O,
d 
 –78 °C to rt, 24 h 
one major isomer  
(94% purity) / 39%e 
a) hexane was used as solvent;    b) after aqueous workup and transesterification with pinacol;    c) after aqueous 
workup and Kugelrohr distillation;    d) precooled to –78 °C;    e) after aqueous workup and crystallization. 
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After acidic aqueous workup and extraction using diethyl ether, 268 could be isolated as a 
mixture with n-BuBpin resulting from incomplete consumption of hexadiene and direct addition of n-
BuLi to i-PrOBpin. Removal of this byproduct was successful via chromatography, but 268 slowly 
decomposed on all the stationary phases examined (Al2O3, SiO2, Davisil, B(OH)2-modified SiO2, 
Et3N-treated SiO2).
[314]
 Nevertheless, isolation of a pure sample of the major product formed during the 
reactions was possible, and definitive structural proof was obtained by X-Ray analysis. As shown in 
Scheme 75, The (Z,Z)-stereochemistry of the product 268 suggests that in the hydrocarbon solvent 
TMEDA stabilizes the hexadienyl dianion in an S-shaped conformation that is retained to a high 
degree during the addition of i-PrOBpin even in the more coordinating Et2O. In a final optimization 
round, conducted in collaboration with Marius Schmicker, we realized that complete deprotonation of 
hexadiene was slow and required longer (at least 24 h) to reach appreciable conversion.
[315]
 
Furthermore, 268 could be purified via Kugelrohr distillation to with an isomeric purity of 85:7:7 
(Z,Z):(E,E):(E,Z) (Table 41, entry 9). This additional purification step could be avoided with cautious 
monitoring or the reaction temperature and by slow addition of a precooled (–78 °C) solution of 
i-PrOBpin, together with vigorous stirring to ensure adequate mixing of the reaction partners. In doing 
so, 268 solidified directly after aqueous workup and removal of the solvent, and could be isolated on a 
110 mmol scale in 94% isomeric purity and 38% yield after precipitation from hexane at –25 °C 
(Table 41, entry 10). 
 
Scheme 75. Synthesis of (Z,Z)-bisallylboronic acid pinacol ester 268. 
Both (Z)- and (E)-pinacol crotylboronates are reported to react with equimolar amounts of 
aldehydes in non-polar, aprotic solvents to afford homoallylic alcohols in good yield.
[303]
 We expected 
that the C2-symmetrical bifunctional allylation reagent 268 should afford a twofold addition product. 
Compared to the pioneering work by Bubnov (see Scheme 70), the diastereoselectivity should be 
enhanced for reagent 268 given its higher isomeric purity compared to 262, which exists as mixture of 
interconverting stereoisomers. 
Dienyl boronate 268 was treated with an excess of phenylpropionaldehyde at room 
temperature for 48 h (Table 42, Entry 1). An oxidative workup was performed to facilitate product 
isolation by destruction of the intermediate O-bound pinacolboronate. Unfortunately, no double 
allylation product (278) was obtained. The major product was determined to be the 1,5-diol 279 
resulting from single addition of 268. Interestingly, it was isolated as a 9 to 1 mixture of 
diastereoisomers and thorough purification and spectroscopic analysis by Belinda Hetzler showed that 
the major product formed is the syn-product (in accordance with the Zimmerman-Traxler transition 
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state depicted in Scheme 73).
[316]
 Twofold addition product 278 could not be observed at higher 
temperatures either (Entry 3). The addition of Brønsted and Lewis acid catalysts was investigated by 
Belinda Hetzler and did not change the outcome, although it did improve the rate of single 
allylboration at ambient temperature (Entries 6 and 7). Under more forcing conditions, complex 
mixtures were obtained (Entry 8). Evidently, the additional steric hindrance of the pinacolboronate 
ester transferred in the first allylation step combined with the branched substitution adjacent to the 
pendant allylboronic ester discourage compound 280 from undergoing a second allylboration reaction 
to give 278.  
Table 42. Screening of conditions for the allylation of phenylpropionaldehyde with 268. 
 
 Entrya Catalystb Solvent Temp (°C) Time (h) Outcome/Yield (%)  
1 none CH2Cl2 rt 48 only 279 / n.d. 
2 none toluene rt 72 only 279 / 67 
3 none toluene 100 24 only 279 / n.d. 
4 Sc(OTf)3 toluene rt 24 decomposition 
5 In(OTf)3 toluene rt 24 decomposition 
6 AlCl3 toluene rt 24 only 279 / n.d. 
7 TFA CH2Cl2 rt 24 only 279 / 57 
8 TFA toluene 100 24 decomposition 
a) all reactions performed with 3.0 eq. of phenylpropionaldehyde;   b) 10 mol %;     
c) after oxidative workup with NaOH/H2O2. 
   
A similar difficulty was faced by Aggarwal and co-workers in their investigation of sterically 
hindered 3,3-disubstituted allylpinacolboronates.
[317,318]
 By converting the boronic ester to the more 
reactive borinic ester, the desired addition to aldehydes was found to take place. The mechanism of 
this activation mode, together with its intended application to 268, is shown in Scheme 76. At low 
temperature, alkyllithium reagents can add to the electrophilic boron center to form intermediate 
borate 281. Addition of an oxophilic electrophile such as TFAA leads to ring-opening of 281 with 
scission of the B–O bond, and the expelled alkoxide is trapped to form a trifluoroacetyl ester. This 
effectively generates the tricoordinated borinic ester 282, a more Lewis acidic species that is markedly 
more reactive towards carbonyl compounds. If 282 could indeed be generated, it might be reactive 
enough to undergo a second allylation to give 278 despite the added steric bulk imparted by the first 
carbonyl addition. 
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Scheme 76. Projected activation of 268 via borinic ester and twofold aldehyde allylation. 
After treatment of 268 with n-BuLi (2 eq.) at 78 °C for 15 minutes, TFAA was added. After 
30 minutes at 78 °C, phenylpropionaldehyde (2 eq.) was added and the mixture was allowed to reach 
ambient temperature (Scheme 77). Following aqueous workup, one major product was obtained in 
62% yield. Its structure could be confirmed by X-ray crystallography, indicating that the desired 
allylation does indeed proceed as desired. The plane of symmetry exhibited by 278 reflects the 
stereospecific reactivity of C2-symmetric reagent 268 via a chair-like transition state. Additionally, the 
syn-stereochemistry of the homoallylic alcohol product confirms that the (Z)-allylboron species 
underwent allylation without isomerization via 1,3-borotropic shift. Having successfully developed a 
more practical preparation of the desired 1,4-diol motif, we moved to apply the reaction to the 
synthesis of herqulines A and B. 
 
Scheme 77. Diastereoselective double allylation of borinic ester 282 with phenylpropionaldehyde. 
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2.2.4. Application Towards the Synthesis of Herqulines A and B. 
2.2.4.1. Model Studies 
Before submitting an elaborated aldehyde partner to the abovementioned double allylation 
reaction, we wanted to systematically assess eventual limitations and functional group compatibility of 
the method. In this context, Lewis-basic protecting groups might inhibit the desired reactivity towards 
the aldehydes in both the allylation as well as the metathesis reactions. Therefore, a model substrate 
was prepared with the intent to test the suitability and robustness of the planned sequence. 
Phenylpropionaldehyde was chosen as starting material, and allylic alcohol 284 was obtained 
after α-methenylation to 283 and reduction (Scheme 78).[319] Chain extension via Eschenmoser–
Claisen rearrangement and reduction furnished aldehyde 286, which was subjected to the allylation 
protocol with in situ generated borinic ester 282 to give 287.
[148,320]
 Ring closing metathesis reaction of 
286 was successful using the Hoveyda–Grubbs’ 2nd generation catalyst.[321] The relative configuration 
of the product (288) could be assigned by X-ray crystallographic analyses. Analogous to the model 
reaction with phenylpropionaldehyde, the twofold allylation reaction proceeded without isomerization 
of the allylborinic ester to give syn-homoallylic alcohol 287.  
 
Scheme 78. Model study for the double allylation / ring closing metathesis sequence. 
A second substrate bearing a protected hydroxyl functionality as a handle for amin oacid 
synthesis was synthesized starting from PMB-protected allyl alcohol (289). After hydroboration using 
9-BBN, Suzuki cross-coupling with alkenyl bromide 290, derived from 4-pentynol, delivered the 
allylic alcohol 291.
[322,323]
 Swern oxidation to the aldehyde followed by double allylation delivered diol 
293, which was subjected to RCM conditions. Interestingly, this substrate proved more reluctant to 
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participate in metathesis reaction than 287. While first-generation metathesis catalysts converted the 
product even at high temperature (Entries 2 and 6), second-generation catalysts bearing an NHC-
ligand delivered the tandem metathesis product, although the reaction did not exhibit a clean reaction 
profile with Grubbs’ 2nd generation catalyst (Entry 4). The use of phosphine-free Hoveyda–Grubbs’ 
2
nd
 generation catalyst, on the other hand, delivered the desired product 294 in good yield but required 
elevated temperatures. (Entries 11 and 12).
[324]
  
 
Scheme 79. Synthesis of long-chain model study via twofold allylation and metathesis.  
 
 Entry Catalysta Solventb Conc. (mM) Temp (°C) Time (h) Yieldc (%)  
1 G1 toluene 0.01 rt 7 no reaction 
2 G1 toluene 0.01 90 7 no reaction 
3 G2 toluene 0.01 rt 3 <5% 
4 G2 toluene 0.01 90 7 18% 
5 HG1 toluene 0.01 rt 7 no reaction 
6 HG1 toluene 0.01 90 7 no reaction 
7 HG2 benzene 0.025 40 16 38% 
8 HG2 CH2Cl2 0.025 40 16 <5% 
9 HG2 1,2-DCE 0.025 40 16 <5% 
10 HG2 toluene 0.01 rt 7 no reaction 
11 HG2 toluene 0.025 40 16 39% 
12 HG2 toluene 0.01 90 4 75%
d 
a) 10 mol%;  b) solvents were deoxygenated by purging with N2 for 20 min;    c) determined 
by NMR using tetrachloroethane as external standard, except for entry 12;   d) isolated yield 
after silica gel chromatography. 
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2.2.4.2. Synthesis of Amino Acid-derived Coupling partners 
Both model substrates 292 and 286 underwent allylation and ring-closing metathesis reaction, 
but the reaction conditions for the formation of the cyclohexenone rings needed to be adjusted for the 
more sterically hindered and more coordinating PMB-protected 293. Further aldehyde substrates 
exhibiting variation of oxidation state and protecting group patterns on the amino acid-derived 
terminus were prepared next.  
2.2.4.2.1. Aminoalcohol Oxidation Level 
L-glutamic acid was treated with TMSCl in MeOH to give 295, which was Boc-protected to 
afford 296. After ester reduction to alcohol 297, the Boc-protected amine and the proximal hydroxyl 
group were protected as the N,O-acetonide (298).
[325]
 Then, the primary alcohol was oxidized under 
Swern conditions to give aldehyde 299. Organocatalytic methylenation gave 300, but proceeded only 
in moderate yield (see Table in Scheme 80 , entry 1), analogous to reactions using Bohme’s salt (302) 
or Eschenmoser’s salt (303).[326] The in situ generation of the electrophilic iminium intermediate was 
more successful, and best results were obtained using TFAA as the activating agent for the 1,3-
diamine 304.
[327,328]
 Next, aldehyde 300 reduced to corresponding alcohol 301.
[329]
  
Scheme 80. Synthesis of Claisen rearrangement precursor from L-glutamic acid. 
 
Entry Reaction conditions Solvent Temp (°C) Time (h) Yield (%) 
1 
Formaldehyde (1.0 eq.), pyrrolidine (0.1 eq.), 
4-dimethylaminobenzoic acid (0.2 eq.) 
CH2Cl2 45 2 47 
2 DIPEA (1.0 eq.), TFA (1.0 eq), 1,3,5-Trioxane (2.0 eq.) THF 60 6 29 
3 Eschenmoser’s salt (303) (2.0 eq.), Et3N (3.0 eq.) CH2Cl2 0 to rt 2 48 
4 Böhme’s salt (302) (2.0 eq.), Et3N (3.0 eq.) CH2Cl2 0 to rt 4.5 51 
5 AcOH (2.4 eq), 304 (4.2 eq) THF 0 to rt 18 56 
6 TFAA (1.1 eq.), 304 (1.1 eq) CH2Cl2 0 to rt 18 66 
 
Direct access to the desired aldehyde required a two-carbon homologation, which was 
attempted via Claisen rearrangement of vinyl ether 305.  The desired product was best synthesized 
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using conditions reported by Fukuyama and coworker´s using the high-boiling n-butyl vinyl ether 
(Scheme 81).
[330]
  
 
Scheme 81. Mercury-catalyzed Claisen rearrangement to give aldehyde 306.  
Nevertheless, the low yield prompted us to examine different Claisen protocols (Scheme 82). 
While Ireland–Claisen rearrangement of allylic acetate derived from 301 was not successful (not 
depicted), Aylin Hirschvogel has shown that Johnson–Claisen protocol afforded the product in 
acceptable yield, provided the reaction was carried out under microwave irradiation (8 min at 
150 °C).
[331]
 Unfortunately, material throughput was only possible using sequential reactions carried 
out on 150 mg scale, as larger reaction volumes led to longer reaction times and lower yields due to 
slow decomposition of the acid-sensitive substrate (e.g. a reaction carried out on 1.99 gram scale gave 
307 in only 34 % yield). Reduction of the ester followed by oxidation afforded the target aldehyde 
(306). In an effort to avoid redox manipulations, we conducted an Eschenmoser–Claisen 
rearrangement to obtain tertiary amide 309. The reduction to aldehyde 306 using the conditions that 
were successful on the model systems (Ti(Oi-Pr)4/Ph2SiH2) afforded the product in 30% yield, but 
better results were obtained using a hydridic aluminate complex generated in situ from DIBALH and 
lithium morpholide (Scheme 82).
[332]
 
 
Scheme 82. Synthesis of allylation precursor with aminoalcohol oxidation level. 
2.2.4.2.2. Amino Acid Oxidation Level 
For the synthesis of aldehyde 306 described above, a linear synthetic route starting with the 
reduction of both the ester functions of L-glutamic acid was used, wherein the side-chain was oxidized 
as at a later stage while the 1,2-aminohydroxy group was protected as the acetonide. If the desired 
product was an α-amino acid, the synthesis would require additional protection and oxidation steps. 
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Alternatively, a synthesis starting from L-glutamic acid featuring the selective reduction of the 
side chain is conceivable. However, literature precedent suggests that a judicious choice of protecting 
groups would be necessary to differentiate the two ester portions of L-glutamate.
[333]
 This would 
invariably add additional steps to the synthesis. Therefore, we decided to pursue a cross-coupling 
strategy of an amino acid-derived building block with a pre-reduced side chain. Jackson and co-
workers demonstrated that serine-derived organozinc reagents can be coupled with alkenyl and aryl 
halides under palladium catalysis to deliver unnatural amino acids, and we chose this method to access 
the desired substrates.
[167,334]
 Synthesis of protected iodoalanines 311 and 317 was carried out via 
iodination of the respective serine derivatives (310 and 316).
[335,336]
 The side chain was synthesized 
from TBS-protected 4-pentynol followed by Ni-catalyzed branch-selective alkyne hydroalumination-
bromination reaction.
[323]
 Formation of the organozinc reagent from the iodide, followed by Negishi 
coupling with 315, delivered TBS protected methallylglycine derivative 312. Desilylation to afford the 
free alcohol 313 and Dess–Martin oxidation gave aldehyde 314. The same sequence was also applied 
to the Cbz-derived substrate to afford, 320 in a similar overall efficiency. 
 
Scheme 83. Synthesis of two allylation precursors bearing amino acid oxidation level. 
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 Summary and Future Work 3.
In summary, two strategies for the synthesis of the alkaloids herquline A and B were pursued. 
Following previous work carried out in the Trauner group, L-glutamic acid could be converted into 
α,β-unsaturated ketone 205. Attempted isomerization to the β,γ-unsaturated isomer 207 required for an 
intramolecular oxidative enolate coupling reaction was not possible. However, 207 could be prepared 
from L-tyrosine. Several reaction conditions for the formation of the 12-membered ring in 221 were 
examined. Unfortunately, the desired product could not be isolated, and control experiments suggest 
that β,γ-unsaturated ketones are not viable substrates for oxidative coupling reaction both in intra-, as 
well as intermolecular fashion.  
 
Scheme 84. Oxidative enolate coupling approach starting from glutamic acid or tyrosine. 
All previous synthetic efforts that relied on the early formation of a piperazine (or 
diketopiperazine) ring were thwarted by the inability to form the required 12-membered ring by C-C 
bond formation. This prompted us to redesign our approach and carry out the piperazine formation at a 
later stage in the synthesis. Inspired by the pseudosymmetrical nature of herquline B, a twofold 
allylation-metathesis approach was devised. Using an isomerically pure bifunctional allylboron 
reagent (268) activated in situ by formation of a borinic ester, several aldehydes were shown to 
undergo sequential double allylation to deliver 1,4-divinyl alcohol in a diastereospecific manner. Ring-
closing metathesis on model systems could afford the bis-cyclohexenone core of herquline B. 
Additionally, several aldehyde precursors bearing different oxidation states and protecting groups 
were prepared.  
Part II: Summary and Future Work 
197 
 
Scheme 85. Model studies towards the cyclohexenone moiety of herquline B via allylation. 
In future, they will be subjected to the twofold allylation conditions using 268. Two different 
aldehyde substrates bearing either different oxidation states or protecting group patterns could be 
added sequentially to the allylboron reagent 268 to afford unsymmetrical products of type 321 in order 
to facilitate intramolecular macrocyclization after ring-closing metathesis. Formation of the 12-
membered ring could be achieved by alkylation or amide bond formation, and the six-membered ring 
could be formed thereafter. After routine manipulations and N-methylation, herquline B could be 
accessed, and herquline A could be formed by olefin isomerization and aza-Michael reaction. 
 
Scheme 86. Planned fragment union of two different aldehydes via double allylation 
for the total synthesis of herqulines A and B. 
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 Experimental Part 4.
4.1. General Experimental Details 
4.1.1. Materials and Methods 
Unless noted otherwise, all reactions were performed in flame-dried glassware fitted with rubber septa 
under a positive pressure of nitrogen. Air- and moisture-sensitive liquids were transferred via syringe 
or stainless steel cannula through rubber septa. Solids were added under inert gas or were dissolved in 
appropriate solvents. The reactions were magnetically stirred and monitored by NMR spectroscopy 
where noted or analytical thin-layer chromatography (TLC) using glass plates precoated with silica gel 
(0.25 mm, 60-Å pore size, Merck) impregnated with a fluorescent indicator (254 nm). TLC plates 
were visualized by exposure to ultraviolet light (UV, 254 or 366 nm), were stained by submersion in 
aqueous potassium permanganate solution (KMnO4), ceric ammonium molybdate solution (CAM) or 
acidic p-anisaldehyde solution (PAA) and were developed by heating with a heat gun. Flash-column 
chromatography on silica gel (60 Å pore size, 40–63 µm, Merck KGaA) was performed as described 
by Still
[185]
 or using a Biotage Isolera™ Prime Automated Flash Purification system. Triethylamine-
deactivated silica was obtained by preparing a slurry of silica gel (20% v/v in the initial eluent mixture 
+ 5% v/v Et3N) followed by magnetic stirring for 1 h. The slurry was poured into a chromatography 
column and flushed with 5 column volumes of amine-free eluent prior to sample loading and elution.  
Tetrahydrofuran (THF) and diethyl ether (Et2O) were distilled from Na/benzophenone prior to use. 
Dichloromethane (CH2Cl2), triethylamine (Et3N), N,N-diisopropylamine (DIPA) were distilled under 
nitrogen atmosphere from CaH2 prior to use. Benzene, 1,2-dichloroethane (DCE), dimethyl sulfoxide 
(DMSO), 1,2-dichlorobenzene (DCB) were purchased from Acros Organics as 'extra dry' and used as 
received. All other reagents and solvents were purchased from chemical suppliers (Sigma-Aldrich, 
Acros Organics, Alfa Aesar, Strem Chemicals, ABCR) and were used as received. Solvents for 
extraction, crystallization and flash-column chromatography on silica gel were purchased as technical 
grade and distilled under reduced pressure prior to use. The molarity of n-butyllithium solutions was 
determined by titration to a blue endpoint against N-benzylbenzamide
[186]
  at −40 °C (average of three 
determinations).  
Unless noted otherwise, yields refer to chromatographically and spectroscopically (
1
H and 
13
C NMR) 
pure material. 
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4.1.2. Melting Point  
Melting points were measured on a Stanford Research Systems MPA120 EZ-Melt apparatus in open 
glass capillaries. 
4.1.3. NMR Spectroscopy  
NMR spectra were measured at room temperature (22 °C) on a Bruker Avance III HD 800 MHz 
spectrometer equipped with a CryoProbe
TM
 operating at 800 MHz for proton nuclei and 200 MHz for 
carbon nuclei or a Bruker Avance III HD 400 MHz spectrometer equipped with a CryoProbe
TM
 
operating at 400 MHz for proton nuclei and 100 MHz for carbon nuclei. Proton chemical shifts are 
expressed in parts per million (ppm, δ scale) and are referenced to residual protium in the NMR 
solvent (CHCl3: δ 7.26, C6HD5: 7.16, CH3SOCD2H: 2.50, MeOH: 3.31). Carbon chemical shifts are 
expressed in parts per million (ppm, δ scale) and are referenced to the carbon resonance of the NMR 
solvent (CDCl3: δ 77.16, C6D6: 128.06, CH3SOCD2H: 39.52, MeOH: 49.0). 
1
H NMR spectroscopic 
data are reported as follows: Chemical shift in ppm (multiplicity, coupling constants J (Hz), 
integration intensity). The multiplicities are abbreviated with s (singlet), d (doublet), t (triplet), q 
(quartet), app (apparent), broad (br), combinations thereof, and m (multiplet). In case of combined 
multiplicities, the multiplicity with the larger coupling constant is stated first. Except for complex and 
overlapping multiplets, where a resonance range is given, the chemical shift of all other symmetric 
signals is reported as the center of the resonance range. 
13
C NMR spectroscopic data are reported as 
follows: Chemical shift in ppm. Additionally to 
1
H and 
13
C NMR measurements, 2D NMR techniques 
such as homonuclear correlation spectroscopy (COSY), heteronuclear single quantum coherence 
(HSQC) and heteronuclear multiple bond coherence (HMBC) were used to assist signal assignment. 
For further elucidation of 3D structures of the products, nuclear Overhauser enhancement 
spectroscopy (NOESY) was conducted. All raw FID files were processed and the spectra analyzed 
using the program Mnova 10.0.2 from Mestrelab Research S. L.  
4.1.4. Mass Spectrometry  
All mass spectra were measured by the Analytical division of the Department of Chemistry, Ludwig-
Maximilians-Universität München. Mass spectra were recorded on the following spectrometers 
(ionisation mode in brackets): MAT 95 (EI) and MAT 90 (ESI) from Thermo Finnigan GmbH and 
were recorded in high-resolution. The method used is reported in the relevant section of the 
experimental part.  
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4.1.5. IR Spectroscopy  
IR spectra were recorded on a Perkin Elmer Spectrum BX II FT-IR system and the compound was 
applied as thin film directly on the ATR unit (either as neat substance or as solution in CH2Cl2). Data 
are represented as follows: absorption frequency (expressed in cm
−1
) and intensity of absorption: s 
(strong), m (medium), w (weak), br (broad).  
4.1.6. Optical Rotation  
Optical rotation values were recorded on an Anton Paar MCP 200 or a Krüss Optronic  P8000-T 
polarimeter. The specific rotation is calculated as follows:  
    
 
 
       
   
 
Thereby, the wavelength λ is reported in nm and the measuring temperature in °C. α represents the 
recorded optical rotation, c the concentration of the analyte in 10 mg/mL and d the length of the 
cuvette in dm. Thus, the specific rotation is given in 10
−1
·deg·cm
2
 ·g
−1
 . Use of the sodium D line 
(λ = 589 nm) is indicated by D instead of the wavelength in nm. The sample concentration as well as 
the solvent is reported in the relevant section of the experimental part 
4.1.7. HPLC Analyses 
Analytical HPLC on Chiral Stationary Phase was performed on a computer-operated Shimadzu system 
(Windows 10, LabSolutions Software, two LC-20AP pumps, manual injection (2 mL sample loop), 
CTO-20A column oven, SPD-M20A Diode Array detector). Column, oven temperature, solvent 
system, flow rate, detection mode and retention times are given in the relevant section of the 
experimental part.  
Preparative HPLC was performed on a computer-operated Varian instrument (Windows XP, Galaxie 
Chromatography Software, two PrepStar SD-1 pumps, manual injection with 2 mL sample loop, 
ProStar 335 Photo Diode Array Detector, Agilent 440-LC Fraction Collector). Column, solvent 
system, flow rate, detection mode and retention times are given in the relevant section of the 
experimental part. 
4.1.8. X-ray Diffraction Analysis 
Experiments were carried out by Dr. Peter Mayer (Ludwig-Maximilians-Universität München). The 
data collections were performed an a Bruker Nonius KappaCCD, Bruker D8Venture, or an Oxford 
Xcalibur diffractometer using MoKα-radiation (λ = 0.71073 Å, graphite monochromator). The 
CrysAlisPro software (version 1.171.33.41) was applied for the integration, scaling and multi-scan 
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absorption correction of the data. The structures were solved by direct methods with SIR9713 and 
refined by least-squares methods against F2 with SHELXL-97.14. All nonhydrogen atoms were 
refined anisotropically. The hydrogen atoms were placed in ideal geometry riding on their parent 
atoms. Further details are summarized in the tables at the different sections. Plotting of thermal 
ellipsoids in this document and in the main text was carried out using Ortep-3 for Windows.
[187]
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4.2. Experimental Procedures  
(5aS,10aS)-tetrahydro-3H,5H-dipyrrolo[1,2-a:1',2'-d]pyrazine-3,5,8,10(2H,5aH)-
tetraone (198) 
 
To a preheated (110 °C) solution of acetic anhydride (442 mL, 4.70 mol, 6.10 eq) and pyridine 
(82 mL, 1.00 mol, 1.30 eq) was added (S)-pyroglutamic acid (99.5 g, 771 mmol, 1.00 eq) portionwise. 
After 5 min, 198 began to precipitate and a slight orange discoloration of the reaction mixture was 
observed. After 10 min, the vessel was cooled to 0 °C (ice bath), the precipitate was collected by 
filtration and transferred to an Erlenmeyer flask containing cold MeOH (200 mL). The solid was 
filtered on and washed with cold water (200 mL). The product was dried overnight under vacuum to 
give 198 (45.9 g, 208 mmol, 54%) as a colorless crystalline solid. Spectral data match the previously 
reported values.
[250]
 
Rf = not determined. 
Melting point = 284 °C (decomposition). 
1
H NMR (400 MHz, DMSO) δ = 4.84 (t, J = 8.5 Hz, 2H), 2.64 – 2.38 (m, 4H, partially obscured by 
solvent), 2.27 – 2.13 (m, 4H). 
13
C NMR (100 MHz, DMSO) δ = 172.7, 165.7, 58.4, 31.2, 18.9. 
HRMS (EI) for C10H10N2O4
·+
 [M]
·+
: calcd.: 222.0641, found: 222.0634. 
IR (ATR):  ̃ = 2941 (w), 1764 (s), 1690 (m), 1463 (w), 1353 (m), 1273 (s), 1247 (s), 1148 (m), 
927 (m). 
    
   = −96.1 (c = 1.00, DMSO). 
3,3'-((2S,5S)-3,6-dioxopiperazine-2,5-diyl)dipropanoic acid (199) 
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Pyroglutamic diketopiperazine (198) (45.9 g, 207 mmol, 1 eq) was added portionwise and under rapid 
magnetic stirring to H2SO4 (96% w/w 166 mL, 15 eq). The reaction mixture was stirred until complete 
dissolution of 198 (3 hours). The resulting solution was cooled to 0 °C and H2O (300 mL) was added 
slowly dropwise. The mixture was stirred for 1 hour and the resulting precipitate was collected by 
filtration to afford 199 as white solid (35 g, 136 mmol, 66%). Spectral data match the previously 
reported values.
[250]
 
Rf = not determined. 
Melting point = 242 °C (decomposition). 
1
H NMR (400 MHz, DMSO) δ = 12.13 (s, 2H), 8.20 (s, 2H), 3.88 (t, J = 5.3 Hz, 2H), 2.38 – 2.23 
(m, 4H), 2.01 – 1.77 (m, 4H). 
13
C NMR (100 MHz, DMSO) δ = 173.9, 167.9, 53.2, 39.5, 29.3, 28.1. 
HRMS (EI) for C10H14N2O6
∙+ 
[M]
∙+
:
 
calcd.: 258.0852, found: 258.0831. 
IR (ATR):  ̃ = 3200 (b, w), 2822 (b, w), 2518 (b, w), 1677 (s), 1640 (s), 1402 (s), 1291 (s), 1266 (s), 
1192 (s), 887 (m), 814 (s). 
    
   = –41.9 (c = 1.00, DMSO). 
dimethyl 3,3'-((2S,5S)-3,6-dioxopiperazine-2,5-diyl)dipropanoate (200) 
 
A suspension of 199 (6.25 g, 24.2 mmol, 1.00 eq), MeOH (300 mL) and CBr4 (803 mg, 2.42 mmol, 
0.10 eq) was heated to reflux for 36 hours under. The resulting solution was cooled to room 
temperature and concentrated in vacuo to ca. 50 mL, at which point a white solid formed. Et2O 
(150 mL) was added and the reaction flask was stored overnight at –25 °C to ensure complete 
precipitation. Filtration of the solid afforded, after drying at 60 °C for 2 hours, 200 as a white solid 
(6.33 g, 22.0 mmol, 91%). Spectral data match the previously reported values.
[250]
 
Rf = 0.17 (CH2Cl2/MeOH = 95/5, CAM).  
Melting point = 183.2 – 186.6 °C. 
1
H NMR (400 MHz, DMSO) δ = 4.84 (t, J = 8.5 Hz, 2H), 2.64 – 2.38 (m, 4H, partially obscured by 
solvent), 2.27 – 2.13 (m, 4H). 
13
C NMR (100 MHz, DMSO) δ = 172.7, 165.7, 58.4, 31.2, 18.9. 
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HRMS (ESI) for C12H18N2O6Na
 
[M+Na]
+
: calcd.: 309.1057, found: 309.1058. 
IR (ATR):  ̃ = 2941 (w), 1764 (s), 1690 (m), 1463 (w), 1353 (m), 1273 (s), 1247 (s), 1148 (m), 
927 (m). 
    
   = −42.5 (c = 1.00, DMSO). 
(2S,5S)-di-tert-butyl 2,5-bis(3-hydroxypropyl)piperazine-1,4-dicarboxylate (202) 
 
A suspension of 200 (1.11 g, 3.88 mmol, 1.00 eq.) in THF was cooled to 0 °C and LiAlH4 (2.21 g, 
58.2 mmol, 15.00 eq) was added in five portions. The grey suspension was refluxed for 30 h under N2 
atmosphere and then cooled to 0 °C. Then, H2O (2.2 mL) was added dropwise, followed by aqueous 
NaOH (10% w/w, 2.2 mL), and H2O (6.6 mL). The reaction mixture was heated to reflux for 30 min, 
cooled to ambient temperature and filtered over a glass sintered funnel (Por. 3). To the resulting clear 
filtrate was added 10 mL sat aqueous NaHCO3, and the resulting biphasic mixture with precipitate 
formed was cooled to 0 °C. Boc2O (1.78 g, 8.14 mmol, 2.10 eq) was added in one portion and the 
reaction was stirred for 24 h at room temperature. The solvent was evaporated and the crude oil was 
redissolved in water and extracted with EtOAc (5 x 50 mL). The combined organic layers were 
washed with brine (200 mL), dried over Na2SO4, filtered, and the solvent was evaporated. Purification 
of the crude material by silica gel flash chromatography (SiO2, EtOAc) afforded 202 as a colorless oil, 
which solidified upon trituration with Et2O (577 mg, 1.44 mmol, 37%). 
Crystals suitable for X-ray analysis were grown from Et2O. 
Rf = 0.34 (EtOAc, CAM). 
Melting point = 103 – 104 ºC. 
1
H NMR (600 MHz, CHCl3) δ = 3.97 (br s, 4H), 3.64–3.55 (m, 4H), 2.63 – 2.53 (m, 2H), 1.57 – 1.49 
(m, 6H), 1.40 (br s, 18 H). 
13
C NMR (150 MHz, CHCl3) δ = 155.6, 80.2, 62.4, 53.1, 42.06, 28.6, 28.5. 
HRMS (ESI) for C20H39N2O6 [M+H]
+
: calcd.: 403.2808; found: 403.2808. 
IR (ATR):  ̃ = 3450 (m), 2941 (w), 2866 (w), 1669 (s), 1419 (s), 1366 (m), 1151(s), 1052 (s), 
993 (w), 878 (m), 767 (m). 
    
   = +84.2 (c = 0.50, CH2Cl2). 
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(2S,5S)-di-tert-butyl 2,5-bis(3-oxopropyl)piperazine-1,4-dicarboxylate (203) 
 
To solution of DMSO (0.81 mL, 11.4 mmol, 5.00 eq.) in CH2Cl2 (15 mL) at –78°C was added oxalyl 
chloride (2.0 M in CH2Cl2, 2.86 mL, 5.71 mmol, 2.50 eq.) dropwise. After complete addition, the 
reaction mixture was stirred at –78 °C for 15 min. Then a solution of 202 (920 mg, 2.29 mmol, 1.00 
eq.) in dry CH2Cl2 (10 mL) was added dropwise. After complete addition the reaction mixture was 
stirred at –78°C for 45 min, followed by the dropwise addition of Et3N (3.18 mL, 22.9 mmol, 10.00 
eq.) at the same temperature. The cooling bath was removed, and the reaction was stirred for 1 h. 
Water (20 mL) was added, and the aqueous phase was extracted with CH2Cl2 (2 x 20mL). The 
combined organic phases were washed successively with aqueous HCl (1 M, 30 mL) saturated 
aqueous NaHCO3 (30 mL) and brine (30 mL), dried over Na2SO4, filtered, and concentrated in vacuo. 
Purification by flash column chromatography (SiO2, hexanes/EtOAc = 6/4) afforded aldehyde 203 
(590 mg, 7.41 mmol, 65%) as a clear oil. 
Rf = 0.53 (hexanes/EtOAc = 1/1, PAA). 
1
H NMR (400 MHz, CDCl3) δ = 9.83 – 9.71 (m, 2H), 4.16 – 3.83 (m, 4H), 2.56 – 2.44 (m, 6H), 1.78 – 
1.62 (m, 4 H), 1.43 (s, 18H). 
13
C NMR (100 MHz, CDCl3) δ = 201.5, 155.7, 80.6, 52.7, 42.0, 40.4, 28.5, 24.0. 
HRMS (EI) for C20H34N2O6
∙+ 
[M]
∙+
: calcd.: 398.2411, found: 398.2410. 
IR (ATR):  ̃ = 2973 (w), 2712 (w), 1773 (m), 1684 (s), 1403 (b, m), 1364 (s), 1247 (m), 1153 (s), 
866 (m), 770 (m). 
    
   = +71.3 (c = 1.00. CH2Cl2). 
di-tert-butyl (2S,5S)-2,5-bis(2-formyl-5-oxohexyl)piperazine-1,4-dicarboxylate 
(204) 
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To solution of aldehyde 203 (3.00 g, 7.53 mmol, 1.00 eq.) in MeCN (100 mL) was Et2NSiMe3 
(713 µL, 3.77 mmol, 0.50 eq.). The resulting solution was heated to 80 °C for 16 h. The resulting 
orange solution was cooled to room temperature and concentrated in vacuo. Purification of the crude 
product by flash column chromatography (SiO2, hexanes/EtOAc = 1/1) afforded ketoaldehyde 204 
(3.30 g, 6.13 mmol, 81%) as a light yellow oil and as a 1/1 mixture of diastereoisomers. Spectral data 
match the previously reported values.
[237]
 
Rf = 0.40 (hexanes/EtOAc = 3/7, CAM).  
Note: NMR spectra are complex due to the presence of diastereoisomers.  
1
H NMR (600 MHz, CHCl3) δ = 9.60 (t, J = 2.5 Hz, 1H), 9.54 (t, J = 3.3 Hz, 1H), 4.28 – 3.82 
(m, 4H), 2.55 – 2.36 (m, 8H), 2.13 (d, J = 2.2 Hz, 6H), 1.99 – 1.85 (m, 3H), 1.84 – 1.74 (m, 3H), 1.47 
– 1.39 (m, 20H). 
13
C NMR (150 MHz, CHCl3) δ = 207.6, 203.5, 203.2, 155.5, 80.8, 51.8, 51.5, 48.0, 47.3, 42.2, 40.5, 
40.4, 31.2, 30.8, 30.7, 30.2, 28.5, 23.1, 22.8. 
HRMS (EI) for C28H46N2O8
∙+ 
[M]
∙+
: calcd.: 538.3254, found: 538.3264. 
IR (ATR):  ̃ = 2975 (w), 2931 (w), 1686 (s), 1478 (w), 1413 (m), 1365 (m), 1247 (w), 1153 (m), 
1108 (m), 875 (w), 789 (w). 
    
   = +42.6 (c = 1.0, CH2Cl2). 
di-tert-butyl (2S,5S)-2,5-bis((4-oxocyclohex-2-en-1-yl)methyl)piperazine-1,4-
dicarboxylate (205) 
 
To a mixture of ketoaldehyde 204 (3.86 g, 7.17 mmol, 1.00 eq.) in THF (700 mL), Et2O (1500 mL) 
and aqueous KOH (0.1 M, 700 mL) was added n-Bu4NOH (1 M in MeOH, 1.43 mL, 1.43 mmol, 
0.20 eq.) at 0 ºC and the mixture was heated to 40 °C for 24 h. The organic layer was separated and 
saturated aqueous NH4Cl (500 mL) was added, followed by EtOAc (400 mL). The organic layer was 
separated and the aqueous layer was extracted with EtOAc (2 x 400 mL). The combined organic layers 
were washed with brine (400 mL), dried over MgSO4 and concentrated in vacuo. The crude product 
was purified by flash column chromatography (SiO2, hexanes/EtOAc = 1/1) to afford α,β-unsaturated 
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ketone 205 as an inseparable diastereoisomeric mixture and as colorless oil (2.74 g, 5.45 mmol, 76%). 
Spectral data match the previously reported values.
[237]
 
Rf = 0.21 (hexanes/EtOAc = 4/6, CAM). 
Note: NMR spectra are complex due to the presence of diastereoisomers.  
1
H NMR (400 MHz, CDCl3) δ = 7.03 – 6.89 (m, 2H), 6.81 (ddd, J = 10.4, 2.9, 1.2 Hz, 1H), 5.99 (ddd, 
J = 10.0, 5.3, 2.3 Hz, 2H), 4.27 (s, 2H), 4.05 (s, 3H), 2.65 – 2.43 (m, 4H), 2.43 – 2.26 (m, 2H), 2.22 –
2.06 (m, 1H), 1.84 – 1.52 (m, 5H), 1.52 – 1.39 (m, 18H), 1.40 – 1.25 (m, 1H), 1.03 – 0.79 (m, 1H). 
13
C NMR (100 MHz, CDCl3) δ = 199.3, 199.2, 155.5, 155.4, 153.7, 129.4, 129.1, 80.7, 51.2, 51.1, 
50.8, 50.7, 36.7, 36.6, 33.0, 32.5, 29.0, 28.9, 28.4, 28.4. 
HRMS (EI) for C28H42N2O6
∙+ 
[M]
∙+
: calcd.: 502.3037, found: 502.3032. 
IR (ATR):  ̃ = 3353 (w), 2973 (w), 2929 (w), 1737 (w), 1676 (s), 1392 (w), 1665 (m), 1245 (m), 
1153 (m), 1033 (w). 
    
   = –6.2 (c = 1.0, CH2Cl2). 
(3S,6S)-3,6-bis(4-methoxybenzyl)piperazine-2,5-dione (264) 
 
NaH (60% w/w in mineral oil, 515 mg, 12.9 mmol, 2.10 eq.) in DMF (47 mL) was cooled to 0 °C and 
diketopiperazine 164 (2.00 g, 6.13 mmol, 1.00 eq.; prepared according to Hutton and co-workers)
[211]
 
was added. After 30 minutes, MeI (1.14 mL, 18.4 mmol, 3.00 eq.) was added dropwise and the 
reaction mixture was stirred for 6 h while warming to room temperature. Then, it is cooled to 0 °C and 
saturated aqueous NH4Cl (30 mL) was added, followed by CHCl3 (50 mL) and i-PrOH (10 mL). The 
layers are separated and the aqueous layer is extracted with an 8/2 mixture of CHCl3/i-PrOH (2 x 50 
mL). The combined organic layers are washed with LiCl (10% w/w, 3 x 30 mL), brine (30 mL), dried 
over MgSO4 and filtered. The solvent is removed in vacuo and the resulting solid is triturated with 
MeOH (20 mL) and filtered to afford 234 as a white solid (1.85 g, 5.22 mmol, 85%).  
Rf = not determined. 
Melting point = 295 °C (decomposition). 
1
H NMR (400 MHz, DMSO) δ = 7.85 (d, J = 2.5 Hz, 2H), 6.95 (d, J = 8.3 Hz, 4H), 6.84 (d, J = 8.5 
Hz, 4H), 4.00 – 3.84 (m, 2H), 3.69 (s, 6H), 2.58 – 2.45 (m, 2H), 2.21 (dd, J = 13.7, 6.2 Hz, 2H). 
13
C NMR (100 MHz, DMSO) δ = 166.2, 158.0, 130.8, 128.4, 113.7, 55.5, 55.0, 38.4. 
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HRMS (ESI) for C20H23N2O4
+
 [M+H]
+
: calcd.: 355.1652, found 355.1651.  
IR (ATR):  ̃ = 3210 (w), 3051 (w), 2933 (w), 1674 (s), 1656 (s), 1612 (m), 1512 (s), 1456 (s), 1338 
(m), 1245 (m), 1179 (m), 1037 (m), 925 (w), 834 (m), 686 (w). 
    
   = –114.4 (c = 0.5, DMSO) 
(2S,5S)-2,5-bis(4-methoxybenzyl)piperazine (235) 
 
Diketopiperazine 234 (2.00 g, 5.64 mmol, 1.00 eq) was added to THF (46 ml) followed by BH3·THF 
complex (1 M in THF, 33.9 mL, 33.9 mmol, 6.00 eq.). The suspension was stirred for 1 h at room 
temperature. Then, the resulting solution was heated to reflux for 36 h. The hot solution was filtered 
(por. 4 glass frit) into a separate flask containing a teflon-coated stir bar and cooled to 0 °C. Then, HBr 
(30% in AcOH, 30.6 ml, 169 mmol, 30.0 eq) was added dropwise (gas evolution!), followed by 
hexane (50 mL). The resulting slurry was aged in a freezer (–24 °C for 12 h). The suspension was 
filtered, and the resulting light yellow solid was recrystallized from EtOH to afford 235 as light tan 
crystals (1.19 g, 2.44 mmol, 43%). 
Crystals suitable for X-ray analysis were grown from EtOH. 
Rf = not determined. 
1
H NMR (400 MHz, MeOD) δ = 7.41 – 7.31 (m, 4H), 7.01 – 6.91 (m, 4H), 4.00 (dtd, J = 9.2, 6.7, 
4.2 Hz, 2H), 3.79 (s, 6H), 3.48 (qd, J = 14.3, 5.4 Hz, 4H), 3.31 – 3.17 (m, 4H). 
13
C NMR (100 MHz, MeOD) δ = 160.98, 131.62, 126.80, 115.73, 55.77, 54.12, 42.32, 34.67 
HRMS (ESI) for C20H27N2O2
+
 [M+H]
+
: calcd.: 327.2076, found: 327.2068 
IR (ATR):  ̃ = 2902 (w), 2718 (m), 1612 (m), 1551 (w), 1514 (s), 1454 (m), 1433 (m), 1257 (s), 1177 
(s), 1097 (m), 1064 (m), 1034 (m), 961 (w), 838 (m), 740 (w), 666 (m). 
    
   =  –3.0 (c = 0.2, MeOH) 
di-tert-butyl (2S,5S)-2,5-bis(4-methoxybenzyl)piperazine-1,4-dicarboxylate (230) 
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Hydrobromide salt 235 (50 mg, 102 μmol, 1.00 eq.) was suspended in CH2Cl2 (650 μL) and Et3N was 
added (62.6 μL, 45.6 μmol, 4.40 eq.), followed by Boc2O (49.2 mg, 225 μmol, 2.20 eq.). After stirring 
for 24 hours, the reaction was diluted with CH2Cl2 (5 mL) and saturated aqueous NH4Cl (5 mL). The 
layers were separated and the aqueous layer was extracted with CH2Cl2 (2 x 10 mL). The combined 
organic layers were washed with brine (20 mL), dried over MgSO4, filtered and concentrated under 
reduced pressure. Purification of the crude product by flash column chromatography (SiO2, 
hexanes/EtOAc = 9/1) gave 230 as a colorless oil (50 mg, 101 mmol, 98%).  
 Rf = 0.69 (hexanes/EtOAc = 8/2, UV 254 nm, CAM). 
1
H NMR (400 MHz, CDCl3) δ = 7.03 – 6.97 (m, 4H), 6.83 – 6.76 (m, 4H), 4.04 (d, J = 7.7 Hz, 2H), 
3.79 (overlap, app s, 6H), 2.78 (dd, J = 13.4, 4.0 Hz, 2H), 2.59 (td, J = 13.1, 8.7 Hz, 4H), 1.43 
(s, 18H). 
13
C NMR (100 MHz, CDCl3) δ = 158.3, 155.1, 130.3, 129.1, 113.9, 80.0, 55.3, 54.5, 41.1, 37.1, 28.4. 
HRMS (ESI) for C30H43N2O6
+ 
[M+H]
+
: calcd.: 527.3116, found: 527.3124. 
IR (ATR):  ̃ = 2973 (w), 2933 (m), 2936 (m), 1688 (s), 1512 (s), 1456 (w), 1404 (m), 1392 (m), 1365 
(m), 1300 (m), 1246 (s), 1113 (m), 1035 (m), 944 (w), 879 (w), 767 (m). 
    
   = +33.4 (c = 2.11, CH2Cl2). 
di-tert-butyl-(2S)-2,5-bis((4-oxocyclohex-1-en-1-yl)methyl)piperazine-1,4-
dicarboxylate (207) 
 
Liquid ammonia (170 mL) was condensed into a three-neck round bottom flask fitted with a teflon-
coated stirbar and a dry ice condenser placed in a –78 °C cooling bath. A solution of 230 (2.10 g, 
3.99 mmol 1.00 eq) in t-BuOH (15 mL) and THF (50 mL) was added slowly. Lithium chips (553 mg, 
79.7 mmol, 20.00 eq.) with vigorous stirring.  The dark blue solution was stirred at –78 °C and the 
reaction progress was monitored by 
1
H NMR after evaporation of withdrawn reaction aliquots and 
dissolution in CDCl3. After 2 h the reaction was deemed complete and H2O was added until 
disappearance of the blue color. The cooling bath was removed and excess ammonia was allowed to 
evaporate under an N2 stream (ca. 6 h). The orange residue was taken up in water (200 mL) and 
extracted with Et2O (3 x 200 mL). The combined organic layers were washed with water (2 x 100 
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mL), brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo to afford the intermediate 
methyl enol ether (236), which was used directly for the next step. 
To a stirred solution of the intermediate methyl enol ether in dioxane (30 mL) was added aqueous HCl 
(1 M, 4 mL). After 2 h, pH 7 buffer (50 mL) and Et2O (50 mL) are added. The layers are separated and 
the aqueous layer was extracted with Et2O (3 x 50 mL). The combined organic layers were washed 
with water (2 x 100 mL), brine (100 mL), dried over MgSO4, filtered and concentrated in vacuo. The 
resulting crude product was purified by flash column chromatography (SiO2, hexanes/EtOAc = 8/2) to 
afford 207 as colorless oil (1.31 g, 2.61 mmol, 66%). 
Note: 207 is sensitive to air oxidation and decomposes if stored at room temperature within 3 days. It 
can be stored in a benzene matrix at –25 °C for > 1 year, and routine manipulations can be 
performed. 
Rf = 0.29 (hexanes/EtOAc = 6/4, KMnO4). 
1
H NMR (400 MHz, CDCl3) δ = 5.48 (t, J = 3.6 Hz, 2H), 4.15 – 3.89 (m, 4H), 2.81 (d, J = 3.6 Hz, 
4H), 2.65 (dd, J = 14.2, 10.5 Hz, 2H), 2.56 – 2.28 (m, 10H), 2.06 (dd, J = 13.3, 8.3 Hz, 2H), 1.41 (s, 
18H). 
13
C NMR (100 MHz, CDCl3) δ = 210.1, 155.0, 134.9, 121.2, 80.3, 51.6, 41.8, 39.7, 38.7, 28.5. 
HRMS (ESI) for C28H46N3O6
+
 [M+NH4]
+
: calcd.: 520.3387, found: 520.3398. 
IR (ATR):  ̃ = 3419 (w), 3052 (w), 2929 (w), 2341 (w), 2177 (w), 2159 (s), 1690 (s), 1478 (w), 1405 
(m), 1366 (m), 1337 (m), 1264 (m), 1161 (m), 1114 (m), 1062 (m), 734 (m) 
    
   = +37.7 (c = 0.60, CH2Cl2). 
di-tert-butyl (2S,5S)-2,5-bis((4-((triethylsilyl)oxy)cyclohexa-1,3-dien-1-
yl)methyl)piperazine-1,4-dicarboxylate (237) 
 
A solution of 207 (107 mg, 213 μmol, 1.00 eq.) in THF (2 mL) was cooled to –78 °C and a solution of 
LiHMDS (1M in THF, 468 μL, 468 μmol, 2.20 eq.) was added dropwise. After 45 min, Et3SiCl was 
introduced and the reaction was allowed to warm to room temperature over the course of 8 hours. 
Then, pH 7 buffer (4 ml) was added, followed by EtOAc (10 mL). The organic layer was separated 
and the aqueous layer was extracted with EtOAc (2 x 10 mL). The combined organic layers were 
washed with brine (10 mL), dried over Na2SO4 and filtered over a plug of silica gel (2 x 2 cm, elution 
with EtOAc). The solvent was removed in vacuo to afford 237 (110 mg, 150 μmol 71%). 
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Note: 237 degrades upon storage at room temperature neat and in solution (CDCl3) within 3 days. 
Rf = 0.81 (hexanes/EtOAc = 9/1, UV 254 nm, KMnO4). 
1
H NMR (400 MHz, CDCl3) δ 5.54 (d, J = 5.9 Hz, 2H), 5.02 (d, J = 5.9 Hz, 2H), 4.00 (s, 4H), 2.68 (d, J = 
14.2 Hz, 2H), 2.43 – 2.31 (m, 2H), 2.31 – 2.14 (m, 7H), 2.05 (dd, J = 13.2, 9.0 Hz, 2H), 1.45 (s, 18H), 0.97 (t, J 
= 7.9 Hz, 18H), 0.72 – 0.59 (m, 12H). 
13
C NMR (100 MHz, CDCl3) δ = 166.2, 158.0, 130.8, 128.4, 113.7, 55.5, 55.0, 40.1, 39.9, 39.7, 39.5, 39.3, 
39.1, 38.9, 38.4. 
(2Z,4Z)-1,6-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexa-2,4-diene (268) 
 
A solution of TMEDA (35 mL, 231 mmol, 2.10 eq.) in hexanes (40 mL) was cooled to –30 °C and 
n-BuLi (11 M in hexanes, 20.5 mL, 225 mmol 2.05 eq.) was added dropwise and the resulting light 
yellow slurry was vigorously stirred until homogeneous.  Hexadiene (13.1 mL, 110 mmol, 1.00 eq.) 
was added dropwise. After complete addition, the flask was sealed with a glass stopper and allowed to 
warm to room temperature over the course of 24 hours. The resulting dark red mixture was shaken 
manually to triturate solid aggregates and is cooled to –78 °C while Et2O (114 mL) was added under 
vigorous stirring. A precooled (–78 °C, jacketed addition funnel) solution of i-PrOBpin (50 mL, 
242 mmol, 2.20 eq.) in Et2O (57 mL) was added dropwise under vigorous stirring (700 rpm). The 
reaction mixture solidifies after addition of approx. 75% of the solution. The setup is allowed to reach 
room temperature over the course of 24 h. Then, saturated aqueous NH4Cl (200 mL) and Et2O 
(300 mL) were added and the mixture was vigorously shaken and triturated with a glass rod to ensure 
adequate mixing. The mixture is filtered through a glass frit (por. 3), the aqueous phase is separated 
and extracted with Et2O (2 x 200 mL). The combined organic layers are washed with brine (300 mL), 
dried over MgSO4 and filtered. The solvent is removed in vacuo and the crude product is dissolved in 
hexanes (50 mL) and left to crystallize at –24 °C. The mother liquor is removed by syringe and hexane 
(30 mL) is added. After aging at –24 °C for further 6 h, the resulting off-white solid is collected by 
filtration (14.06 g, 42.0 mmol, 39%). 
Crystals suitable for X-ray analysis were obtained from pentane by slow evaporation under N2. 
Note: 268 degrades upon prolonged exposure to silica gel. It can be purified in a Kugelrohr apparatus 
(oven temperature = 163 to 245 °C at 2.5 x 10
-2
 mbar) 
Rf = 0.6 (hexanes/Et2O = 8/2, UV 254 nm, CAM). 
Melting point = 67.1 °C. 
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1
H NMR (400 MHz, CDCl3) δ = 6.31 – 6.21 (m, 1H), 5.56 (dt, J = 9.7, 7.6 Hz, 1H), 1.82 (d, J = 8.2 Hz, 2H), 
1.24 (s, 21H). 
13
C NMR (150 MHz, CDCl3) δ = 126.2, 123.8, 83.4, 24.9. 
Note: The peak belonging to the boron-bound carbon was not observed due to quadrupolar 
relaxation. 
HRMS (EI) for C18H32B2O4
∙+ 
[M]
∙+
: calcd.: 334.2487, found: 334.2479. 
IR (ATR):  ̃ = 3403 (w), 2978 (w), 2931 (w), 2166 (w), 1986 (w), 1596 (w), 1479 (w), 1467 (w), 
1379 (m), 1369 (s), 1319 (s), 1271 (m), , 1213 (w), 1164 (m), 983 (w), 964 (m), 844 (m), 817 (w). 
Rac-(4S,5R,Z)-7-phenyl-4-vinylhept-2-ene-1,5-diol (279) 
 
Allylpinacolboronate 268 (167 mg, 500 µmol, 1.00 eq., dried by azeotropic evaporation from benzene) 
was dissolved in toluene (3 mL) and 3-phenylpropionaldehyde (79 µL, 600 µmol, 1.20 eq.) was added 
dropwise and the resulting clear solution was stirred for 3 days at room temperature. After cooling to 
0 °C, THF (3 mL) was added, followed by aqueous NaOH (10% w/w, 600 µL, 1.02 mmol 3.00 eq.) 
and aqueous H2O2 (30% w/w, 610 µL, 6.00 mmol 12.00 eq.). After warming to room temperature over 
the course of 2 h, saturated aqueous NH4Cl (10 mL) was added, followed by EtOAc (20 mL). The 
layers were separated and the aqueous layer was extracted with EtOAc (2 x 20 mL). The combined 
organic layers were washed brine (30 mL), dried over MgSO4 and filtered. The solvent was removed 
in vacuo and the crude product was purified by flash column chromatography (SiO2, hexanes/EtOAc = 
7/3) to afford 278 as colorless oil and as a 9/1 mixture of diastereomers (78 mg, 336 µmol, 67%).  
Note: 278 is copolar with pinacol and separation can only be achieved by careful chromatography 
(staining with PAA). Alternatively, pinacol can be removed by azeotropic removal using MeOH and 
H2O according to Aggarwal and coworkers, or by submitting the crude reaction mixture to NaIO4.
[337]
 
The diastereomers of 278 could also be separated by semipreparative HPLC (Dynamax Microsorb 
60-8 C18, 250 x 21.4 mm; H2O/Acetonitrile containing 0.1% formic acid; gradient: 5% to 50% 
acetonitrile over 55 minutes; flow rate 20 mL/min; detection at 210 nm; tR major isomer = 38.7 min; tR 
minor isomer = 40.0 min) Spectral data match the previously reported values.
[316]
  
Data for syn-279 (major isomer) 
Rf = 0.23 (hexanes/EtOAc = 1/1, PAA).  
1
H NMR (600 MHz, CHCl3) δ = 7.32 – 7.16 (m, 5H), 5.89 – 5.68 (m, 2H), 5.50 (ddt, J = 11.1, 9.9, 1.3 Hz, 
1H), 5.21 – 5.06 (m, 2H), 4.26 – 4.11 (m, 2H), 3.56 (ddd, J = 9.4, 6.3, 2.6 Hz, 1H), 3.22 (dddd, J = 10.0, 7.5, 6.3, 
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1.2 Hz, 1H), 2.85 (ddd, J = 13.7, 10.0, 5.1 Hz, 1H), 2.65 (ddd, J = 13.7, 9.6, 6.8 Hz, 1H), 1.86 (dddd, J = 13.9, 
9.7, 6.8, 2.6 Hz, 1H), 1.64 (dtd, J = 14.5, 9.7, 5.2 Hz, 2H). 
13
C NMR (150 MHz, CHCl3) δ = 142.0, 137.5, 131.0, 130.9, 128.6, 128.6, 126.0, 117.4, 73.1, 58.6, 49.1, 
35.6, 32.5. 
HRMS (ESI) for C15H21O2
+ 
[M+H]
+
: calcd.: 233.1536, found: 233.1539. 
IR (ATR):  ̃ = 3332 (br), 3083 (w), 3024 (w), 2919 (w), 2861 (w), 2361 (w), 2340 (w), 1949 (w), 
1635 (w), 1602 (w), 1495 (w), 1454 (m),  1417 (w), 1316 (w), 1154 (w), 1132 (w), 1029 (s), 823 (w), 
747 (s), 699 (s), 668 (s). 
 
Data for anti-279 (minor isomer) 
Rf = 0.23 (hexanes/EtOAc = 1/1, PAA).  
1
H NMR (600 MHz, CHCl3) δ = 7.47 – 7.07 (m, 5H), 5.93 (dt, J = 10.6, 6.9 Hz, 1H), 5.76 (ddd, J = 17.5, 9.9, 
7.7 Hz, 1H), 5.59 (td, J = 10.4, 9.8, 1.2 Hz, 1H), 5.20 – 5.09 (m, 2H), 4.28 (ddd, J = 12.5, 7.4, 1.4 Hz, 1H), 4.14 
(ddd, J = 12.6, 6.4, 1.0 Hz, 1H), 3.55 (ddd, J = 9.1, 7.3, 2.9 Hz, 1H), 3.28 – 3.17 (m, 1H), 2.92 (ddd, J = 13.7, 
10.0, 5.1 Hz, 1H), 2.72 (ddd, J = 13.7, 9.7, 6.8 Hz, 1H), 1.95 (dddd, J = 14.0, 9.9, 6.8, 2.9 Hz, 1H), 1.75 (dtd, J = 
14.3, 9.5, 5.1 Hz, 1H). 
13
C NMR (150 MHz, CHCl3) δ = 142.1, 137.5, 131.8, 130.9, 128.6, 128.5, 126.0, 117.0, 72.5, 58.3, 49.4, 
36.3, 32.1. 
(3R,4S,5R,6S)-1,8-diphenyl-4,5-divinyloctane-3,6-diol (278) 
 
Allylpinacolboronate 268 (170 mg, 509 µmol, 1.00 eq., dried by azeotropic evaporation from benzene) 
was dissolved in THF (5 mL) and was cooled to –78 °C. Then, n-BuLi (2.5 M in hexanes, 448 µL, 
1.12 mmol, 2.20 eq.) was added dropwise and the light red colored solution was stirred for 15 minutes 
at 78 °C. Afterwards, TFAA (171 µL, 1.23 mmol, 2.40 eq.) was added dropwise and the resulting 
white suspension was stirred for 30 min. Then, a solution of 3-phenylpropionaldehyde (201 µL, 
1.53 mmol, 3.00 eq.) was added dropwise and the resulting mixture was left to warm to room 
temperature over the course of 16 h. After cooling to 0 °C, aqueous NaOH (10% w/w, 407 µL, 
1.02 mmol 2.00 eq.) was added, followed by aqueous H2O2 (30% w/w, 520 µL, 5.09 mmol 10.00 eq.). 
After warming to room temperature over the course of 2 h, saturated aqueous NH4Cl (20 mL) was 
added, followed by EtOAc (20 mL). The layers were separated and the aqueous layer was extracted 
with EtOAc (2 x 20 mL). The combined organic layers were washed brine (30 mL), dried over MgSO4 
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and filtered. The solvent was removed in vacuo and the crude product was purified by flash column 
chromatography (SiO2, hexanes/EtOAc = 9/1 to 8/2) to afford 278 as colorless oil that solidified upon 
standing (109 mg, 311 µmol, 61%).  
Crystals suitable for X-ray analysis were obtained from hexane/i-Pr2O. 
Rf = 0.30 (hexanes/EtOAc = 8/2, PAA).  
Melting point = 86.8 – 88.5 °C. 
1
H NMR (400 MHz, CHCl3) δ = 7.20 – 7.11 (m, 4H), 7.09 – 7.02 (m, 5H), 5.52 (dt, J = 17.1, 10.0 Hz, 
2H), 5.05 – 4.89 (m, 4H), 3.54 (ddd, J = 10.0, 5.7, 2.4 Hz, 2H), 2.73 (ddd, J = 13.6, 10.2, 5.1 Hz, 2H), 
2.47 (ddd, J = 13.7, 9.8, 6.6 Hz, 2H), 2.32 – 2.19 (m, 4H), 1.71 (dddd, J = 14.1, 10.1, 6.7, 2.4 Hz, 2H), 
1.42 (dtd, J = 14.9, 9.8, 5.1 Hz, 2H). 
13
C NMR (100 MHz, CHCl3) δ = 142.3, 136.8, 128.6, 128.5, 125.9, 118.8, 71.5, 52.5, 35.6, 32.4. 
HRMS (ESI) for C24H31O2
+ 
[M+H]
+
: calcd.: 351.2319, found: 351.2327. 
IR (ATR):  ̃ = 3344 (b, w), 3064 (w), 3002 (w), 2860 (w), 1944 (w), 1706 (m), 1637 (w), 1603 (w), 
1584 (w), 1495 (m), 1453 (m), 1419 (m),  1220 (w), 1042 (m), 1030 (m), 999 (m), 916 (s),  844 (w), 
819 (m), 746 (s), 697 (s). 
2-benzylacrylaldehyde (283) 
 
To a solution of 3-phenylpropionaldehyde (2.90 mL, 22.0 mmol, 1.00 eq.) in CH2Cl2 (55 mL) were 
added formaldehyde (37% w/w in H2O, 1.98 ml, 26.4 mmol, 1.20 eq.), pyrrolidine (181 μL, 2.20 
mmol, 0.10 eq) and 4-Dimethylaminobenzoic acid (363 mg, 2.20 mmol, 0.10 eq.). The mixture was 
heated to 35 °C for 2 h. Afterwards, the solution was cooled to room temperature and saturated 
aqueous NaHCO3 (50 mL) was added. The organic layer was separated, and the aqueous layer was 
extracted with CH2Cl2 (2 x 30 mL). The combined organic layers were washed with brine, dried over 
MgSO4, filtered and concentrated in vacuo. The resulting oil was purified by flash column 
chromatography (SiO2, hexane/Et2O = 9/1) to afford 283 as a colorless oil (1.975 g, 13.5 mmol, 61%). 
Spectral data match the previously reported values.
[319]
 
Rf  = 0.52 (hexanes/Et2O = 9/1, UV 254 nm, CAM). 
1
H NMR (400 MHz, CDCl3) δ = 9.57 (s, 1H), 7.29 – 7.11 (m, 5H), 6.08 – 6.05 (m, 1H), 
6.03 (d, J = 0.9, 1H), 3.53 (t, J = 1.1, 2H). 
13
C NMR (100 MHz, CDCl3) δ = 194.1, 149.8, 138.2, 135.4, 129.3, 128.7, 126.6, 34.3. 
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HRMS (EI) for C10H10O
·+
: calcd.: 146.0732 [M]
·+
, found: 146.0708. 
IR (ATR):  ̃ = 3361 (w), 3086 (w), 3029 (w), 2922 (w), 2700 (w), 1686 (s), 1602 (w), 1496 (m), 1453 
(m), 1344 (w), 1313 (w), 1245 (w), 1075 (w), 950 (m), 737 (m), 698 (s). 
2-benzylprop-2-en-1-ol (284) 
 
Aldehyde 283 (2.70 g, 18.5 mmol, 1.00 eq.) was dissolved in MeOH (22 mL). CeCl3·H2O (8.95 g, 
24.00 mmol, 1.30 eq.) was added and the solution was cooled to 0 °C. NaBH4 (838 mg, 22.2 mmol, 
1.20 eq.) was added slowly (gas evolution) and the mixture was allowed to warm to room temperature 
for 2 h. Saturated aqueous NaHCO3 (20 mL) was added and the aqueous layer was and extracted with 
EtOAc (3 x 20 mL). The combined organic layers were washed with brine (25 mL), dried over MgSO4 
and concentrated in vacuo. The crude product was purified by flash column chromatography (SiO2, 
hexanes/EtOAc = 8/2) to afford allylic alcohol 284 (1.65 g, 11.10 mmol, 60%) as colorless oil. 
Spectral data match the previously reported values.
[338]
 
Rf  = 0.78 (hexanes/EtOAc = 7/3, UV 254 nm, CAM). 
1
H NMR (400 MHz, CDCl3) δ = 7.34 – 7.28 (m, 2H), 7.25 – 7.20 (m, 3H), 5.13 (q, J = 1.6 Hz, 1H), 
4.91 (p, J = 1.3 Hz, 1H), 4.04 (s, 2H), 3.42 (s, 2H). 
13
C NMR (100 MHz, CDCl3) δ = 148.3, 139.1, 129.0, 128.5, 126.4, 111.5, 65.4, 40.0. 
HRMS (EI) for C10H12O
·+
 [M]
·+
: calcd.: 148.0888, found: 148.0881. 
IR (ATR):  ̃ = 3321 (br, w), 3027 (w), 2915 (w), 1882 (w), 1650 (w), 1494 (m), 1452 (m), 1432 (w), 
1226 (w), 1154 (w), 1054 (m), 899 (m), 739 (m), 696 (s). 
4-benzyl-N,N-dimethylpent-4-enamide (285) 
 
Alcohol 284 (1.66 g, 11.2 mmol, 1.00 eq.) was dissolved in toluene (48 mL) and 
N,N-dimethylacetamide dimethyl acetal (2.46 mL, 16.8 mmol, 1.50 eq.) was added. The colorless 
solution was heated to 110 °C open to air and a gentle stream of N2 was bubbled through the solvent 
via a thin glass capillary to remove liberated MeOH. After 3 h, the resulting yellow solution was 
cooled to room temperature and the volatiles were removed in vacuo. The crude product was purified 
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by flash column chromatography (SiO2, hexanes/EtOAc = 7/3) to give 285 (2.23 g, 10.3 mmol, 92%) 
as colorless oil. 
Rf  = 0.18 (hexanes/EtOAc = 7/3, UV 254 nm, CAM). 
1
H NMR (400 MHz, CDCl3) δ = 7.37 – 7.27 (m, 2H), 7.25 – 7.20 (m, 3H), 4.86 (dd, J = 14.7, 1.9 Hz, 
2H), 3.41 (s, 2H), 2.94 (d, J = 1.6 Hz, 6H), 2.53 – 2.29 (m, 4H). 
13
C NMR (100 MHz, CDCl3) δ = 172.2, 148.0, 139.3, 128.8, 128.2, 126.0, 111.2, 43.3, 37.0, 35.2, 
31.6, 30.5. 
HRMS (ESI) for C14H20ON
+
 [M+H]
+
: calcd.: 217.1467, found: 218.1537. 
IR (ATR):  ̃ = 3062 (w), 2917 (w), 1946 (w), 1639 (s), 1493 (m), 1452 (m), 1432 (w), 1395 (m), 
1265 (m), 1137 (m), 1029 (w), 981 (w), 891 (m), 828 (w), 735 (m), 699 (s). 
4-benzylpent-4-enal (286) 
 
Amide 285 (1037 mg, 4.77 mmol, 1.00 eq.) was dissolved in THF (24 ml), cooled to 0 °C and 
Ti(Oi-Pr)4 (1.50 ml, 5.01 mmol, 1.05 eq.) was added. Then, diphenylsilane (1022 μL, 5.49 mmol, 1.15 
eq.) was added dropwise and the resulting solution was stirred for 15 h while warming to room 
temperature. Then, the solution was cooled to 0 °C and aqueous HCl (1 M, 10 mL) was added slowly 
(exotherm!) and a white precipitate was observed. Et2O (30 mL) was added, the phases were separated 
and the aqueous layer was extracted with Et2O (2 x 30 mL). The combined organic layers were 
washed with brine, dried over MgSO4, filtered, and concentrated in vacuo. The resulting crude product 
was purified by flash column chromatography (SiO2, hexanes/EtOAc = 9/1 to 7/3) to afford 286 as 
colorless oil (587 mg, 3.37 mmol, 70%). Spectral data match the previously reported values.
[151]
 
Rf  = 0.29 (hexanes/EtOAc = 7/3, UV 254 nm, CAM). 
1
H NMR (400 MHz, CDCl3) δ = 9.72 (t, J = 1.7, 1H), 7.34 – 7.28 (m, 2H), 7.25 – 7.16 (m, 2H), 4.85 
(dd, J = 8.6, 1.4, 2H), 3.38 (s, 2H), 2.56 (td, J = 7.5, 1.7, 2H), 2.35 – 2.29 (m, 2H).  
13
C NMR (100 MHz, CDCl3) δ = 202.1, 147.0, 139.2, 129.0, 128.5, 126.4, 112.0, 43.5, 41.8, 27.5. 
HRMS (EI) for C12H14O
·+ 
[M]
·+
: calcd.: 174.1045, found: 174.1042. 
IR (ATR):  ̃ = 3431 (br, w), 3066 (w), 3026 (w), 2918 (w), 2724 (w), 2362 (w), 2138 (w), 1950 (w), 
1722 (m), 1645 (w), 1601 (w), 1591 (w), 1494 (w), 1452 (w), 1429 (m), 1388 (w), 1335 (w), 1262 
(w), 1182 (w), 1124 (m), 1074 (m), 1028 (m), 997 (w), 949 (w), 893 (m), 822 (w), 737 (m), 716 (m), 
697 (s). 
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(5R,6S,7R,8S)-2,11-dibenzyl-6,7-divinyldodeca-1,11-diene-5,8-diol (287)  
 
Allylpinacolboronate 268 (511 mg, 1.53 mmol, 1.00 eq., dried by azeotropic evaporation from 
benzene) was dissolved in THF (15 mL) and was cooled to –78 °C. Then, n-BuLi (2.3 M in hexanes, 
1.46 mL, 3.37 mmol, 2.20 eq.) was added dropwise and the light red colored solution was stirred for 
15 minutes at 78 °C. Afterwards, TFAA (515 µL, 3.7 mmol, 2.40 eq.) was added dropwise and the 
resulting white suspension was stirred for 30 min. Then, a solution of aldehyde 286 (587 mg, 
3.37 mmol, 2.20 eq.) in THF (1 mL) was added dropwise and the resulting mixture was left to warm to 
room temperature over the course of 16 h. After cooling to 0 °C, aqueous NaOH (10% w/w, 1.22 mL, 
3.06 mmol, 2.00 eq.) was added, followed by aqueous H2O2 (30% w/w, 1.56, 15.3 mmol, 10.00 eq.). 
After warming to room temperature over the course of 2 h, saturated aqueous NH4Cl (30 mL) was 
added, followed by EtOAc (50 mL). The layers were separated and the aqueous layer was extracted 
with EtOAc (2 x 50 mL). The combined organic layers were washed brine (50 mL), dried over MgSO4 
and filtered. The solvent was removed in vacuo and the crude product was purified by flash column 
chromatography (SiO2, hexanes/EtOAc = 9/1) to afford 287 as colorless oil (440 mg, 1.02 µmol, 
67%).  
Rf = 0.66 (hexanes/EtOAc = 8/2, PAA, violet). 
1
H NMR (400 MHz, CDCl3) δ = 7.31 – 7.25 (m, 4H), 7.22 – 7.16 (m, 6H), 5.74 – 5.60 (m, 2H), 5.17 – 
5.04 (m, 4H), 4.81 (dd, J = 30.5, 1.8 Hz, 4H), 3.59 (ddd, J = 9.3, 5.7, 2.4 Hz, 2H), 3.34 (s, 4H), 2.41 
(s, 2H), 2.37 – 2.28 (m, 2H), 2.19 (ddd, J = 15.0, 10.0, 5.1 Hz, 2H), 1.98 (ddd, J = 15.3, 9.7, 6.5 Hz, 
2H), 1.69 (dddd, J = 13.9, 10.0, 6.3, 2.6 Hz, 2H), 1.45 – 1.23 (m, 2H). 
13
C NMR (100 MHz, CDCl3) δ = 149.0, 139.7, 137.1, 129.1, 128.4, 126.2, 118.4, 111.5, 71.6, 52.4, 
43.2, 31.9, 31.8. 
HRMS (ESI) for C30H39O2
+
 [M+H]
+
: calcd.: 431.2945, found: 431.2945. 
IR (ATR):  ̃ = 3697 (w), 3663 (w), 3275 (w), 3072 (w), 1805 (w), 1642 (m), 1511 (w), 1494 (m), 
1452 (m), 1332 (w), 1072 (m), 999 (w), 915 (m), 734 (s), 697 (s). 
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(1R,1'S,2S,2'R)-5,5'-dibenzyl-[1,1'-bi(cyclohexane)]-5,5'-diene-2,2'-diol (288) 
 
A solution of 287 (113 mg, 262 µmol, 1.00 eq) in CH2Cl2 (10.8 mL) was deoxygenated by subsurface 
purging of N2 for 20 min. Then, HG2 (16.5 mg, 26.2 µmol, 0.1 eq.) was added and the green solution 
was heated to 40 °C. After 24 h, the brown solution was cooled to room temperature and the solvent 
was removed in vacuo. The resulting crude product was purified by flash column chromatography 
(SiO2, hexanes/EtOAc = 9/1 to 1/1) to afford 288 as a light grey solid (56 mg, 150 µmol, 57%). 
Crystals suitable for X-ray analysis were obtained from CH2Cl2 by slow evaporation. 
Rf = 0.32 (hexanes/EtOAc = 2/1, CAM). 
Melting point = 141.1 – 143.5 °C. 
1
H NMR (400 MHz, CDCl3) δ = 7.28 – 7.14 (m, 4H), 7.15 – 7.10 (m, 2H), 7.08 – 7.03 (m, 4H), 5.07 
(q, J = 1.6, 2H), 3.73 (ddd, J = 11.2, 7.9, 3.6, 2H), 3.19 (s, 4H), 2.38 (dt, J = 8.0, 2.2, 2H), 2.27 (s, 
2H), 1.96 – 1.87 (m, 4H), 1.80 (dq, J = 12.1, 4.0, 2H), 1.53 (tt, J = 11.9, 8.7, 2H). 
13
C NMR (100 MHz, CDCl3) δ = 139.9, 138.8, 128.8, 128.3, 126.1, 123.8, 69.6, 45.8, 44.0, 31.9, 27.4. 
HRMS (ESI) for C26H34NO2
+
 [M+NH4]
+
: calcd.: 392.2584, found: 392.2588. 
IR (ATR):  ̃ = 3300 (br, w), 2930 (w), 2828 (w), 1599 (w), 1349 (w), 1224 (w), 1157 (w), 1080 (m), 
1038 (m), 785 (w), 746 (w), 699 (s), 597 (m). 
7-((4-methoxybenzyl)oxy)-4-methyleneheptan-1-ol (291) 
 
 
To a solution of 289 (891 mg, 5.00 mmol, 1.0 eq.) in THF (10 mL) at 0 °C was added 
9-Borabicyclo[3.3.1]nonane (0.5 M in THF, 12.0 mL, 6.00 mmol, 1.2 eq.) and the reaction mixture 
was stirred for 2 h. In a separate flask, a solution of Cs2CO3 (3.25 g 10.0 mmol, 2 eq.) in H2O (5 mL) 
and DMF (10 mL) was deoxygenated by subsurface purging with N2 for 20 minutes. Then, the 
reaction mixture containing hydroborated 289 was added to the Cs2CO3 solution via cannula. 
Thereafter, 2
nd
 generation SPhos palladacycle (90.3 mg, 125 µmol, 0.025 eq.), SPhos (51.3 mg, 
125 µmol, 0.025 eq.), and 290 (825 mg, 5.00 mmol, 1.0 eq., prepared according to Hoveyda and 
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Gao)
[323]
 were added. The resulting orange mixture was heated to 40°C for 2 h. Then, it was cooled to 
room temperature and saturated aqueous NH4Cl (30 mL) was added, followed by EtOAc (30 mL). The 
layers were separated and the aqueous layer was extracted with EtOAc (2 x 50 mL). The combined 
organic layers were washed with LiCl (10% w/w, 3 x 30 mL), brine (30 mL), dried over MgSO4, 
filtered and concentrated in vacuo. The crude product was purified by flash column chromatography 
(SiO2, hexanes/EtOAc = 8/2 to 1/1) to afford 291 as colorless oil (810 mg, 3.06 mmol, 61%).  
Rf = 0.50 (hexanes/EtOAc = 1/1, UV 254 nm, CAM). 
1
H NMR (400 MHz, CDCl3) δ = 7.29 – 7.23 (m, 2H), 6.92 – 6.84 (m, 2H), 4.77 – 4.72 (m, 2H), 4.43 
(s, 2H), 3.81 (s, 3H), 3.69 – 3.60 (m, 2H), 3.45 (t, J = 6.5 Hz, 2H), 2.10 (t, J = 7.7 Hz, 4H), 1.78 – 1.65 
(m, 4H). 
13
C NMR (100 MHz, CDCl3) δ = 159.2, 148.9, 130.8, 129.4, 129.4, 113.9, 109.5, 72.7, 69.8, 62.9, 
55.4, 32.6, 32.5, 30.8, 28.0. 
HRMS (ESI): for C16H25O3
+ 
[M+H]
+ 
calcd.: 265.1798, found: 265.1798.
 
IR (ATR):  ̃ = 3379 (br, w), 2397 (m), 1612 (m), 1513 (m), 1548 (w), 1502 (w), 1462 (w), 1302 (m), 
1247 (s), 1173 (m), 1099 (m), 1035 (w), 861 (w), 820 (m), 611 (w), 556 (w). 
7-((4-methoxybenzyl)oxy)-4-methyleneheptanal (292) 
 
To solution of DMSO (537 µL, 7.57 mmol, 4.00 eq.) in CH2Cl2 (9 mL) at –78°C was added oxalyl 
chloride (2.0 M in CH2Cl2, 1.89 mL, 3.78 mmol, 2.00 eq.) dropwise. After complete addition, the 
reaction mixture was stirred at –78 °C for 15 min. Then a solution of 291 (500 mg, 1.89 mmol, 
1.00 eq.) in CH2Cl2 (128 mL) was added dropwise. After complete addition the reaction mixture was 
stirred at –78°C for 45 min, followed by the dropwise addition of Et3N (1.57 mL, 11.3 mmol, 6.00 eq.) 
at the same temperature. The cooling bath was removed, and the reaction was stirred for 1 h. Water 
(100 mL) was added, and the aqueous phase was extracted with CH2Cl2 (2 x 100 mL). The combined 
organic phases were washed successively with aqueous HCl (1 M, 100 mL) saturated aqueous 
NaHCO3 (100 mL) and brine (100 mL), dried over MgSO4, filtered, and concentrated in vacuo. 
Purification by flash column chromatography (SiO2, hexanes/EtOAc = 8/2) afforded aldehyde 292 
(450 mg, 1.72 mmol, 91%) as a clear oil. It was immediately used for the next step (synthesis of 293) 
without further purification. 
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 (7R,8S,9R,10S)-1,17-bis((4-methoxybenzyl)oxy)-4,14-dimethylene-8,9-
divinylheptadecane-7,10-diol (293) 
 
Allylpinacolboronate 268 (287 mg, 858 µmol, 1.00 eq., dried by azeotropic evaporation from benzene) 
was dissolved in THF (6 mL) and was cooled to –78 °C. Then, n-BuLi (2.14 M in hexanes, 882 µL, 
1.89 mmol, 2.20 eq.) was added dropwise and the light red colored solution was stirred for 15 minutes 
at 78 °C. Afterwards, TFAA (289 µL, 2.08 mmol, 2.40 eq.) was added dropwise and the resulting 
white suspension was stirred for 30 min. Then, a solution of aldehyde 292 (450 mg, 1.72 mmol, 
2.00 eq.) in THF (3 mL) was added dropwise and the resulting mixture was left to warm to room 
temperature over the course of 16 h. After cooling to 0 °C, aqueous NaOH (10% w/w, 1.02 mL, 
2.57 mmol 3.00 eq.) was added, followed by aqueous H2O2 (30% w/w, 964 µL, 9.43 mmol 11.00 eq.). 
After warming to room temperature over the course of 2 h, saturated aqueous NH4Cl (20 mL) was 
added, followed by EtOAc (20 mL). The layers were separated and the aqueous layer was extracted 
with EtOAc (2 x 20 mL). The combined organic layers were washed brine (30 mL), dried over MgSO4 
and filtered. The solvent was removed in vacuo and the crude product was purified by flash column 
chromatography (SiO2, hexanes/EtOAc = 9/1 to 3/7) to afford 293 as colorless oil (208 mg, 461 µmol, 
54%).  
Rf  = 0.45 (hexanes/EtOAc = 1/1, UV 254 nm, PAA). 
1
H NMR (400 MHz, CDCl3) δ  = 7.31 – 7.21 (m, 4H), 6.92 – 6.83 (m, 4H), 5.68 (ddd, J = 17.1, 11.2, 
8.5 Hz, 2H), 5.24 – 5.00 (m, 4H), 4.73 (s, 4H), 4.42 (s, 4H), 3.80 (s, 6H), 3.69 – 3.58 (m, 2H), 3.44 (t, 
J = 6.5 Hz, 4H), 2.41 – 2.32 (m, 3H), 2.23 (ddd, J = 14.9, 9.9, 5.1 Hz, 3H), 2.14 – 1.92 (m, 6H), 1.85 – 
1.54 (m, 6H), 1.34 (dtd, J = 14.6, 9.7, 5.2 Hz, 2H). 
13
C NMR (100 MHz, CDCl3) δ = 159.1, 149.2, 137.0, 130.7, 129.3, 118.4, 113.8, 109.3, 72.6, 71.7, 
69.7, 55.3, 52.4, 32.5, 32.4, 31.8, 27.8. 
HRMS (ESI) for C38H58NO6
+
 [M+H]
+
: calcd.: 624.4259, found: 624.4279. 
IR (ATR):  ̃ = 3374 (br, w), 3073 (w), 2936 (w), 2857 (w), 1612 (m), 1512 (m), 1463 (w), 1245 (s), 
1172 (m), 1097 (m), 1034 (m), 912 (m), 819 (m), 731 (s), 574 (m). 
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(1R,1'S,2S,2'R)-5,5'-bis(3-((4-methoxybenzyl)oxy)propyl)-[1,1'-bi(cyclohexane)]-
5,5'-diene-2,2'-diol (294) 
 
A solution of 293 (22 mg, 36.3 µmol, 1.00 eq) in toluene (1.45 mL) was deoxygenated by subsurface 
purging of N2 for 20 min. Then, HG2 (2.27 mg, 3.63 µmol, 0.1 eq.) was added and the green solution 
was heated to 90 °C. After 4 h, the brown solution was cooled to room temperature and the solvent 
was removed in vacuo. The resulting crude product was purified by flash column chromatography 
(SiO2, hexanes/EtOAc = 1/1 to EtOAc) to afford 294 as a colorless oil (15 mg, 27.2 µmol, 75%). 
Rf = 0.58 (EtOAc, UV 254 nm, CAM). 
1
H NMR (400 MHz, CDCl3) δ = 7.18 (dd, J = 8.3, 1.8 Hz, 4H), 6.86 – 6.74 (m, 4H), 4.97 (s, 2H), 4.34 
(s, 4H), 3.72 (s, 8H), 3.34 (t, J = 6.6 Hz, 2H), 2.36 – 2.18 (m, 2H), 2.04 – 1.89 (m, 4H), 1.88 – 1.79 
(m, 1H), 1.70 – 1.48 (m, 8H). 
13
C NMR (100 MHz, CDCl3) δ = 159.1, 138.7, 130.7, 129.3, 121.9, 113.8, 72.6, 69.7, 69.7, 55.3, 45.8, 
33.8, 31.9, 27.9, 27.6. 
HRMS (ESI) for C34H50NO6
+
 [M+NH4]
+
: calcd.: 568,3638, found 568.3647. 
IR (ATR):  ̃ = 3377 (br, w), 2926 (m), 2855 (m), 1725 (w), 1691 (w), 1658 (w), 1513 (w), 1462 (w), 
1365 (w), 1302 (w), 1247 (m), 1173 (m), 1097 (m), 1035 (m), 819 (w), 612 (w). 
tert-butyl (S)-(1,5-dihydroxypentan-2-yl)carbamate (297) 
 
L-glutamic acid (20.0 g, 135.9 mmol, 1.00 eq.) was dissolved in MeOH (220 mL) and the solution was 
cooled to 0 °C. TMSCl (64.9 g, 598.1 mmol, 4.40 eq.) was added dropwise and the reaction mixture 
was stirred at room temperature for 16 hours.  
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The resulting solution containing L-glutamic acid dimethyl ester (295) was cooled to 0 °C and Et3N 
(146 mL, 1052 mmol, 6.50 eq.) was added dropwise. Then, a solution of Boc2O (38.9 g, 178.1 mmol, 
1.10 eq.) in MeOH (80 mL) was added slowly and the reaction mixture was stirred at room 
temperature for 24 h. The solvent was removed in vacuo and the residue was dissolved in water (100 
mL). The aqueous layer was extracted with EtOAc (3 x 100 mL), the combined organic layers were 
washed with water (150 mL) and brine (150 mL), dried over MgSO4 and concentrated in vacuo. 
The crude product (296) was dissolved in THF (250 mL) and MeOH (50 mL) and the solution was 
cooled to 0 °C. NaBH4 (16.6 g, 438 mmol, 4.00 eq.) was added slowly (gas evolution!). The mixture 
was stirred for 24 h and allowed to warm to room temperature. The solvent was removed under 
reduced pressure and the residue was diluted in water (200 mL). Citric acid was added until pH = 6. 
The aqueous solution was extracted with EtOAc (3 x 150 mL) and the combined organic layers were 
dried over MgSO4 and concentrated in vacuo. The resulting crude product 297 was used in the next 
step without purification. An aliquot was purified by flash column chromatography (SiO2, 
hexanes/EtOAc = 7/3) for analysis. Spectral data match the previously reported values.
[325]
 
Rf = 0.10 (hexanes/EtOAc = 8/2, CAM). 
Note: NMR spectra are complex due to the presence of rotamers.  
1
H NMR (400 MHz, CDCl3) δ = 4.86 (br s, 1H), 3.84-3.50 (m, 5H), 2.84 (br s, 1H), 2.29 (br s, 1H), 
1.85–1.55 (m, 3H), 1.52–1.28 (m, 10H). 
13
C NMR (100 MHz, CDCl3) δ = 156.7, 79.8, 79.4, 65.6, 62.5, 62.0, 52.5, 50.3, 28.9, 28.5, 28.1. 
HRMS (ESI): for C10H22O4N
+ 
[M+H]
+
:
 
calcd.: 220.1549, found: 220.1543. 
IR (ATR):  ̃ = 3338 (m), 2938 (m), 1688 (s), 1530 (m), 1392 (m), 1366 (m), 1170 (s), 1052 (m). 
    
   = –15.7 (c = 1.00, CH2Cl2).  
tert-butyl (S)-4-(3-hydroxypropyl)-2,2-dimethyloxazolidine-3-carboxylate (298) 
 
Crude product 297 (24.0 g, 109.5 mmol, 1 eq., 100% yield assumed from the previous step) was 
dissolved in acetone (200 mL) and 2,2-Dimethoxypropane (60 mL) was added. The solution was 
cooled to 0 °C and boron trifluoride diethyl etherate (0.31 g, 2.17 mmol, 0.02 eq.) was added. After 
24 h the solvent was removed under reduced pressure and the residue was diluted with water (100 mL) 
and the pH adjusted to 7 using saturated aqueous NaHCO3. The aqueous layer was extracted with 
EtOAc (3 x 100 mL) and the combined organic layers were washed with water (100 mL) and brine 
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(100 mL). The solution was dried over MgSO4 and concentrated in vacuo. An aliquot of the crude 
product was separated for the analytical data and purified by flash column chromatography (SiO2, 
hexanes/EtOAc = 4/6). Protecting product 298 was obtained as colorless oil. The residual crude 
product (27.1 g, 104.4 mmol, 95 %) was used in the next step without purification. Spectral data match 
the previously reported values.
[325]
 
Rf = 0.14 (hexanes/EtOAc = 3/7, CAM). 
Note: NMR spectra are complex due to the presence of rotamers.  
1
H NMR (400 MHz, CDCl3) δ = 3.98–3.66 (m, 5H), 2.24 (br, 1H), 1.86–1.71 (m, 1H), 1.66–
1.31 (m, 18H). 
13
C NMR (100 MHz, CDCl3) δ = 152.6, 151.9, 93.9, 93.4, 80.4, 79.7, 67.2, 62.8, 62.6, 57.2, 30.1, 
29.9, 29.5, 29.1, 28.6, 27.7, 26.9, 24.6, 23.4. 
HRMS (ESI) for C13H26O4N
+ 
[M+H]
+
: calcd.: 260.1856, found: 260.1858.  
IR (ATR):  ̃ = 3442 (w), 2936 (w), 2870 (w), 1692 (s), 1364 (s), 1256 (m), 1171 (m), 1083 (s), 844 
(m), 768 (m). 
    
  = +21.9 (c = 0.98, CH2Cl2). 
tert-butyl (S)-2,2-dimethyl-4-(3-oxopropyl)oxazolidine-3-carboxylate (299) 
 
To solution of DMSO (4.69 mL, 66.0 mmol, 3.30 eq.) in CH2Cl2 (15 mL) at –78°C was added oxalyl 
chloride (2.0 M in CH2Cl2, 12.00 mL, 24.00 mmol, 1.20 eq.) dropwise. After complete addition, the 
reaction mixture was stirred at –78 °C for 15 min. Then a solution of 298 (5.19 g, 20.0 mmol, 1.00 eq.) 
in CH2Cl2 (128 mL) was added dropwise. After complete addition the reaction mixture was stirred at  
–78°C for 45 min, followed by the dropwise addition of Et3N (18.3 mL, 132.0 mmol, 6.60 eq.) at the 
same temperature. The cooling bath was removed, and the reaction was stirred for 1 h. Water 
(100 mL) was added, and the aqueous phase was extracted with CH2Cl2 (2 x 100 mL). The combined 
organic phases were washed successively with aqueous HCl (1 M, 100 mL) saturated aqueous 
NaHCO3 (100 mL) and brine (100 mL), dried over MgSO4, filtered, and concentrated in vacuo. 
Purification by flash column chromatography (SiO2, hexanes/EtOAc = 8/2) afforded aldehyde 299 
(3.66 g, 14.2 mmol, 71%) as a clear oil. Spectral data match the previously reported values.
[325]
 
Rf = 0.42 (hexanes/EtOAc = 7/3, CAM) 
Note: NMR spectra are complex due to the presence of rotamers.  
Part II: Experimental Part 
224 
1
H NMR (400 MHz, CDCl3) δ = 9.77 (br, 1H), 4.02–3.80 (m, 2H), 3.73-3.68 (m, 1H), 2.55–2.33 (m, 
2H), 2.05–1.84 (m, 2H), 1.56–1.52 (m, 3H), 1.47 (s, 12H). 
13
C NMR (100 MHz, CDCl3) δ = 201.7, 201.4, 152.6, 151.9, 94.1, 93.6, 80.4, 80.0, 67.1, 56.7, 56.3, 
40.6, 40.4, 28.7, 28.6, 28.5, 28.5, 28.4, 27.7, 26.9, 26.1, 26.0, 24.6, 24.4, 23.1. 
HRMS (ESI) for C13H24O4N
+ 
[M+H]
+
: calcd.: 258.1700, found: 258.1700.  
IR (ATR):  ̃ = 2979 (w), 1695 (s), 1390 (s), 1367 (s), 1257 (m), 1171 (m), 1084 (m), 855 (w), 767 
(w). 
    
  = +3.8 (c = 1.05, CH2Cl2). 
tert-butyl (S)-4-(2-formylallyl)-2,2-dimethyloxazolidine-3-carboxylate (300) 
 
N,N,N′,N′–Tetramethyldiaminomethane (2.00 mL, 14.7 mmol, 1.10 eq.) was dissolved in CH2Cl2 
(25 mL) and the solution was cooled to 0 °C. TFAA (2.10 mL, 14.7 mmol, 1.10 eq.) was added slowly 
dropwise. The cooling bath was removed and the reaction mixture was stirred at room temperature for 
5 min and cooled to 0 °C. A solution of aldehyde 299 (3.45 g, 13.4 mmol, 1 eq.) in CH2Cl2 (20 mL) 
was prepared in a second flask, cooled to 0 ° and transferred to the other flask via cannula. After 
stirring at room temperature for 18 h, it saturated aqueous NaHCO3 (40 mL) was added and the 
organic layer was and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed 
with brine (75 mL), dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
flash column chromatography (SiO2, hexanes/EtOAc = 7/3) to afford 300 (2.37 g, 8.80 mmol, 66%) as 
colorless oil. Spectral data match the previously reported values.
[329]
 
Rf = 0.46 (hexanes/EtOAc = 7/3, CAM) 
Note: NMR spectra are complex due to the presence of rotamers. 
1
H NMR (400 MHz, CDCl3) δ = 9.53 (d, J = 8.5 Hz, 1H), 6.27 (d, J = 18.0 Hz, 1H), 6.05 (d, J = 24.0 
Hz, 1H), 4.18 – 3.95 (m, 1H), 3.86 (ddd, J = 14.1, 8.9, 5.6 Hz, 1H), 3.69 (d, J = 9.0 Hz, 1H), 2.69 – 
2.39 (m, 2H), 1.59 (d, J = 22.8 Hz, 3H), 1.49 – 1.42 (m, 12H). 
13
C NMR (100 MHz, CDCl3) δ = 194.3, 194.2, 152.4, 151.9, 147.2, 146.9, 136.6, 135.3, 94.1, 93.6, 
80.3, 80.1, 67.0, 66.7, 56.5, 55.9, 32.8, 31.9, 28.6, 28.5, 27.8, 27.2, 24.5, 23.3. 
HRMS (ESI) for C14H24O4N
+ 
[M+H]
+
: calcd.: 270.1700, found: 270.1701.  
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IR (ATR):  ̃ = 2980 (w), 1688 (s), 1456 (w), 1385 (s), 1364 (s), 1255 (m), 1172 (m), 1059 (m), 
949 (w), 856 (m), 769 (m).  
    
   = –4.0 (c = 1.09, CH2Cl2). 
tert-butyl (S)-4-(2-(hydroxymethyl)allyl)-2,2-dimethyloxazolidine-3-carboxylate 
(301) 
 
Enal 300 (0.25 g, 0.91 mmol, 1.00 eq.) was dissolved in MeOH (4.4 mL). CeCl3 H2O (0.41 g, 1.09 
mmol, 1.20 eq.) was added and the solution was cooled to 0 °C. NaBH4 (0.04 g, 1.09 mmol, 1.20 eq.) 
was added slowly (gas evolution!). The mixture was allowed to warm to room temperature over the 
course of 2 h, and saturated aqueous NaHCO3 (10 mL) was added. The mixture was extracted with 
EtOAc (3 x 15 mL) and the combined organic layers were washed with brine (25 mL), dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by flash column chromatography 
(SiO2, hexanes/EtOAc = 6/4). Allylic alcohol 301 (0.22 g, 0.81 mmol, 88%) was obtained as colorless 
oil.  
Rf = 0.36 (hexanes/EtOAc = 6/4, CAM) 
Note: NMR spectra are complex due to the presence of rotamers. 
1
H NMR (400 MHz, CDCl3) δ = 5.21 – 4.78 (m, 2H), 4.21 (q, J = 6.6 Hz, 1H), 4.16 – 4.05 (m, 2H), 
3.98 – 3.67 (m, 2H), 3.61 – 3.53 (m, 1H), 2.58 – 2.18 (m, 2H), 1.59 (s, 3H), 1.46 (s, 12H). 
13
C NMR (100 MHz, CDCl3) δ = 152.9, 151.7, 146.0, 145.8, 113.4, 112.6, 94.0, 93.7, 80.7, 79.9, 67.5, 
67.0, 66.5, 65.7, 56.6, 56.1, 39.0, 37.5, 28.6, 28.5, 27.9, 27.1, 24.5, 23.3. 
HRMS (ESI) for C14H26O4N
+ 
[M+H]
+
: calcd.: 272.1856, found: 272.185. 
IR (ATR):  ̃ = 3436 (w), 2979 (w), 2874 (w), 1694 (m), 1386 (s), 1365 (s), 1246 (m), 1171 (m), 
1096 (m), 900 (w), 852 (m), 769 (w).  
    
   = +10.8 (c = 1.03, CH2Cl2). 
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tert-butyl (S)-4-(5-methoxy-2-methylene-5-oxopentyl)-2,2-dimethyloxazolidine-
3-carboxylate (307) 
 
Alcohol 301 (150.0 mg, 550 mol, 1.00 eq.), propionic acid (2 μL, 30.0 μmol, 0.05 eq.) and 1,1,1-
trimethoxyethane (1.06 mL, 8.29 mmol, 15.0 eq.) were added in a 10 mL glass microwave tube. The 
reaction mixture was irradiated in a CEM Discover microwave apparatus (200 watt, 150 °C) for 8 min. 
After cooling to room temperature, the solvent was removed under reduced pressure. The crude 
product was purified by flash column chromatography (SiO2, hexanes/EtOAc = 9/1 to 8/2) to afford 
rearrangement product 307 (130 mg, 380 μmol, 69%) as colorless oil. 
Rf = 0.18 (hexanes/EtOAc = 9/1, CAM) 
Note: NMR spectra are complex due to the presence of rotamers. 
1
H NMR (400 MHz, CDCl3) δ = 4.81–4.78 (m, 2H), 4.09–3.76 (m, 3H), 3.66 (s, 3H), 2.60–2.04 (m, 
6H), 1.58 (app d, J = 20.0 Hz, 1H), 1.48 (s, 12H). 
13
C NMR (100 MHz, CDCl3) δ = 173.5, 173.4, 152.0, 151.6, 145.1, 144.7, 112.7, 112.1, 93.8, 93.3, 
80.0, 79.7, 66.1, 66.0, 55.8, 55.7, 51.6, 51.6, 40.3, 39.3, 32.4, 32.3, 30.8, 30.5, 28.5, 28.5, 28.4, 27.8, 
26.9, 24.5, 23.2. 
HRMS (ESI) for C17H30O5N
+ 
[M+H]
+
: calcd.: 328.2124, found: 328.2119. 
IR (ATR):  ̃ = 2980 (w), 1740 (m), 1693 (s), 1438 (w), 1385 (s), 1364 (s), 1244 (m), 1170 (s), 1078 
(m), 898 (w), 852 (m), 769 (m).  
    
   = +11.8 (c = 1.11, CH2Cl2). 
tert-butyl (S)-4-(5-hydroxy-2-methylenepentyl)-2,2-dimethyloxazolidine-3-
carboxylate (308) 
 
Methyl ester 307 (650 mg, 1.99 mmol, 1.00 eq.) was dissolved in THF (16.1 mL) and the solution was 
cooled to 0 °C. LiAlH4 (2 M in THF, 1.09 mL, 2.18 mmol, 1.10 eq.) was added dropwise and the 
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reaction mixture was stirred at 0 °C for 2 h. The reaction was quenched by the slow addition of EtOAc 
(20 mL). Water (20 mL) was added, the layers were separated and the aqueous layer was extracted 
with EtOAc (3 x 25 mL). The combined organic layers were washed with brine (50 mL), dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by flash column chromatography 
(SiO2, hexanes/EtOAc = 6/4) to afford 308 as colorless oil (587 mg, 1.98 mmol, 99%).  
Rf = 0.23 (hexanes/EtOAc = 7/3, CAM). 
Note: NMR spectra are complex due to the presence of rotamers. 
1
H NMR (400 MHz, CDCl3) δ = 4.80 (app dd, J = 22.3, 10.4 Hz, 2H), 4.15 – 3.56 (m, 6H), 2.63 – 
2.42 (m, 1H), 2.25 – 1.99 (m, 3H), 1.80 – 1.66 (m, 2H), 1.58 (app d, J = 18.8 Hz, 3H), 1.47 (s, 12H). 
13
C NMR (100 MHz, CDCl3) δ = 152.3, 151.7, 146.3, 146.1, 113.5, 112.7, 112.2, 93.9, 93.5, 80.3, 
79.8, 66.3, 62.5, 62.3, 55.9, 40.0, 39.7, 32.2, 31.7, 30.8, 28.7, 28.6, 28.5, 27.9, 27.1, 24.6, 23.3. 
HRMS (ESI) for C16H30O4N
+
 [M+H]
+
: calcd.: 300.2169, found: 300.2172.  
IR (ATR):  ̃ = 3441 (w), 2979 (w), 2873 (w), 1694 (s), 1386 (s), 1365 (s), 1254 (m), 1171 (m), 1061 
(s), 897 (w), 850 (m), 768 (m).  
    
   = +16.8 (c = 1.01, CH2Cl2). 
 
tert-butyl(S)-4-(5-(dimethylamino)-2-methylene-5-oxopentyl)-2,2-
dimethyloxazolidine-3-carboxylate (309) 
 
Alcohol 301 (4.81 g, 17.7 mmol, 1.00 eq.) was dissolved in toluene (150 mL) and N,N-
dimethylacetamide dimethyl acetal (3.89 mL, 26.6 mmol, 1.50 eq.) was added. The colorless solution 
heated to 100 °C open to air and a gentle stream of N2 was bubbled through the solvent via a thin glass 
capillary to remove liberated MeOH. After 3 h, the resulting yellow solution was cooled to room 
temperature and the volatiles were removed in vacuo. The crude product was purified by flash column 
chromatography (SiO2, hexanes/EtOAc = 1/1) to afford 309 as light yellow oil (5.30 g, 15.6 mmol, 
88%). 
Rf = 0.21 (hexanes/EtOAc = 1/1, KMnO4). 
Note: NMR spectra are complex due to the presence of rotamers. 
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1
H NMR (400 MHz, CDCl3) δ = 
1
H NMR (400 MHz, CDCl3) δ 4.78 – 4.67 (m, 2H), 4.06 – 3.86 (m, 
1H), 3.83 – 3.76 (m, 1H), 3.76 – 3.67 (m, 1H), 2.96 (d, J = 3.6 Hz, 3H), 2.88 (d, J = 2.8 Hz, 3H), 2.61 
– 2.19 (m, 5H), 2.10 (ddd, J = 23.4, 13.7, 11.0 Hz, 1H), 1.52 (app d, J = 20.9 Hz, 3H), 1.41 (s, 12H). 
13
C NMR (100 MHz, CDCl3) δ = 172.6, 172.2, 152.2, 151.8, 145.9, 112.2, 93.9, 93.4, 80.1, 79.8, 66.3, 
66.3, 56.0, 56.0, 40.6, 39.3, 37.4, 37.3, 35.6, 31.7, 31.6, 31.4, 30.8, 28.7, 28.6, 27.9, 27.1, 24.6, 23.3. 
HRMS (ESI): for C18H33N2O4
+ 
[M+H]
+
: calcd.: 341.2435, found:  341.2437. 
IR (ATR):  ̃ = 2978 (m), 2935 (w), 3029 (w), 1692 (s), 1643 (m), 1686 (s), 1547 (w), 1480 (w), 1446 
(m), 1365 (s), 1256 (m), 1173 (m), 1096 (m), 1061 (m), 894 (w), 848 (w). 
    
   = +16.0 (c = 2.00, CH2Cl2). 
tert-butyl(S)-2,2-dimethyl-4-(2-methylene-5-oxopentyl)oxazolidine-3-carboxylate 
(306) 
 
DMSO (90 μL, 1.27 mmol, 4.00 eq.) was diluted with CH2Cl2 (2 mL) and the solution was cooled to 
–78 °C. Oxalyl chloride (2 M in CH2Cl2, 270 μL, 540 μmol, 1.70 eq.) was added dropwise and the 
reaction mixture was stirred at –78 °C for 15 min. Alcohol 308 (100 mg, 320 μmol, 1.00 eq.) was 
dissolved in CH2Cl2 (1 mL) and the solution was added dropwise to the reaction mixture. After further 
stirring at –78 °C for 45 min, Et3N (350 μL, 2.54 mmol, 8.00 eq.) was slowly added. The cooling bath 
was removed and the mixture was allowed to reach room temperature for 2 h. The reaction was 
quenched with water (5 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined organic layers 
were washed with aqueous HCl (1 M, 20 mL), saturated aqueous NaHCO3 (20 mL), brine (20 mL), 
dried over MgSO4 and concentrated in vacuo. The crude product was purified by flash column 
chromatography (SiO2, hexanes/EtOAc = 8/2) to afford aldehyde 306 as colorless oil (70 mg, 
240 μmol, 74%). 
 
Alternative Procedure for the Synthesis of 306 by reduction of 309: 
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Morpholine (227 μL, 2.29 mmol, 1,70 eq.) was dissolved in THF (4.4 mL) and cooled to 0 °C and 
n-BuLi (2.4 M in hexane, 900 μL, 2.17 mmol, 1.60 eq.). After 30 minutes, DIBALH (1.0 M in THF, 
1.00 mL, 2.03 mmol, 1.50 eq.) was added. The resulting aluminate reagent solution was allowed to 
warm to room temperature over 2 h and added dropwise to a precooled solution (0 °C) of amide 309 
(460 mg, 1.35 mmol, 1.00 eq.) in THF (8 mL). After 2 hours, the reaction was quenched with 
saturated aqueous NH4Cl (20 mL). After the addition of EtOAc (20 mL) the layers were separated and 
the aqueous phase was extracted with EtOAc (2 x 20 mL). The combined organic layers were dried 
over MgSO4, filtered and concentrated under reduced pressure. The crude product was purified by 
flash column chromatography (SiO2, hexanes/EtOAc = 8/2) to afford aldehyde 306 as colorless oil 
(312 mg, 1.05 mmol, 78%). 
Rf = 0.43 (hexanes/EtOAc = 8/2, CAM) 
Note: NMR spectra are complex due to the presence of rotamers. 
1
H NMR (400 MHz, CDCl3): δ = 9.77 (s, 1H), 4.82 – 4.78 (m, 2H), 4.07 – 3.67 (m, 3H), 2.69 – 2.25 
(m, 5H), 2.21 – 2.10 (m, 1H), 1.58 (d, J = 19.6 Hz, 1H), 1.46 (s, 12H). 
13
C NMR (100 MHz, CDCl3): δ = 202.2, 201.6, 152.2, 151.6, 144.8, 144.6, 113.0, 112.7, 94.0, 93.5, 
80.2, 79.8, 66.2, 66.2, 55.8, 55.8, 41.9, 41.8, 40.5, 39.5, 28.7, 28.6, 28.5, 28.5, 28.2, 27.9, 27.8, 27.0, 
24.5, 23.3. 
IR (ATR):  ̃ = 2979 (w), 1726 (w), 1692 (s), 1454 (w), 1386 (s), 1365 (s), 1256 (m), 1172 (m), 
1097 (m), 852 (w), 769 (w).  
HRMS (ESI) for C16H28O4N
+ 
[M+H]
+
: calcd. 298.2013, found: 298.2014.  
    
   = +15.2 (c = 1.08, CH2Cl2).  
methyl (R)-2-((tert-butoxycarbonyl)amino)-3-iodopropanoate (311) 
 
Methyl (tert-butoxycarbonyl)-L-serinate (310, 3.00 g, 13.7 mmol, 1.00 eq.) was dissolved in DMF 
(30 mL) and methyltriphenoxyphosphonium iodide (6.50 g, 14.4 mmol, 1.05 equiv.) was added 
portionwise. After 4 h, the reaction mixture was cooled to 0 °C and solid NaHCO3 (3.45 g, 41.1 mmol, 
3.00 eq.) was added. The mixture was stirred vigorously for 15 min, and Et2O (50 mL) and H2O 
(50 mL) were added. The organic phase was separated and the aqueous layer was extracted with Et2O 
(2 x 50 mL). The combined organic extracts were washed with aqueous NaOH (0.2 M, 4 x 20 mL), 
brine (50 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified 
by flash column chromatography (SiO2, hexanes/EtOAc = 9/1 to 7/3) to afford 311 as a light orange 
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oil that solidified upon storage at–24 °C (3.74 g, 11.4 mmol, 83%). Spectral data match the previously 
reported values.
[339]
 
Note: 311 degrades upon prolonged exposure to silica gel; rapid chromatography is recommended.  
Rf  = 0.55 (hexanes/EtOAc = 8/2, KMnO4). 
HRMS (ESI) for C9H16INO4Na
+
 [M+Na]
+
: calcd.: 352.0016, found: 352.0021. 
    
   =  –3.7 (c = 2.78, MeOH). 
methyl (S)-2-((tert-butoxycarbonyl)amino)-7-((tert-butyldimethylsilyl)oxy)-4-
methyleneheptanoate (312) 
 
Zn dust (2.05 g, 31.4 mmol, 4.0 eq.) was added to DMF (31.6 mL). 1,2-dibromoethane (295 mg, 1.57 
mmol, 0.2 eq.) was added and the suspension was brought to ebullition by heating with a heat gun. 
After cooling to room temperature, TMSCl (201 µL, 1.57 mmol, 0.2 eq.) was added and the reaction 
mixture was stirred for 15 min. Then, a solution of 311 (2.58 g, 7.85 mmol, 1.0 eq., prepared 
according to Hoveyda and Gao)
[323]
 in DMF (2 mL) was added and the reaction mixture is stirred until 
complete disappearance of the starting material (1 h, monitored by TLC of reaction aliquots quenched 
with NH4Cl). Then, stirring was discontinued and after 5 min. To remove excess Zn dust the 
supernatant solution was transferred via syringe to a separate flask (washing with DMF 2 x 2 mL). To 
the solution was added Pd2(dba)3 (144 mg, 0.157 mmol, 0.02 eq.), SPhos (129 mg, 0.314 mmol, 0.02 
eq.), and vinyl bromide 316 (1.75 g, 6.28 mmol, 0.8 eq.). The resulting red solution was heated to 40 
°C for 2 h. Then, it is cooled to room temperature and saturated aqueous NH4Cl (50 mL) was added, 
followed by EtOAc (50 mL). The mixture was filtered over cotton, the aqueous layer was separated 
and extracted with EtOAc (2 x 50 mL). The combined organic layers are washed with brine, dried over 
MgSO4, filtered and evaporated in vacuo. The crude product was purified by flash column 
chromatography (SiO2, hexanes/EtOAc = 1/0 to 9/1) to afford 312 as an orange oil (2.11 g, 5.26 mmol, 
84%).  
Rf  = 0.72 (hexanes/EtOAc = 8/2, KMnO4). 
1
H NMR (400 MHz, CDCl3) δ = 4.92 (d, J = 8.0 Hz, 1H), 4.88 – 4.75 (m, 2H), 4.38 (td, J = 8.2, 5.5 
Hz, 1H), 3.71 (s, 3H), 3.59 (t, J = 6.4 Hz, 2H), 2.53 (dd, J = 14.2, 5.6 Hz, 1H), 2.35 (dd, J = 14.2, 8.3 
Hz, 1H), 2.05 (dd, J = 8.7, 6.7 Hz, 2H), 1.69 – 1.57 (m, 2H), 1.42 (s, 9H), 0.88 (s, 9H), 0.03 (s, 6H). 
13
C NMR (100 MHz, CDCl3) δ = 173.2, 155.3, 144.2, 113.5, 80.0, 62.7, 52.3, 52.1, 39.2, 31.5, 30.8, 
28.4, 26.1, 18.5, -5.2. 
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HRMS (ESI) for C20H40O5NSi
+
 [M+H]
+
: calcd.: 402.2676, found: 402.2676. 
IR (ATR):  ̃ = 3444 (w), 3378 (br, w), 3076 (w), 2953 (m), 2857 (m), 1746 (m), 1719 (s), 1501 (m), 
1439 (m), 1390 (m), 1366 (m), 1213 (w), 1168 (s), 1053 (m), 1023 (s), 939 (w). 
    
   =  +3.7 (c = 2.78, CH2Cl2). 
methyl (S)-2-((tert-butoxycarbonyl)amino)-7-hydroxy-4-methyleneheptanoate 
(313) 
 
A solution of alcohol 312 (2.11 g, 5.26 mmol, 1.00 eq.) in THF (28 mL) was cooled to 0 °C and a 
solution of TBAF (1 M in THF, 7.89 mL, 1.50 eq.) was added dropwise over 15 minutes. The reaction 
was stirred for 2 h 0 °C, quenched with saturated aqueous NH4Cl (20 mL) and diluted with EtOAc 
(30 mL). The layers were separated and the aqueous phase was extracted with EtOAc (3 x 30 mL). 
The combined organic layers were washed with brine, dried over MgSO4 and concentrated under 
reduced pressure. Purification by flash column chromatography (SiO2, hexanes/EtOAc = 7/3 to 1/1) 
gave 313 as a yellow oil (1.80 g, 6.28 mmol, 98%).  
Rf  = 0.31 (hexanes/EtOAc = 1/1, KMnO4). 
1
H NMR (400 MHz, CDCl3) δ = 5.05 (d, J = 8.3 Hz, 1H), 4.87 – 4.75 (m, 2H), 4.37 (td, J = 8.4, 5.4 
Hz, 1H), 3.68 (s, 3H), 3.59 (t, J = 6.4 Hz, 2H), 2.55 – 2.25 (m, 3H), 2.16 – 2.01 (m, 2H), 1.73 – 1.63 
(m, 2H), 1.38 (s, 9H). 
13
C NMR (100 MHz, CDCl3) δ = 173.1, 155.4, 143.8, 113.4, 80.0, 61.9, 52.3, 52.0, 39.6, 31.0, 30.3, 
28.3. 
HRMS (ESI) for C14H26NO5
+
 [M+H]
+
: calcd.: 288.1805, found: 288.1808. 
IR (ATR):  ̃ = 3361 (br, w), 3077 (w), 2977 (m), 2875 (w), 1740 (m), 1692 (s), 1648 (m), 1612 (m), 
1562 (m), 1513 (m), 1248 (w), 1163 (s), 1053 (m), 1023 (s), 901 (m). 
    
   = +6.9 (c = 2.86, CH2Cl2). 
methyl (S)-2-((tert-butoxycarbonyl)amino)-4-methylene-7-oxoheptanoate (314) 
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A solution of 313 (110 mg, 383 µmol, 1.00 eq.) in CH2Cl2 (3.93 mL) was cooled to 0 °C and powdered 
NaHCO3 (276 mg, 2.29 mmol, 6.00 eq.) was added, followed by Dess-Martin periodinane (276 mg, 
651 µmol, 1.70 eq.). After 1 h, a half-saturated solution of Na2SO3 (10 mL) was added and the reaction 
mixture was vigorously stirred for 30 minutes. The reaction was diluted with water (10 mL) and 
CH2Cl2 (20 mL). The layers were separated and the aqueous layer was extracted with CH2Cl2 (2 x 20 
mL). The combined organic layers brine (20 mL), dried over MgSO4, filtered and concentrated under 
reduced pressure. Purification of the crude product by flash column chromatography (SiO2, 
hexanes/EtOAc = 8/2) gave 314 as a yellow oil (108 mg, 383 µmol, 99%).  
Note: 314 decomposes within a week if stored neat at room temperature. 
Rf  = 0.67 (hexanes/EtOAc = 1/1, KMnO4). 
1
H NMR (400 MHz, CDCl3) δ = 9.75 (t, J = 1.6 Hz, 1H), 4.99 (d, J = 8.4 Hz, 1H), 4.85 (d, J = 7.8 Hz, 
2H), 4.43 (td, J = 8.3, 5.6 Hz, 1H), 3.72 (s, 3H), 2.65 – 2.46 (m, 3H), 2.43 – 2.28 (m, 3H), 1.42 (s, 
9H). 
13
C NMR (100 MHz, CDCl3) δ = 201.9, 173.0, 155.3, 142.7, 114.1, 80.1, 52.4, 52.1, 41.7, 39.8, 28.4, 
28.3, 27.4. 
HRMS (ESI) for C14H24NO5
+
 [M+H]
+
: calcd.: 286.1654, found: 286.1650. 
IR (ATR):  ̃ = 3790 (w),  3363 (br, w),  3082 (w),  2932 (w),  2728 (w),  1742  (m),  1711 (s), 1512 
(m), 1438 (m), 1391 (m),  1366 (m),  1277 (m), 1249 (m),  1164 (s), 1052 (m),  904 (m). 
    
   = +10.2 (c = 1.26, CH2Cl2). 
methyl (R)-2-(((benzyloxy)carbonyl)amino)-3-iodopropanoate (317) 
 
methyl ((benzyloxy)carbonyl)-L-serinate (316, 1.00 g, 3.95.7 mmol, 1.00 eq.) was dissolved in DMF 
(10 mL) and methyltriphenoxyphosphonium iodide (1.87 g, 4.15 mmol, 1.05 equiv.) was added 
portionwise. After 4 h, the reaction mixture was cooled to 0 °C and solid NaHCO3 (995 mg, 11.8 
mmol, 3.00 eq.) was added. The mixture was stirred vigorously for 15 min, and Et2O (20 mL) and H2O 
(20 mL) were added. The organic phase was separated and the aqueous layer was extracted with Et2O 
(2 x 20 mL). The combined organic extracts were washed with aqueous NaOH (0.2 M, 4 x 20 mL), 
brine (20 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified 
by flash column chromatography (SiO2, hexanes/EtOAc = 9/1 to 7/3) to afford 317 as a light yellow 
oil (1.21 g, 3.3 mmol, 84%). Spectral data match the previously reported values.
[340]
 
Note: 317 degrades upon prolonged exposure to silica gel; rapid chromatography is recommended.  
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Rf  = 0.50 (hexanes/EtOAc = 8/2, KMnO4). 
HRMS (ESI) for C12H14INO4Na+ [M+Na]+: calcd.: 385.9860, found: 385.9862. 
    
   =  –6.3 (c = 1.01, CHCl3). 
methyl (S)-2-(((benzyloxy)carbonyl)amino)-7-((tert-butyldimethylsilyl)oxy)-4-
methyleneheptanoate (318) 
 
Zn dust (1.37 g, 21.0 mmol, 4.00 eq.) was added to DMF (24.0 mL). 1,2-dibromoethane (91 µL, 1.05 
mmol, 0.20 eq.) was added and the suspension was brought to ebullition by heating with a heat gun. 
After cooling to room temperature, TMSCl (134 µL, 1.05 mmol, 0.20 eq.) was added and the reaction 
mixture was stirred for 15 min. Then, a solution of 317 (1.91 g, 5.25 mmol, 1.0 eq.) in DMF (2 mL) 
was added and the reaction mixture is stirred until complete disappearance of the starting material (1 h, 
monitored by TLC of reaction aliquots quenched with NH4Cl). Then, stirring was discontinued and 
after 5 min. To remove excess Zn dust the supernatant solution is transferred via syringe to a separate 
flask (washing with DMF 2 x 2 mL). To the solution was added Pd2(dba3) (48.1 mg, 52.5 µmol, 0.01 
eq.), SPhos (43.1 mg, 105 µmol, 0.02 eq.), and vinyl bromide 315 (1.3 g, 4.68 mmol, 0.89 eq.). The 
resulting red solution was heated to 40 °C for 2 h. Then, it is cooled to room temperature and saturated 
aqueous NH4Cl (50 mL) was added, followed by EtOAc (50 mL). The mixture was filtered over 
cotton, the aqueous layer was separated and extracted with EtOAc (2 x 50 mL). The combined organic 
layers are washed with brine, dried over MgSO4, filtered and evaporated in vacuo. The crude product 
was purified by flash column chromatography (SiO2, hexanes/EtOAc = 95/5 to 8/2) to afford 318 as a 
slightly red oil (1.71 g, 3.92 mmol, 75%).  
Rf = 0.62 (hexanes/EtOAc = 8/2, CAM). 
1
H NMR (400 MHz, CDCl3) δ = 7.32 – 7.21 (m, 4H), 5.23 (d, J = 8.1 Hz, 1H), 5.03 (s, 1H), 4.88 – 
4.68 (m, 2H), 4.41 (td, J = 8.2, 5.5 Hz, 1H), 3.66 (s, 3H), 3.54 (t, J = 6.4 Hz, 2H), 2.51 (dd, J = 14.2, 
5.5 Hz, 1H), 2.33 (dd, J = 14.2, 8.4 Hz, 1H), 2.00 (t, J = 7.7 Hz, 2H), 1.69 – 1.39 (m, 2H), 0.84 (s, 
9H), -0.01 (s, 6H). 
13
C NMR (100 MHz, CDCl3) δ = 172.8, 155.8, 143.9, 136.3, 128.5, 128.2, 128.1, 113.6, 67.0, 62.6, 
52.4, 52.3, 39.0, 31.4, 30.7, 26.0, 18.4, -5.2. 
HRMS (ESI) for C23H41N2O5Si
+
 [M+NH4]
+
: calcd.: 453.2779, found: 453.2786 
IR (ATR):  ̃ = 3344 (br, w),  2952 (m),  2929 (m),  2857 (m),  1724 (s),  1647 (w), 1521 (m), 1472 
(m), 1347 (s),  1254 (s),  1212 (s), 1100 (s),  1053 (m), 1028 (m),  899(m). 
    
   = +5.3 (c = 1.90, CH2Cl2). 
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methyl (S)-2-(((benzyloxy)carbonyl)amino)-7-hydroxy-4-methyleneheptanoate 
(319) 
 
A solution of alcohol 318 (1.50 g, 3.44 mmol, 1.00 eq.) in THF (17.2 mL) was cooled to 0 °C and a 
solution of TBAF (1 M in THF, 5.16 mL, 1.50 eq.) was added dropwise over 15 minutes. The reaction 
was stirred for 2 h 0 °C, quenched with saturated aqueous NH4Cl (20 mL) and diluted with EtOAc 
(30 mL). The layers were separated and the aqueous phase was extracted with EtOAc (3 x 30 mL). 
The combined organic layers were washed with brine, dried over MgSO4 and concentrated under 
reduced pressure. Purification by flash column chromatography (SiO2, hexanes/EtOAc = 9/1 to 1/9) 
gave 319 as a yellow oil (930 mg, 2.89 mmol, 84%).  
Rf = 0.32 (hexanes/EtOAc = 1/1, CAM). 
1
H NMR (400 MHz, CDCl3) δ = 7.29 – 7.22 (m, 5H), 5.16 (t, J = 6.9 Hz, 1H), 5.00 (d, J = 2.2 Hz, 
2H), 4.86 – 4.67 (m, 2H), 4.40 (td, J = 8.4, 5.3 Hz, 1H), 3.64 (s, 3H), 3.52 (t, J = 6.5 Hz, 2H), 2.48 
(dd, J = 14.1, 5.4 Hz, 1H), 2.29 (dd, J = 14.1, 8.5 Hz, 1H), 2.02 (q, J = 7.6 Hz, 2H), 1.84 – 1.41 (m, 
3H). 
13
C NMR (100 MHz, CDCl3) δ = 172.8, 156.0, 143.6, 136.3, 128.7, 128.3, 128.2, 113.9, 67.2, 62.2, 
52.5, 52.5, 52.4, 39.6, 31.1, 30.3. 
HRMS (ESI) for C17H24NO5
+
 [M+H]
+
: calcd.: 322.1649, found: 322.1650. 
IR (ATR):  ̃ = 3349 (br, m), 3068 (w), 2950 (m), 1703 (s), 1647 (w), 1530 (m), 1438 (m), 1345 (m), 
1265 (m), 1215 (s), 1180 (m), 1054 (m), 1028 (m), 904 (m). 
    
   = +2.2 (c = 1.20, CH2Cl2). 
methyl (S)-2-(((benzyloxy)carbonyl)amino)-4-methylene-7-oxoheptanoate (320) 
 
A solution of 319 (122 mg, 380 µmol, 1.00 eq.) in CH2Cl2 (3.65 mL) was cooled to 0 °C and powdered 
NaHCO3 (159 mg, 1.90 mmol, 5.00 eq.) was added, followed by Dess-Martin periodinane (242 mg, 
569 µmol, 1.50 eq.). After 1 h, a half-saturated solution of Na2SO3 (10 mL) was added and the reaction 
mixture was vigorously stirred for 30 minutes. The reaction was diluted with water (10 mL) and 
CH2Cl2 (20 mL). The layers were separated and the aqueous layer was extracted with CH2Cl2 (2 x 20 
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mL). The combined organic layers brine (20 mL), dried over MgSO4, filtered and concentrated under 
reduced pressure. Purification of the crude product by flash column chromatography (SiO2, 
hexanes/EtOAc = 9/1 to 1/1) gave 320 as a yellow oil (100 mg, 313 µmol, 83%).  
Rf  = 0.62 (hexanes/EtOAc = 1/1, CAM). 
1
H NMR (400 MHz, CDCl3) δ = 9.72 (d, J = 1.7 Hz, 1H), 7.37 – 7.27 (m, 5H), 5.34 (d, J = 8.3 Hz, 
1H), 5.08 (d, J = 2.6 Hz, 2H), 4.88 – 4.77 (m, 2H), 4.50 (td, J = 8.3, 5.6 Hz, 1H), 3.72 (s, 3H), 2.63 – 
2.49 (m, 3H), 2.46 – 2.28 (m, 3H). 
13
C NMR (100 MHz, CDCl3) δ = 201.7, 172.6, 155.8, 142.4, 136.3, 128.6, 128.3, 128.2, 114.2, 67.1, 
52.5, 52.4, 41.6, 39.6, 27.3. 
HRMS (ESI) for C17H22NO5
+
 [M+H]
+
: calcd.: 320,1492, found: 320,1494. 
IR (ATR):  ̃ = 3338 (br, w), 3066 (w), 3034 (w), 2953 (w), 2846 (w), 1715 (s), 1648 (w), 1524 (m), 
1454 (m), 1437 (m), 1345 (m) 1261 (m), 1213 (s), 1050 (m), 1027 (m), 905 (w) 741 (w), 698 (m).  
    
   = +3.1 (c = 1.86, CH2Cl2). 
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4.3. X-Ray Crystallographic Data  
Data for piperazine 201 (hydrochloride salt). 
  
Figure 18. ORTEP plot of the molecular structure of 201. 
net formula C10H24Cl2N2O2 
Mr/g mol
−1 275.21 
crystal size/mm 0.100 × 0.080 × 0.040 
T/K 100(2) 
radiation MoKα 
diffractometer 'Bruker D8Venture' 
crystal system orthorhombic 
space group 'P 21 21 21' 
a/Å 5.9400(2) 
b/Å 12.7285(4) 
c/Å 18.5201(6) 
α/° 90 
β/° 90 
γ/° 90 
V/Å3 1400.25(8) 
Z 4 
calc. density/g cm−3 1.305 
μ/mm−1 0.454 
absorption correction Multi-Scan 
transmission factor range 0.9211–0.9590 
refls. measured 69977 
Rint 0.0392 
mean σ(I)/I 0.0163 
θ range 2.720–27.52 
observed refls. 3166 
x, y (weighting scheme) 0.0225, 0.3030 
hydrogen refinement mixed 
Flack parameter −0.011(13) 
refls in refinement 3214 
parameters 169 
restraints 0 
R(Fobs) 0.0177 
Rw(F
2) 0.0484 
S 1.115 
shift/errormax 0.001 
max electron density/e Å−3 0.252 
min electron density/e Å−3 −0.154 
  
C-H: constr, N-H and O-H: refall. 
Part II: X-Ray Crystallographic Data 
237 
Data for Boc-piperazine 202. 
  
Figure 19. ORTEP plot of the molecular structure of piperazine 202 
net formula C20H38N2O6 
Mr/g mol
−1 402.526 
crystal size/mm 0.16 × 0.12 × 0.09 
T/K 173(2) 
radiation MoKα 
diffractometer 'KappaCCD' 
crystal system orthorhombic 
space group P212121 
a/Å 9.4705(6) 
b/Å 10.3778(6) 
c/Å 23.7593(14) 
α/° 90 
β/° 90 
γ/° 90 
V/Å3 2335.1(2) 
Z 4 
calc. density/g cm−3 1.14499(10) 
μ/mm−1 0.084 
absorption correction none 
refls. measured 9417 
Rint 0.1936 
mean σ(I)/I 0.1095 
θ range 3.24–23.07 
observed refls. 1498 
x, y (weighting scheme) 0.0637, 2.5081 
hydrogen refinement constr 
Flack parameter 5(4) 
refls in refinement 1872 
parameters 259 
restraints 0 
R(Fobs) 0.0829 
Rw(F
2) 0.1736 
S 1.099 
shift/errormax 0.001 
max electron density/e Å−3 0.232 
min electron density/e Å−3 −0.291 
  
The absolute configuration could not be determined due to a meaningless Flack-parameter (caused by 
missing heavy atoms und the use of MoKα radiation) 
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Data for piperazine 235 (hydrobromide salt). 
 
Figure 20. ORTEP plot of the molecular structure of piperazine 235. 
net formula C20H28Br2N2O2 
Mr/g mol−1 488.257 
crystal size/mm 0.132 × 0.107 × 0.034 
T/K 173(2) 
radiation 'Mo Kα 
diffractometer 'Bruker D8Venture' 
crystal system monoclinic 
space group P21 
a/Å 13.0595(6) 
b/Å 6.0367(3) 
c/Å 27.1867(14) 
α/° 90 
β/° 101.8222(15) 
γ/° 90 
V/Å3 2097.83(18) 
Z 4 
calc. density/g cm−3 1.54594(13) 
μ/mm−1 3.881 
absorption correction multi-scan 
transmission factor range 0.8118–0.9585 
refls. measured 23315 
Rint 0.0437 
mean σ(I)/I 0.0630 
θ range 2.30–26.45 
observed refls. 6964 
x, y (weighting scheme) 0.0292, 0.4909 
hydrogen refinement mixed 
Flack parameter −0.005(10) 
refls in refinement 8497 
parameters 490 
restraints 1 
R(Fobs) 0.0395 
Rw(F2) 0.0823 
S 1.037 
shift/errormax 0.001 
max electron density/e Å−3 1.020 
  
C-bound H: constr, N-bound H: refxyz. Disorder in phenyl ring and methyl moiety handled by split 
models. The figure shows only one (the better one) of the two symmetrically independent formula 
units. 
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Data for allylic boronate 268. 
 
Figure 21. ORTEP plot of the molecular structure of 268. 
net formula C18H32B2O4 
Mr/g mol
−1 334.05 
crystal size/mm 0.574 × 0.435 × 0.366 
T/K 173(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system monoclinic 
space group 'C 2/c' 
a/Å 12.4424(5) 
b/Å 11.3140(6) 
c/Å 14.7187(7) 
α/° 90 
β/° 99.507(4) 
γ/° 90 
V/Å3 2043.55(17) 
Z 4 
calc. density/g cm−3 1.086 
μ/mm−1 0.072 
absorption correction 'multi-scan' 
transmission factor range 0.94622–1.00000 
refls. measured 5891 
Rint 0.0206 
mean σ(I)/I 0.0232 
θ range 4.568–26.367 
observed refls. 1697 
x, y (weighting scheme) 0.0573, 1.3019 
hydrogen refinement constr 
refls in refinement 2083 
parameters 113 
restraints 0 
R(Fobs) 0.0491 
Rw(F
2) 0.1328 
S 1.055 
shift/errormax 0.001 
max electron density/e Å−3 0.299 
min electron density/e Å−3 −0.172 
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Data for 1,4-diol 278. 
 
Figure 22. ORTEP plot of the molecular structure of 1,4-diol 278. 
net formula C78H104O7 
Mr/g mol
−1 1153.61 
crystal size/mm 0.447 × 0.283 × 0.130 
T/K 123(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system monoclinic 
space group 'P 21/n' 
a/Å 17.4355(13) 
b/Å 12.1380(7) 
c/Å 32.989(2) 
α/° 90 
β/° 101.288(7) 
γ/° 90 
V/Å3 6846.6(8) 
Z 4 
calc. density/g cm−3 1.119 
μ/mm−1 0.069 
absorption correction 'multi-scan' 
transmission factor range 0.95282–1.00000 
refls. measured 35251 
Rint 0.0743 
mean σ(I)/I 0.1065 
θ range 4.227–25.024 
observed refls. 6026 
x, y (weighting scheme) 0.0640, 0.6413 
hydrogen refinement mixed 
refls in refinement 12035 
parameters 791 
restraints 9 
R(Fobs) 0.0742 
Rw(F
2) 0.1907 
S 1.020 
shift/errormax 0.001 
max electron density/e Å−3 0.434 
min electron density/e Å−3 −0.243 
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Only one molecule shown (solvent omitted); C-H: constr; O-H: located from difference map, then 
fixed, U(H)=1.5U(O). Each hydroxyl function has two hydrogen positions, each with sof 0.5. 
Disorder described by split models. 
Data for cyclohexene 288. 
  
Figure 23. ORTEP plot of the molecular structure of cyclohexene 288. 
net formula C26H30O2 
Mr/g mol
−1 374.50 
crystal size/mm 0.434 × 0.066 × 0.054 
T/K 123(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system monoclinic 
space group 'C 2' 
a/Å 18.945(2) 
b/Å 5.3576(6) 
c/Å 20.611(2) 
α/° 90 
β/° 90.200(9) 
γ/° 90 
V/Å3 2092.0(4) 
Z 4 
calc. density/g cm−3 1.189 
μ/mm−1 0.073 
absorption correction 'multi-scan' 
transmission factor range 0.83264–1.00000 
refls. measured 5427 
Rint 0.0355 
mean σ(I)/I 0.0793 
θ range 4.303–25.342 
observed refls. 2651 
x, y (weighting scheme) 0.0262, 0.0000 
hydrogen refinement mixed 
Flack parameter 0.5 
refls in refinement 3470 
parameters 261 
restraints 1 
R(Fobs) 0.0511 
Rw(F
2) 0.0917 
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S 0.996 
shift/errormax 0.001 
max electron density/e Å−3 0.161 
  
Refined as perfect racemic twin. C-H: constr, O-H: refall. 
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4.4. NMR Spectra 
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